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Abstract 
Investigations into radical and palladium (0) cyclisations onto the C-2 position of the 
3H-quinazolin-4-one moiety have been made. This has led to the syntheses of a 
number of biologically active quinazolinone natural products using alkyl, heteroaryl 
and acyl radical cyclisations. The reactions proceeded via a homolytic aromatic 
substitution mechanism. As such, fully rearomatised products were recovered. 
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A C-2 radical 3H-quinazolin-4-one building block was also prepared. This turned out 
to have only limited synthetic applications. Radical cyclisations onto aryl groups were 
carried out using this building block. 
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Chapter 1. Introduction 
The research described in this thesis involves the use free radicals as reactive intermediates in 
the synthesis of 3H-quinazolin-4-one natural products. Therefore, the following introduction 
will include a review of free radical chemistry in organic syntheses, followed by a description 
of quinazolinone natural products, drugs, biosynthesis and organic syntheses of this moiety. 
1.1 Free radicals 
Radicals are usually defined as atoms or compounds containing an unpaired electron. Hence 
by definition radical species contain an odd number of electrons (e.g. H· and Br· contain 1 
and 7 electrons in their outer valence shell respectively). This single unpaired electron is 
denoted by a dot. They are usually very unstable and highly reactive intermediates. This is 
due to their strong desire to pair with another electron to form a 2-electron covalent bond or 
lone pair. 
However, not all radicals are highly reactive and NO· or 02 are good examples of naturally 
occurring non-reactive radicals. Molecular oxygen is best thought of as a diradical, containing 
two unpaired radicals and is usually considered as •0--0•. Being a diradical 0 2 contains 12 
valence electrons i.e. an even number of electrons unlike the earlier definition. 
Radicals can be formed by the homolysis or homolytic cleavage of a chemical bond. The 
bonding electrons are divided evenly and represented by single headed arrows (scheme 1). 
X • + y • 
X-Y 
Scheme 1. Radical formation and combination. 
As radicals are inherently neutral, they do not suffer from solvent effects that are observed in 
ionic reactions. It is this inherent neutrality that gives radicals a major advantage over ionic 
intermediates, as a result high functional group tolerance is often observed. A radical can 
become charged though if reduced by an electron source to an anion, or loss of an electron 
producing an oxidised cation. Being uncharged radicals don't have surrounding solvent shells. 
The exception to this is radical anions and cations that have counter ions. 
1 
1.2 Radical stability 
The formation of a radical is dependant on its thermodynamic stability. This can be 
empirically considered as its bond dissociation energy (BDE}, i.e. the energy required for 
homolysis of the bond. An understanding of the BDE is crucial in organic synthesis in 
. predicting a radical reactions outcome. The lower the BDE value the more easily the bond is 
cleaved. Some BDE values are given (table 1 ). 
Table 1. Bond dissociation energy values.1 
Bond type 
BDE (kJ mol-1) 
H-H 
435 
H-F 
565 
H-Cl 
431 
H-Br 
364 
H-1 
297 
H--OH 
498 
Although radicals are considered electronically neutral, they can still be thought of as electron 
deficient As a result, they are generally stabilized by electron donating substituents. This 
means they display the same trend in stability as carbocations (figure 1). 
Tertiary Secondary Primary 
R R R 
Carbocation R~R > R~H >H~H stability 
R R R 
Radical R~R > R~H >H~H Stability 
Figure 1. Stability of carbocations and radicals. 
1.3 Radical polarity 
The polarity of a radical is different to that of an ion. For an ion an EDG would aid the 
formation of an electrophilic centre and an EWG would aid the formation of a nucleophilic 
centre (figure 2). For radicals both electron withdrawing and donating groups can be used to 
stabilize the radical. The substituents then play a vital role in influencing the polarity of the 
radical. Electron donating groups cause the radical to be nucleophilic in nature 1, whereas an 
EWG creates an electrophilic radical 2. This reversal of reactivity can be described by the 
term umpolung. 
2 
Nucleophilic radical Electrophilic radical 
.0. <±>8 
RO-CR2~ RO-CHR2 
• 
1 
Electrophilic cation Nucleophilic anion 
Figure 2. Comparison of polarity of radicals and ions. 
1.4 Regioselectivity of intramolecular radical cyclisations 
The reaction of a hex-5-en-1-yl radical 3 has two regio possibilities for cyclisation (scheme 
2).1 However it is the 5-exo-trig cyclised product 6 which predominates over the 6-endo-trfg 
cyclised product 7. The 6-endo-trig cyclisation is the thermodynamic product, because the 
secondary intermediate radical 5 is more stable than the primary intermediate radical4 (which 
forms the 5-exo-trig product). 
6 [ 6] ~ 0 
/ 4 BrV Bu3SnH, AIBN [l(] Benzene, heat 63% 
~[C) l ~ 0 
5 7 
Scheme 2. Relative product ratios from hex-5-en-1-yl radical5-exo: 6-endo (49:1). 
3 
This appears to be a contradiction. We know that the 5-exo cyclisation is the major reaction 
product. The explanation for this lies in the more favoured transition state of the 5-exo radical. 
This transition state is described as the 'Beckwith model' (figure 3).2 
Figure 3. Favoured 5-exo chair like transition state 'Beckwith model'. 
This mode of cyclisation is observed for many other related systems. Baldwin's rules can be 
used to predict the size of ring formation.3 Cyclisations onto alkynes are often slower than 
those onto alkenes. If a heteroatom is placed into the carbon chain this can greatly affect the 
regio selectivity. For example if nitrogen is inserted in the cyclising chain then the bond angle 
C-N-C becomes smaller (107.8 °) compared to the tetrahedral C-C-C angle (109 °). 
The C-N carbon bond length is also shorter (1.47 A) than the C-C bond length (1.52 A). 
As a result the radical is closer to the internal carbon providing an even better overlap in the 
5-exotransition state and higher yield of the 5-exo product. 
1.5 Tin Hydrides and azo initiators 
There are a great variety of the reagents that are used in radical reactions. Commonly group 
14 organometallic hydride reagents (often tin hydrides) are used in conjunction with azo 
initiators. The most common radical reagent is tributyltin hydride. This reagent readily 
facilitates either inter or intra-molecular radical reactions. Aryl and alkyl radicals are 
commonly generated from halides, selenides or sulphides. To minimize any undesired 
termination steps, low concentrations of radicals are used. This can be achieved by addition of 
Bu3SnH with a syringe pump, for example. 
As stated, initiation is commonly carried out using azo compounds such as AIBN (scheme 3). 
Usually 5-10% initiator is required. There are examples where high concentrations of initiator 
must be used, and these are discussed later. AIBN can be thermally cleaved and has a half life 
of I hat 81 "C.1 This half life drops to 30 min in refluxing toluene (110 °C). The rate of 
forming the isobutyronitrile radical is much slower than rates of other radical propagation 
steps in the chain reaction. The isobutyronitrile radical abstracts hydrogen from Bu3SnH. This 
4 
is a strongly favoured reaction as a strong C-H bond is formed at the expense of a weak Sn 
-Hbond. 
CN f> 
N=N:fj 
NC 
ABCN 
+-~~ 
NC ~T 
AIBN CN 
NCtN=N+CN 
AMBN ) 
or hu 
? ~ 
2 X t 
)=c=N • 
heat 
Scheme 3. Initiation of azo compounds and their resonance stability. 
Importantly, the isobutyronitrile radical is tertiary and resonance stabilized. This decreases its 
expected reactivity. As a result, the abstraction of the hydrogen occurs solely from the 
Bu3SnH and not any other organic compounds in the reaction containing stronger C-H 
bonds. This gives a good functional group tolerance, compared with many other ionic reaction 
processes. 
The newly formed tributyltin radical can react with alkyl or aryl halides (except fluorides), 
selenides and sulphides. Formation of a strong tributyltin halide bond over a weaker carbon 
halide makes this reaction a highly favoured reaction (scheme 4). Depending on the leaving 
group on the carbon the rate of abstraction can vary widely. Stronger bond strengths in aryl 
and vinyl halides, means chlorides are rarely used as precursors. 
5 
Me 
Bu3Sn-0 • ~Me Me i) Bu3Sn • + H+Me ~ ~ 
CN CN 
ii) Bu3Sn n 0 X-R Bu3SnH + R • u 
cyclisation 
R1• lii) R • 
iv) Bu3Sn-0 •R1 
~ u R
1
-H + Bu3Sn • 
R1 = cyclised radical 
Scheme 4. Chain reaction sequence of isobutyronitrile radical and Bu3SnH. 
Unwanted side reactions may occur, for instance, with terminal alkynes, Bu3Sn· addition is 
commonly observed and can disrupt the chain reaction. 
Step v) is known as reduction and can be minimized by using low concentrations of Bu3SnH 
(scheme 5). In the case of intramolecular reactions this is less of a problem. Here entropy will 
favour a unimolecular reaction over a bimolecular one with the Bu3SnH. In practical terms the 
concentration of Bu3SnH in the reaction can be kept low by slow addition using a syringe 
pump over several hours. At first glance step vi) looks like a problem, as we do not want to 
reform a carbon halogen bond. However, the reaction ofR· with a halide causes no problem. 
This is because a further reaction with Bu3Sn· will lead to the initial starting radical being 
reformed. Organohalide products are rarely isolated when using Bu3SnH. 
v} + H-R 
vi) R1n X-n-R 
\___) + 
R• 
Scheme 5. Undesired propagation reactions. 
6 
There are some major drawbacks to using BuJSnH. Breakdown products can be very difficult 
to separate from the reaction. There are ways of avoiding stoichiometric amounts of Bu3SnH. 
Using a reducing agent such as NaBH4 (scheme 6) means Bu3SnH can be used catalytically. 
This readily reduces the tin-halogen bond to a tin-hydrogen bond. However this isn't always a 
viable option if sensitive functional groups are present in the reaction. Corey and Suggs first 
described this reaction in 1975. They found that Bu3SnH (10 mol%) and stoichiometric 
amounts ofNaBH4 were suitable to dehalogenate bromides and iodides in good yield.4 
RH 
RX 
Scheme 6. Regeneration ofBu3SnH using NaBH4. 
1.6 Trialkylboranes as radical initiators 
Azo compounds such as AIBN, ABCN and AMBN have proved to be very popular free 
radical initiators for a long time. However, the use of organoborane species has been pioneerd 
by Brown.5 They pioneered the use of organoborane species in radical mediated reactions. 
Brown later went on to win the Nobel Prize in 1979 for his work on organoborane reagents in 
organic synthesis. 
Trialkylborane species are now very popular initiating reagents as they easily undergo 
bimolecular homolytic substitution at the boron atom by oxygen.6 The alkyl radical can be 
displaced by a range of radicals such as peroxyl or thiyl radicals. 6 They are 
thermodynamically favoured due to the high bond strengths of the newly formed B-X bond 
(table 2). 
7 
Table 2. Relative BDE for various borane species. 
Compound Bond BDE (kJ/mol) 
Et3B B-C 344 
(Et0)3B B-0 519 
((CH3)2N]3B B-N 422 
(Et3S)3B B-S 377 
One of the most common organoborane reagents used in radical chemistry is triethylborane, 
which readily undergoes auto-oxidation in air.6 Renaud has proposed a mechanism of this 
auto-oxidation. Alkyl radical 9 is liberated after a homolytic substitution reaction between 
triplet oxygen and triethylborane 8 (scheme 7). The alkyl radical 9 is then believed to react 
with oxygen to form a peroxyl radical10. This radical can undergo a SH2 reaction producing a 
monoperoxyborane species 11 (the rate constant for this reaction has been recorded) can also 
occur. The monoperoxyborane 11 species can then react with oxygen to produce the 
diperoxyborane species 12, which is believed to be inert to oxygen. Alternatively, a reaction 
can take place where the monoperoxyborane species 11 reacts with Et3B yielding a dialkyl 
borinate species 13 which can undergo a further reaction with oxygen to yield the trialkyl 
borate species 14. 
Initiation 
Propagation R· + 02 
9 
ROO· + R3B 
10 8 
Further reactions {ROO)BR2 + 
11 
{ROO)BR2 + 
11 
{RO)BR2 + 
13 
SH2 
02 
R38 
02 
-
ROO• 
10 
{ROO)BR2 + 
11 
{R00)2BR 
12 
2 {RO)BR2 
13 
+ R· 
9 
R· 
[{RO){ROO)BR] ~ {RO)JB 
14 
Scheme 7. Proposed mechanism for auto-oxidation oftrialkylborane species. 
8 
Trialkylborane reagents have a number of advantages over azo-initiators such as AIBN. For 
instance, reactions can be carried out at low temperatures (down to -78.C). This allows 
enantioselective reactions to be carried out. Residual AIBN can make purification difficult, 
this is not so using trialkylborane species. 
1. 7 Silicon and Germanium hydrides 
Due to the toxicity problems and purification problems ofR3SnH an attractive alternative is to 
use tri-organosilicon hydrides instead. Like tri-organotin hydrides the R3Si· radical will react 
in the same fashion with organohalides, selenides and sulphides at similar rates. The Si-H 
bond is 65 kJ mol-1 stronger than the Sn--H bond. As a result their reaction with alkyl 
radicals is slower. This can be overcome in two separate ways. 
The first involves the addition of a catalytic amount of alkyl thiol to the reaction. Alkyl 
radicals can more easily abstract hydrogen from the thiol.7 This results in a stronger carbon 
hydrogen bond over a weaker sulfur hydrogen bond. The silicon hydrogen bond is similar in 
strength to the thiol hydrogen bond. This means that it is not the BDE here that is playing the 
crucial role. It is by looking at polarities that we can gain insight into how the reaction 
proceeds. The hydrogen of the thiol can be thought of as electron poor due to the 
electronegative sulfur. As a result a nucleophilic alkyl radical will rapidly extract this 
hydrogen. The hydrogen in the Si-H can be thought of as electron rich because 
electropositive nature of silicon. This means the electrophilic thiyl radical will look to abstract 
the hydrogen from the Si-H. This reaction proceeds despite not being an exothermic one. 
The silyl radical can then undergo halogen abstraction forming a strong silicon halide bond. 
Secondly, the silicon hydride bond can be weakened by the addition of bulky substituents. 
This forms a more hindered and stable silyl radical. The most common reagent of this type is 
tris-(trimethylsilyl)silane (ITMSS) and is often used over Bu3SnH (scheme 8). 
The slower rate of hydrogen abstraction of Si-H compared to the Sn--H can help lower 
amounts of reduced product in a reaction. Silicon by products are easier to remove than their 
tin counter parts during purification. As with tri-organotin hydrides, the addition of a reducing 
agent like NaBH4 can be used. This allows silicon hydrides to be used catalytically. 
9 
R·~i(SiMe3)3 
Scheme 8. TIMSS initiation of silyl radical. 
R-H + · Si(SiMe3)3 
Another reagent of much interest is tributylgermanium hydride.8 Like silicon hydrides they 
have lower toxicity than tin hydrides, ease of work up and good stability. Tributylgermanium 
hydride has recently been used to generate radicals from iodides, bromides, activated 
chlorides and phenyl selenides. Bowman has shown similar yields of cyclised product can be 
obtained using Bu3GeH as compared with Bu3SnH (scheme 9).8 Initial studies indicate as 
with tin and silicon, the use of NaBH4 enables catalytic amount of the Bu3GeH to be used. 
The rate of hydrogen abstraction from the germanium is 20 times slower than Bu3SnH. As 
with silicon hydrides, polarity reversal catalysis using thiols can also be use. 
CC~ 01 f-7" _A_B_C_N_, M_e_P_h_ .,., reflux, Bu3XH ~ llJ-l 
X= Ge after 3 h, (91%) 
= Sn after 2 h, (86%) 
Scheme 9. Comparison between Bu3GeH and Bu3SnH. 
1.8 Intramolecular homolytic oxidative radical cyclisations 
Our work is concerned with studying intramolecular radical cyclisation reactions onto the 
quinazolinone moiety 16 (scheme 10) from halide precursors such as 15. Importantly, we 
hope to achieve rearomatisation of the quinazolinone radical intermediate 17, in the presence 
of reagents such as Bu3SnH. These reaction conditions are reductive, yet we are aiming for 
rearomatisation. This would involve oxidation to form quinazolinone 18. 
10 
0 0 
cr)J Bu3SnH, OOJ N \ AIBN 
Br 
15 16 ~ 
0 
oo~ -H • 
18 17 
Scheme 10. Desired rearomatised quinazolinone products using Bu3SnH/AIBN. 
However, Bu3SnH mediated radical cyclisations of arenes and heteroarenes can produce 
rearomatised products in good yield. The mechanism of such reactions can be described as 
intramolecular homolytic aromatic substitution. Reactions like these proceed with the initial 
Bu3Sn• producing the R· radical, which then adds onto an aromatic ring. This yields an 
intermediate substituted cyclohexadienyl radical19 (figure 4). It has been widely debated the 
exact mechanism that leads to fully aromatic products 21. Bowman et al. has extensively 
investigated this mechanism.9 There have been many possible explanations such as 
disproportionation of 19 or hydrogen-atom transfer by the Bu3SnH producing rearomatised 
21. Some have argued the reaction· may go via a dihydro compound such as 20, which 
becomes oxidised on work up. However, dihydro compound 20 does not readily oxidize in 
air. 10 
OH R I ) 
19 
H R Q 
H H 
20 
Figure 4. Key structures in rearomatisation arguments. 
21 
One fact is common to many of the reported examples of intramolecular homolytic aromatic 
substitution is the need for stoichiometric amounts of the radical initiator. Bowman et al. 
have carried out detailed work in this field and correlated reaction products of imidazole 22 to 
11 
amounts of initiator used (scheme 11}.9 The use of 1H NMR spectroscopy with an internal 
standard revealed a clear relationship between the ratio of AMBN added and the amount of 
cyclised product (e.g. AMBN: 1.0 equiv, cyclised 23 [92%], reduced 24 [0%]; 0.5 equiv, 
cyclised 23 [43 %], reduced 24 [53%]; 0.25 equiv, cyclised 23 [8%], reduced 24 [9 %]). This 
suggests along with work carried out by Curran et al. that it is the initiator that acts as the 
oxidizing agent in these reactions. 11 However the exact mechanism is still unknown. 
MeCN, reflux 
22 
23 24 
Scheme 11. Synthesis ofbicyclic imidazole 22. 
1.9 Heterocyclic synthesis via intramolecular radical cyclisations 
There is a rich history of radical cyclisations being employed in the synthesis of a wide range 
of heterocycles. Some noteworthy examples will now be discussed in relation to various 
heterocyclic systems. A wide ranging type of radical reagents will be shown. Some of these 
can be described as nucleophilic aromatic homolytic substitutions radical reactions. 
The chemistry of pyridines has been studied for over a hundred years and examples of inter-
~olecular oxidative radical substitution reactions have been reported by Minisci. 12 Murphy et 
al. has reported an intramolecular radical substitution reactions of pyridinium rings (scheme 
12).13 Murphy reached [6,6]-bicyclic rearomatised pyridinium 26 from the simple alkylated 
pyridinium salt 25. He noted the need for excess initiator to reach rearomatised pyridinium 
26. 
12 
w Bu3SnH, Tt5 
1
e r (I -A-IB_N_(-ex_c_e-ss_}_ 
1
_ 
V reflux, PhMe 
25 26 
Scheme 12. Murphy's radical cyclisations onto pyridinium salts. 
This reaction was extended to formation of a [6,5]-bicyclic system 28 from pyridinium salt 27 
(scheme 13). On hydrogenation ofthe [6,5]-bicyclic system 28, the indolizidine backbone 29 
is formed. This is an important backbone for anti-viral drugs such as castanospermine 30.13 
Analogous [6,7]-bicyclic ring systems were also formed by Murphy.13 
AIBN (excess} 
reflux · I~ 
28 (65%} 
Hydrogenation 
·--------------
Scheme 13. Synthesis of bicyclic core of castanospermine. 
CO 
29 
30 
Jones et al. has carried out work using pyridine centred radicals from 2-bromo-N-alkyl 
pyridinium salts 31 and 34 (scheme 14}.14 Pyridinium salts 31a and 31b gave rise to 5-exo-
trig cyclisation, to give [6,5]-bicycle 32 and 6-exo-trig cyclisation to give [6,6]-bicycle 33 
products. These cyclisations again allowed easy access to indolizine and quinolizidine 
skeletons with subsequent hydrogenation. 14 When steric bulk was added to the alkene 34, a 
mixture of 5-exo-trig product 35 and 6-endo-trig product 36 and were obtained.14 
13 
A ll~A N Br AIBN, reflux 
6oTt~ 
31a, n = 1 
b, n =2 
G)_ 
N Br 
8 ort lA_ 
34 
AIBN, reflux 
32 n = 1 (74%) 33 n = 2 (53%) 
eo~ eoT~ 
(1:3.5) 76% 
35 36 
Scheme 14. Radical cyclisations of2-bromopyridinium salts. 
Cyclisation of pyridinium radical 37 onto an aromatic ring proceeded in moderate yield 
(scheme 15). This reaction produced the fully rearomatised benzene ring 38 and reduced 
product 39. Jones could not successfully extended this work to include cyclisations onto 
alkynes. 14 
c 
E>oTfNOBr 
I ~ 
.--: 
AIBN, reflux 
37 38 (30%) 39 (61%) 
Scheme 15. 5-Membered radical cyclisation onto benzene. 
An unusual radical double ipso substitution reaction on pyridine has been used by Zhang and 
Pugh in the synthesis of azacoumarins 45 from bromoaryl benzoate pyridine precursor 40 
(scheme 16}.15 The mechanism proposes an initial 1,5 ipso attack of the aryl radical 41 at the 
2-position of the pyridine. This is followed by the opening of the lactone 42 to form the acyl 
oxy radical 43. This acyl oxy radical then undergoes a 1,6 ipso attack displacing the methoxy 
group on the pyridine ring to form the tricycle 45. The displacement of the inethoxy group 
was found to be crucial in reaching the azacoumarin core. Further studies on unsubstituted 
14 
methoxy pyridines predominantly revealed reduced products, and a substantial fall in yields 
of azacoumarins. 
cc; ~~OMe 015 TIMSS 1 ,5-ipso cat. AIBN, OD Me Ph 
0 N h- 0 N h- 0 
40 41 42 
1~ 
M eO 
1 ,6-ipso 
..-
0 0 0 
45 (62%) 44 43 
Scheme 16. Zhang and Pugh's unusual radical double ipso substitution reaction on pyridine. 
Radical cyclisations of pyrroles have also been extensively investigated. De La Cruz et al. 
showed that aryl radicals cyclise onto pyrroles 46 (scheme 17).16 The pyrrole nucleus requires 
· activation with an electron withdrawing group (aldehydes or sulfones) without which cyclised 
pyrrole 47 was not observed and only the reduction product 48 isolated. 
3 
~ R~(t 
46 u 
R=H 
R=CHO 
R 
AIBN, benzene 
47 
R = H, (0%) 
= CHO, (43%) 
Scheme 17. Aryl radical cyclisations onto pyrroles. 
R = H, (70%) 
= CHO, (<10%) 
Likewise it was found that by moving the EWG on the pyrrole ring to C-3 49 no cyclisation 
occurred only reduction to pyrrole 50 (scheme 18). This demonstrates how finely balanced 
radical cyclisations can be. De La Cruz also postulates the mechanism of oxidative radical 
cyclisation is likely to be that proposed by Bowman.9 
15 
Scheme 18. Failed radical cyclisation onto pyrrole. 
The cyclisation of aryl radicals onto pyrroles has been further investigated by Jones et al. 17 It 
was the interest in synthesis of the potent gastric A TPase inhibitor 51 that led to this work 
(figure 5). 
Figure 5. Pyrrole containing gastric inhibitor. 
The regiochemistry of aryl radical cyclisations onto pyrrole rings proved interesting (scheme 
19}.17 The two nitrogen protecting groups Rand R1 proved to be very influential to reaction 
products. When the pyrrole nitrogen was unprotected (R1 = H) 52a, a mixture of 
pyrroloquinoline regioisomers 53a and 54a from a 6-endo cyclisation were isolated .. When R1 
was electron withdrawing, as in ester 52b, a spiropyrrolidinyloxindole product 55b (the result 
of a 5-exo reduction radical cyclisation) and the 6-endo product 53b were observed. When the 
pyrrole was protected with an EDG, as in methyl 52c only one regioisomer product 53c was 
recovered. 
16 
OMe 
~Br/ RNyO 
0 
52a, R = Me, R 1 = H 
MePh, reflux 
b, R = SEM, R1 = C02Me 
c, R = SEM, R1 =Me 
OMe 
0 
53a, (37%} 
b, (15%} 
C, (43%} 
OMe 
OMe 
55a, (0%} 
b, (32%} 
c, (0%} 
0 
54a, (15%} 
b, (0%} 
c, (0%} 
Scheme 19. Jone's regioselective radical cyclisations onto pyrroles. 
Bicyclic heterocycles such as quinolines have provided interesting results to radical chemists 
over the years. Harrowven et al. has investigated radical cyclisations onto the C-2, C-3 and C-
4 of quinolines (scheme 20}. 18 Radical cyclisation of the 2-substituted quinoline 56 resulted in 
selective cyclisation onto the C-3 position, forming pentacycle 57 in good yield. With 4-
substitu.ted quinoline 58 the sole reaction product was cyclisation onto C-3, resulting in 
pentacycle 59. The cyclisation of 3-substititued quinoline 60 in contrast produced a mixture of 
cyclisation onto C-4 and C-2, resulting in pentacycles 57 and 59. In all cases fully 
rearomatised products were observed. This work also highlights how radical methodology can 
be used to create large polycyclic heterocyclic compounds. 
17 
------------------------------------
(70%) 
~) 
56 57 
~%) 
(67%) 
0> 0 60 
58 59 
Scheme 20. Harrowven's quinoline radical cyclisations using Bu3SnH/AIBN. 
Quinoline centred radicals have also been studied. Formal synthesis of the natural product 
target camptothecin 61 (figure 6) has been completed by Bennasar et al. using a quinoline 
radical.19 
61 ,,, .. I OH 0 
Figure 6. Important anticancer drug camptothecin. 
This simple approach allowed access to the analogue of camptothecin, 20-deoxycampothtecin 
64 (scheme 21 ). The key step involved generation of a C-2 quinoline radical from 62 followed 
by a 5-exo-trig intramolecular radical cyclisation forming tetracyclic quinoline pyridone 63. 
Use ofTTMSS and AIBN brought about radical arylation and desulfurisation in high yield. 
18 
0 
62 
TTMSS (2 equiv.) 
C02f.Pr AIBN, benzene, reflux 
SMe 
63 (70%) 
+! 
Scheme 21. Cyclisation of quinoline radicals in natural product synthesis. 
One of the most common heterocyclic systems to be investigated by radical chemists are 
indoles. With so many natural products containing the indole core this is not surprising. 
Bremner and Sengpracha have utilised an iodoacetamide based radical in the synthesis of 
paullone type natural product 66 which is a potent cyclin dependant kinase inhibitors (scheme 
22).20 These natural products are traditionally made using a nitrogen carbon bond forming 
reaction between C-6 and N-5. Bremner's route involved employing a radical cyclisation onto 
the C-3 carbon of indole core 65.20 The desired paullone product 66 was produced in high 
yield (53%) using mesitylene as a solvent (high boiling). 
0 
reflux, mesitylene 
65 66 (53%) 
Scheme 22. Bremner and Sengpracha's indole cyclisations. 
When using toluene a mixture of cyclised 66 and spiro compound 67 were retrieved from the 
reaction (scheme 23). The formation of the spiro type indole 67 products is not unique in 
radical cyclisations onto indoles. Further examples will be shown later. 
19 
66 {18%) + 
reflux, MePh 
65 67 {13%) 
Scheme 23. Spiro cyclic indole product in toluene. 
Miranda et al. have used a tandem carbonyl~tion/radical cyclisation onto an indole core 
(scheme 24).21 By treating indole 68a under the radical conditions and 80 atmospheres of CO 
pressure, Miranda successfully generated an acyl radical. Cyclisation of the acyl radical onto 
the C-2 position of the indole core 69a was then observed, along with reduction and carbon 
monoxide trapped product 71. Addition of an aldehyde at the C-3 position of indole 68b 
increased the yield of cyclised indole 69b along with only reduced product 70. In this respect 
the work shares similarities with De La Cruz's pyrrole cyclisations previously discussed 
(scheme 17 and 18). The two reduced products 70a and 70b were also isolated along with 
alkyl carbonylated indole 71. 
68a, R = H 
b, R= CHO 
CO, 80 atm. 
benzene 
R 
69a, R = H {39%) 70a, R = H {22%) 
b, R = CHO {62%) b, R = CHO {32%) 
R 
oj 
\__/0 
71a, R = H {30%) 
b, R = CHO {0%) 
Scheme 24. Miranda's tandem carbonylation/radical cyclisation onto indole. 
Although not nucleophilic homolytic aromatic substitution reactions, the next two examples 
are applicable in this general discussion through there use of radical indole synthesis. The first 
20 
example by Murphy employs a radical synthesis of indole core in the formal synthesis of 
pentacyclic (±)-aspidospermidine 74 (scheme 25).22 The aryl radical precursor 72 underwent a 
5-exo radical cyclisation onto the near by alkene. This was followed by another 5-exo 
cyclisation onto the azide, with the elimination of nitrogen gas. The resulting aminyl radical 
picks up a hydrogen atom to yield tetracycle 73. Minor elaboration then lead to a formal 
synthesis of (±)-aspidospermidine 74. 
TTMSS,AIBN 
·-----. 
CaH6, reflux 
72 73 {40%} 74 
Scheme 25. Key tandem radical cyclisation reaction leading to (±)-aspidospermidine. 
Generation of an indol-2-yl radical is of great interest and has been described many times in 
the literature.23 Gribble et al. has successfully used an indol-2-yl radical to generate 
hexahydropyrrolo[3,4-b]indole 79 (scheme 26).24 The bromination ofthe C-2 carbon of indole 
precursor 75 was achieved using the Bergman methodology for N-carboxy-indoles.25 The 
radical cyclisation proceeds via a 1,5 H-abstraction ofthe indol-2-yl radical 76 to create the a-
amidoyl radical 77 which then undergoes a 5-endo-trig cyclisation onto the indole double 
bond to form 78. Reintroduction of the double bond in indole 78 was carried out using DDQ 
to form the fully aromatic indole 79. The reduced indole product 80 was also obtained (42%). 
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00 
-""- }-N Br Bu3SnH, AIBN ~r MePh, reflux 
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~ 
0 fr) 
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Me 
76 
78 
0 
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~0 
77 Me 
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0 
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Scheme 26. 1,5 Radical translocation followed by 5-endo-trig cyclisation to the indole C-2 
position. 
Bennasar has extended the interest of this work by examining the behaviour of 2-indolylacyl 
radicals onto aromatic rings (scheme 27).26 The 2-indolylacyl radical was generated from the 
corresponding seleno esters 81. Crich has reported the use of seleno esters in radical 
chemistry before.27 The 2-indolacyl radical doesn't undergo decarbonylation. This is because 
of stabilization ·provided by the indole core. Cyclisations of the 2-indolylacyl radical was 
limited to the formation ofthe 6-membered ring product 82. Use ofBu3SnH gave rise to only 
reduced product 83 (90%). By using (Bu3Sn)2(0.2 mol%) the yield of indole tetracycle 82 was 
increased (40%), although reduced product 83 (10%) and starting material (25%) were also 
recovered. The desired tetracycle 82 was formed as the sole reaction product (65%) after 
increasing the amount of (Bu3Sn)2 in the reaction to 2.2 mol equivalent %·with respect to 
starting material. 
~ 
~N/ "sePh 
~ hU, benzene 
81 82 
Scheme 27. 2-Indolylacyl radical cyclisation to form indole tetracycle. 
22 
~0 
~N~ 
83 ~ 
Despite considerable effort by Bennasar, the work could not be extended to form 5 or 7-
membered tetracycles from the precursors 84 and 85 (scheme 28). There was no apparent 
reason for these failures.27 
84 
Scheme 28. Failed cyclised starting materials. 
An example of a · spirocyclic heterocycle has already been shown by Bremner and 
Sengpracha's indole cyclisations forming the spirocycle 67 as an unwanted side product 
(scheme 23).20 These spirocyclic indole cores constitute a wide range of natural products. One 
such is mytraginine pseudoindoxyl86 (figure 7). 
86 0 
Figure 7. Spirocyclic indole natural product. 
Baldwin et al. recently investigated radical dearomatisation of indoles and benzofurans to 
access these heterospirocyclic cores in high yield (scheme 29).28 When indole 87a and 
benzofuran 87b were treated with Bu3SnH, the resulting aryl radicals formed the desired ipso-
type spirocyclic indole product 88a and benzofuran 88b in good yield. 
23 
87a, X= NMe 
b,X=O 
Bu3SnH, AIBN, 
benzene, reflux 
then PhSH 0 
88a, X = NMe (89%) 
b, X= 0 (80%) 
Scheme 29. Aryl radical ipso 5-exo-trig cyclisation to reach spirocyclic cores. 
Formation of a stable intermediate benzylic radical on the indole and benzofuran C-3 aided 
formation of the desired products. Bald win then investigated cyclisation of vinyl groups onto 
these systems, an unexpected result appeared. The cyclisation of the indole 89 proceeded well 
although the spirocyclic indole 90 was formed in lower yield than previous aryl analogue 88a 
(scheme 30).28 
89 
Bu3SnH, AIBN 
benzene, reflux 
then PhSH 
0 
90 (41%) 
Scheme 30. Vinyl radical ipso 5-exo-trig cyclisation onto indoles and benzofuran. 
Cyclisation of the benzofuran 91 yielded the unexpected phenol 92 (scheme 31).28 A 
mechanism for this product 92 was proposed involving a fragmentation of the spirocyclic 
intermediate forming a stable phenoxy radical. The authors attribute the difference in the 
reaction pathways of indole 89 and benzofuran 91 to the extra lone pair stability provided by 
the nitrogen in indole. 
24 
benzene, reflux 
then PhSH 
92 (46%} 
Scheme 31. Unexpected phenol product from radical cyclisation. 
Examples of radical cyclisations onto sulphur containing heterocycles have also been carried 
out. For instance Ganguly et al. compared radical cyclisations onto thiophenes, carboxamides, 
furans and in doles to obtain a range of products. 29 Aryl radical cyclisation onto thiophene and 
alkene substituted 93 resulted in the spiro thiophene reduced product 94 (62%) and the 5-exo-
trig product 95 onto the alkene (20%) (scheme 32). This indicated that addition of the radical 
to the vinyl group or thiophene proceeded well, but possible rearrangement to fused aromatic 
compound 96 was unfavourable. 
Scheme 32. Aryl radical cyclisation onto alkene and thiophene. 
~ 
~0 96(0%)~ s 
In the case of cyclisation onto the carboxyamide furan 97 only the spiro reduced furan 
compound 98 was obtained (scheme 33). The spiro furan is formed in similar yield to the 
previous thiophene cyclisation 94, even though there is no competing pendant alkene for the 
radical to cyclise onto.29 
Vci=o 
0 
98 (59%} 
Scheme 33. Aryl radical cyclisation onto furan. 
25 
These results contrast with cyclisations carried out onto indole 99 (scheme 34).29 Here the 
major product was the fused tetracycle compound 100 (47%). Minor products from this 
reaction included the cyclised reduced products 101 (20%) and 102 (16%) as well as the spiro 
compound 103 (8%). 
~~fue 0 
Vl-sr lj I ~ 
N h-
99 Me 
100 (47%} 
102 (16%} 
Scheme 34. Aryl radical cyclisation onto indole. 
101 (20%} 
Heterocycles containing three heteroatoms have also been the subject of investigations by 
radical chemists. Marco-Contelles et al. have made sugar templates using 5-exo-trig radical 
cyclisations onto the triazole 104 (scheme 35).30 The 5-exo-trig cyclisation of the triazole 104 
was only feasible with the activation ofthe triazole with an ester group, yielding the cyclized 
triazole 105 and the reduced triazole 106. 
TTMSS 
AIBN, MePh 
104 
-CO and EtH 
105 (14%} 
Scheme 35. 5-Membered ring radical cyclisations onto triazole. 
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106 (33%} 
In the case of 6-exo-trig cyclisation of the triazole 107 no activation was required (scheme 
36). 6-Exo-trig cyclisation was found to be more favourable than 5-exo-trig ones. Here higher 
yields of the cyclised triazole 108 were recovered over the reduced triazole 109 (the yields for 
this reaction were based on hydrolysis ofthe AcO group) . 
. P+ 
Ac" H ... t_)····O 
~-~ --------~ 
Br 11 \ N_j' 
TT MSS 
AIBN, MePh 
107 
HO 
N, 
N ~ IJ N 
108 (48%) 
Scheme 36. 6-Membered ring radical cyclisation onto triazole. 
Chemists have often turned to radical methodology when other synthetic methods have failed, 
without the need to alter precursors. When a key Heck reaction of the aryl iodide 110 could 
only be carried out in poor yield, Cossy et al. quickly altered their strategy towards (±)-y-
lycorane by using radical methodology (scheme 37).31 Although the final 6-exo-trig radical 
cyclisation was achieved in o.nly a modest yield to (±)-y-lycorane template 112 (30%) it was 
higher than previous palladium Heck conditions. Reduced compound 111 was also recovered 
from the reaction. 
<0~8 0~ H~ H 
111 (25%) ~ 
benzene, reflux, 5 h 
110 H 
112 (30%) 
Scheme 37. Synthesis of(±)-y-lycorane using an unplanned radical cyclisation. 
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Formation of a radical on a heteroatom can be very advantageous in organic synthesis. In the 
synthesis of (±)-y-lycorane Cossy also used a 5-exo-trig aminyl radical cyclisation to form the 
octahydro indole 114 from aminyl chloride 113 in the syntheses (scheme 38). 
CuCI/CuCI2 Ha~) 
-uCI 
113 114 (75%) 
Scheme 38. Aminyl radical cyclisation. 
Steric bulk can play an important role in the formation of products under radical cyclisations 
(shown in Jones work scheme 14).14 Orito et al. have shown how a favourable 6-endo 
cyclisation can be made to undergo the less favourable 5-endo radical cyclisation (scheme 39) 
by the use of steric bulk.32 With 3,4-dihydroisoquinoline 115 the effect of two neighbouring 
methoxy groups resulted in just one product 5,6-dihydroindolo[2,1-a]-isoquinoline 116. 
OMe 
M eO 
Bu3SnH, AIBN 
MePh, reflux, 4 h 
M eO 
Br H 
115 116 (68%) 
Scheme 39. Use ofsteric bulk to form the unfavoured 5-endo product. 
By removal of one of these methoxy groups 117 two products were achieved, the fully 
rearomatised 6a,7-dehydroaporphine 118 resulted via a 6-endo cyclisation and a small amount 
of 5,6-dihydroindolo[2,1-a]-isoquinoline 116 was obtained (scheme 40).32 Examples of such 
unfavoured 5-endo radical cyclisations onto nitrogen atoms of a CN double bond have been 
reported before, although rare.33 
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OMe 
OMe 
Bu3SnH, AIBN M eO 
M eO + 116 (3%) 
MePh, reflux, 4 h 
M eO 
H 
Br 117 118 (62%) 
Scheme 40. Removal of steric bulk to give two radical cyclisation products. 
Heterocycles containing 7 -memebered rings have also been formed by radical cyclisation 
reactions. Nadin et al. have shown 5, 6 and 7-membered ring formation oftricyclic pyridones 
(scheme 41).34 The yields oftricyclic 120 appeared to be remarkably independent of ring size. 
Unfortunately this work could not be carried out using the alkyl radical analogues of 119. 
This could be attributed to the greater drive to rearomatise by aryl radicals. 
benzene 
o s:) ~<tN~N lY~cBr ~ N r 
OBn 
119 
Scheme 41. 5-,6- and 7-membered ring formation. 
120 n = 1 (37%) 
= 2 (35%) 
= 3 (50%) 
The ability to form several bonds in one step has attracted synthetic chemists to cascade 
reactions for a long time. There are numerous examples where cascade reactions have been 
carried out using radical cyclisations. One such example is the synthesis of the natural product 
(S)-mappicine 123 (scheme 42) by Curran et al. The key radical reaction involved a [4+1] 
cascade reaction of isonitrile 121 and bromo pyridone 122.35 This is a rare example in radical 
cascade chemistry, as the initial step is inter-molecular. The addition onto the isonitrile has 
been utilized by Curran for several other notable natural product syntheses including the 
anticancer agent camptothesin.35 Interestingly, when the reaction was carried out using a 
ketone (in place of the hydroxy group) on bromopyridone 122 the reaction yield was lower. 
29 
OH 
121 122 123 (38%) 
Hd 
Scheme 42. Curran's synthesis of (S)-mappicine. 
Nanni et al. have carried out the synthesis of cyclpentaquinoxaline 126 using a radical 
cascade reaction (scheme 43).36 Alkyl iodide 124 and biphenyl isonitriles 125 were found to 
cyclise using (Me3Sn)2 to form cyclopentaquinoxaline 126. The associated amine 127 was 
also isolated from the reaction. 
NC 
9 I~CN 9 hu, (Me3Sn)2, Ph'(XND ~I ..-:;. + t-BuPh N 
Ph Ph 
124 125 126 (50%) 127 
Scheme 43. Nanni's cyclopentaquinoxaline formation. 
The formation of amine 127 is not obvious. It is postulated that intermediate imidoyl radical 
128 (arising from electron then proton transfer) picks up a radical species and then hydrolyses 
to the amine 127 (scheme 44).36 
Ph'CC· ,'. N~ 
l, ~ -~- N ·Q Ph"(:(·': ND l , ..-:;. -~- N Q 
Q Ph 
127 
125 Ph 
Hydrolysis Ph~ X 
~~ N H 
XYor X• 
Scheme 44. Possible mechanism of amine formation. 
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Bowman et al. has also used a radical cascade reaction in the total synthesis of ellipticine 135 
(scheme 45).37 The key radical intermediate was the imidoyl radical 130. This was generated 
from the imidoyl selenide 129, which is stable and easy to handle. The imidoyl radical firstly 
undergoes a 5-exo-dig cyclisation to form the alkenyl radical 131. This radical may then 
proceed either by a 5-ipso-trig cyclisation to form spiro intermediate 133 followed by neophyl 
rearrangement reaction or a 6-endo-trig cyclisation to form intermediate 132. Both routes lead 
to the tetracycle intermediate 134. On tautomerism this leads to ellipticine 135. The 
mechanism ofH-abstraction has previously been discussed (section 1.8). 
129 
134 
131 
neophyl 
rearrangement 
ellipticine 
(61%) 
Scheme 45. Radical cascade synthesis of ellipticine. 
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1.10 Introduction to quinazolines and quinazolinones 
We are interested in developing and testing radical methodology to form 2,3-cyclised-3H-
quinazolin-4-ones 18 (figure 8). 3H-Quinazolin-4-ones 136 comprise of a 3H-pyramidin-4-
one (A) ring and fully aromatic benzene (B) ring. It closely relates to quinazoline 137, which 
also appear in many natural products and pharmaceutical drugs substitution. While it can be 
said that the A ring of a quinazoline is fully aromatic, the same cannot be said of 3H-
quinazolin-4-ones. During the course of our studies we have found few examples of radical 
methodology being employed in the synthesis of quinazolines or quinazolinones. We 
therefore feel our investigations are timely. Syntheses of quinazolines and quinazolinones 
have recently been reviewed by Guiry.38 
18 
Figure 8. 3H- Quinazolin-4-ones and quinazoline structures. 
Both 3H-quinazolin-4-ones and quinazolines have shown a vast array of biological activitY 
over the years.39 The 2,3-disubstistuted-3H-quinazolin-4-one skeleton therefore, has become 
particular interest, and provides a rich source of synthetic targets. Herein, we concentrate on 
the chemistry of quinazolines and quinazolinones. 
The 3H-quinazolin-4-one moiety has been extensively used as a drug like scaffold in 
medicinal chemistry and is therefore, considered 'privileged' .39 The term 'privileged' was first 
coined by Evans et al. in 1988 and was defined as " a single molecular framework able to 
provide ligands for diverse receptors".40 
The rich variety of quinazoline drugs stem from the countless natural products that contain the 
quinazoline moiety. The chemistry of recently isolated naturally occurring quinazolinones has 
been reviewed by Mhaske and Argade.41 One of the earliest isolated quinazoline natural 
products was vasicine 138. It was first isolated by Hooper in 1888, from Adhatoda vasica (an 
Indian plant) and the seeds of Pegnum harmala. It is unsaturated at the C-4 position of the 
quinazoline (figure 9).42 Febrifugine 139 (first fully characterised by Koepfli et al.) was one 
of the first 3H-quinazolin-4-ones to be isolated.43 Contained within the powdered root of 
32 
Dichroa febrifuga, which had a long history of being used in Chinese medicines such as 
Ch'ang Shan. Febrifugine and was shown to possess anti-malarial properties.43 
0 HQ 
ex) ![X) 
(+)-vasicine 138 (+)-febrifugine 139 
Figure 9. Early quinazoline and quinazolinone natural products. 
A large amount of structural diversity is seen in quinazoline natural products, dictoquinazol B 
140 (figure 10), for instance, contains the unusual N-formyl substituents at the N-1 position, 
and the rare 1,2,3,4-tetrahydroquinazoline moiety.44 The continual discovery of new 
quinazolinones is highlighted by discovery in 2005 of complex plant metabolite lapatins A 
141.45 
dictoquinazol B 140 
d:ON ~ N 
HN Me·~~N 
0 lapatins A 141 
Figure 10. Unusual quinazoline and quinazolinone natural products. 
Indeed, some structures are so complex they have yet to be fully synthesized. Hinckdentine A 
142, is such a structure. Synthetic routes to hinckdentine A have been reviewed by 
McWhorter Jr (figure 11).46 One ofthe most powerful and famous non-protein neurotoxins in 
the world, tetrodotoxin 143, is worth mentioning here. It is famous for being found in the 
ovaries of the Japanese puffer fish Sphoerides rubripes and S. phyreus as well as the 
Californian salamander Taricha torosa.47 Stripped of its hydroxy and ether bridges it is a fully 
saturated 2-amino substituted quinazoline. 
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Figure 11. Other natural products containing the quinazolinone and quinazoline skeleton. 
The total synthesis of 3H-quinazolin-4-one natural products luotonin A 144, rutaecarpine 145, 
tryptanthrin 146, deoxyvasicinone 147 and mackinazolinone 148 and will be discussed in 
more detail later in this thesis (figure 12). 
cCON ~ N 
luotonin A 144 
d.:xP 
tryptanthrin 146 0 
~N U~.~ N 
deoxyvasicinone 147 
Figure 12. 3H-quinazolin-4-one natural product targets. 
mackinazolinone 148 
So far, only natural products have been discussed. There are also a myriad of pharmaceutical 
drugs available and in clinical trials containing the 3H-quinazolin-4-one core skeleton (figure 
13). Raltitrexed 149 (Tomudex®), is substituted at the C-2 and C-6 (on the B ring), and is 
marketed as a colorectal cancer treatment.48 lspinesib 150, is substituted at C-2 and N-3, and 
is currently in nine different phase two clinical trials for various cancers.49 
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Figure 13. Quinazolin-4-one containing drugs. 
Di-keto quinazolines such as Kentanserin 151 (figure 14), have found applications as selective 
serotonin receptor antagonist. 50 Quinazolinones such as Quinethazone 152, are used as 
diuretics and contains the thiazide functional group at C-6 (on the Bring). 51 
0 
~N~N 
~~.A ~ 0 Kentanserin 151 
Figure 14. More quinazolinone and quinazoline drugs of interest. 
The drug Tempostatin™ 153 (figure 15), is in phase II clinical trials for bladder, liver and 
others cancers.52 Tempostatin™ 153 bears a remarkable structural similarity with febrifugine 
139 (figure 9). The side arm of febrifugine has been moved from the N-3 position to the C-2 
position in Tempostatin™. The generic drug methaqualone 154 (Revonal®) has been 
available since the 1960's as a sedative. 53 Its biological activity should not be surprising given 
its structural similarities to barbiturates which, are largely pyramidinone in structure. 
0 
CI~~H g'iO•,,,(l 
BrAAN~~,) 
Tempostatin 153 
Figure 15. Other quinazolinone containing drugs. 
35 
0~ ce1~ 
N Me 
Methaqualone 154 
Another common functional group found attached to quinazolines is the amino group. 
Prazosin 155 (figure 16), which is used to lower high blood pressure, is a di-amino substituted 
quinazoline.54 Gefitinib 156, which is a new class of lung cancer treatment drugs and is only a 
mono-amino substituted quinazoline.55 
NH2 
MeO ~ '-'N 
~I A 
~N 0 
Prazosin 155 0 
Figure 16. 4-Amino substituted quinazoline drugs. 
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Gefitinib 156 
It is the vast collection of drugs and natural products that has caught our imagination. We 
want further expand the interest within the field of 3H-quinazolin-4-ones by carrying out 
further investigations into the field. 
1.11 Biosynthesis of quinazolines and quinazolinones 
Natural products containing the quinazolin-4-one moiety are most likely all derived from the 
amino acid anthranilic acid, which is a product of the shikimic acid pathway. This pathway 
also provides routes to other amino acids and heterocyclic compounds. Solely 
microorganisms and plants carry it out. 56 Thus it is no surprise that the amino acids derived 
from this sequence are considered essential to humans. There are very few studies reported for 
the biosynthesis of quinazolinones natural products. As mentioned those that do exist all 
derive from anthranilic acid, whose biosynthesis will now be discussed. 
The shikimic acid pathway begins with the coupling of phosphoenol pyruvate 157 (PEPA) 
and D-erythrose 4-phosphate 158 (E4P) producing the seven carbon compound D-arabino-
heptulosonic acid 7-phosphate 159 (DAHP) (scheme 46).57 Although at first glance this 
reaction appears to be an aldol type condensation, the enzyme catalysed mechanism is known 
to be more complex. The first carbocyclic structure 3-dehydroquinic acid 161 is formed after 
elimination of the phosphoric acid from DAHP, yielding intermediate 160 which then 
undergoes an intramolecular aldol type reaction to form 3-dehydroquinic acid 161. Again, this 
mechanism is more complex than stated. It is known NAD+ plays a key role in the oxidation 
of the central hydroxyl group. A single enzyme controls all these changes. Dehydration of 3-
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dehydroquinic acid 161 leads to 3-dehydroshikimic acid 162, which is then reduced leading to 
shikimic acid 163. 
COzH 
~~ 157 p:k'I-
HO' : 0 W 
158 OH 
C02H 
HO')::iOH 
OH 
163 
C02H -::::;N;::AD=P=H~ ii -H,O 
0 - OH 
OH 
162 
Scheme 46. Biosynthesis of shikimic acid. 
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DH 
0 - OH 
OH 
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A key intermediate from the shikimic acid pathway is chorismic acid 167 (scheme 47).57 
When shikimic acid 163 is phosphorylated by ATP 164, it then reacts with PEPA via an 
addition reaction forming intermediate 165. This is followed by a 1,2-elimination reaction of 
phosphoric acid yielding 3-enolpyruvylshikimic acid 3-phosphate (EPSP) 166. The enzyme 
EPSP synthase, catalyses this reaction. 1,4-Elimination of phosphoric acid ofEPSP then leads 
to chorismic acid 167. Chorismic acid can then be further transformed to a number of amino 
acids such as L-phenylalanine and L-tyrosine .. 
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Scheme 47. Biosynthesis to chorismic acid. 
-HOP 
When glutamine acts to aminate at the C-2 position of chorismic acid, 167, 2-amino-2-deoxy-
isochorismic acid 168 is formed (scheme 48).57 Elimination then leads to the formation of 
anthranilic acid 169. This is the key intermediate to the formation of quinazolinone natural 
products, the amino acid L-tryptophan and other related indole alkaloids. 
C02H 
Ci:lco,:-
168 
J::NHz 
u 
169 
' 
' , ' 
1 ~ 
L-Trp 
Quinazoline alkaloids 
Scheme 48. Final biosynthesis steps to anthranilic acid. 
The exact biosynthesis of quinazoline alkaloids varies and not many have been studied in 
great detail. The proposed biosynthesis ofthe bronchodilator vasicine 138 (already shown in 
figure 9) is shown (scheme 49).56 The anthranilate nitrogen of anthraniloyl-CoA 170 
undergoes nucleophilic attack of the pyrrolinium cation derived from L-omithine which is 
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followed by amide formation 171 to form tricycle 172. Vasicine 138 is found in the Peganum 
harmala plant and this proposed biosynthesis is specific to this species only.56 
C(OSCoA 
NH2 
170 ______./ 
- ~0-c(n 
171 HNjJ : H 172 
I 
' ~C02H 
HzN ----~-H-- NHz 
L-Omithine OCL< 
138 OH 
Scheme 49. Biosynthesis ofvasicine. 
Yamazaki et al. has reported a possible biosynthesis of rutaecarpine 145 (already shown in 
figure 12) and its analogue evodiamine 174 (scheme 50).58 Using feeding experiments with 
radio-labelled 14C-tryptophan, sodium 14C-formate (or methionine) and anthranilic acid, 
Yamazaki showed all three units to be fully incorporated into the Evodia rutaecarpa plant. 
The 3,4-dihydro-p-carboline intermediate 173 has not been proven. Yamazaki showed that 
position 13-b ofboth rutaecarpine and evodiamine come from the incorporation of formate or 
methionine. Incorporation of this unit into evodiamine was slower than for rutaecarpine 145 
and so the suggestion is that evodiamine 174 is not formed as result of N-methylation of 
rutaecarpine. 
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Scheme 50. Rutaecarpine and evodiamine biosynthesis. 
Takagi has also argued a role for N-methylamino acid 175 in the biosynthesis of evodiamine 
174 (scheme 51 ).59 It seems possible this could be derived from methylation of anthranilic 
acid 169. This could not be proven but provides an answer into how the nitrogen is 
methylated in evodiamine 174. 
oc:::~---- r oc::H 1 ------
0 
o=hb 
169 175 174 
Scheme 51. Alternative route to evodiamine. 
It has also been noted that 7-carboxyevodiamine 177 but not 7-carboxyrutaecarpine 176 have 
been isolated from Evodia rutaecarpa (figure 17).59 There is still much work to be done in 
this field to fully understand the biosynthesis of rutaecarpine 145 and other quinazolinone 
natural products. 
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Figure 17. Other isolated rutaecarpine and evodiamine analogues. 
1.12 Synthetic developments in quinazoline and quinazolinone chemistry 
There is an expanding interest in quinazolines and quinazolinones and thus, new synthetic 
methodology is growing rapidly in this field. Some of these novel approaches to quinazoline 
and quinazolinone synthesis are now discussed. 
Bergman et al. recently demonstrated a novel rhodium(!) catalysed route involving 
unactivated alkene additions to 3,4-dihydroquinazolines (scheme 52).60 Both inter and 
intramolecular couplings from similar heterocycles 178 had been previously carried out by the 
group. It was proposed that the reaction proceeds via a catalytic-substrate, complexed with the 
aromatic heterocycle 179. This could occur through rhodium acting as a N-heterocyclic 
carbine ligand. Once the alkene is complexed to the Rh, heterocyclic coupling to the alkene 
180 can occur. 
41-90% 
180 
Scheme 52. Rhodium(!) catalysis route to quinazolines. 
By coupling the 3,4-dihydroquinazoline 181 with a range of alkenes, quinazoline products 
like 182 were formed in good yield (scheme 53). An oxidative workup using Mn02 was 
required. 
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1. 2.5 mol% [RhCI(coe)2]2 
4 mol% PCy3.2HCI 
2.5 mol% PCy3 
2. Mn02, benzene, reflux 
Scheme 53. Alkene coupling onto quinazoline using rhodium. 
The intramolecular reaction of quinazoline 183 underwent Rh(I) cyclisation to tricyclic 
quinazoline 185 in good yield (scheme 54). Further elaboration of this product then lead to the 
natural product vasicoline 186. 
COlL~ 
N _)-_) 
· 183 Cl 
~ 
184 
[RhCI(coe)2]2 5 mol% 
18415 mol% 
Scheme 54. Intramolecular alkene coupling to vasicoline. 
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Couture et al. have used nitriles and lithiated 2-aminobenzamides to form 2-aryl and 2-
alkylquinazolin-4-ones 189 (scheme 55).61 It was shown that anthranilamide 187 forms the 
lithium 2-( diethylaminocarbonyl)anilide 188 species which reacts rapidly with the appropriate 
nitrile. Even for alkyl nitriles containing an acidic a-proton, conversion was good. One may 
have expected that an acidic a-proton could undergo a reaction with the lithium intermediate. 
Couture demonstrated a large range of alkyl and aryl nitrites were compatible with this 
reaction and so allows a very simple route to 2-aryl and 2-alkylquinazolin-4-ones 189. 
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Scheme 55. Use oflithiated 2-aminobenzamides in quinazolinone synthesis. 
Kundu and Chaudhuri have developed a very mild method using copper catalysis in synthesis 
ofC-2 substituted quinazolinones (scheme 56).62 The terminal alkyne 190 was initially reacted 
with aryl iodides under Sonogashira-Hagihara c~nditions to yield the alkyne 191. The 
substituted alkyne 191 then underwent a highly regia and stereo selective reaction in the 
presence of Cui, K2C03 and n-Bu4NBr in acetonitrile to yield the quinazolinone 193. E-
Stereochemistry was observed at the vinylic group. The proposed Cui mechanism suggests 
the alkyne 191 can rearrange to form the allene 192. Attack by the amide nitrogen then leads 
to ring closure. 
~~/ Art, (PPh3)PdCI2, 
lAN~ Cui, Et3N, MeCN, rt 
19o I ~ 
~N/ 
UN~Ar 
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o N/ 
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Scheme 56. Palladium/copper catalysed cyclisation quinazolinone synthesis. 
Larksarp and Alper have developed a Pd system for the carbonylation of the o-iodoanilines 
194 (scheme 57).63 Under an atmosphere of CO, the carbodiimide 195 and the ketenimine 196 
were found to react with o-iodoanilines to form either the 2-amino quinazolinones 197 or the 
2-alkyl quinazolinones 198. The reaction tolerated hydroxy and nitrile groups on the o-
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iodoaniline 194 (R1), but not electron donating groups. There was found to be some sensitivity 
issues regarding the substitution of carbodiimide 195 ketenimine 196. 
0 0 R~ R4 Rul R~ R5 :I ~~R' i. I~ i. ::?' N..-R4 ~ NH2 Rs ~I ~ R5 N..- N..- N N..-
R21R3 ~ 
H 
198 (98%) R2 194 197•(63%) 
S"N R 
196 195 
Scheme 57. Palladium catalysed cyclocarbonylation to quit;tazolinones; i) CO, Pd(OAc)z, 
dppf, THF, KzC03, 100 °C. 
A mechanism was proposed for the reaction of the carbodiimide 195 and can easily be 
considered analogous for the ketenimine 196 (scheme 58}.63 Initially the o-iodoaniline 194 
and the carbodiimide 195 form the guanidine intermediate 199. Analogously in the case ofthe 
reaction with ketenimine 196 one of two amidine intermediates can be formed. Oxidative 
addition of Pd(O) to the C-1 bond gives the intermediate palladium complex 200. Insertion of 
carbon monoxide and coordination ofNHPh could give rise to the palladium carbocycle 202. 
This could be followed by reductive elimination forming the 2-imine quinazolinone 202. 
which could rearrange to the more stable 2-amino quinazolinone 197. 
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Scheme 58. Proposed catalytic cycle for Pd(O) formation of quinazolinones. 
The intramolecular aza-Staudinger-Wittig reaction has lent itself well to heterocyclic 
synthesis.64 Eguchi et al. have increased the scope of this reaction by applying it in 
quinazolinone synthesis (scheme 59).65 From condensation of o-azid~benzoyl chloride 203 
with a lactam, Eguchi formed the key azide intermediate 204. The intramolecular aza-
Staudinger-Wittig reaction was carried out using tri-n-butylphosphine. The silyl protected /-
vasicinone quinazolinone 205 was obtained in excellent yield. 
203 
O~OTBDMS O O~OTBDMS 
HN~ (Si~ n-Bu3P, MePh 
NaH, THF 1 '\:: N3 reflux 
-- 204 (83%) 
~JJ 
20S (?6%) OTBDMS 
Scheme 59. Aza-Staudinger-Wittig route to /-vasicinone quinazolinone. 
Hetero Diels Alder approaches to quinazolinones have been carried out by Croce et al. 
(scheme 60).66 The yields of 2-substituted quinazolinones such as 210 were good for a range 
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of the dienes 206. The presence of the electron rich dimethyl amino group on the diene 206 
was crucial in facilitating the elimination of the N,N-dimethylformamidine 207 as a side 
product by destabilizing the cycloaddition adduct. The authors recognised the mechanism of 
this reaction could proceeds via an initial [2+2] cycloaddition instead of the [4+2] routes. 
Either route can go through a 4-membered ring· diazidinone 208 which could open up to the 
imidoylisocyanates 209. These are well known to thermally cyclise to form quinazolinones. 
Ph 
'NJ N \ 1 R Me N-<\-o-
I 206 \\ 11 
[2/ Me + ~[4+2] 
Ph N=C=O ptf 
Me Ph reflux, 4 days 
210 R = H, (84%} 
=Me, (88%} 
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H N~ 
Me ~ N-Ar 
'N Nq 
Me,.... ptf 0 
Scheme 60. Diels Alder approach to quinazolinone products. 
Simple thermolysis of the benzotriazin-4-ones 211 has been used by Smalley et al. in the 
synthesis of the 2-arylquinazolinones 214 (scheme 61 ).67 During the thermolysis of 
benzotriazin-4-ones loss of nitrogen is observed followed by a 1,3-hydrogen shift in the 
intermediate 212 with the loss of aryl cyanide. The aryl cyanide then participates in a [4+2] 
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cycloaddition of the imino ketene 213. The reaction tolerated a wide range of substituted aryl 
substituents in good yield. 
3oo ·c 
214 R =(56%) 
M eO~ 
lA 
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Scheme 61. [4+2] Cycloaddition route to quinazolinones from benzotriazin-4-ones. 
A number of synthetic strategies to quinazolinone can be started from anthranilic acid 169. 
Much of this work was started in the 1960's by Re id et al. 68 Continuation of this work has 
been carried out by Guiry et al. who successfully reacted a range of alkyl and aryl imidates 
with anthranilic acid to form the 2-substituted quinazolinones 215 in good yield (scheme 
62).69 The imidates were prepared by reacting nitrites with gaseous HCl in MeOH. These 
imidate salts were then neutralized by an equivalent of base. Although not high yielding this 
route allows access to rapid synthesis of simple quinazolinone from cheap starting materials. 
169 
MeOH, 
1. 25 ·c. 30 min 
2. so ·c 6 h cCO NH A N R 
215 R =Me, (42%) 
=Ph, (46%) 
Scheme 62. Imidate condensation with anthranilic acid to form quinazolinones. 
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1.13 Conclusion 
This introduction has covered a variety of chemistry. An overview into radical reactions and 
the types of reagents commonly used have been shown. This has been followed by a review 
of some notable radical cyclisations to form heterocycles, some of which can be described as 
aromatic homolytic substitution reaction. A summary of common quinazoline and 
quinazolinone natural products and drugs has been followed by a discussion of the 
biosynthesis of some of these natural products. Finally time has been taken to demonstrate 
some of the other approaches chemists have used to quinazolinone and quinazoline synthesis. 
1.14 Project Objective 
Heterocyclic syntheses have been of great interest for many years to organic chemists. Many 
different heterocyclic systems are seen within n'atural product compounds isolated from plants 
and animal species. The pharmaceutical industries rely on seeking inspiration from such 
natural products to develop new drug candidates. Some heterocyclic systems are considered 
"privileged" because of their ability to bind to many types of receptor sites in the human 
body. One such "privileged" heterocyclic structure is the 3H-quinazolin-4-one system. There 
are a great number of natural products that contain this moiety. To date there are only 
sporadic reports of free radical chemistry being employed as a synthetic tool in the syntheses 
of such natural products. 
The aim was to develop a new synthetic methodology to apply to the syntheses of our chosen 
quinazolinone natural product targets. We have attempted and completed the synthesis of a 
number of biologically active 3H-quinazolin-4-one targets via radical chemistry. The 
feasibility of radical cyclisation onto the C-2 position of the quinazolinone template was 
tested, and used as the basis for this work. Determination of mechanisms of these radical 
reactions has been carried out. Where possible non-tin radical reagents were used to avoid the 
toxicity and purification issues surrounding tin reagents. 
Pharmaceutical companies are particularly interested in heterocyclic building blocks, as they 
can apply combinatorial chemical methods to access new compound libraries. We were keen 
to make use of a C-2 indole radical building block of which there are reports in the literature. 
We also felt preparation of a C-2 radical quinazolinone building block would be of much 
interest. At our initial outset, there were no reports in the literature of C-2 radical 
quinazolinone building blocks. We hoped this work would open a new door to the syntheses 
of many quinazolinone natural products using radical or palladium chemistry. 
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Chapter 2. Aryl and Alkyl radical cyclisations onto 3H-quinazolin-4-
one 
In this chapter work describing investigations of aryl radical cyclisations onto the 3H-
quinazolinone moiety are presented. This will be followed by a discussion of alkyl 
radical cyclisations carried out which led to the synthesis of the two quinazolinone 
natural products deoxyvasicinone and mackinazolinone. A brief introduction to each . 
natural product is given. Unsuccessful cyclisations of organometallic species onto the 
3H-quinazolin-4-one template are also shown. 
2.1 Aryl radical cyclisations onto 3H-quinazolin-4-one 
Before undertaking the synthesis of the quinazolin-4-one derived natural products, 
investigation of simple aryl radical cyclisations onto the C-2 position of 3H-
quinazolin-4-one was carried out. It was hoped to rapidly access quinazolinone 
tetracycles 216 (scheme 63). The first aim was to learn more about the reactivity of 
aryl radicals 217 towards the commercially available 3H-quinazolin-4-one 219. The 
required aryl building blocks 218 had been prepared previously.70 A number of 
examples using these building blocks in aryl radical cyclisations are detailed in the 
introduction. This work ahs now been extended. 
ciJD~o6:o~ 
216 217 
o6H 
N 
219 
X~ X~ 
218 
Scheme 63. Retrosynthesis of quinazolinones 216 using aryl radical cyclisations. 
The first concern was to avoid the competition between 0- and N-alkylation and to 
develop a methodology to obtain selective alkylation onto the N-3 position of the 3H-
quinazolin-4-one 219 to yield quinazolinone 220 and not quinazolinone 221. 
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Alkylation on N-1 is possible but there are few reports indicating that this regioisomer 
is favourable. Previous work has shown that alkylations of pyridinone 222 yielded a-
substituted pyridinones 224 and N-substituted pyridinones 223 (scheme 64).71 It was 
unclear whether this problem would be encountered for the alkylation of 3H-
quinazolin-4-one 219. 
clJ~R 
N 
220 
5NH 
~CN 
222 
Base 
5N~R 
ll;lCN 
223 
Scheme 64. Pyridinone alkylation problems. 
224 
Alkylation of quinazolinones has been carried out in one-pot using lithiu!ll bromide, 
dry ethylene glycol dimethyl ether and NaH in DMF.72 Reports in the literature 
suggest that under these conditions, lithium can chelate to the oxygen atom, hence 
directing the alkylation towards N-3.72 The ethylene glycol dimethyl ether can bind to 
the lithium, increasing the steric hindrance, which should favour the alkylation onto 
N-3. Using these conditions, methylation of 3H-quinazolin-4-one 219 (scheme 65) 
gave 3-methyl-3H-quinazolin-4-one 225. Yields for 3H-quinazolin-4-one alkylation 
reported in the literature are rarely greater than 60%. 
d:O NH Mel, NaH, LiBr ) DME,DMF N 
219 
Scheme 65. 
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Difficulties were encountered in distinguishing whether alkylation had taken place on 
the nitrogen or the oxygen atom using standard NMR spectroscopic techniques. In 
theory, the IR spectrum of the final product should have shown the disappearance of 
the NH bond in the wavelength range of::::: 3000 cm·1• However, the NH and OH bond 
wavelengths in the IR spectrum of the starting material were close, and therefore it 
was not distinguishable which heteroatom was alkylated in the product. A NOE NMR 
spectroscopic experiment was carried out. The three hydrogen atoms (Hb) on the 
methyl group of quinazolinone 225 were irradiated and a slight change in intensity 
was noticed for the signal ofthe hydrogen atom on the C-2 position (Ha) of3-methyl-
3H-quinazolin-4-one 225 suggesting that the product was alkylated at N-3. 
The alkylation reaction using cinnamyl bromide was carried out and quinazolinone 
226 was obtained (scheme 66). A similar 1H NMR spectroscopic experiment was 
carried out to prove the structure. The alkylation of N-1 can be ruled out. Previous 
work has shown that if alkylation occurs on N-1 there is a strong NOE correlation 
between the CH2 hydrogen atoms and the hydrogen atom at C-8 227 (figure 18).73 
Analysis of the NOE spectra of quinazolinones 225 and 226 showed no such 
correlation. The synthesis of quinazolinone 227 was undertaken by an alternative 
route involving ring synthesis to rule out the formation of side reaction products from 
the radical cascade approach to luotonin A (scheme 93). 
Scheme 66. 
Figure 18. 
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The use of t-BuOK as a base was reported to give selective alkylation onto N-3 of3H-
quinazolin-4-one 219.74 This procedure did not require any additional reagents such as 
LiBr. The alkylation was carried out using methyl iodide and 3-methyl-3H-
quinazolin-4-one, 225 was obtained in good yield (scheme 67). The 0-alkylated 
product was also isolated in a low yield (less than 5%). As a result, it was chosen to 
use the latter method instead ofthe previously described lithium bromide reaction. 
cr>H 
219 
Scheme 67. 
t-BuOK, Mel 
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Attention was then turned to the synthesis of the first aryl radical precursors (scheme 
68). Alkylation of3H-quinazolin-4-one 219 using 2-iodobenzyl bromide proceeded in 
good yield giving the desired quinazolinone 228. 
~NH 1-BuOK, DMF lJl~.) N Br'))~ 
219 
I h-
oO')) 
N I 
228 {63%) 
Scheme 68. Synthesis ofthe aryl radical precursor. 
In order to prepare the six-membered ring precursor 231, 2-(2-bromophenyl)ethanol 
229 was converted to the mesylate 230 (scheme 69). However, alkylation of the 
quinazolinone 219 using the mesylate 230 did not proceed in as high a yield as the 
synthesis of the quinazolinone 228. 
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Scheme 69. 
The initial radical investigations began with the quinazolinone 228. The radical 
cyclisations were investigated using Bu3SnH and a range of initiators (table 3). No 
traces of the desired five-membered cyclised quinazolinone 233 were observed and 
the only product isolated was the reduced quinazolinone 232. 
Table 3. Radical reactions of quinazolinone 228 with Bu3SnH. 
d;J~ 
N I 
radical 
Me Ph 
~N~~7~ ~)V~~~ 
228 
Initiator (equiv.) 
Et3B (0.1) 
Et3B (0.1) 
AIBN (2.0) 
232 233 
Radical reagent (equiv.) 
Bu3SnH (fast) (2.0) 
Bu3SnH (slow) (2.0) 
Bu3SnH (slow) (2.0) 
Reflux 
No 
No 
Yes 
Product 
232 (96%) 
232 (30%) 
232 (45%) 
Initially, triethylborane was chosen as the initiator. The advantages of triethylborane 
over AIBN have already been described previously.6 When triethylborane is used, the 
solvent was purged for 30 min with nitrogen to remove any traces of oxygen. Once 
the triethylborane is added, a needle was placed through the septum on the flask and 
atmospheric oxygen allowed to re-enter. It is not known how quickly the 
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triethylborane is consumed in these reactions. This depends on the rate of diffusion of 
oxygen through the needle into the vessel. In an attempt to slow down the rate of the 
ethyl radical generation from triethylborane, cotton wool was placed in the needle 
head. During the course of the work, additional triethylborane was added to radical 
reactions at different time intervals. The reaction mixtures were purged for 30 min 
with nitrogen before additional triethylborane was added, to remove unwanted oxygen 
which had re-entered the reaction vessel. 
These results show that the rate of H-abstraction (kH) by the intermediate aryl radical 
from Bu3SnH is faster than the rate of cyclisation (keyc). Hydrogen atom is most likely 
extracted from Bu3SnH, however a possible explanation for the lack of cyclisation 
was that a 1,5-hydrogen shift could be occurring in radical234 (scheme 70). If a 1,5-
hydrogen shift had taken place, to form the radical 235 this radical could then have 
abstracted a hydrogen atom from Bu3SnH or another molecule within the reaction 
mixture. 
235 
Scheme 70. Possible 1,5-H abstraction. 
In order to determine whether this 1,5-hydrogen shift was taking place, a simple 
experiment was devised. The quinazolinone 228 was treated with Bu3SnD in place of 
Bu3SnH (scheme 71). The 1H NMR spectrum showed that the hydrogen atom on the 
C-2 position of the quinazolinone 228 was still present on the reduced product (as 
were the CH2 protons). It therefore appeared as though the intermediate radical 234 
had abstracted a deuterium atom from Bu3SnD. We hoped that the 13C NMR spectrum 
of the quinazolinone 236 would indicate a triplet for the carbon bearing the deuterium 
atom. However, even after increasing the number of scans for the 13C NMR analysis, 
this triplet was not detected. Mass spectral analysis confirmed the formation of the 
quinazolinone 236. The major benzyl ion produced had an increased mass of 92, 
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indicating a deuterium atom replacing a hydrogen atom on this fragment. This 
experiment eliminated the possibility of a 1,5-hydrogen shift (scheme 70). 
toluene 
236 
Scheme 71. 
Once it had been established that kH>>kcyc, it was chosen to use reagents where the 
rate of hydrogen abstraction would be lower than that for Bu3SnH. The first reagent 
used was TTMSS, which is a poorer H-donor than Bu3SnH. Again, triethylborane was 
used as the initiator. However, only the reduced quinazolinone 232 (35%) was 
isolated, although GC-MS did reveal a trace amount of a compound with a molecular 
ion corresponding to the cyclised product. 
To minimise the opportunity for the intermediate phenyl radical to abstract a 
hydrogen atom, it was decided to use hexamethylditin [(Me3Sn)2]. The proposed 
mechanism of this reagent is shown below (scheme 72). Homolysis ofthe tin-tin bond 
is caused by heat and light irradiatio~, leading to the formation of Me3Sn· radicals, 
which can then go on to carry out the desired radical reaction. Alternatively, it can 
break down to form a stanylene and Me· radical. In reactions where homolytic 
aromatic substitution takes place, Me· radicals have been suggested to facilitate the 
hydrogen abstraction step.75 The dimethyl tin polymer is often seen as a sticky yellow 
residue on the inside of the reaction vessel. 
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Me3Sn-SnMe3 
UV ! Heat Probable H-abstraction t 
2 x Me
3
Sn · _____ __.. Me2Sn: + Me· ! Polymerisation 
Radical reaction 
Me3Sn. ~ ~I_AJ Me3sn-fs!: ). SnMe, 
Scheme 72. Mechanism of (Me3Sn)2 homolysis. 
The reaction between the quinazolinone 228 and (Me3Sn)2 showed only one spot by 
TLC (table 4) but GC-MS analysis of the crude reaction mixture showed the reduced 
and cyclised product in a ratio of ea. 4: 1. A closer inspection of the 1H NMR spectra 
also revealed that quinazolinones 233 and 232 were present. The two compounds 
could not be separated using column chromatography (attempts were made using 
silica and alumina gel as absorbent). However, having already obtained a clean 1H 
NMR spectrum ofthe reduced compound, calculation for the reactions yields could be 
carried out. 
Table 4. Radical reaction between 3-(2-iodobenzyl)-3H-quinazolin-4-one 228 and 
(Me3Sn)2. 
228-----~7~ ~N~ Ur-o UN) V {3.0 equiv.) 
Initiator Reflux 
hu Yes 
Et3B No 
233 232 
Solvent 
t-Butylbenzene 
t-Butylbenzene 
Product 
233 (18%) 232 (65%) 
Trace 233 
It is not known whether EhB can be used to initiate the (Me3Sn)2 reaction. The bond 
dissociation constants for Sn-Sn bonds are similar to those of Sn-Et. It seemed 
valuable to test whether triethylborane could be used to initiate the homolysis of the 
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Sn-Sn bond. So far, there is no mention in the literature of triethylborane and 
(Me3Sn)2 being used together (scheme 73). A 1H NMR spectrum of the reaction using 
EhB and (Me3Sn)2 showed possible cyclised product 233 but in a trace amount. A 
reaction was also attempted using only triethylborane, with no (Me3Sn)2, heat or light 
irradiation. This resulted in only starting material being recovered which, was 
expected, due to the high bond strength of the aryl-halide bond. 
-
Et.J 
Me3Sn-SnMe3 
V 
- Me3Sn • + Me3SnEt 
Scheme 73. Possible mechanism for the formation of the radical Me3Sn·. 
Having obtained some cyclised product, attention was turned to the radical cyclisation 
of the quinazolinone 231 (scheme 74). From the initial studies it was shown that H-
abstraction of intermediate aryl radical was favoured. Therefore, the cyclisation using 
(Me3Sn)2 was attempted first. An excellent yield of cyclised quinazolinone 237 was 
obtained with none of the reduced quinazolinone 238. The reaction was also carried 
out using fast Bu3SnH!Et3B conditions, which gave the cyclised quinazolinone 237 
(8%) and the reduced quinazolinone 238 (50%). It was surprising that the 
quinazolinone 237 was obtained using these conditions. The increased yield and ease 
of cyclisation here can be attributed to ring strain. The amount of ring strain for the 
five-membered ring is higher than the six-membered ring. This is highlighted by the 
ability of the quinazolinone 231 to cyclise using Bu3SnH. 
~N(;adical ~~) ~ Br 
N I 
231 ~ 
Scheme 74. i, (Me3Sn)2, t-butylbenzene heated under reflux and hu; cyclised 237 
(92%) and reduced 238 (0%); ii, Bu3SnH/E1JB and toluene; cyclised 237 (8%) and 
reduced 238 (50%). 
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The mechanism for this reaction is shown (scheme 75). Phenyl radicals are slightly 
nucleophilic and attack the electron deficient carbon of the imine. The reaction can be 
regarded as a 6-exo radical cyclisation onto an imine leading to an aminyl radical. A 
disproportionation reaction does not occur. The yield of cyclisation product was high 
when using (Me3Sn)2. The stability of the n-radical means the unpaired electron is 
delocalised over a large part of the molecule. Other species that could abstract the 
hydrogen include Me3SnOO· (Me3Sn· + 02 always present in trace quantities). The 
strong drive for rearomatisation leads to the high yield of cyclisation using (Me3Sn)2. 
Bu3SnH, Et38, PhMe, r.t. 
(Me3Sn)2, h1l, t-BuPh, reflux 
Scheme 75. Mechanism of 6-exo aryl radical cyclisation onto 3H-quinazolin-4-one. 
2.2 Palladium cyclisations onto 3H-quinazolin-4-one 
Palladium(O) catalysed cyclisations on quinazolinone 228 should also be possible. A 
Heck type reaction could be used to form the desired cyclised tetracycle 233 (scheme 
76). 
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0 
0 228 
Pd0 
233 -
~~~ ~N~ UN~ U&~ 
~df"H ~ I 
'I 
Scheme 76. Proposed Heck reaction on ~-(2-iodobenzyl)-3H-quinazolin-4-one 228. 
There are only a few examples of Heck reactions onto imines reported in the 
literature. 76 Therefore, it was considered an investigation would be novel. Harayama 
has shown that Cy3P is an excellent ligand for Heck reactions onto quinazolinones.74 
Despite trying a variety of conditions the tetracycle 233 could not be observed or 
isolated. In every attempt the starting material was recovered (table 5). 
Table 5. Attempted Pd(O) cyclisations 
oCO N')) Heck "- oCOxo I I ---------X--- I ~ .0 THF "- ::::..... h 1 ~ N I N 
-228 233 
Pd source Ligand Base (2.0 equiv.) 
Pd(OAc)z (5%) PPh3 (10%) KOAc 
Pd(0Ac)2 (5%) n-Bu3P (10%) KOAc 
Pd(0Ac)z(5%) PCy3 (10%) KOAc 
Pd(OAc)z (5%) PCy3 (10%) KzC03 
Pd(PPh3)4 (5%) ZnBrz (as Lewis acid) KzC03 
* The reaction was carried out in a microwave reactor. 
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Reflux 
Yes 
Yes 
Yes 
Sealed tube 
10 min* 
With no success in fonning a five-membered ring, focus was turned to the 
quinazolinone 231 (table 6). The Cy3P ligand is extremely air sensitive and a 31P 
NMR spectrum of the ligand revealed that it was about 20% oxidised. The amount of 
Cy3P added was increased from 10% to 15%. Different bases, solvents, Pd sources 
and ligands were all investigated. These extensive investigations only lead to starting 
material being recovered and the tetracycle 233 was not isolated which was 
dissapointing. 
Table 6. Attempted Heck reactions of quinazolinone 231. 
o6') .Br 
231 (J 
. .'::~_"-/. __ ~?=a 
THF /'-.. u~ ~ 
237 ~ I 
Pd source Ligand Base (2.0 equiv.) Reflux 
Pd(OAc)2 (5%) PCy3 (10%) KOAc Yes 
Pd(OAc)2 (5%) PCy3(15%) KOAc Yes 
Pd(OAc)2 (5%) * PCy3 (15%) KOAc 60°C 
Pd(OAc)2 (5%) PCy3 (15%) K2C03 Yes 
Pd(PPh3)4 (5%) Dppe (10%) KOAc Yes 
Pd(PPh3)4 (5%) None KOAc Yes 
Pd(OAc)2 (5%) PCy3 (10%) KzC03 Sealed tube 
*The reaction was carried out in DMF as solvent. 
As only starting material was recovered, it suggested to us that the insertion of Pd(O) 
into the carbon-halide bond was not happening and that the Pd(O) may coordinate to 
the N-1 of the quinazolin-4-one to fonn a car bene type complex. This may compete 
with the initial oxidative insertion into the carbon-halide bond. To test this hypothesis, 
a reaction was carried out using stoichiometric amounts of quinazolinone 231 and 
Pd(PPh3)4 in deuterated DMF. A blank 1H NMR spectrum of the catalyst enabled us to 
determine where the phenyl proton signal of the catalyst came in the 1H NMR 
spectrum. No additional ligands had to be added as Pd(PPh3)4 is a source of Pd(O). 
The reaction was heated, and 1H NMR spectra were taken of the crude reaction 
mixture at regular intervals. It was hoped to see shifting of signals to indicate Pd(O) 
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insertion into the carbon-halide bond or nitrogen coordination. However, no change in 
any signals was observed and therefore it could not be explained why cyclisation was 
not occurring using Pd(O). 
It was decided to end these Pd investigations in order to follow the initial radical 
work. However the area is still open to more investigation and further catalysts, 
ligands, bases and solvents could be tested. 
2.3 Radical cyclisations from 3H-quinazolin-4-one onto aryl groups 
Having carried out radical cyclisations onto the quinazolinone moiety, it was decided 
to determine if the quinazolinone radical 239 could be cyclised onto aryl groups 
(scheme 77). The aim was to form a radical at the C-2 position of the 2-bromo 
substituted quinazolin-4-one 240. First, a synthesis of the 2-bromo-3H-quinazolin-4-
one 241 building block needed to be developed. 
~N~ ~N~ l0l~.J "0 0 :::::::> l0l~Br V 
239 N . 240 
0 il ~NHX~ l0l~.A V N Br 
241 
Scheme 77. Retrosynthesis of radical cyclisation using a radical precursor from the 
3H-quinazolin-4-one. 
A synthesis of the 2-bromo-3H-quinazolin-4-one building block 241 was developed 
involving treating the ~-mercapto-3H-quinazolin-4-one 242 with bromine. A detailed 
discussion of this building block, its uses and most importantly its limitations is 
reported in chapter 5. Firstly, the alkylation onto the N-3 position using benzyl 
bromide to yield the quinazolinone 240 was carried out (scheme 78). Only very 
limited a-alkylation was observed when t-BuOK or NaH were used and the N-
alkylated quinazolinone 240 predominated. 
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0 
~NH Br2 
~NAsMeOH 
H 
242 
JNH t-BuOKorNaH 
~NABr BnBr, DMF 
241 
Scheme 78. 
As already described, cyclised and reduced products were obtained from attempts to 
carry out 5-membered ring cyclisation onto the quinazolinone. The highest yield of 
cyclisation onto quinazolinone to form a five-membered ring was 18% alongside the 
reduced quinazolinone (65%). It was felt that a comparison of yields obtained via both 
radical methodologies would be interesting. 
Initially the radical reaction was carried out using slow addition of Bu3SnH!Et3B 
(table 7). As previously observed, only the reduced quinazolinone 232 was isolated. 
Slow addition of Bu3GeH!EtJB was then attempted. The rate of hydrogen abstraction 
from Bu3GeH is about twenty times slower than from Bu3SnH. Again, only the 
reduced quinazolinone 232 was obtained. The use of (Me3Sn)2 yielded an inseparable 
mixture ofthe cyclised quinazolinone 233 (27%) and the reduced quinazolinone 232 
( 41% ). The overall recovery of the two products is similar to the recovery obtained 
from the cyclisation of228. 
Table 7. Radical cyclisations of quinazolinone 240. 
JN~ ~~.Ao.V N Br 
240 
radical 
Me Ph 
Radical reagent (equiv.) Initiator (equiv.) 
Bu3SnH (2.2) Et3B (20) 
Bu3GeH (2.2) Et3B (20) 
(Me3Sn)2 (3.0) * hu and !l. 
* The reaction was carried out using t-BuPh as solvent. 
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JN~ ~)V 
232 
Product 
232 (62%) 
232 (47%) 
233 (27%) 232 (41%) 
It was concluded that as before kH>>keyc and that sources of accessible hydrogen 
needed to be removed. An investigation of Pd chemistry with the precursor was not . 
carried out given previous failures. 
Attention was turned to the synthesis of the six-membered ring precursor 243 (scheme 
79). Alkylation of 2-bromo-3H-quinazolin-4-one 241 with (2-bromoethyl)benzene 
gave the quinazolinone 243 in very low yield. An extensive discussion concerning the 
attempts to improve the yield of quinazolinone 243 is given in chapter 5. 
0 ~ 
NaH,DMF ~~U~.;l ~NH u~~Br N Br 
243 (6%) 
Br 
241 
Scheme 79. Synthesis of quinazolinone radical precursor. 
Although only a limited amount of the quinazolinone 243 was obtained, the radical 
reaction was attempted (scheme 80). From previous experience, it was chosen to carry 
out the radical cyclisation using (Me3Sn)z. The reaction gave the cyclised 
quinazolinone 237 in a excellant yield. Other radical conditions or possible Pd(O) 
catalysed cyclisations could have been attempted but were precluded by the 
difficulties in preparing the precursor 243. 
0~ ~N ::::..... (Me3Sn)2, t-BuPh 
U~.A N Br hU, Reflux 
243 
Scheme 80. 
In this section, the competition between H-abstraction and aryl radical cyclisation 
onto the 3H-quinazolin-4-one has been observed. Cyclisation was favoured when 
using the reagent (Me3Sn)z and reduction when Bu3SnH was used. 
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2.4 Alkyl radical cyclisations onto 3H-quinazolin-4-one 
The synthesis of deoxyvasicinone 147 and mackinazolinone 148 were attempted 
using an alkyl radical cyclisation onto the 3H-quinazolin-4-one template (scheme 81). 
The aim was to carry out alkyl radical cyclisations using the methodology described 
in the previous section for aryl radicals. It was not known whether, unlike the 
previous aryl radical cyclisations, any cyclised reduced quinazolinone 244 would also 
be recovered from these reactions. 
deoxyvasicinone 147 n = 1 
mackinazolinone 148 n = 2 
245 
Scheme 81. Planned retrosynthesis of deoxyvasicinone and mackinazolinone. 
2.5 Introduction to deoxyvasicinone and mackinazolinone 
Although neither compound has shown great biological activity, they are interesting 
synthetic targets. Deoxyvasicinone 147 is found in the seeds ofthe Peganum harmala 
plant and has been used as an antiseptic in Iraq (figure 19). Careful studies of the 
plant showed that the antimicrobial behaviour is predominantly due to the compound 
harmine 246 which is more potent than the deoxyvasicinone 147, and is also found in 
the same plant.77 However, deoxyvasicinone 147 is also of interest as it can be used as 
a precursor to vasicinone 247 which is a bronchodilator. 78 
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d.:n N M eO d.: X? 
147 247 OH 
Figure 19. Deoxyvasicinone and ciosely related natural products. 
There are many syntheses of deoxyvasicinone 147 in the literature.79 Hamid et al. 
have used an intramolecular aza displacement of a methylthio group as the key 
synthetic step (scheme 82).79 The spontaneous cyclodehydration of methyl 
anthranilamide and 5-methylsulfanyl-3,4-dihydro-2H-pyrrole 248 was shown to work 
in high yield, and utilised for a number of other closely related syntheses. 
12 h d.:n N NaH, DMF 
147 (86%) 
Scheme 82. Rapid synthesis of deoxyvasicinone by Ham id et al. 
The other target, mackinazolinone 148, was first isolated by Johns and Lamberton 
from the Mackinlaya species of plants which are found in highlands ofNew Guinea.80 
A closely related quinazoline, 6, 7,8,9-tetrahydro-11H-pyrido[2, 1-b ]quinazoline 249, 
was also isolated from the same plant (figure 20). This natural quinazoline and 
mackinazolinone are both closely related in structure to vasicine 138. The 
biosynthesis of vasicine has already been described. It could easily be envisaged that 
the biosynthesis of mackinazolinone is very similar to that of vasicine. The major 
difference would be the condensation of anthranilic acid with lysine instead of 
ornithine. Mackinazolinone 148· has been shown to possess a broad range of 
pharmacological activities.81 
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d,:u OCD N oc~ 
148 249 138 OH 
Figure 20. Vasicine and related alkaloids. 
A number of syntheses of deoxyvasicinone 147 have been modified to access 
mackinazolinone 148. One such example has been carried out by Liu et al. using a 
microwave-assisted, three-component domino reaction (scheme 83). 82 The one-pot 
process is carried with anthranilic acid 169, the protected amino acid 250, triphenyl 
phosphite and pyridine. Liu proposed an initial intermediate Boc-benzoxazinone 251. 
Deprotection and ring expansion would give the diamide intermediate 252. Upon ring 
closure mackinazolinone 148 would be formed. 
0 0 0 ~/Boc cr;i) o(oH HO 250 ~ 
NH2 P(OPhh, Pyridine, 10 min, 
169 microwave I 148 \ 
251 
- ~Q 
252 6) 
Scheme 83. Three-component microwave-assisted synthesis of mackinazolinone. 
2.6 Radical synthesis of deoxyvasicinone and mackinazolinone 
The first step of the synthesis of deoxyvasicinone and mackinazolinone was the 
alkylation of3H-quinazolin-4-one 219. In the aryl radical investigations t-BuOK was 
used to minimise the 0-alkylation. Here NaH was used and no 0-alkylation was 
observed (scheme 84). The alkylated quinazolinones 253a and 253b were treated 
under Finkelstein conditions to convert them to the iodoquinazolinones 254a and 
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254b. Unusually the yields for both Finkelstein reactions were low whereas the 
reaction is normally quantitative. Part of the products were lost during the workup of 
the reaction, this accounts for the good but not quantitative yields. 
219 253a, n = 1 (51%) 
b, n = 2 (65%) 
254a, n = 1 (53%) 
b, n = 2 (67%) 
Scheme 84. i. a) 1-Chloro-3-iodopropane, NaH, DMF; b) 1-Chloro-4-iodobutane, 
NaH, DMF; ii. Nal, acetone, reflux. 
There was concern about the stability of the alkyl iodoquinazolinones 254a and 254b. 
For this reason, the synthesis of the alkyl phenylselanide 256 was carried out (scheme 
85). The carbon-selenium bond is polarisable and can break under homolytic 
conditions but is stable to SNl and SN2 reactions. The alkyl bromide 255 was 
converted to the phenylselanide 256 in good yield. This was followed by a Finkelstein 
reaction yielding the iodophenylselanide 257. Attempted alkylation of the 3H-
quinazolin-4-one 219 was not carried out using the iodophenylselanide 257 because 
the alkyl iodides 254a and 254b proved to be stable. 
CI~Br 
255 
0 
(PhSe)2, Na8H4 
MeOH 
~N~SePh not attempted 
~~) ·----x-----
N 258 
Scheme 85. 
CI~SePh 
256 (81%) 
Nal! Acetone 
I~SePh 
257 (22%) 
The first reaction investigated was between quinazolinone 254a and (Me3Sn)z to 
synthesise deoxyvasicinone (table 8). This reaction yielded three products, 
deoxyvasicinone 147, the cyclised reduced quinazolinone 259 and the reduced 
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quinazolinone 260 in moderate yields. It was reasoned that triethylborane could be 
used to form the alkyl radical without the need for other radical propagating reagents. 
The reaction was repeated using just triethylborane and increased yields were 
observed. Triethylborane is known to generate radicals from alkyl iodides.6 
Unsurprisingly, when quinazolinone 254a was reacted with Bu3SnH only the reduced 
quinazolinone 260 was obtained. As seen above, this showed that kH>>keyc, and that 
the formation of a five-membered ring is not favoured in the case of alkyl and aryl 
radicals. It was proposed that the reduced cyclised quinazolinone 259 was obtained 
because the drive for rearomatisation is not as great as in the case of the aryl radical 
cyclisations. The source of the reducing hydrogen is not clear, possibly a small 
amount of disproportionation is occurring. 
Table 8. Radical cyclisations to form deoxyvasicinone and other products 
254a radical 
Radical reagent 
(Me3Sn)2 
EhB 
Bu3SnH 
~ncin ~N.-;:: N 
H 
147 259 260 
Initiator 
hu and !1 
02 
Et3B 
Solvent 
t-BuPh 
t-BuPh 
Me Ph 
Product 
147 (20%) 259 (12%) 260 (6%) 
147 (40%) 259 (10%) 260 (30%) 
260 (78%) 
To help with characterisation, the reduced quinazolinone 260 was prepared using a 
different route, via the alkylation of 3H-quinazolin-4-one 219 using 1-iodopropane 
(scheme 86). 
ctO NH NaH, DMF ) N 1-iodopropane d.;J~ N 
219 260 (64%) 
Scheme 86. 
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A sample of the crude reaction mixture for the triethylborane reaction (2nd entry, table 
8) was analysed by GC-MS. The analysis revealed two other minor products which 
appeared to result from the addition of ethyl radical onto the propyl chain and onto 3 
propyl quinazolinone 261 (scheme 87). Both compounds have relative molecular 
masses of 216. The fragmentation pattern of one product had a large ion of mlz 145, 
due to the loss of pentane chain from quinazolinone 262. The other product had two 
major ions of mlz 187 (loss of ethyl) and m/z 173 (loss of propyl) from quinazolinone 
263. However, these are only postulated structures which could not be further 
characterised. The reaction provides extra evidence that hydrogen abstraction is 
carried out by ethyl radical. 
~~] U~.J ·Et 
261 N '-__/ 
Scheme 87. Possible by-products in the reactions with Et3B. 
Attention was turned to the ~adical cyclisation of the quinazolinone 254b to form 
mackinazolinone 148. The radical reaction was carried out using only Et3B because 
these conditions had proved successful in the deoxyvasicinone synthesis. 
Mackinazolinone 148 was formed in an excellent yield (61 %) under these conditions 
(scheme 88). It was surprising to find the only other isolatable product to be the 
cyclised reduced quinazolinone 264. The reaction was also carried out using (Me3Sn)2 
and again the same two products were isolated but in lower yields. These results are in 
stark contrast to the previous cyclisation of deoxyvasicinone where three products 
were isolated. The higher yields observed for mackinazolinone 148 and the cyclised 
reduced quinazolinone 264 show the preferential formation of six-membered rings 
over five-membered rings. The same trend was observed when studying aryl radical 
cyclisations. 
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radical 
t-BuPh 
148 264 
Scheme 88. i. Et3B; mackinazolinone 148 (61%) and cyclised 264 (17%); ii. 
(Me3Sn)2, hu, reflux; mackinazolinone 148 (30%) and cyclised 264 (23%). 
It was proposed that the formation of the cyclised reduced quinazolinone 264 arises 
via a disproportionation reaction. In the case of the reaction using (Me3Sn)2 the two 
quinazolinone products 148 and 264 are formed in similar yield which suggests a 
disproportionation reaction (scheme 89). The reduced quinazolinone 266 was not 
obtained, indicating that cyclisation is highly favourable. The formation of reduced 
cyclised product was not observed in any other cyclisation reactions. The extra 
conjugation given by products with aryl and heteroaryl radicals may be important. 
'( .. 
265 1 
7 oO) 
266 
llt -radical 2671- I cr -radical 2681 
0 0 
otpN OCD 
PI ·---.., 
~~ 
0 
d,u 
H 264 
ciu N 
149 
Scheme 89. Putative disproportionation mechanism. 
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2.7 Investigations into indium-mediated cyclisations onto 3H-
quinazolin-4-one 
With the iodoquinazolinones 254a and 254b in hand, organometallic reactions using 
these substrates were investigated. Heck reactions could not be carried out due to the 
presence of P-hydrogen atoms. However, we were curious to see if a reaction induced 
by indium would lead to Barbier type reactions on these substrates. Indium is 
relatively non-toxic and can also be used under aqueous conditions. 83 It was hoped 
that indium would insert into the carbon iodine bond 269 and possibly cyclise onto the 
quinazolin-4-one (scheme 90). Indium powder was added to both the quinazolinones 
254a and 254b. These reactions were carried out using a mixture of water and DMF 
or THF to get the quinazolin-4-one into solution. Reactions were also undertaken with 
gentle heating. However, only trace quantities of possible cyclised compound could 
be seen in the 1H NMR spectra and could never be isolated. As this was not the main 
focus of the work, no other organometallic investigations were carried out on alkyl 
halides. 
0 
oo~~ ___ ]o __ ~ 
254a 
b 
0 
w~ln-1 
N 
269 "~ /~ 
0 t OCn).., 
N 
147 n = 1 
148 n = 2 
Scheme 90. Attempted indium mediated cyclisations. 
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2.8 Conclusion 
In this chapter, it has been shown the strong competition between hydrogen 
abstraction and cyclisation of aryl and alkyl radicals onto the C-2 position of the 
quinazolinone. The syntheses of deoxyvasicinone and mackinazolinone have been 
achieved. Attempts at using organometallic cyclisation chemistry proved 
unsuccessful. 
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Chapter 3. Heterocyclic radical cyclisations onto 3H-quinazolin-4-
one 
Having successfully carried out aryl and alkyl radical ·cyclisations onto 3H-
quinazolin-4-one, focus was turned to heteroarene radical cyclisations. Many 
examples of heteroarene radical cyclisation are known and have been reviewed in 
chapter 1. The aim was to extend this work to the field of 3H-quinazolin-4-one 
chemistry. 
3.1 Introduction to luotonin A 
Heterocyclic radical cyclisations onto the 3H-quinazolin-4-one moiety were 
investigated with the aim of natural product synthesis. One of the synthetic targets 
was the recently discovered pyrroloquinazolinequinoline alkaloids luotonins 144a A, 
B and E (scheme 91). These natural products have been isolated from Peganum 
nigellastrum, a Chinese medicinal plant that has been used in the treatment of 
rheumatism, inflammation and abscesses. 84 They have proved to be popular targets for 
synthetic chemists, and, at the time of writing twelve syntheses in six years of 
luotonin A have been reported. 85 It was envisaged a possible synthesis of the luotonin 
A by radical cyclisation of the quinoline radical 266 onto the C-2 position of a 
quinazolinone core. This could be achieved from the synthesis of the quinoline 
building block 267 and 3H-quinazolin-4-one 219. 
~N 
lJlN)_/ 
R 
144a, luotonin A, R = H 
b, luotonin B, R = OH 
c, luotonin E, R = OMe 
Scheme 91. Retrosynthesis of the luotonins. 
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The biological activity of the luotonins is of particular interest and has recently been 
explored further by Hecht and coworkers.86 It was noted that luotonin A 145a exhibits 
reasonable potency as a topoisomerase I poison by stabilising the enzyme linked 
DNA, with the same selectivity as the anticancer drug camptothecin 61 (figure 21).87 
Camptotheein stablised covalent complex 
I 
DNA double helix 
Figure 21. Camptothecin acting as topoisomerase I poison 
Topoisomerase I wrapped round 
DNA during transcription 
The stereochemistry in the lactone E-ring for camptothecin is critical in its role to 
form a topoisomerase I-DNA covalent binary complex (figure 22). Hecht showed that 
removal of the hydroxyl group from the lactone E-ring (compound 268) resulted in 
complete loss of covalent binary complex stabilisation. Notably, luotonin A 145a has 
a very different E-ring to camptothecin 61. The other major difference between the . 
two compounds is that luotonin A 145a contains an additional nitrogen in the D-ring 
at position C-14. Hecht has shown that removal of this extra nitrogen at N-14 leads to 
complete loss of activity for analogue 269. 
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Figure 22. Luotonin A, camptothecin and analogues. 
Hecht has now reported the synthesis of 10, 11-methylenedioxy-14-azacampotothecin 
271, which incorporates the extra nitrogen in the D-ring of Iuotonin A into 
camptothecin (scheme 92). 88 The compound represents another important step to the 
development of camptothecin analogues in anti cancer treatment. Hecht employed a 
radical cyclisation in the synthesis from the quinoline 270 but in poor yield. The aim 
was to develop improved radical methodology for the synthesis of luotonin A. 
O~ ~0 TTMSS,AIBN, < :71 ~ N 
0 ::::-,.. N.--::: Br \ !J o Benzene, reflux 
270 /····· 
HO O 
<on;q~ N o ::::-... I .--::: 0 N ~ /) 
N 
271 (6%) 
Scheme 92. 
There have been a number of syntheses of luotonin A to date. The Bowman group has 
previously used a radical cascade reaction via an iminyl radical in the synthesis of 
luotonin A (scheme 93).73 The reaction proceeds via an initial 5-exo-dig cyclisation of 
a vinyl radical formed from the substituted quinazolinone 272. The resulting 
intermediate iminyl radical, then undergoes a 6-endo or 5-exo (followed by neophyl 
rearrangement) yielding luotonin A 144a in a 21% yield. The radical reaction was 
carried out using (Me3Sn)2 to overcome H-abstraction which led to unwanted side 
products. 
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0 
t-BuPh 
~N U~.'i N (MeSn)2, hv, 
Scheme 93. Bowman~s previous synthesis ofluotonin A. 
3.2 Radical synthesis of luotonin A 
The synthesis of the radical precursor for luotonin A is shown in scheme 94. Attempts 
to formylate 2-chloroquinoline 273 at C-3 failed (scheme 94). It was hoped that 
deprotonation with LDA at the C-3 on the quinoline 273 would access the aldehyde 
274 using DMF as the formylating agent. However, after several attempts this was 
abandoned as only starting material was recovered. Instead, aldehyde 274 was 
purchased from Sigma-Aidrich. Literature methodology by Harayama was followed 
to reach quinazolinone 277.74 Reduction of the aldehyde 274 to the alcohol275, was 
followed by bromination and deoxybromination leading to the quinoline 276 in good 
yield. The dibromoquinoline 276 was used to alkylate 3H-quinazolin-4-one yielding 
the desired radical precursor 276. 
0 
~H~cxxOH UN~CI N Cl ii (XX ___ Br N Br 
274 275 276 
>t< 
Wcl 
~iii 0 
~l~ ~NABr ~N)l) 
273 277 
Scheme 94. i. NaBH4, EtOH (75%); ii. PBr3, THF (55%); iii. t-BuOK, 3H-quinazolin-
4-one, DMF (65%). 
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Studies were considered to optimise the dibromination step. Following the reaction by 
TLC, an initial spot was seen for the rapid deoxybromination of the alcohol 275. 
However, it took twenty-four hours before the nucleophilic aromatic substitution of 
the chlorine atom had taken place, yielding the dibromoquinazoline 276. 
The results of cyclisation studies are shown in table 9. Initial attempts at the radical 
cyclisations of the quinazolinone 277 were carried out using (Me3Sn2). As discussed 
previously this was to minimise the possibility of H-abstraction by the intermediate 
quinol-2-yl radical. Luotonin A 144a was produced in good yield on the first attempt 
with only a small amount of the reduced quinazolinone 278. 
Table 9. Radical synthesis ofluotonin A. 
radical 
277 
Me Ph ~ ( ~ N N 
144a ___ 278 
Radical reagent (equiv.) Initiator (equiv.) 
(Me3Sn)2 (3.0) * hu and 11 
Bu3SnH fast (2.5) EhB (20) 
BuJSnH slow (2.5) EhB (20) 
Bu3GeH slow (2.5) Et3B (20) 
* The reaction was carried out in t-BuPh 
Product 
144a (51%) 278 (15%) 
278 (53%) 
144a (14%) 278 (32%) 
144a (18%) 278 (11%) 
As expected, fast addition ofBu3SnH (all added in one portion at the beginning of the 
reaction) yielded only the reduced quinazolinone 278. However, when slow addition 
ofBuJSnH (with a syringe pump) was used a small amount of luotonin A 144a was 
also formed. This was the first time a five-membered ring cyclisation was carried out 
onto the quinazolinone using Bu3SnH. The conclusion can be drawn that the 
cyclisation of the quinoline radical is more favoured than the aryl or all~yl radicals 
previously investigated. Slow addition of Bu3GeH produced a mixture of both the 
reduced quinazolinone 278 and the cyclised luotonin A 144a. This slight increase in 
yield of luotonin A using Bu3GeH can be attributed to the stronger bond between 
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germanium-hydrogen compared to the tin-hydrogen bond, which means H-
abstraction is less favourable when using Bu3GeH. 
From earlier investigations, there was concern that the separation of luotonin A 144a 
and reduced quinazolinone 278 may be difficult. Separation of products had been a 
major problem in the formation of five-membered rings from aryl radicals. Therefore, 
the synthesis of the reduced quinazolinone 278 was attempted by an alternative route 
(scheme 95). The conversion of the commercially available 3-bromoquinoline 279 to 
the quinoline-3-carbaldehyde 280 worked well using DMF as a formylating agent 
utilising a literature procedure by Doumachel et al. 89 The authors proposed that the 
reaction proceeded via a tri-quinoyl co-ordinate magnesium ion to explain why only 
one third of an equivalent of BuMgCl is needed in the reaction. Reduction to the 3-
hydroxymethylquinoline 281 proceeded smoothly. The aim was to convert the 3-
hydroxymethylquinoline 281 to a suitable leaving group 282 and alkylate onto 3H-
quinazolin-4-one to yield quinazolinone 278 unambiguously. However, this route was 
not further pursued after finding luotonin A 144a and quinazolinone 278 were 
separable by careful column chromatography. 
roBr BuMgCI, n-Buli DMF, toluene N 
279 
Scheme 95. 
~ NaBH4 UNJ -E-tO-H~ 
280 (70%) 
-------· 
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cdH 
N 
281 (54%) 
: Not attempted 
cXY N 
282 
3.3 Introduction to rutaecarpine 
The next target synthesis was the indoloquinazolinone natural product rutaecarpine 
145 (figure 23). This natural product can be considered a quinazolinone or indole 
alkaloid and its biosynthesis from tryptophan and anthranilic acid has been 
discussed.58 
crP~~ 
H 145 -
Figure 23. 
Rutaecarpine 145 was first isolated in 1915.90 Ashina et al. reported the first synthesis 
another decade later.91 Rutaecarpine is isolated from the plants Evodia, Horita, 
Zanthoxylum, Euxylophorea and Phellodendron which are all members of the 
Rutaceae family.92 The dried fruit of Evodia rutaecarpa has been used in traditional 
Chinese herbal medicines such as Wu-Chu-Yu and Shih-Hu.93 These medicines have 
been used to treat a number of medical conditions such as headaches, dysentery, 
cholera, worm infections and postpartum disturbances. Recent literature has also 
shown that rutaecarpine displays strong inhibitory activity against cycloxygenase 
(COX-2) and suppression of platelet plug formation in mesenteric venules and 
increased ea+ concentration in endothelial cells.94• 95 
There have been a number of different synthetic approaches to rutaecarpine. Recently 
Chavan et. al. have carried a total synthesis using the Fischer indole reaction (scheme 
96).92 Although several steps were required to reach the indole precursor 283, the 
Fischer indole cyclisation using PPA afforded rutaecarpine 145 in excellent yield. 
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cty Fischer indole synthesis PPA, 180 °C ciN 
283 NHNPh 145 (95%} 
Scheme 96. Rutaecarpine synthesis using a Fischer indole reaction. 
3.4 Radical synthesis of rutaecarpine 
The key to the synthetic strategy to rutaecarpine 145 was to prepare the indole 
building block 284 which could be used to alkylate 3H-quinazolin-4-one 219 (scheme 
97). It was considered that insertion of the required functionality at the C-2 position of 
indole 285 would be facile. 
d.:t~ ~NHX~ U~.) x\Jl) N H 
145 219 284 
Scheme 97. Retrosynthesis ofrutaecarpine. 
~N ;/\Jl) 
H 
285 
The aim was to develop a synthesis of the indole building block 284 which would 
provide radical routes to other indole natural products, e.g. as shown in scheme 98. 
deplancheine 
Scheme 98. 
~X 
H 
284 harmacine 
There are two methods for C-2 halogenation of indole reported in the literature 
(scheme 99). Katritzky has shown that C-2 substitution of lH-indole 286 can be 
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carried out using carbon dioxide as a temporary protecting group for nitrogen.% 
Bergman and Venemalm elaborated this method to make 2-bromo-lH-indole 287.25 
Cook et al. have described a second method of C-2 halogenation, where NBS in CC14 
is used to carry bromination of 3-methyl-lH-indole 288 to 2-bromo-3-methyl-lH-
indole 289 at C-2.97 The latter method requires the C-3 position to be blocked, or 
bromination is directed onto C-3. The major problem for both these procedures is the 
instability of 2-haloindoles. Bergman and Venemalm noted the curious stability trend 
of2-iodoindole > 2-chloroindole > 2-bromoindole.25 However, Jones who has carried 
out studies with 2-bromoindoles has shown that once pure, the stability of C-2 
bromoindoles increases greatly.98 
Katritzky approach 
i. n-Buli 
~ ii.C02 ~ 
VJ-NI iii. t-Buli ~Nr-Br 
H iv. BrCI2CCCI2Br H 
286 287 (87%) 
Cook approach 
m NBS, CCI4 
H 
288 
Scheme 99. C-2 Bromination of indole . 
. 
CJO-s, 
H 
289 (97%) 
It was chosen to use the NBS reaction which appeared experimentally simpler than 
the Katritzky method. Initially, the commercially available indole, tryptophol 290 was 
treated with NBS to form 2-(2-bromo-1H-indol-3-yl)ethanol291 in low yield (scheme 
1 00). This compound appeared quite stable in air once purified. 
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~N'' OH U---.1 NBS, CCI, 
H 
290 
Scheme 100. 
This chemistry obviously needed more investigation to optimise reaction conditions 
and yields. Therefore, initially a number of studies were carried out on 3-methyl-1H-
indole 288 (scheme 101). 3-Methyl-1H-indole 288 was COJ;Iverted to 2-bromo-3-
methyl-1H-indole 289a and 2-(phenylselanyl)-3-methyl-1H-indole 289b. Once pure 
both compounds proved stable. An attempt to replace NBS with NIS to form the 2-
iodo-3-methyl-indole failed. The use of 2-(phenylselany1)-3-methyl-1H-indole 289b 
was considered for radical reactions. However, there is no precedent in the literature 
of the homolysis of a sp2C-SePh bond in radical reactions. 
oO 
H 
NBS or PhSeCI, Et3N a=>-
~ Nx 
CCI4 
H 
288 289a, X= Br {48%) 
b, X= SePh {11%) 
Scheme 101. 
It was thought that protection of the nitrogen indole might increase reaction yields for 
bromination. Therefore, the benzyl protected indole 292 was prepared in excellent 
yield from the 3-methyl-1H-indole 288 (scheme 102). However, once brominated 
indole 293 appeared very unstable in air. 
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cri NaH, BnBr cri NBS, CCI4 o:)-Br N DMF reflux N H N 
288 d d 
292 (78%) 293 (33%) 
Scheme 102. 
A less bulky protecting group on the nitrogen might make a difference to the stability 
ofthe C-2 brominated indole. Therefore 1;3-dimethyi-1H-indole 294 was synthesised 
(scheme I 03). Treatment of this compound with NBS gave a very poor yield of 2-
bromo-1,3-dimethyl-1H-indole 295, which also proved very unstable in air. An 
attempt to insert phenylselanide at C-2 using PhSeCI and 1,3-dimethyl-1H-indole 294 
failed. Only (PhSe )2 and starting material were recovered from this procedure. 
cri NaH, Met cri NBS, CCI4 o:)-Br DMF reflux N N N H \ \ 
288 294 (74%) 295 (5%) 
Scheme 103. 
At this point, considering the results obtained, another pathway was investigated and 
the synthesis of C-2 oxindole was attempted that could then be halogenated (scheme 
104). A literature procedure was used to prepare 3-methyl-1,3-dihydroindol-2-one 
296 from 3-methyl-1H-indole 288.99 Subsequent chlorination to 2-chloro-3-methyl-
1H-indole 297 was carried out using POCh in poor yield. When the same pathway 
was tried using tryptophol 290, the oxindole 298 was not obtained. With poor results 
obtained, this route was abandoned. 
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oo 
H 
NBS 
288 
Scheme 104. 
a)= a 
. H 
296 (43%} 
m-Cl 
H 
297 (20%} 
The next direction followed was to use the precursor tryptophol 290, and try different 
methods of nitrogen protection and subsequent br~mination. Methyl protection of the 
nitrogen was carried out to yield the 2-(1-methyl-1-H-indol-3-yl)ethanol299 (scheme 
1 05). A range of bases were used to deprotonate the nitrogen. Although KOH and 
NaOH were used, NaH proved to be the highest yielding. Minor amounts of the di-
OHofo-
+ '/"I~ 
~ N 
\ \ 
290 299 (55%} 300 minor 
Scheme 105. 
The methylated indole 299 was successfully brominated using NBS to yield the 
bromoindole 301 (scheme 106). The yield of the bromoindole 301 was low but the 
compound appeared quite stable in air. Attempts at mesylation of this compound 
resulted in inseparable mixtures of unidentified products. Attempts to form the 
phenylselanide indole 302 using PhSeCI and N-(phenylselanyl)phthalimide also 
failed. 
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~OH lJL' NBS, CCI4 
\ 
~OH MsCI, Et3N lJLJ-sr ---X----
\ DCM 
299 ',, 301 (30%) 
fail~d·-.,~ 
OH 
~ I '\: SePh 
~ N 
\ 
302 
Scheme 106. 
inseparable 
mixture 
After the failure to convert the pendant alcohol of the bromoindole 301 to the 
mesylate, studies were carried out to see if the alcohol could be converted to a 
mesylate prior to bromination (scheme 107). The N-methyl tryptophol 299 was 
converted to the mesylate 303 in high yield. However, reactions with NBS and 
PhSeCl failed to produce either the bromoindole 304a or the selanylindole 304b. 
cr)OH MsCI, Et3N 
DCM \ 
m OMs --x--N \ failed 
299 303 (87%) 304a, X= Br 
b, X= SePh 
Scheme 107. 
With little success using N-methyl tryptophol the N-benzylated tryptophol 305, was 
prepared in good yield (scheme 108). However, no bromination of this compound 
could be achieved using NBS and bromotryptophol 306 was not obtained. When 
protection of the nitrogen atom of tryptophol 290 using (Boc)20 was attempted, the 
Boc indole 307 was obtained in a poor yield, which precluded this route being 
explored further. 
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290 
(Boc}20 DMAP 
THF 
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oS~ }-o . 
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307(11%) 
Scheme 108. 
NaH,BnBr 
DMF oSOHNBS ~OH ___ ),£. .. '/"' I ~ Br 7'\: ~ N d CCI, d 
305 (68%) 306 
308 
So far the studies had involved carrying out one synthetic transformation at a time. An 
attempt to protect the indole nitrogen and form a leaving group on the alcohol in one 
step was made. Both the di-tosyl indole 309a and di-mesyl indole 309b were isolated 
in low yield from tryptophol 290 (scheme 109) and as a result, no bromination was 
attempted with either compound to synthesise indole 310. 
~~~. Et3N, toluene :)--("0_~~~~~~~!~~ ~~R' V-? ~rTsCI, NaH, THF V-? U--/8 
R k 
290 309a, R, R1 = Ms (15%) 310 
b, R, R1 = Ts (25%) 
Scheme 109. 
All attempts to brominate indole or tryptophol had involved using NBS. However, 
lithium bases can also be used to trap bromine and other electrophiles (e.g. the 
Katritzky method).96 The aim was to use indole 313 to trap electrophiles at C-2 
(scheme 110). Firstly tryptophol 290 was protected with TBDMS to yield the 
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silylindole 311. The nitrogen was then tosyl protected to form the indole 312, and 
subsequent deprotection ofthe alcohol was carried out with TBAF yielding the indole 
313. 
~O_H_T_B_D_M_S_C_I- ~OTB~~H~ TsCI ~~ imidazole, DCM ~~ DMF 
H H 
290 311 (88%) 
~OH ----~~~--· ~:;r--E E+ 
Ts 
Scheme 110. Stepwise protection and deprotection oftryptophol. 
ofOTBDMS 
Ts 
312 (86%) 
TBPElTHF 
of OH 
Ts 
313 (78%) 
Insertion of iodine and bromine at the C-2 position of indole 313 was attempted using 
various bases according to a literature procedure (table 1 0). 100 The halogenated 
products 315a and 315b were not obtained, and only starting material was recovered. 
In all cases, at least two equivalents of base were used to ensure the dianion was 
formed. We considered that this dianion may help facilitate chelation with the indolo 
lithium intermediate 314 to enable electrophiles to be trapped. 
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Table 10 Attempted conditions for halogenation of indole at the C-2 position. 
mOHBase 
Ts 
313 
o:Poe 
Ts 
314 
--x-~OH 
Base (equiv.) 
LDA(4.4) 
t-BuLi (4.0) 
t-BuLi (8.0) 
n-BuLi (4.6) refluxed 
t-BuLi (4.4) 
Halogen source (equiv.) 
h (2.0) 
NIS (4.6) 
NIS (4.0) 
h(8.0) 
1,2-dibromoethane (4.4) 
Ts 
315a, X= Br 
b,X=I 
Solvent 
MTBE 
MTBE 
MTBE 
MTBE 
THF 
Literature procedures using iodine were carried out on substrate 313.100 However, 
these reactions failed. The reaction with 1,2-dibromoethane was unsuccessful. 1,2-
Dibromotetrafluoroethane had been used in the literature and clearly contains a more 
reactive source of bromine, possibly explaining the failed attempts.98 No commercial 
source of 1 ,2-dibromotetrafluroethane could be located. An excess of base with the 
NIS reaction was also used without success. 
A literature procedure of Smith et al. had successfully used lithium 
tetramethylpiperidide (LiTMP) to deprotonate protected indole 316 (scheme 111).91 It 
was interesting to note that Smith reported that bromoindole 291 was very unstable. 
o:)_O_T_HL-~T_M_P __ ._ ~~THP NaOMe 
~oc Br2F4C2, THF Boc MeOH 
316 317 291 
Scheme 111. Smith's deprotonation using LiTMP. 
It was chosen to use the protected alcohol 311 and convert it to the N-Boc protected 
indole 318, this was carried out in excellent yield (scheme 112). This compound was 
88 
then treated with LiTMP and phenylselanyl chloride to form the C-2 phenylselanide 
indole. Without further purification, the (phenylselanyl)indole was deprotected with 
TBAF in situ to yield (phenylselanyl)indole 319. An attempt to remove the 
phenylselanide group with Bu3SnH failed which indicated that the sp2C-Se bond was 
too strong to undergo abstraction. The bromo analogue of indole 319 could not be 
prepared as the reagent Br2F4C2could not be acquired. 
OTBDMS cr00TBDMS 
{Boc}20 ~ I ~ i} LiTMP, PhSeCI, THF ro=:::h 
H DMAP THF ~ N8 ii} TBAF, THF ' oc 
311 318 {89%} 
Scheme 112. Use ofLiTMP as a base 
Boc 
319 {22%} 
I 
excess '\..:/ 
Bu3SnmH ~'\.. OH 
~ 
N 
Boc 
At this point, Harayama et al. reported a Pd catalysed synthesis of rutaecarpine 
145which contained the required radical precursor 321 that was desired (scheme 
113).102 Attempts to repeat Harayama's procedure proved unsuccessful. Harayama 
reacted 3-(2-bromoethyl)-IH-indole with NBS and alkylated the crude C-2 bromo 
indole product with 3H-quinazolin-4-one 219. Realising that other groups may exploit 
the potential radical reaction of this precursor, Harayama's reaction sequence was 
further developed. 
89 
321 (64%) 
219 
Scheme 113. Harayama's Pd catalysed synthesis ofrutaecarpine 
N:oo I "' 
~ 0 
N 
145 
The indole 320 was added onto the quinazolinone by alkylation and then the C-2 
bromination was carried out. In effect, it was hoped to use the quinazolinone as a 
protecting group for the ethyl arm of tryptophol 322 (scheme 114). Conversion of 
tryptophol 290 to the 3-(2-bromoethyl)-lH-indole 320 worked well, and was followed 
by alkylation to yield the indoloquinazolinone 322. The alkylated product 322 was 
treated with NBS and the bromoindoloquinazolinone 321 was formed after 15 min, 
albeit it in poor yield. 
£0_L~_sr3_.oc_M __ ~fz~ ~ ~ ii. t-BuOK, DMF U-1 c N-z;; 
290 H 322 (47%) a~r NBS l DCM/C~I4 
219 of;{):) 
H 321 (15%) 
Scheme 114. 
Encouraged by this result a careful study was carried out to optimise the NBS reaction 
(table 11 ). A longer reaction time gave an increased yield of 
bromoindoloquinazolinone 321. Other products from side reactions that were showing 
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up on TLC were minimised by carrying out the reaction out 0 ·c which slightly 
increased the yield. An attempt to carry out the reaction at -78 ·c proved 
unsuccessful. In this reaction 1.0 equivalent of NBS was initially added and after 40 
min a very faint new spot appeared on the TLC plate, so an additional 1.0 equivalent 
was added. However, this gave a completely inseparable mixture of products and 
bromoindoloquinazolinone 321 could not be isolated from this reaction mixture. The 
reaction appeared to be almost instantaneous at room temperature as shown when the 
reaction was halted after just one minute. Therefore, half an equivalent of NBS was 
used so that side reactions would be minimised. However, this made no real impact on 
the reaction yield. Optimum reaction conditions were found to be a reaction time of 
30 min at 0 ·c with exactly 1.0 equivalent ofNBS. The NBS was recrystallised from 
hot water prior to use. The side reactions may be due to lack of protection of the 
indole NH. Unlike earlier 2-bromoindoles, the bromoindoloquinazolinone 321 was 
stable in air. 
Table 11. Synthesis of the bromoindoloquinazolinone 321. 
0 0 
d>to bromination d>:ro 322~ ~ I :: N.) Br ~ / ~ 321 N ~ H H 
NBS (equiv.) Solvent Time (ruin) Temperature Yield 
1.0 CClJDCM (1: 1) 15 rt 15% 
1.2 DCM 30 rt 27% 
1.2 DCM 25 o ·c 34% 
2.0* DCM 40 -78 ·c decomposition 
1.2 DCM 1 rt 15% 
0.5 DCM 30 o·c 5% 
1.0 DCM 30 o·c 39% 
* A second equivalent was added after 40 min. 
NBS was stirred with one equivalent of 3H-quinazolin-4-one for one week in DCM 
and revealed no new reaction products. Therefore, side reactions observed in table 11 
are not due to the reaction between NBS and the quinazolinone moiety. 
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Having obtained the bromoindoloquinazolinone 321 in acceptable yield, the radical 
cyclisations were investigated. The first attempt at radical cyclisation was carried out 
using (Me3Sn)2 (table 12). Rutaecarpine 145 was produced as the sole product in 
good yield after 6 h. Increasing the reaction time lead to a mixture of inseparable 
products. The reaction was carried out using slow addition of Bu3SnH which 
produced rutaecarpine 145 and reduced quinazolinone 322. Earlier six-membered aryl 
radical cyclisations had shown that Bu3SnH could be used to form cyclised products 
and therefore the formation of rutaecarpine from the slow Bu3SnH reaction was not 
unexpected. Due to time constraints no further radical reactions were attempted. 
Table 12. Radical synthesis of rutaecarpine 
~N~ U~,J Br-( __ Jlj -t--8-uP_h_ 
N N 
radical 
321 H 
rutaecarpine 
145 
Radical reagent (equiv.) Initiator (equiv.) Time 
6h 
24h 
12 h 
(Me3Sn)2 (3.0) hu and !!. 
(Me3Sn)2 (3.0) hu and!!. 
Bu3SnH (2.4) * Et3B (46) 
* The reaction was carried out in toluene. 
3.5 Conclusions 
oO N 
322 
Product 
145 (55%) 
Unidentifiable 
145 (15%) 322 (57%) 
In this chapter there has been a discussion of the syntheses of important natural 
products luotonin A and rutaecarpine. A brief introduction to each target has also been 
given along with previous syntheses and important biological effects. Luotonin A was 
successfully prepared using a variety of radical reagents. The planned procedure for 
the synthesis of rutaecarpine is the first radical synthesis of this natural product. The 
syntheses show that cyclisation of heteroaryl radicals on the C-2 of the 3H-
quinazolin-4-one provide a productive route to natural products. Considerable effort 
was made to prepare a C-2 halogenated indole building block. Unfortunately time did 
not permit us to fully exploit this building block in the synthesis of other indole 
alkaloids. 
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Chapter 4. Acyl and Alkenyl radical cyclisations onto 3H.:.quinazolin-
4-one 
Having carried out alkyl, aryl and heteroaryl radical cyclisations onto quinazolinones 
the focus turned to the radical synthesis of two different natural products, tryptanthrin 
146 and isaindigotone 323 (scheme 115). Neither of these natural products have been 
prepared using radical chemistry. It was envisaged the synthesis of tryptanthrin 146 
could be reached using the acyl radical 324 and isaindigotone via the alkenyl radical 
325. 
d:N;? 0 d.:N N~~ N~j ~ 
146 0 323 
11 11 OMe 
d:N:P 0 d.:N\ N~\_. ~ ~ .)\_.,. N ~ 
0 
324 325 
OMe 
Scheme 115. Retrosyntheses oftryptanthrin and isaindigotone. 
4.1 Introduction to tryptanthrin 
Tryptanthrin 146 has been shown to have a rich and varied biological activity. 102 It is 
isolated from Isatis tinctoria commonly known as woad. 102 For many years this plant 
has been used as a herbal remedy.102 A recent report attributed anti-inflammatory 
activity from the leaves of woad to tryptanthrin as the principle source of this effect. 102 
In particular the HPLC-based activity profiling of tryptanthrin highlighted 
cyclooxygenase-2 (COX-2) inhibition. Hamburger has studied in great detail the 
biological activity oftryptanthrin. 102 
In vitro tests on tryptanthrin implicated that it has key enzymatic effects in 
eicosanoids. It has shown almost a hundred fold selectivity to COX-2 inhibition over 
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COX-I, by suppressing 6-ketoprostaglandin F1a as well as inhibition of 5-
lipoxygenase (via inhibition of leukotriene B4). This makes it a rare example of a 
plant metabolite that shows dual effects on prostaglandin and leukotriene synthesis. 104 
Tryptanthrin has also shown inhibition of interferon-y and interleukin-2 I production 
of lymphocytes in response to Staphylococcal enterotoxin B. This means it has 
potential applications in control of food borne disease of the intestine. 105 
Hamburger observed that tryptanthrin could be absorbed through the skin when 
handling the leaves of Isatis tinctoria. However, in solution the pure alkaloid could 
not be absorbed through the skin. 106 This is important to note for laboratory workers. 
There are several syntheses oftryptanthrin in the literature. For example, Ajaykumur 
et al. have carried out a rapid synthesis of substituted tryptanthrin analogues 328 
using the condensation of substituted isatoic anhydrides 326 and isatins 327 in boiling 
toluene with triethylamine (scheme 116). A library of analogues of tryptanthrin was 
prepared using this method. 107 
R
1
-J? \--(}R2_E_t3_N_._ ~N~O O~N)-_./ toluene 
H H 
326 327 328 (70-85%} 
Scheme 116. Rapid access to substituted tryptanthrin analogues. 
4.2 Radical synthesis of tryptanthrin 
The planned synthesis involved acyl radical cyclisation onto C-2 of 3H-quinazolin-4-
on (scheme 117). There was a reliance that the acyl radical would cyclise and not 
decarbonylate. It was envisaged that loss of CO from the acyl radical intermediate 
would not be a problem because of the strong sp2 carbon bond. In the introduction, 
reports of reactions by Bennasar in which 2-acyl indolyl radicals were used in 
cyclisations without the loss of CO have been given (scheme 27).26 There are no 
examples of 5-exo/endo acyl radical cyclisations onto heteroarenes in the literature to 
our knowledge.108 
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Generation of the acyl radical 324 from the stable acyl selanide 329 was envisaged 
(scheme 117). Acyl selanides are easily formed from the respective carboxylic acids 
330. Unlike the other syntheses the required carboxylic acid 330 could not be 
prepared by N-3 alkylation. Therefore, it was planned to synthesise the acid 330 using 
condensation chemistry derived from anthranilic acid 169. 
~C02H 
~ NH2 
169 
OJQ oO·~O~Ph 
329 
Scheme 117. Retrosynthesis oftryptanthrin using an acyl radical cyclisation. 
The intermediate 331, which has been reported by Khajavi et al. via the condensation 
of anthranilic acid and trimethyl orthoformate; looked a useful precursor (scheme 
118).'09 Reaction between the intermediate 331 and anthranilic acid 169 should give 
the acid 330. However, all attempts to make the intermediate 331 using the method 
reported by Khajavi failed and a new route was investigated to prepare the acid 330. 
CCC02H + NH2 
169 
Scheme 118. 
HC(OMe)J 
o o JQI 
reflux ~O ~N ~ 
·-X-~~ ·---------- ~NJ co2H 
331 r(YC02H 330 
~NH2 
169 
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Aliterature method reported by Johne and Stisse involving the condensation ofisatoic 
anhydride with anthranilic acid to form the amide 332 was used instead (scheme 
119).110 The amide 332 was reacted crude after workup with triethyl orthoformate to 
yield the acid 330. An attempt to carry out the reaction neat in a one- pot procedure 
using isatoic anhydride, anthranilic acid and excess HC(OEt)3 resulted in a mixture of 
unidentifiable products. The acid 330 was readily converted to the acyl selanide 329 
yielding the desired tryptanthrin radical precursor. 
reflux 
o() 
HC(OEI)s, ~N~ 
---- U~~. . J COzH MeOH, reflux N 
4 h 330 (40%) 
J 
(PhSe)z, Bu3P 
DCM OJ? c) ;SePh 
329 (73%) 
Scheme 119. Synthesis oftryptanthrin acyl radical precursor 
Bennasar has shown a number of unusual products arising from acyl selanide radical 
cyclisations onto heteroarenes.111 For example the reaction of the 2-acylselanide 333 
with AIBN and light irradiation produced the addition product 334 and the over 
oxidised product 335 (scheme 120). As previously stated, it was believed there are no 
examples of 5-exo/endo acyl radical cyclisations onto heteroarenes. 
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AIBN, benzene reflux 
300 W sun lamp 
Scheme 120. Unusual acyl radical cyclisation products. 
334 
(1:1) 
An initial attempt at radical cyclisation of the acyl selanide 329 was carried out using 
(Me3Sn)2 in t-BuPh (table 13). After careful workup and purification a trace amount of 
tryptanthrin 146 was recovered along with an unidentified compound. When the 
reaction was carried out in benzene which has a lower boiling point, and with 
irradiation, no R3Sn• species was required to obtain tryptanthrin in a higher yield. The 
reaction mixture turned yellow before the boiling point had been reached. With this in 
mind, a third reaction was carried out at rt with just irradiation from a 300 W 
sunlamp. This resulted in the highest yield oftryptanthrin 146 (15%). The yields are 
poor, but as already mentioned no examples of this type of acyl radical cyclisation 
have been reported in the literature. An attempt to carry out a reaction using hu/ AIBN 
conditions as described by Bennasar lead to a mixture of unidentifiable productsY1 A 
final reaction was carried out in the absence of light. irradiation, and the acyl selanide 
329 was heated under reflux in benzene. Only starting material was recovered from 
this reaction, showing light irradiation was crucial to radical cyclisation. 
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Table 13. Radical cyclisation of329 yielding tryptanthrin 146. 
o() ~~ radical Ut...J COSePh benzene 
N d.:r? 
329 146 0 
Reagent (equiv.) Initiator Time Product 
(Me3Sn)2 (3.0) * hu 4 h Tryptanthrin 146 (3%) +unidentifiable 
None hu 10 h Tryptanthrin 146 (13%) +unidentifiable 
None** hu 12 h Tryptanthrin 146 (15%) +unidentifiable 
None No 24 h SM 
None hu/AIBN 8 h unidentifiable 
* The reaction was carried out in t-BuPh. 
**The reaction was carried out at rt. 
The mechanism of the formation of tryptanthrin in the absence of any radical reagent 
is unclear. The reaction rapidly turns to a yellow solution under light irradiation and 
the major isolated product is (PhSe)z. No characteristic smell was detected, indicating 
the formation of phenylselanol is unlikely. A putative mechanism, involving initial 
homolysis ofthe Se-CO bond ofthe acyl selanide 329 is shown in scheme 121. The 
subsequent acyl radical 324 can cyclise and the phenylselanyl radical can propagate 
the reaction by forming diphenyl diselanide either by abstraction of PhSe from the 
acyl selanide or by dimerisation. The rearomatisation step yielding tryptanthrin 146 
could arise from disproportionation of the a-radical 336. However, no products other 
than tryptanthrin and diphenyl diselanide were identified. The cyclised reduced 
quinazolinone 337 was not isolated. 
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Scheme 121. Putative radical mechanism for the synthesis oftryptanthrin. 
Although the cyclised reduced quinazolinone 337 was not isolated, it may have been 
an unidentified reaction product. Its formation could be aided by the extra resonance 
stability from tautomer 338 which includes a weak hydrogen bonding interaction 
(scheme 122). It is stressed this is only a proposed mechanism based on observations 
from the reaction. 
qx)o~~)o 
0 H 0........._ ,' H 
337 H 338 
Scheme 122. Possible resonance stabilisation of dihydrotryptanthrin. 
Although the yields oftryptanthrin 146 were low, the new protocol described gives a 
novel use of 5-exo/endo acyl radical cyclisation onto heteroarenes and a novel radical 
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synthesis oftryptanthrin. The reason for the success ofthe 5-exo/endo cyclisation may 
be explained by the 1-N to 2-C imine bond being localised, and not fully incorporated 
into the aromatic ring. This means the reaction could be envisaged as a 5-exo 
cyclisation onto an imine rather than 5-exo/endo cyclisation onto a heteroarene. 
An authentic sample of tryptanthrin 146 was prepared using the method described by 
Ajaykumur et al. (scheme 123).107 The 1H and 13C NMR spectra were identical to the 
product of the radical syntheses of tryptanthrin. Mitscher et al. have shown NaH can 
be used instead ofEt3N, but this method failed to yield tryptanthrin in our hands.112 
~0 l:J_N}= 
H 
0 
~~ 0 N 
H 
d,:;:p 
146 (88%} 0 
toluene 
Scheme 123. Non radical synthesis of an authentic sample oftryptanthrin. 
4.3 Radical synthesis of six-membered ring tryptanthrin analogue 
The synthesis of the six-membered ring analogue 339 of tryptanthrin 146 was also 
investigated (scheme 124). The aim was to compare the 5-exo acyl radical cyclisation 
with the 6-exo acyl radical cyclisation ofthe intermediate 341. From previous studies 
it was presumed that the cyclisation of the acyl radical340 would be more favourable, 
and give the tetracyclic compound 339 in good yield. Numerous examples have 
already shown that 6-exo cyclisation is strongly favoured over 5-exo/endo cyclisation 
onto aromatic rings. Similarly to the previous tryptanthrin synthesis, it was planned to 
access the acyl radical from the acyl selanide 341. 
d.:t~ ~ a>YJ ~ o)'~ePh 
339 ° 340 ° 341 
Scheme 124. Planned 6-exo acyl radical cyclisation. 
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The acyl selanide 341 proved harder to obtain than expected. Bromination of the o-
methyl toluate 342 was carried using a literature procedure, but in poor yield (scheme 
125).113 This reaction had previously been used and yielded the 2-
(bromomethyl)toluate 343 was obtained in poor yield. Attempts at using a large 
excess ofNBS had no effect, nor did carrying the reaction in the dark. Alkylation of 
3H-quinazolin-4-one 219 using the 2-(bromomethyl)toluate 343 gave an overall 
disappointing yield of 34% of the quinazolinone ester 344. Ester hydrolysis was 
carried out followed by formation of the acyl selenide using the same procedure for 
the previous tryptanthrin synthesis. The radical precursor acyl selenide 341 proved to 
be stable in air. 
0 0 2Me NBS,AIBN cyclohexane 
342 
(r2~~BuOK ~N~Me 
UoMF~jl) 
343 ~NH 
~u) 
344 (34%} l i. LiOH, EtOH, H20 
ii. (PhSe}2, Bu3P 
DCM N 
219 ~N~ePh 
~N) u 
341 (34%} 
Scheme 125. Synthesis of the radical precursor 341. 
With the acyl selanide 341 in hand, various radical conditions were investigated to 
form the tetracycle 339. It quickly became apparent that the formation of the 
tetracycle 339 was not favourable (table 14). The first attempt at cyclisation using 
(Me3Sn)2 produced a mixture of unidentifiable products. When this method was 
repeated, under a shortened reaction time, the unexpected hydroxytetracycle 345 was 
formed in moderate yield. Various other radical conditions were tried and resulted in 
starting material recovery or unidentifiable products. The other result of note occurred 
when the reaction was carried using only light irradiation. A 1H NMR spectra of the 
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crude reaction mixture appeared to show a peak at 10 ppm, which may have 
corresponded to an aldehyde. However, the aldehyde was not isolated. 
Table 14. Attempts at forming tetracycle 339. 
~N~·::dical 
~~.J V 12h N 
341 
Reagents (equiv.)* 
(Me3Sn)2 (3.0) 
(Me3Sn)2 (3.0) ** 
hu 
Et3B (10.0) 
AIBN (3.0) 
TIMSS (3.0) and Et3B (10) 
* The reaction time was 12 h. 
**The reaction time was 3 h. 
~7111~~~ ~N'~~N'~ 
339 0 345 0 
Solvent Reflux Product 
Benzene Yes Unidentifiable 
Benzene Yes 345 (40%) 
Me Ph No Possible aldehyde 
DCM No SM 
Me Ph Yes Unidentifiable 
Me Ph No Unidentifiable 
An X-ray crystal structure was obtained for the tetracycle 345 (figure 24). Until this 
point, the 1H and 13C NMR spectra of this compound had been perplexing as 
identification ofthe formation of a hydroxyl group had not been envisaged. 
Figure 24. X-ray structure ofhydroxytetracycle 345. 
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A possible mechanism for the formation of the hydroxytetracycle 345 is shown in the 
scheme 126. Firstly, the acyl radical 340 undergoes a 6-exo cyclisation onto the 
quinazolinone. After rearomatisation of the n-:-intermediate 346 by loss ofH• by some 
means (most likely Me• or MeOO•) quinazolinone tetracycle 339 is produced. MeSn• 
radicals can react rapidly with Oz to form Me3SnO-O• radicals which could then 
abstract one of the benzylic hydrogens, forming the benzylic stabilised radical 347. 
Presumably the benzylic radical 347 has a sufficiently long lifetime to react further 
with Me3SnO-O• and form the intermediate 348. This could break down to leave the 
oxy radical intermediate 349, which after H-abstraction forms the hydroxytetracycle 
341. It is surprising that the hydroxytetracycle 341 did not go on further to form the 
oxidised product 350. 
~Nyo U;J: I~ 
340 d 
~~o I"'U .... ~ ~ N 
349 0 
~ 
oeo~oHI"' ~ ~ N 
345 0 
~- . . 
Me,Sn· o-o Me3Sn0-0 ) 
0 0 H H 
6-exo (~-~ --: :wo~ "' ~ ~~~ ~~----) -- ~ U .... ~ ~ N N 
11 
346 o 339 I o 
(-H·)t 
-----· 
~q,o I"'U .... ~ ~ N 
350 ° 
Scheme 126. Possible mechanism for formation of the hydroxytetracycle 345. 
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Whilst carrying out radical investigations of the acyl six-membered ring synthesis, 
simultaneous attempts to prepare the related acyl selenide precursor 351 were made 
(scheme 127). It was hoped that the acyl selanide precursor 351 might be easier to 
prepare and provide some interesting results given the apparent odd results previously 
obtained. It was considered that the acyl selenide analogue 351 would be easy to 
prepare from the acid 352 which in turn could be prepared by the reaction between 
3H-quinazolin-4-one 219 and phthalic anhydride 353. 
~NH U~.J N 
351 352 0~ 
0 353 
Scheme 127. Planned route to new the acyl precursors 351. 
However, the reaction of 3H-quinazolin-4-one with phthalic anhydride proved 
unsuccessful under a variety of reaction conditions (table 15). It was clear that the 3-
N quinazolinone anion 356 was being formed, because the colour of the reaction 
mixture turned yellow, however, no indication of the possible alkylation with phthalic 
anhydride 353 was seen in any crude 1H NMR spectra. 
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Table 15. Attempted synthesis ofthe acid 352. 
~NH lJl~) N 
219 
0~ 
0 353 
t-BuOK 
------------
352 
Solvent Temperature Product 
Unidentifiable 
Unidentifiable 
Unidentifiable 
Unidentifiable 
Unidentifiable 
Unidentifiable 
DMF rt 
DMF 80 ·c 
THF Reflux 
DMF* rt 
DMF* Reflux 
MeCN* Reflux 
*A catalytic amount ofDMAP added. 
An attempt to prepare the acid 352 starting from anthranilamide 354 and isatoic 
anhydride was undertaken (scheme 128). However, this route proved unsuccessful 
and the amide 355 was never isolated. An attempt to carry out this synthesis in one-
pot also failed. 
0 0 CO~ 0 0 CO~ 
oH X ~ N ":: ~ N ":: 
·--- ~---- ~ 1 H 1 .0 ----x--- ~ 1 J 1 .0 
H2N I NH2 N 355 352 
H02C 
354 
Scheme 128. Attempted synthesis ofthe acid 352. 
A final attempt to synthesise the acyl selanide 351 was made using phthaloyl 
dichloride 357 (scheme 129). It was hoped the 3-N quinazolinone anion 356 would 
react with phthaloyl dichloride 357. The crude product 358 (if formed) of this reaction 
was reacted with PhSe8, but no acyl selenide 351 was formed. Mixtures of 
unidentifiable products were obtained. 
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~e 
N 
356 ·--x-
CIJo0 I"'
Cl ~ 
357 
358 351 
0 
Scheme 129. Attempted synthesis of the acyl selenide 351. 
With attempts to form the acyl selanide 351 not proving profitable and failed attempts 
to form desired tetracycle 339 under radical condition, work was halted on acyl 
radical studies. The results from cyclisations of acyl radicals onto C-2 of 3H-
quinazolin-4-one 219, are unusual and in most part unexplained. Cyclisation of the 
five:..membered ring to form tryptanthrin was observed, albeit in low yield. The six-
membered ring acyl radical cyclisations results were disappointing, however, the 
unexpected hydroxytetracycle 345 was obtained in moderate yield. 
4.4 Investigations into alkenyl and vinyl radical cyclisations onto 3H-
quinazolin-4-one 
Having investigated aryl, alkyl and acyl radical cyclisations onto the 3H-
quinazolinone moiety, attention was turned to the investigation of alkenyl radical 
cyclisations in the synthesis of natural product isaindigotone 323 (scheme 130). Only 
recently isolated, its biological activity is still under investigation. 114 To date, there are 
very few syntheses of this quinazolinone natural product. The only notable synthesis 
was by Liu et al. using a one-pot microwave reaction already shown for the synthesis 
of mackinazolinone 148 (scheme 83).82 The planned synthesis of isaindigotone 
required alkylation of 3H-quinazolin-4-one with alkenyl radical precursor 359 side 
chain. 
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00~ 
323 ~ 
isaindigotone OH 
OMe 
cCO NH Br ) N 
OMe 
OH 
OMe 
219 359 
Scheme 130. Retrosynthesis of isaindigotone. 
Alkenyl radical cyclisations onto the 3H-quinazolin-4-one template are unknown and 
therefore, it was decided to investigate a number of simpler systems before attempting 
the total synthesis of isaindigotone (scheme 131 ). The unhindered vinyl 360 and 
alkenyl 361 radicals were planned as the first experiments. This required the synthesis 
of substituted alkenes 363 and 364 for alkylation with 3H-quinazolin-4-one. The 
simpler alkenyl radical analogue of isaindigotone 362 was also planned from alkene 
365 which did not contain the methoxy or hydroxy groups present on isaindigotone. 
There is a possibility these groups may hinder the radical cyclisation. 
0 0 0 
cCNJ cCN~·' cCN J~ N.)\.....·~ N)'--'. ~ N C· 
360 
361 ~ 362 ~ ~ 
X~ X~ x~Q 1.2 Br 
363 364 X 365 X I ~ 
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Scheme 131. Planned routes to vinyl and alkenyl radical cyclisations onto 3H-
quinazolin-4-one 
The initial investigation began with the study of the vinyl radical 360 (scheme 132). 
The planned retrosynthesis involved a Wittig reaction to make the key vinyl bromide 
366."5 The aldehyde 367 could be reached by either alkylation of 3H-quinazolin-4-
one using 1-hydroxy-3-chloropropane and then oxidation or condensation chemistry 
of anthranilic acid, 1-amino-3-hydroxypropane and triethyl orthoformate. 
360 366 Br 367 
Scheme 132. Retro synthesis ofvinyl radical366. 
A condensation chemistry route with anthranilic acid was chosen (scheme 133). The 
reaction of anthranilic acid 169 and triethyl orthoformate was carried out followed by 
addition of 3-aminopropan-1-ol after the removal of excess triethyl orthoformate. The 
previous attempt to use the intermediate 331 reported by Khajavi et al. had been 
unsuccessful (scheme 118).109 The overall yield of alcohol 368 was moderate. An 
attempt to adapt this procedure into a one-pot synthesis failed. 
o6 N 
169 331 
Scheme 133. Synthesis of the alcohol precursor 368. 
With the alcohol 368 in hand, oxidation was carried out to the aldehyde 367 using 2-
iodoxybenzoic acid (IBX) in excellent yield (scheme 134). Kuroda and Masakatsu 
have reported Wittig reactions to form vinylbromides. 115 The authors emphasized the 
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problem of the acetylene formation in the presence of an excess of base. The Wittig 
reaction with aldehyde 367 and bromomethylenetriphenylphosphorane was found to 
be problematic. Alkyne 369 was never isolated as a reaction side product. Eventually, 
the vinyl bromide 366 was formed in low yield (table 16). 
0 
OCN~OH IBX, EtOAc ) N reflux 
0 
OCN~o ) . N 
368 367 (93%) 
ci('~ ---1 Table16 
369 undesired by product 
Scheme 134. Synthesis of the vinyl bromide 366. 
Table 16. Wittig reaction conditions (see scheme 134) 
Base Temperature Solvent Product 
t-BuLi -78°C THF Unidentifiable 
n-BuLi -78°C THF Unidentifiable 
NaH rt DCM Unidentifiable 
t-BuOK rt DCM Unidentifiable 
t-BuOK -78°C THF 366 (15%) 
The radical reaction of vinyl bromide 366 using (Me3Sn)z resulted in a mixture of 
unidentifiable products. Given the poor yield of the Wittig reaction it was decided not 
to pursue this work any further. It was decided to concentrate on the synthesis of 
alkene radicals 360 and 361 which were more closely related to isaindigotone. 
The synthesis of the bromoalkene quinazolinone 372 was the first target (scheme 135) 
which could undergo radical cyclisation to form a six-membered ring onto the 3H-
quinazolin-4-one 219 moiety. The literature procedure of Kollner and Molander was 
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chosen for the bromination of alkynes using HBr in AcOH. 116 Using Kollner and 
Molander's methodology, 5-chloro-1-pentyne was cleanly converted to the 
bromoalkene 370. A Finkelstein reaction was carried out to form iodobromo alkene 
371. Alkylation onto the 3H-quinazolin-4-one 219 gave the desired bromoalkene 
quinazolinone 372. 
Cl~ HBr Cl~ 
370 (66%) Br 
(A eO H) 
Nal, acetone 
reflux 
I~ 
Br 
371 (72%) 
HN~I ~ I t-BuOK ~ ... N DMF 
N 
219 
s=<:o 
372 (47%) 
Scheme 135. Synthesis of the vinyl radical precursor 372. 
To reduce the number of synthetic step it was decided to by alkylate 3H-quinazolin-4-
one 219 with 5-chloro-1-pentyne (scheme 136). However, the alkylation using 5-
chloro-1-pentyne to produce the terminal alkyne 373 proceeded in a poor yield. It was 
disappointing when this alkyne was treated with HBr in DCM, no bromination took 
place, even after two days. Complete recovery of the starting material was observed. 
This result was most unexpected and given the poor yield of the alkylation reaction 
this particular route was not investigated further. It was decided to use the previous 
synthesis ofbromoalkene quinazolinone 372 (scheme 129). 
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DMF 
Cl~ t-BuOK, Nal, 
cCO NH ) N 
219 
373 (10%) 
I 
>k HBr (in AcOH), DCM 
:"- no reaction 
t 
o6~ N 
372 
Scheme 136. Attempted synthesis of the bromoalkene quinazolinone 372. 
However, the radical reaction of the bromoalkene quinazolinone 372 did not prove 
straightforward. The initial attempts using (Me3Sn)2 resulted in a mixture of starting 
material and unidentifiable products (table 17). The reaction was repeated using a 
fresh ampoule of (Me3Sn)2, but the reaction failed again. Use of Bu3SnH and Et3B 
also failed. A GC-MS chromatogram ofthis reaction revealed three peaks. Two of the 
peaks on the chromatogram are likely to be the cyclised quinazolinone 374 and the 
reduced quinazolinone 376. No clean 1H NMR spectra could be obtained from this 
reaction. In the reaction using Bu3SnH and AIBN, a 1H NMR spectrum of the reduced 
quinazolinone 376 was obtained. However, the yield of this product was low (<5%). 
The reduced cyclised quinazolinone 375 was never identified in any of these 
reactions. The reduced quinazolinone 376 was prepared unambiguously via the 
reaction of 3H-quinazolin-4-one 219, t-BuOK and 5-bromopent-1-ene in DMF in 
good yield (44%) to help with characterisation. 
Ill 
Table 17. Attempted radical reactions ofthe alkenylbromide 372. 
(N~ _rad-ical 
/rB'l,_N)l) MePh 
372 
Radical reagent (equiv.) Initiator (equiv.) Reflux Product 
(MeJSn)2(3.0)* hu Yes SM + decomposition 
Bu3SnH ( 4.0) Et3B (1 0) No SM + decomposition 
Bu3SnH (2.0) Et3B (1 0) No SM + decomposition 
Bu3SnH (2.2) AIBN (2.2) Yes 376 (<5%) decomposition 
TIMSS (3.0) Et3B (10) No SM +decomposition 
*The reaction was carried out in t-BuPh. 
An explanation for the failures may be explained by the potential addition of •SnR3 to 
the bromoalkene 372 (scheme 137). Quinazolinone radical intermediate 377 could 
react further to produce quinazolinone 378. Quinazolinone 378 was not isolated, but 
its formation cannot be ruled out. 
JN=< ~NJBr 
372 
~·SnR3 
0 
~N~SnR3 ~~.J Br 
N l \._ 377 ·SnR3 
OCo~ N _, SnR3 J N 
378 
Scheme 137. Possible unwanted radical side reactions. 
With the unexpected failure of the radical reaction and having a large quantity of the 
precursor to hand it was chosen to investigate some Pd-catalysed reactions (table 18). 
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These proved unsuccessful and were not pursued as new work was undertaken. There 
was disappointment that no Pd-catalysed reactions for bromoalkenes were observed. 
These results were similar to those observed in the case of arylbromides above. 
Table 18. Failed Heck conditions 
rN~ _He_ck_.. 
frs'l,NM 
372 
0 
~~ 
374 
Pd source Ligand Base Solvent 
Pdz(dba)3 PBu3 CyzNMe Dioxane 
Pdz(dba)3 PBu3 NEt3 Dioxane 
Pd(OAc)z PPh3 i-PrzNEt DMF 
Pd(OAc)z PPh3 NEt3 neat 
Pd(OAc)z PPh3 KzC03 DMF 
Pd(PPh3)4 none NEh MeCN 
Pd(PPh3)4 none i-PrzNEt THF 
*The reaction was carried out in a microwave reactor. 
Temperature 
Reflux 
Reflux 
Reflux 
Reflux 
Reflux 
10 min* 
10 min * 
With both radical and Pd-catalysed cyclisations not provmg successful for the 
bromoalkenequinazolinone 372, it was decided to move onto the synthesis of the 
alkene 379 (scheme 138). It was hoped dibromo compound 380 could be accessed via 
the ring-opening of the cyclopropene 381 with CuBrz as shown by Brinker and 
Nordvik.117 The cyclopropene 381 should be synthesised from a Wittig reaction of 4-
methylbenzaldehyde 382 and the commercially available cyclopropane Wittig reagent 
383. 
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Scheme 138. Retrosynthesis of the alkene radical precursor 379. 
After several attempts, the Wittig reaction was successfully carried out (table 19). The 
reaction worked best when the Wittig reagent, the base and the aldehyde were reacted 
in one-pot. This indicated the intermediate ylid has a short lifetime. 
Table 19. Wittig synthesis of the cyclopropene 383. 
---cyo• [>--0 Wittig PPh3(Br) 
382 383 
Base Solvent Time Temperature Product 
NaH THF 12 h Reflux SM 
n-BuLi THF 12 h -78 ·c- rt Unidentifiable 
NaH(slow) THF (ultra dry) 4h Reflux SM 
NaH (slow) THF +4A sieves 12 h Reflux SM 
t-BuOK DCM 12 h rt 381 (<5%) 
t-BuOK DCM 12 h Reflux 381 (44%) 
After successfully preparing the cyclopropene 381, the ring-opening reaction was 
carried out using CuBr2 to yield dibromide 380 (scheme 139). It wasn't envisage that 
the alkylation of 3H-quinazolin-4-one 219 using the dibromide 380 would prove 
difficult not prove difficult. However, after several attempts, it was realised that the 
styrene 384 was the major reaction product and the yield of the alkylation 
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quinazolinone 379 was lower than expected. This is the first example of an attempted 
alkylation of 3H-quinazolin-4-one 219 where the elimination reaction competed with 
the SN2 substitution. Finally a small amount of the alkylated product 379 was obtained 
which was reacted under radical conditions using (Me3Sn)2. It was disappointing that 
cyclisation did not occur and a number of unidentifiable products were recovered. The 
reaction was investigated twice more using Bu3SnH!Et3B and Bu3SnH/ AIBN but this 
also resulted in number of unidentifiable products being produced. The cyclised 
product quinazolinone 385 was never obtained. 
~ 
384 
Br Br~~ ('N~ 
DMF 0 ~Br~Nv ~NH 37~ (20%) 
ul.i) "-:/ Failed 
N /:"- radical 
DCM 
Me 
;l~ 
Af"N 
---\J 385 
219 381 380 (60%) 
Scheme 139. Failed radical reactions ofthe hindered alkene. 
A final alkene radical synthesis was attempted in which it was hoped to form a six-
membered ring quinazolinone 389 using radical cyclisation using with the 
bromoalkene quinazolinone 388 similar to quinazolinone 385 (scheme 140). Key to 
this synthesis was the bromination of alkyne 386 which had been prepared via a 
literature procedure. 118 However, bromination using HBr appeared to give a mixture 
of unidentified products. As a result, dibromide 387 was never obtained. Had time 
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permitted, further investigations of this route would have been pursued. It is believed 
that bromination of the alkyne could be achieved given more time. 
Scheme 140. 
1 ,3-dibromo propane 
n-Buli, THF 386(80%) 
I 
I 
)KHBr 
I 
I 
't 
Br 
N~ not attempted Br~t..~ •-·--·-··-··· 
N 
I 388 ·-----••• 
~Br V Br 
' 
'"'-..., 
radical reaction ·, 
not attempted 
387 
N:J)o I "' 
~ 0 
N 
389 
It was disappointing that alkenyl and vinyl radical cyclisations onto quinazolinones 
were not successful. It has been shown that these types of radical cyclisations onto 
quinazolinones are largely unfavourable. Had time permitted further attempts at 
radical cyclisations would have been carried out. 
4.5 Conclusions 
This chapter concludes the work in natural product synthesis usmg the radical 
cyclisation chemistry. A novel synthesis of tryptanthrin 146 has been shown and 
further discussion of acyl radical cyclisations. An unusual hydroxytetracycle 345 was 
identified in the six-membered ring radical cyclisation. The discussion and 
investigations of vinyl radical cyclisations onto 3H-quinazolin-4-ones has also been 
shown. This was not successful and no radical cyclisation products were obtained 
from these reactions. It had been hoped this would allow access to the natural product 
isaindigotone 323. 
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Chapter 5. Syntheses of 2-bromo-3H-quinazolin-4-one 
During the investigations of radical cyclisations, it was also considered whether it 
would be possible to form a radical on the C-2 position o~ the quinazolinone 390 
(scheme 141). At the time no reports of the insertion of suitable functionality (e.g. 
bromine) have been described at this position on the 3H-quinazolin-4-one 391. It was 
hoped that if it could be formed open up a new area of radical reactions. 
391 
Scheme 141. Proposed radical cyclisation from C-2 of3H-quinazolin-4-one. 
5.1 Investigation into the syntheses of a C-2 radical quinazolinone 
building block 
2-Chloro-3H-quinazolin-4-one 394 is well reported in the literature and can be 
prepared from the 2,4-diketoquinazolinone 392 (scheme 142).119 It was hoped that a 
method could be developed to convert the chlorine of 2-chloro-3H-quinazolin-4-one 
394 to a better radical leaving group as in quinazolinone 396. 2-Chloro-3H-
quinazolin-4-one 394 was prepared using a procedure by Hess. It was found the 2,4-
diketoquinazolinone 392 and 2-chloro-3H-quinazolin-4-one 394 difficult to handle, 
both were insoluble in organic solvents, even m DMF. Hydrolysis of 2,4-
dichloroquinazolinone 393 occurs solely at C-4. Confirmation of the 2-
chloroquinazolinone 394 came from an IR spectral analysis, which clearly showed a 
secondary amide carbonyl peak at 1653 cm·1• 
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N, N-diethylamine 
393 (17%) 394 (12%) 
395 
Scheme 142. Synthesis of2-chloroquinazolinone. 
The question remained whether 2-chloro-3H-quinazolin-4-one 394 could be converted 
to the 2-iodo-3H-quinazolin-4-one 396 via a Finkelstein SNAr type reaction (scheme 
143). Normally Finkelstein reactions are limited to alkyl halides. However, Janeba et 
al. have shown N-heterocycles can also undergo these reactions in the presence of an 
acid such as TF A. 120 Janeba showed that 6-chloro purine 397 was converted to 6-
iodopurine 398. 
Scheme 143. 
0 
~NH Finkelstein 
~NAc~--------------
394 
397 
Nal, TFA 
2-butanone 
-so ·c to -40 ·c 
~NH ~~I 
396 
398 (80%) 
Before attempting this reaction on 2-chloro-3H-quinazolin-4-one 394, the simpler 2-
chloroquinoline 399 substrate was tested first (scheme 144). The method appeared to 
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work well using Nal and TF A and 2-iodoquinoline 400 was formed in good yield. It 
was presumed the acid is required to protonate the quinoline to facilitate nucleophilic 
attack of the iodine. Janeba et al. reported that such reactions need to be carried out at 
low temperature to increase the lifetime of the intermediate. 120 However, it was found 
that the low temperature was not necessary and reached the highest yield of 2-
icidoquinoline 400 at room temperature. Attempt to carry out the same reaction using 
2-chloro-3H-quinazolin-4-one 394, gave several unidentifiable products. It was clear 
that reaction was not compatible using the 2-chloroquinazolin-4-one 394 and no 
further attempts at preparing 2-iodo-3H-quinazolin-4-one 396 were made using this 
reaction. 
Nal, TFA m m 2-butanone N Cl N I 
399 400 (56%) 
0 0 
Nal, TFA oCNH OCNH 
----X-----
NACI NAI 2-butanone 
394 396 
Scheme 144. 
Next, it was considered if the 2-chloro-3H-quinazolin-4-one 394 could be converted 
to the 2-(phenylselanyl)-3H-quinazolin-4-one 401 even though there was uncertianty 
whether this would be synthetically useful in radical chemistry (scheme 145). The 
results previous from the 3-(2-hydroxyethyl)-2-(phenylselanyl)-NBoc-indole 319 
showed no reaction when treated under radical conditions (scheme 112). 
Nevertheless, it was decided to prepare the selanide which was carried out by the 
reaction of (PhSe)2 and K-selectride in THF, which is a well known method of 
forming imidoyl selanides from their chloro analogues within the group.37 Although 
the 2-(phenylselanyl)-3H-quinazolin-4-one 401 was made in reasonable yield, no 
reaction took place when treated under radical conditions using Bu3SnH/Et3B. The 
sp2C-Se bond is obviously too strong. There are no reports in the literature of cleaving 
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the Ph-Se bond in radical reactions so the result is not unusual. Given this result and 
that ofthe 3-(2-hydroxyethyl)-2-(phenylselanyl)-NBoc-indole 319, this work was not 
continued. Given these disappointing results in attempting to make a suitable C-2 
radical quinazolin-4-one precursor inspiration from the literature was sought. 
K-selectride cto R3sn· cto NH '\.. -:?' NH A ----X---- ~ I ) N SePh N (PhSe)2, THF 
401 (36%} 219 
Scheme 145. Unsuccessful radical reaction of2-phenylselanyl-3H-quinazolin-4-one. 
5.2 Introduction to bromination of thioamides and thioureas 
A reaction by Hull and Swain caught our attention (scheme 146). The authors had 
reported the reaction of 1,2,3,4-tetrahydro-2-thioxoquinazolin-4-yl-acetic acid 402 
with bromine in acetic acid, leading to 2-bromo-3,4-dihydroquinazolin-4-yl-acetic 
acid 403. 121 This immediately posed the question whether the same reaction could be 
carried out to provide a route to C-2 substituted quinazolin-4-one 395. Hull and Swain 
gave no account of the possible mechanism. It was decided to look more closely in the 
literature to find out more about the reaction of thioureas and thioamides with 
bromine. The next few pages consist of an introduction covering the notable reactions 
of thioureas and thioamides with bromine or other brominating species. This short 
review is intended to provide an introduction into the work, which was carried out to 
form a 2-bromo-3H-quinazolin-4-one building block 241 (scheme 77). 
OCCO,H oCco,H 
NH 
Br2 NH 
NAS AcOH NABr 
H 
402 403 (98%} 
Scheme 146. Bromination of 1,2,3,4-tetrahydro-2-thioxoquinazolin-4-yl-acetic acid 
402 by Hull and Swain.121 
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The reaction of thioamides and thioureas with bromine is not unprecedented in the 
literature. However, the reactions do not usually produce imidoyl-bromides as Hull 
and Swain had shown and more often result in cyclisation via a sulfanylbromide 
intermediate. 121 A classic example of this is the Hugerschoff reaction to form 
benzothiazoles. Jordan et al. have used this reaction recently in the synthesis of 
various substituted benzothiazoles 407 (scheme 147).122 For example, the reaction 
between thiourea 404 and bromine forms intermediate sulfanylbromide 405, which is 
followed by cyclisation and rearomatisation 406 to produce benzothiazole 407. 
HBr + 
()
NlNHM_e __ 
SH -HBr 
(" 
~-Br 
407 
Scheme 147. The Hugerschoffsynthesis ofbenzothiazole. 
~NlNHMe 
V~sBr 
405 l 
G>-NHMe 
H 
406 
Similar reactions exist in the literature using thioamides. Moghaddam and Boeini 
have reported the cyclisation of thioamide 408 using organic ammonium tribromide 
species (OATB) to form benzothiazole 409 (scheme 148).123 Organic ammonium 
tribromide species were used instead of bromine as they· are usually solid and much 
easier to handle. Cyclisation presumably takes place via a similar mechanism as 
described in scheme 14 7. 
DCM/CCI4 
408 409 (63%) 
Scheme 148. Oxidative cyclisation ofthioamide using OATB. 
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The driving force for rearomatisation plays a major role in these reactions. 
Shanmugam et al. have shown a similar reaction for 2-thioquinoline 410 which 
cyclised to form tricyclic quinoline 413 (scheme 149}.124 However, the authors believe 
this reaction takes place via bromination of the alkene 412 rather than the double bond 
attacking sulfanylbromide 411. None the less this reaction constitutes a possible 
example of bromine addition to a thioamide. The 5-exo cyclisation of the alkene onto 
the sulfanylbromide 411 appears more favoured than the 5-endo cyclisation of the 
thioamide 412 onto the alkene. 
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Scheme 149. Cyclisation of a thioquinoline using bromine. 
The bromination of thioamides and thioureas has also been shown to give a wide 
range of different products. There are examples where bromination of thioamides has 
lead to disulfides (scheme 150). Ali and McDermott have shown that the reaction of 
2-thiopyridine 414 leads to formation of bis(2-pyridyl) disulfide 415.125 This is 
perhaps expected due to the strong aromatic nature of 2-thiopyridine. Other examples 
of disulfide formation of 2-thiobenzimidazole are also reported in the literature. 126 
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u N S 
H 
Ut.J N s-s N hyrdrated silica gel 
414 415 (45%) 
Scheme 150. Formation of disulfides. 
A related reaction is the reaction between thioacyl urea compounds 416 and bromine 
to form dithiazoles 417 (scheme 151). Verma et al. has reported a number of these 
examples. 127 Ali and McDermott's reaction in scheme 145 proceeded via the 
sulfanylbromide being trapped by intermolecular sulfur addition, 125 whereas in the 
examples by Verma, intramolecular sulfur addition is seen.127 
416 417 (70%) 
Scheme 151. Formation of a dithiazole using bromine. 
Gewald et al. have shown that the sulfanylbromide intermediate can be trapped with 
nitrites (scheme 152).128 However, nitrogen attack ofthe nitrile 418 is only facilitated 
by concomitant addition of bromide to the nitrile, this explains the presence of a 
bromine atom on cyclised product 419. This is not the only example of nitrogen 
intercepting such intermediates. Bossio et al. have shown a similar example of 
nitrogen interception of sulfanylbromide intermediate using benzimidazoles. 129 The 
literature also contains examples of nitrogen attack from ami dines and amides. 130• 131 
418 419 (45%) 
Scheme 152. Isonitrile cyclisation onto sulfur using bromine. 
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There are other examples in the literature where brominated products such as Hull and 
Swain's 2-bromo-3,4-dihydroquinazolin-yl-acetic acid 403 have been isolated. A very 
early example of a nearly identical reaction of 4-phenyl-3,4-dihydro-1H-quinazolin-2-
thione 420 with bromine has been reported by Gabriel and Stelzner in 1896 (scheme 
153).132 The reaction was carried out using bromine in acetic acid and water but no 
yield was given. The dibromo-intermediate 421 was reportedly isolated prior to 
formation of 2-bromo-4-phenyl-3,4-dihydroquinazoline 422. 
AcOH 
420 
NH 
~Br 
N Br H 
421 
Scheme 153. Early reported bromination ofthioquinazoline. 
422 
Robins et al. used the procedure for the preparation of mono-, di- and tri-substituted 
bromopurines 423, 424 and 425 (scheme 154}.133 Robins postulated the mechanism 
involved an oxidised sulfur intermediate (sulfanyl bromide) being displaced by a 
bromide ion in solution. 
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N H N H (XN>---SH Br2 aq. HBr (X}-sr 
N~ N MeOH N~ N 423 
N H N H 
r;JC>---sH Br2 aq. HBr r;f~)-Br N~ N MeOH N~ N 
424 
SH Br 
HS N H Br N H Y~)C>---sH Br2 aq. HBr y~N}-Br N~ N Me OH N~ N 
425 
SH Br 
Scheme 154. Bromination ofpurines 
Robins et al. extended the same procedure for the conversion of thiopyramidine 426 
to the brominated analogue 427 (scheme 155).134 They also showed that this protocol 
can be extended to form iodo compounds by treating thiopurines with iodine under 
basic conditions, e.g. 9-furanol-8-iodo-9H-purin-6-ylamine 428. 135 
0 0 HN~t HBr, Br~ HN~X> 
SAN N A I Me OH Br N N H H H 
426 427 
£H N£N N N 12, Kl ~ )=s 
NaHC03 ~NI N)-1 N N 
HO HO 
HO HO 428 
Scheme 155. Bromination ofthiopyramidine. 
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5.3 Reactions and bromination of 2-Mercapto-3H-quinazolin-4-one 
Having carefully reviewed the literature, it was considered there was enough evidence 
that the synthesis of the 2-bromo-3H-quinazolinone 241 building block could be 
successfully made using this method. 2-Mercapto-3H-quinazolin-4-one 242 was 
commercially available, and to our delight, treatment with bromine formed the desired 
2-bromoquinazolinone 241 (table 20). Characterisation by 1H and 13C NMR 
spectroscopy was inconclusive and mass spectral data was relied upon to verifY the 
presence of a bromine atom. There was concern that the hydrobromide salt product 
may form, which could have affected subsequent alkylations at the N-3 position. At 
this stage the mechanism of the reaction was unclear. No smell of HzS was detected 
indicating it was not formed in the reaction. The move away from acetic acid was 
made and found the yields were similar in ethanol. 
Table 20. Optimisation for 2-bromo-3H-quinazolin-4-one synthesis. 
Br2, solvent 
241 
Brz (equiv.) Time (min) Solvent Yield(%) 
1.5 30 MeOH 24 
1.5 10 AcOH 35 
1.5 15. AcOH/HzO (5:1) 48 
1.5 120 EtOH 50 
3.0* 30 AcOH 35 
3.0 180 AcOH 40 
3.0** 30 AcOH 14 
3.5 20 AcOH/HzO (5:1) 42 
3.5 30 AcOHIHzO (5:1) 40 
4.0 40 AcOHIH20 (5:1) 37 
* Dried in a vacuum oven for 24 h over P20s (1H NMR spectroscopy showed slight 
decomposition). 
•• Extracted into DCM and washed with NazSz03 (1H NMR spectroscopy showed 
evidence of some debromination). 
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Due to the high polarity of the product, work ups and purification were extremely 
difficult. When the crude reaction was washed with 5% aqueous NazSz03 a loss in 
product yield was observed. It was also found that a slight excess of bromine was 
required. The reactions were not homogenous and therefore monitoring by TLC was 
precluded. 
A 1H NMR spectrum showed that when the reaction was carried out in AcOH, an 
unknown intermediate appears in the spectra before the reaction goes to completion. 
This is not the case when the reaction is carried out in MeOH or EtOH. There is very 
little difference in the 1H NMR spectra of the compounds. However, careful study of 
the 1H NMR spectra of some of the reactions indicated a loss ofNH peaks (about 13 
ppm for 242 and 11 ppm for 241). It is proposed that the loss of NH peaks could 
imply the formation of a 2,4-dibromoquinazoline 429 as the unknown intermediate. 
An attempt to determine if the 2,4-dibromoquinazolinone 429 could be made by 
treating 2-mercapto-3H-quinazolin-4-one 242 with an excess of Brz in AcOH was 
carried out (scheme 156). However, this failed and no further evidence could be found 
to identify the unknown intermediate of the reaction in AcOH. 
0:.:0 Br2 oCBr NH '\. -::?" "-' N A ·-0- ~I A N S AcOH N Br 
H 
242 429 
Scheme 156. Attempt synthesis of2,4-dibromoquinazoline. 
With the 2-bromo-3H-quinazolin-4-one 242 building block in hand, alkylation using 
benzyl bromide was carried out in good yield to give quinazolinone 241 (scheme 
157). The radical reaction of quinazolinone 213 has already been described in chapter 
one, and is not the focus here. 
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BnBr, NaH d.:~(X) DMF 
240 {46%) 
Scheme 157. 
However, the alkylation of 2-bromo-3H-quinazolin-4-one 241 with (2-
bromoethyl)benzene proceeded extremely poorly. A number of different conditions 
were attempted and the yields are reported in table 21. Even when the reaction was 
attempted using the triflate derived from (2-hydroxyethyl)benzene, no alkylation was 
observed. It appeared to us that the ambident anion formed is not reactive enough. 
Table 21. Alkylation conditions of(2-bromoethyl)benzene (BEB) in DMF. 
0 0~ OCNH OCN ~ 
NABr A N Br 
241 243 
Base (equiv.) BEB (equiv.) Deprotonation Reaction Temperature Yield 
time time 
NaH (1.5) 1.5 1 h 12 h rt 3% 
NaH (1.5)* 1.2 1h 4h rt 6% 
NaH (1.2}*• 1.5 10 min 12 h rt <2% 
NaH (1.5) 3.0 1 h 12 h 80 oc <5% 
t-BuOK (1.5) 1.5 3h 12 h 120 oc <5% 
Cs2C03 ( 1.5) 1.5 1 h 12 h 120 oc. <5% 
Cs2C03 ( 1.5) 5.0 1 h 48 h 120 oc <5% 
* Nal (20.0 equiv.) was added at the beginning of the reaction. 
** Nal (5.0 equiv.) was added at the beginning of the reaction. 
2-Bromo-3H-quinazolin-4-one 241 is insoluble in EhO, MeCN, toluene, DCM and 
THF which left no other obvious highly polar solvents to use other than DMF. 
Cs2C03 has been shown to be a good base for deactivated amine alkylations, but in 
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this case made no improvement. 136 However, it was noted that 0-alkylation appeared 
to increase when Cs2C03 was used. Molecular sieves were added to the (2-
bromoethyl)benzene to ensure its dryness. A fresh new bottle of anhydrous DMF also 
had no effect. Increased yield was not observed when Nai was added to see if a 
Finkelstein type reaction could be carried. Attempts to carry out the reaction at a 
higher temperature had little effect. 
An attempt to carry out the reaction under Mitsunobu conditions using DIAD, PPhJ, 
quinazolinone 219 and 2-(2-bromophenyl)ethanol was made, but that produced a 
complex mixture of inseparable products. Comins et al. have extensively investigated 
this reaction with respect to oxygen and nitrogen alkylation of 2-pyridones. 137 
Attention was turned to studying the alkylation with active bromides instead (scheme 
158). At this point, the mesylquinoline 430 was made from the previously prepared 
quinoline 275. It was hoped this might open a new route to luotonin A. However, the 
alkylation of quinoline 430 with 2-bromo-3H-quinazolin-4-one 241 occurred in such 
poor yield that no radical reactions were attempted with the quinazolinone 431. 
Alkylation of 2-bromo-3H-quinazolin-4-one 241 was successfully carried out using 
allyl bromide to give quinazolinone 432. 
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Scheme 158. Successful alkylations of2-bromoquinazolin-4-one 
Attempts to alkylate 2-bromo-3H-quinazolin-4-one 241 using methyl bromoacetate 
433 which we hoped would be sufficiently active were not successful (figure 25) and 
no alkylation was observed. Three other alkylation reactions were attempted using 
propargyl bromide 434, bromopropyl benzene 435 and 3-(2-bromoethyl)indole 320. 
All failed to give any 3-N alkylated product. At the completion of the studies, Curran 
reported the successful alkylation of 2-bromo-3H-quinazolin-4-one 241 with 
propargyl halides.138 
0 
Br 11 ~OMe 
433 
Figure 25. 
~~ Br~-- Br~ 
434 435 V 
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In summary, the electron withdrawing effect (-I) of the bromine, the aromatic imine 
and amide in 436 are deactivating the anion, making it unreactive towards 
electrophiles (figure 26). It is not believed that the steric bulk of the bromine plays a 
role. 
436 
Figure 26. Ambident anion of2-bromo-3H-quinazolin-4-one. 
At this point, consideration of overcoming the problem encountered in the alkylation 
reaction was sought. We investigated a method developed by Robinsand Stout for the 
alkylation of 3H-quinazolin-4-one 219 (scheme 159) using a TMS protected 
quinazolin-4-one 437.139 This was shown to react rapidly with the activated 
bromofuranose 439 to yield the alkylated quinazolinone 438. 
0 
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Ur.. . J toluene 
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Scheme 159. 
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It was hoped to form 3-N-alkylated 2-bromo-3H-quinazolin-4-ones 441 from the 2-
bromo-3H-quinazolin-4-one 241 building block using this method (scheme 160). 
There was uncertainty whether the TMS protected intermediate 440 would be reactive 
enough towards unactivated alkyl halides. Several unsuccessful attempts were made 
to carry out this reaction. 
241 440 441 
Scheme 160. 
c~ 
Preparation of the same TMS quinazolinone 437 that Robins and Stout had reported 
was unsuccessful (scheme 159). A range of conditions were employed without 
success. It was decided this work should be put to one side to concentrate on more 
profitable research. 
A Chapman rearrangement as described by Chern et al. could be applied to 
quinazolin-4-one chemistry was considered next (scheme 161).14° Chern has described 
a 1,3-shift from oxygen ofthe quinazolinone 442 to the nitrogen of the quinazolinone 
443 of alkyl halides in excellent yield. Aryl, allyl and alkyl groups have all been 
shown to undergo this migration. A small amount of 0-alkylated quinazolinone 444 
had been recovered from previous alkylation experiments, and so the reaction the 
solution of quinazolinone 444 in MeCN overnight was heated overnight under reflux. 
However, no reaction was observed. An attempt to carry out the same reaction under 
microwave conditions also failed to yield quinazolinone 432. 
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Scheme 161. Chapman rearrangement and failed attempt. 
At this point, the reaction order was considered. It was not known if the alkylation of 
the nitrogen could be carried out first, before bromination to yield 3-N alkylated 
bromoquinazolinone 441 (scheme 162). The obvious problem with this route is that 
alkylation of 2-mercaptoquinazolinone 242 would most likely give undesired 
quinazolinone 446 rather than quinazolinone 445. 
446 
Scheme 162. Planned retrosynthesis of alkylated bromoquinazolinone. 
It was reasoned that the dianion of 2-mercaptoquinazolin-4-one (NG and SG), might 
preferentially alkylate on the nitrogen (scheme 163). This was reasoned as the 
nitrogen anion would be less stable than the sulfur anion thus reacting faster to yield 
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quinazolinone 447. However, when this hypothesis was tested by treating 2-
mercaptoquinazolinone 242 with 2 equivalents of base, only the sulfur alkylated 
product 448 was observed. 
0 
~NH I Desired route I UNAS -----------
242 H 
NaH!DMF 
0 'I o-b-s-erv-ed-pr_o_d-uc-t I 
~NH ~ UNAS~ 
448 (75%) 
Scheme 163. 
However, undeterred further investigations were made. It was not know whether the 
alkylated sulfur quinazolinone could be displaced at the C-2 position using bromine. 
This was tested by treating 3-methyl-2-methylsulfanyl-3H-quinazolin-4-one 449 with 
bromine (scheme 164). However, only starting material was recovered from this 
reaction. The reaction was repeated using Mel, but again this failed to facilitate a 
SNAr reaction. Bromo- or iodo-quinazolinone 451 or 450 were not obtained. 
· DMF efts NaH, Mel 
242 H 450 
Scheme 164. 
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The next method investigated was to introduce the N-alkyl substituents during the ring 
synthesis and convert the thio group to the 2-bromoquinazolin-4-one (scheme 165). 
Drushlyak et al. have shown that 2-(methoxycarbonyl)phenyl isothiocyanate 452 
reacts rapidly with amines to form N-alkylated 2-thioquinazolin-4-ones 453.141 This 
looked promising and should allow access to quinazolinone 454. 
Scheme 165. 
Two of the desired mercaptoquinazolinones 456 and 457 were prepared in excellent 
yields from a commercially available isothiocyanate 455 (scheme 166). A crystal 
structure of the quinazolinone 456 was obtained to prove the structure (figure 27). 
NCS 2-propanol 
455 
Scheme 166. 
135 
~N~R 
UNAS 
H 
456 R =Ph (92%} 
457 R =OH (99%} 
CllSI 
Figure 27. X-ray structure of quinazolinone 456. 
Investigations were then carried out to brominate at the C-2 position of the 2-
thioquinazolinones 456 and 457. When 2-thioquinazolinone 456 was treated with 
bromine (2.0 equivalents) in MeOH, only one product was obtained (scheme 167). 
The 1H NMR spectrum of the reaction showed the presence of a broad NH peak at 
10.42 ppm (confirmed by a 0 20 shake). The 1H NMR spectrum was clearly different 
to that of the starting material. The mass spectrum revealed that the product was the 3-
(2-phenylethyl)-1H-quinazoline-2,4-dione 458. This product is likely to have arisen 
by attack of water present in the MeOH on the sulfanylbromide intermediate. 
aeoN 0 o_ 0 ~ Br2 (2.0equiv) ~~N~S ------M-e--OH __ _. ~N~O 
H H 
456 458 (87%) 
Scheme 167. 
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When the 3-(2-hydroxyethyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 457 was 
treated with bromine in MeOH a mixture of unidentifiable products were obtained. It 
is believed that the pendant hydroxyl group is interfering in the reaction. 
The reaction under anhydrous conditions between 3-(2-phenylethyl)-2-thioxo-2,3-
dihydro-1H-quinazolin-4-one 456 and bromine gave a new product (scheme 168). 
The 1H NMR spectra revealed no NH peaks, suggesting the formation of the 2-bromo 
product. However, the mass spectrum showed no bromine isotope patterns and 
indicated that the dimer 459 had been formed. 
Br2 {2.0 equiv) ~N~Ph ~N~S -d-~--M-eO-H--~ 
H 
456 459 {59%) 2 
Scheme 168. Unexpected disulfide formation using bromine 
The disulfide formation can be rationalised by reaction between a second 
thioquinazolinone molecule 456 and the sulfanylbromide intermediate 460 (scheme 
169). It is now known that this sulfanylbromide intermediate 460 is also susceptible to 
attack by water to form 3-(2-phenylethyl)-1H-quinazoline-2,4-dione 458. It is now 
clear that bromo substitution of this sulfanylbromide intermediate 461 can only occur 
when 3-N is unsubstituted. 
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Scheme 169. Proposed routes to the quinazolin-4-one products. 
Initially, it was considered that the NH at the 3-N position was not important in the 
mechanism for the bromination of 2-mercapto-3H-quinazolin-4-one 242. However, 
observations show that bromination does not occur with 3-N-alkylated 2-
thioquinazolin-4-ones 462 to yield the desired 2-bromoquinazolin-4-one 465 (scheme 
170). This indicates that the 3-NH is involved in the mechanism, hence it is unlikely 
that intermediates 463 and 464 of route A would be obtained. The 3-NH is more 
acidic than the 1-NH and it could be predicted to be preferentially abstracted in the 
bromination/SNAr reaction shown, therefore it is proposed route A is unlikely for the 
mechanism. 
462 463 464 465 
Scheme 170. 
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An alternative route B could also be proposed by loss of H+ from 242 to form 
intermediate 466 should be rapid because the 3-NH is acidic (scheme 171). The 
alternative is that tautomerism to the thio-imine 469 is required prior to attack by 
bromine to form 470. This would be followed by SNAr attack by a bromide ion 
followed by loss of HSBr on 467 and 471 to yield product 468, which would rapidly 
tautomerise to 2-bromo-3H-quinazolin-4-one 241. 
Alternatively route C, which takes into account the lone pair electrons of 3-N 242 
could occur. This is followed by attack of a bromide ion on intermediate 472. It could 
be envisaged that the lone pair of the 1-N of intermediate 473 becomes involved. Loss 
of HSBr from intermediate 473 should yield 3H-quinazolin-4-one 241. Route C 
should work out equally well whether the 3-N substituents are hydrogen or R as only 
the lone pair is involved, hence route C is ruled out. It is postulated that the loss of the 
· 3-NH is crucial to the bromination mechanism. If this loss of a proton is crucial in the 
mechanism then 3-N alkylated starting material 458 will yield other products as 
observed. The conclusion therefore is that this synthetic method of alkylation 
followed by bromination will not provide a route to the required 2-bromo-3H-
quinazolin-4-ones 465. 
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Scheme 171. Possible bromination mechanisms of 3H-quinazolin-4-one 
Consideration for the synthetic use of the disulfide 459 was given (scheme 172). 
There was an interest to see how this might react in the presence of an excess of 
bromine and whether this may lead to the bromo analogues 474. The conversion of 
disulfides to sulfanyl halides is well known.142 
140 
Br8 
----- ci;:Br 
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Scheme 172. Possible use of2-thioquinazolin-4-one disulfide. 
When quinazolin-4-one disulfide 459 was treated with an excess of bromine, TLC 
showed two products (scheme 173). Lithium bromide was added to ensure the excess 
of bromide ions in the reaction. Of the two products only one could be fully identified 
as unsubstituted C-2 quinazolin-4-one 238 in a very low yield. The mechanism ofthis 
dethionation to yield quinazolin-4-one product 238 is unclear. Even after repeating the 
reaction the other product could not be identified. However, both were obtained in 
low yields and the route did not look promising. A reaction was also carried out 
stirring disulfide 459 and Brz in MeOH, but no new products were observed after 24 
h. 
0 0 
cCNR Br2, LiBr ceN~Ph 
NAS 
J + unknown DMF N 
R=CH2CH2Ph 
459 238 {< 5%) 
Scheme 173. 
Although this route was unsuccessful the reaction of an unsubstituted disulfide 475 at 
the 3-N position was given, and how it may react if treated with bromine (scheme 
174). However, had bromination occurred, the problem of the low reactivity of 2-
141 
bromo-3H-quinazolin-4-one 241 would still have needed overcoming. As a result 
termination of the disulfide work was decided. Up to here the investigations in the 
bromination reactions of 2-mercapto-3H-quinazolin-4-one were thorough, but, at this 
point it was decided to concentrate on returning to the natural product syntheses. 
Br2 
·--------· 
Scheme 174. 
0 
OC can't alkylate NH A ----x-----N Br 
241 
In the course of this study a report of radical reactions at C-2 of quinazolinone was 
published in the literature. Curran et al. has recently carried out a cascade radical 
annulation reaction using a C-2 quinazolinone radical (scheme 175).138 Curran 
describe the synthesis of 2,4-dibromo-3H-quinazoline 429 from 2,4-
diketoquinazolinone 392 in good yield. This idea had been considered, but then 
abandoned after the fairly unsuccessful attempts at making the 2,4-dichloro-3H-
quinazolin-4-one 393. Curran reported no problems in the propgarylation of2-bromo-
3H-quinazolin-4-one 241 to radical precursor 476. This had been unsuccessful in our 
hands. 
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Scheme 175. 
Although disappointed that the 2-bromoquinazolinone 2.:11 could not be fully 
exploited in natural product syntheses ourselves, we were pleased to see it being 
explored by other chemists and that these results showed the potential of cyclisation 
onto arenes. 
5.4 Conclusions 
This chapter has given a detailed account of attempts to prepare a C-2 radical of 3H-
quinazolin-4-one. Various methods were attempted. The most successful of which 
was the bromination of2-mercapto-3H-quinazolin-4-one. However, great difficulty in 
attempting to carry out alkylations at the 3-N position was encountered. Attempts at 
carrying out the bromination once substituents have been added at 3-N failed. It has 
been shown that unexpected products lead us to help propose a mechanism for the 
bromination of 3-mercapto-3H-quinazolin-4-one. 
143 
Chapter 6. Experimental 
6.1 General experimental 
Commercial dry solvents were used in all reactions except light petroleum and ethyl acetate 
that were distilled from CaCb and dichloromethane that was distilled over CaH2. Light 
petroleum refers to the bp 40-60 ·c fractions. All reactions were carried out under an 
atmosphere of nitrogen unless stated otherwise. Sodium hydride was obtained as 60% 
dispersion in oil. A 2.5 M solution of n-butyllithium in hexane was used in all stated cases. A 
1.0 M solution of Et3B in hexane was used in all cases. A 1.0 M solution of t-BuLi in THF 
was used in all cases. A solution of 1 M TBAF in THF was used in all cases. Melting points 
were determined on a Stuart Scientific SMP3 melting point apparatus and are uncorrected. 
Elemental analyses were determined on a Perkin Elmer 2400 CHN Elemental Analyser in 
conjunction with a Perkin Elmer AD-4 Autobalance. Infrared spectra were recorded on a 
Perkin-Elmer Paragon 1000 FT-IR spectrophotometer on NaCl plates. 1H (400 MHz) and 13 C 
(100 MHz) NMR spectra were recorded on a Bruker DPX-400 spectrometer (400 MHz). 'H 
(250 MHz) were also carried out on a Bruker AC-250 spectrometer. Samples were run as 
solutions of CDCh with TMS as the internal standard for 1H NMR spectra and 
deuteriochloroform the standard for 13C NMR spectra unless otherwise specified. Chemical 
shifts are given in parts per million (ppm) and J values in hertz (Hz). Mass spectra were 
recorded on a Jeol JMS-SX102 quadrupole high resolution mass spectrometer or carried out 
by the EPSRC MS Service at University of Wales, Swansea. GCMS was carried out on 
Fisons 8000 series GCMS using a 15 m x 0.25 mm DB-5 column and an electron impact low 
resolution mass spectrometer. TLC using silica gel as absorbent was carried out with 
aluminium backed plates coated with silica gel (Merck Kieselgel 60 F 2s4), and TLC using 
alumina as absorbent was carried out with aluminium backed plates coated with neutral 
aluminium oxide (Merck 150 F2s4,TypeT). Silica gel (Merck Kieselgel 60 H silica) was used 
for column chromatography unless otherwise specified. Column chromatography using 
alumina was carried out with Aldrich aluminium oxide, activated neutral, Brockmann 1, STD 
Grade, 150 mesh size. Prep-TLC was carried out using aluminium oxide (Merck 60 PF2s4, 
Type E). 
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6.2 Experimental for Chapter 2 
3-Methyl-3H-quinazolin-4-one 
225 
Method A using sodium hydride and lithium bromide 
Sodium hydride (0.40 g, 10.0 mmol) was added to 3H-quinazolin-4-one (0.73 g, 5.0 mmol) at 
0 oc in dry DMF (5 cm3) and dry ethylene glycol dimethyl ether (10 cm3) and stirred for 40 
min. Lithium bromide (0.87 g, 10.0 mmol) was added and the reaction mixture stirred for 
another 15 min. Methyl iodide (1.25 cm3, 20.0 mmol) was added with stirring for another 3 h. 
The reaction mixture was quenched by dropwise addition of H20 (5 cm3). The reaction 
mixture was extracted into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and evaporated to dryness under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (1:1) as eluent yielding 3-methyl-3H-quinazolin-4-one as yellow crystals 
(0.33 g, 2.0 mmol, 41%), mp 103-104 oc (lit. 143 104-105 °C); (Found: MH+, 161.0708. 
C9H9N20 requires 161.0708); Vmax(thin film)/cm·1 3377, 2923, 1664, 1612, 1340, and 779; oH 
3.59 (3 H, s, CH3), 7.45 (1 H, dd, J 8.2 7.2, 6-H), 7.72-7.63 (2 H, m, ArH), 8.04 (1 H, s, 2-H) 
and 8.25 (1 H, d, J 8.0, 5-H); oc 33.91 (CH3), 121.73 (4a-C), 126.24 (8-C), 127.03 (6-C), 
127.22 (5-C), 133.92 (7-C), 146.78 (2-C), 148.06 (Sa-C) and 161.27 (4-C); NMR spectral 
assignments were confirmed by NOESY, COSY and 1H-13C correlation NMR techniques; 
m/z(Electrospray) 161 (M+, 34%), 160 (100), 132 (36), 119 (30), 97 (35), 83 (40), 71 (47), 69 
(59), 57 (65) and 43 (85). 
Method B using potassium t-butoxide 
Potassium t-butoxide (0.50 g, 4.5 mmol) was added to 3H-quinazolin-4-one (0.44 g, 3.0 
mmol) in dry DMF (20 cm3) and stirred for 1 h. Methyl iodide (0.43 cm3, 5.0 mmol) was 
added and the reaction mixture stirred for a further 10 h. The reaction mixture was extracted 
into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer was dried 
over MgS04 and evaporated to dryness under reduced pressure. The crude product was 
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purified by column chromatography using silica gel as absorbent with light petroleum!EtOAc 
(2: 1) yielding 3-methyl-3H-quinazolin-4-one as yellow crystals (0.17 g, 1.1 mmol, 3 7% ). 
The data were consistent to the literature. 143 
3-(3-Phenylallyi)-3H-quinazolin-4-one73 
0 
6~N~Ph 7U:.J 
8 
BaN 2 
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Sodium hydride (0.39 g, 10.0 mmol) was added at 0 octo 3H-quinazolin-4-one (0.73 g, 5.0 
mmol) in dry DMF (5 cm3) and dry ethylene glycol dimethyl ether (10 cm3} and stirred for 1 
h. Lithium bromide (0.86 g, 10.0 mmol) was added and the reaction mixture stirred for a 
further 15 min. Cinnamyl bromide (3.9 g, 20.0 mmol) was added and the reaction mixture 
stirred for an additional 2 h. The reaction mixture was quenched by dropwise addition of H20 
(5 cm3). The reaction mixture was extracted into DCM (50 cm3} and washed with H20 (5 x 50 
cm3) and with brine (50 cm3). The organic layer was dried over MgS04 and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleum!EtOAc ( 4: 1) as eluent to yield 3-(3-
phenylallyl)-3H-quinazolin-4-one as yellow crystals (0.51 g, 2.0 mmol, 40% ); mp 115-116 oc 
(lit.'3 115-116 °C}; (Found: MH+, 263.1182. C11HisN20 requires 263.1179); Vmax(thin film)/cm· 
1 3423, 1670, 1652, 1608, 1558, 1473 and 773; oH 4.79 (2 H, dd, J 6.4, 1.4, CH2}, 6.34 ( 1 H, 
dt, J 15.8, 6.4, propenyl-2-H), 6.66 (1 H, dt, J 15.8, 1.4, propenyl-CHb}, 7.23-7.38 (5 H, m, 
ArH), 7.53, (1 H, ddd, J 8.0, 8.0, 1.0, 6-H), 7.73 (1 H, ddd, J 8.0, 8.0, 1.0, 7-HJ, 8.11 (1 H, s, 
2-H}, 7.76 (1 H, dd, J 8.0, 1.0, 8-H) and 8.34 (1 H, dd, J 8.0, 1.0, 5-H); oc 48.15 (CH2), 
122.16 (4a-C}, 122.77 (propenyl2-C}, 126.50 (phenyl-2,6 or 3,5}, 126.82 (5-C), 127.41 (6-C}, 
127.54 (7-C}, 128.30 (phenyl-4-C}, 128.68 (phenyl-2,6 or 3,5-C}, 134.35 and 134.50 
(propenyl-3-C and 8-C), 135.75 (phenyl-I-C}, 146.19 (2-C}, 148.11 (8a-C) and 160.95 
(O=C); NMR spectral assignments were confirmed by NOESY, COSY and 1H-13C correlation 
NMR techniques; m/z(Electrospray) 263 (M+, 21 %}, 147 (42}, 121 (100), 79 (87) and 74 (26). 
146 
3-(2-Iodobenzyl)-3H-q uinazolin-4-one 
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Potassium t-butoxide (1.35 g, 12.0 mmol) was added to 3-H-quinazolin-4-one (1.17 g, 8.0 
mmol) in dry DMF (50 cm3) and stirred for 1 h. 2-Iodobenzyl bromide (2.96 g, 10.0 mmol) 
was added to the reaction mixture and stirred for a further 16 h. The reaction mixture was 
extracted into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer 
was dried over MgS04 and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography using silica gel as absorbent with light 
petroleum!EtOAc (2:1) as eluent yielding 3-(2-iodobenzyl)-3H-quinazolin-4-one as yellow 
crystals (1.82 g, 5.03 mmol, 63%); mp 94-95 oc; (Found: M+, 362.9987. C1sHuiN20 requires 
362.9989); Vmax(thin film)/cm·1 3055, 1689, 1469, 1230, 962 and 734; OH 5.71 (2 H, s, CH2), 
6.93 (1 H, ddd, J7.9, 7.4, 1.6, 4-PhH), 7.09 (1 H, dd, J7.9, 1.6, 3-PhH), 7.22 (1 H, ddd, J7.4, 
7.2, 1.6, 5-PhH), 7.45 (1 H, ddd, J 8.0, 6.2, 1.7, 6-H), 7.75-7.64 (2 H, m, 7,8-H), 7.81 (1 H, 
dd, J 7.2, 1.6, 6-PhH), 8.11 (1 H, s, 2-H) and 8.26 (1 H, dd, J 8.0, 1.6, 5-H); Oc 54.90 (CH2), 
98.60 (1-Ph), 122.14 (4a-C), 126.95 (5-C), 127.48 (6-C), 127.63 (8-C), 128.88 (5-Ph), 129.10 
(3-Ph), 129.94 (4-Ph), 134.46 (7-C), 137.74 (8a-C), 139.92 (6-Ph), 146.44 (2-C), 148.03 (2-
Ph) and 161.11 (4-C); m/z(EI) 252 (M+, 98%), 129 (43), 107 (41), 90 (100), 89 (77), 76 (51), 
63 (58), 50 (42) and 40 (85). 
2-(2-Bromophenyl)ethyl methanesulfonate70 
~OMs 
~Br 
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Methanesulfonyl chloride (2.38 cm3, 30.7 mmol) was slowly added to 2-(2-
bromophenyl)ethanol (4.74 g, 25.6 mmol) in dry DCM (50 cm3) followed by addition of 
triethylamine (5.34 cm3, 38.4 mmol) at 0 oc and stirred for 48 h. The crude reaction mixture 
was washed with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over 
MgS04 and the solvent removed under reduced pressure yielding 2-(2-bromophenyl)ethyl 
methanesulfonate as an orange oil (4.91 g, 18.66 mmol, 75%); Vmax(neat)/cm·1 3057, 3024, 
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2939, 1594, 1568, 1473, 1442, 1038 and 858; oH 2.87 (3 H, s, CH3}, 3.20 (2 H, t, 1 6.9, CHz), 
4.43 (2 H, t, 1 6.9, OCHz), 7.17-7.09 (1 H, m, ArH}, 7.29-7.26 (2 H, m, ArH) and 7.57 (1 H, 
d,17.7, ArH). 
The data were consistent to the literature. 70 
The product was used without further characterisation. 
3-[2-(Bromophenyl)ethyl]-3H-quinazolin-4-one 
6!.Jer8r N I 
~ 
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Potassium t-butoxide (2.61 g, 23.3 mmol) was added to 3-H-quinazolin-4-one (2.27 g, 15.5 
mmol) in dry DMF (150 cm3) and stirred for 1 h. 2-(2-Bromophenyl)ethyl methanesulfonate 
(4.90 g, 18.6 mmol) was added to the reaction mixture and stirred for a further 48 h. The 
reaction mixture was extracted into DCM and washed with HzO (5 x 50 cm3} and brine (50 
cm3). The organic layer was dried over MgS04 and evaporated to dryness under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleurn/EtOAc (4:1) as eluent yielding 3-[2-(bromophenyl)ethyl]-3H-
quinazolin-4-one as colourless crystals (1.93 g, 5.9 mmol, 38%); 119-120 oc; (Found: MH+, 
329.0290. c16H1479BrNzO requires 329.0284); Vmax(thin film)/ cm"1 3423, 1972, 1609, 1470, 
1069, 1027 and 773; 0H3.25 (2 H, t, 17.0, CHz), 4.25 (2 H, t, 17.0, NCH2}, 7.22-7.07 (3 H, m, 
ArH}, 7.58-7.48, (2 H, m, ArH}, 7.78- 7.64 (3 H, m, ArH) and 8.34 (1 H, dd, 1 8.3, 1.5, 5-H); 
Oc 35.35 (CH2}, 46.73 (NCHz), 122.02 (PhC), 124.45 (ArC}, 126.61 (ArH}, 127.24 (ArH}, 
127.49 (ArH), 127.94 (ArH}, 128.94 (ArH}, 131.36 (ArH), 133.14 (ArH}, 134.21 (ArH), 
136.73 (ArC}, 146.36 (ArH}, 148.10 (PhC) and 161.13 (ArC); m/z(Electrospray) 330 (M+, 
98%}, 328 (97}, 251 (49}, 249 (56) and 52 (14). 
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Radical cyclisation of 3-(2-iodobenzyl)-3H-quinazolin-4-one 
233 232 
Method A- Bu3SnH (fast) and EtJB as initiator 
A solution ofBu3SnH (0.76 g, 2.6 mmol) and 3-(2-iodobenzyl)-3H-quinazolin-4-one (0.44 
g, 1.2 mmol) in dry toluene ( 40 cm3) was deoxygenated under nitrogen and stirred for 1 h. 
Triethylborane (3.6 cm3, 3.6 mmol) was added via a needle through a septum; the needle 
was left open to allow air (oxygen) to enter the reaction and the mixture stirred for 1 h. 
More triethylborane (3.6 cm3, 3.6 mmol) was added and the reaction mixture stirred for a 
further 10 h. Dilute hydrochloric acid was added to extract the protonated quinazolone 
products into the aqueous layer. The aqueous layer was washed with light petroleum to 
remove tributyltin residues. The aqueous layer was basified with sodium hydroxide to pH 
14 and extracted with DCM. The combined organic layers were dried over MgS04 and the 
solvent removed under reduced pressure yielding the reduced product 3-benzyl-3H-
quinazolin-4-one 232 as colourless crystals (0.27 g, 1.2 mmol, 96%); mp 116-117 oc 
(lit. 144 117-118 °C ); Vmax(thin film)/cm- 1 3419, 1675, 1609, 1559, 1473, 1369, 1332, 1161, 
1026, 773, 709, 694 and 645; oH5.08 (2 H, s, CH2), 7.24-7.23 (5 H, m), 7.48 (1 H, ddd, J 
8.2 6.3 1.8, 6-H), 7.74-7.68 (2 H, m, 7,8-H), 8.11 (1 H, s, 2-H) and 8.32 (1 H, dd, J 8.2 
2.0, 5-H); Oc49.6 (CH2), 122.2 (4a-C), 126.9 (5-H), 127.4 (6-H), 127.5 (8-H), 128.0 (CH), 
128.3 (CH), 129.0 (CH), 134.3 (7-H), 135.8 (C), 146.4 (2-H), 148.0 (Sa-C) and 161.1 (4-
C). 
The data were consistent to the literature. 144 
Method B - TTMSS (fast) reaction using EtJB as initiator 
The procedure for method A was repeated using TTMSS in place of Bu3SnH to yield 3-
benzyl-3H-quinazolin-4-one 232 (35%). 
Method C - Bu3SnH (slow) reaction using EtJB as initiator 
The general procedure for method A was repeated except that Bu3SnH was added by a 
syringe pump over 6 h to give 3-benzyl-3H-quinazolin-4-one 232 (30%). 
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Method D - BuJSnH (slow) reaction using AIBN as initiator 
The general procedure for method C was repeated except that AIBN (0.25 molar equiv.) 
was used as initiator and the reaction was heated under reflux for 6 h to yield 3-benzyl-
3H-quinazolin-4-one 232 (45%). 
Method E -Photolysis with hexamethylditin 
A solution of 3-(2-iodobenzyl)-3H-quinazolin-4-one (0.36 g, 1.0 mmol) and (Me3Sn)z 
(0.99 g, 3.0 mmol) in t-butylbenzene (20 cm3) in a two-necked pyrex flask (5 x 1 cm and 
25 cm high, wall thickness = 1 mm), was purged with nitrogen for 30 min. The mixture 
was irradiated with a combined 300 W sunlamp at 150 °C for 10 h. The reaction mixture 
was cooled to room temperature, diluted with MeOH and evaporated under reduced 
pressure to a small volume. The residue was purified using column chromatography using 
silica gel as absorbent with light petroleum as eluent to remove the t-butylbenzene. A 
precipitate of polymeric dimethyltin was produced. The product was eluted with ethyl 
acetate and dilute hydrochloric acid was added to extract the protonated quinazolone 
products into the aqueous layer. The aqueous layer was washed with light petroleum to 
remove trimethyltin residues. The aqueous layer was basified with a solution of sodium 
hydroxide to pH 14 and extracted with DCM. The combined organic layers were dried 
over MgS04 and the solvent removed under reduced pressure. The crude product was 
purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (4:1) yielding 3-benzyl-3H-quinazolin-4-one 232(65%) and cyclised 
12H-isoindolo[1,2-b]quinazolin-10-one 233 (18%) as an inseparable colourless crystals. 1H 
NMR spectroscopy was used to calculate the yield of the two products. 12H-
Isoindolo[1,2-b ]quinazolin-1 0-one 233 was identified in the mixture and therefore not 
fully characterised. bH 5.19 (2 H, s, CH2), 7.28-7.35 (3 H, m), 7.51 (1 H, ddd, J 8.0, 8.0, 
1.6, 7-H), 7.81 (1 H, ddd, J 8.0, 8.0, 1.6, 8-H), 7.85 (1 H, dd, 8.0, 1.6, 6-H), 8.21 (1 H, d, 
J 7.2, 4-H) and 8.41 (1 H, dd, J, 8.0, 1.6, 9-H); be 49.6 (CH2), 120.6 (ArC), 123.4 (ArH), 
123.5 (ArH), 126.4 (ArH), 126.4 (ArH), 127.3 (ArH), 128.8 (ArH), 132.3 (ArH), 132.6 
(ArC), 134.2 (ArH), 139.6 (ArC), 149.4 (ArC), 154.9 (ArC) and 160.5 (ArC). 
The data were consistent to the literature. 145 
GC-MS analysis confirmed only two products to be in a rough ratio 4:1 of the reduced 
produced and cyclised product: 
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12H-isoindolo-[1,2-b]-quinazolin-10-one 233; RT 22.8 min, m/z 234 (M+, 100%), 205 (24) 
and 77 (20). 
3-Benzyl-3H-quinazolin-4-one 232; RT 24.5 min, m/z 236 (M+, 51%), 130, (37), 91 (100) and 
65 (27). 
3-(2-Deuterio )benzyi-3H-quinazolin-4-one 
0 
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Tributyltin deuteride (0.54 cm3, 2.0 mmol) and triethylborane (0.20 cm3, 0.2 mmol) were 
added to 3-(2-iodobenzyl)-3H-quinazolin-4-one (0.36 g, 1.0 mmol) in dry toluene ( 40 cm3) 
with an air bleed into the round bottom flask through a needle for 12 h. Dilute hydrochloric 
acid was added to the reaction mixture to extract the protonated quinazolinone products into 
the aqueous layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to 
remove tributyltin residues. The aqueous layer was basified with sodium hydroxide to pH 14 
and extracted with DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 
and the solvent removed under reduced pressure yielding the reduced product 3-(2-
deuterio)benzyl-3H-quinazolin-4-one as colourless crystals (0.10 g, 0.4 mmol, 41%); mp 100-
101 °C; (Found: MH+, 238.1084. ClsHlzDNzO requires 238.1085); Vmax{thin film)/cm·l 3421, 
2359, 1670, 1610, 1471, 1396, 1153 and 773; OH 5.21 (2 H, s, CHz), 7.38-7.29 (4 H, m, PhH), 
7.52 (1 H, ddd, J 8.0, 6.7, 1.4, 6-H), 7.71 (1 H, dd, J 8.2, 1.4 ArH), 7.77 (1 H, ddd, J 8.2, 6.7, 
1.4, 7-H) 8.12 (1 H, s, 2-H) and 8.34 (1 H, dd , J 8.0, 1.4, 5-H); Be 49.66 (CHz), 104.09 
(PhCD), 122.24 (4a-C), 126.91 (5-C), 127.39 (6-C), 127.55 (ArH), 128.03 (ArH), 128.34 
(ArH), 128.94 (ArH), 129.05 (ArH), 134.32 (ArH), 135.66 (PhC), 146.32 (5-C), 148.07 (Sa-
C) and 161.10 (4a-C); m/z(Electrospray) 238 (M+, 50%), 235 (21), 130 (33), 92 (100), 91 
(75), 65 (21) and 51 (23); Anal. Calcd for C1sHuDNzO. C, 75.93; H, 5.52; N, 11.81. Found: 
C, 75.69; H, 5.20; N, 11.64. 
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Radical cyclisation of 3-[2-(bromophenyl)ethyi]-3H-quinazolin-4-one 
237 238 
Method A- Photolysis with hexamethylditin 
The reaction mixture of 3-[2-(bromophenyl)ethyl]-3H-quinazolin-4-one (0.32 g, 1.0 mmol) 
and (Me3Sn)2 (0.99 g, 3.0 mmol) in t-butylbenzene (20 cm3) was purged with nitrogen for 30 
m in, and left to reflux whilst irradiating with a 300 W sunlamp at 150 oc for 10 h. The 
reaction mixture was cooled and dilute hydrochloric acid was added to the cooled reaction 
mixture to extract the protonated quinazolinone products into the aqueous layer. The aqueous 
layer was washed with light petroleum (3 x 50 cm3) to remove trimethyltin residues. The 
aqueous layer was basified with a solution of sodium hydroxide to pH 14 and extracted with 
DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 and the solvent 
removed under reduced pressure yielding 5,6-dihydroisoquino[1 ,2-b ]quinazolin-8-one 237 as 
colourless crystals (0.22 g, 0.92 mmol, 92%); mp 195-197 oc (lit. 146 196 °C); (Found: MH+, 
249.1025. cl6Hl3N20 requires 249.1022); Vmax(thin film)/cm"1 3421, 1682, 1590, 1556, 1471, 
1150, 762 and 692; 8H 3.06 (2 H, t, J 6.4, CH2), 4.35 (2 H, t, J 6.4, NCH2), 7.22-7.13 {1 H, m, 
ArH), 7.43-7.37 (3 H, m, ArH), 7.71-7.69 (2 H, m, ArH), 8.25 (1 H, d, J7.6, ArH) and 8.43-
8.40 (1 H, m, ArH); 8c 27.39 (CH2), 39.54 (NCH2), 120.70 (ArC), 126.48 (ArH), 126.82 
(ArH), 127.40 (ArH), 127.56 (2 x ArH), 127.96 (ArH), 129.48 (ArC), 131.66 (ArH), 134.18 
(ArH), 137.02 (ArC), 147.73 (ArCN), 149.29 (ArCN2) and 161.63 (CO); m/z(Electrospray) 
249 (M+, 17%), 247 (100), 128 (20), 116 (46), 104 (30), 90 (34), 89 (62), 77 (85), 76 (97), 63 
(53) and 39 (54). 
The data were consistent to the literature.146 
Method B - Bu3SnH (fast) and EhB 
Triethylborane (0.20 cm3, 0.20 mmol) and Bu3SnH (0.54 cm3, 2.0 mmol) were added to 3-[2-
(bromophenyl)ethyl]-3H-quinazolin-4-one (0.32 g, 1.0 mmol) in dry toluene ( 40 cm3) and 
stirred for 1 h with an air bleed into the round bottom flask through a needle. More 
triethylborane (0.20 cm\ 0.2 mmol) was added and the reaction left to stir for a further 10 h. 
Dilute hydrochloric acid was added to the reaction mixture to extract the protonated 
quinazolinone products into the aqueous layer. The aqueous layer was washed with light 
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petroleum (3 x 50 cm3) to remove tributyltin residues. The aqueous layer was basified with a 
solution of sodium hydroxide to pH 14 and with DCM (3 x 50 cm3). The combined organic 
layers were dried over MgS04 and the solvent removed under reduced pressure yielding a 
mixture of reduced product 3-[2-(phenyl)ethyl]-3H-quinazolin-4-one 237 and 5,6-
dihydroisoquino[l ,2-b ]quinazolin-8-one as 238 inseparable colourless crystals. 
1H NMR spectral analysis used to calculate yield of cyclised 5,6-dihydro-isoquino[l,2-b] 
quinazolin-8-one 237 (8%) and reduced product 3-[2-(phenyl)ethyl]-3H-quinazolin-4-one 238 
(50%). 
2-Bromo-3H-quinazolin-4-one 
sd±J: 
7 SaN 2 Br 8 
241 
Bromine (0.76 cm3, 15.0 mmol) was slowly added to a solution of2-mercapto-3H-quinazolin-
4-one (0.89 g, 5.0 mmol) in EtOH (20 cm3) and stirred for 2 h. The crude reaction product 
was filtered and triturated with EtOH and DCM. The solid was dried under reduced pressure 
yielding 2-bromo-3H-quinazolin-4-one as colourless crystals (0.55 g, 2.46 mmol, 50%); mp 
134-136 ·c; (Found: M+, 223.9585. CsHs79BrN20 requires 223.9585); Vmax(thin film)/cm-1 
2959,2722,2579,1714,1628,1565,1536,1465,1376,1288,1255,1181,1068,755,721 and 
511; oH (CD3)2SO 7.20-7.16 (2 H, m, 6,8-H), 7.64 (1 H, ddd, J 8.6, 7.0, 1.5, 7-H) and 7.89 (1 
H, dd, J 8.6, 1.5, 5-H); 8c (CD3)2SO 114.27 (4a-C), 115.28 (6/8-C), 122.30 (6/8-C), 126.90 (5-
C), 134.95 (7-C), 140.81 (8a-C), 150.25 (2-C) and 162.80 (4-ArC); m/z(EI) 226 (M+, 51%), 
224 (52), 145 (100), 90 (46), 82 (26) and 80 (27). 
The data were consistent to the literature. 138 
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3-Benzyl-2-bromo-3H-quinazolin-4-one 
5 0 6~N~ U~ADrV 7 SaN 2 Br 
s 
240 
------ -- -- --
Sodium hydride (0.13 g, 3.2 mmol) was added to a solution of2-bromo-3H-quinazolin-4-one 
(0.49 g, 2.1 mmol) in DMF (10 cm3) and stirred for 1 h. Benzyl bromide (0.5 cm3, 4.2 mmol) 
was added and the reaction was stirred for a further 3 h. The reaction mixture was quenched 
with H20 (5 cm3). The crude reaction mixture was extracted into EhO and washed with H20 
(5 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleurn!EtOAc (6:1) as eluent to yield 3-benzyl-2-
bromo-3H-quinazolin-4-one as colourless crystals (0.31 g, 0.97 mmol, 46% ); mp 109-111 oc; 
(Found: MH+, 315.0128. CtsH1279BrN20 requires 315.0128.); Vmax(thin film)/cm·1 3457, 3064, 
1653, 1558, 1494, 1430, 1339, 1234, 1134, 1074, 1023, 901 and 819; 8H 5.56 (2 H, s CH2), 
7.29-7.37 (5 H, m, Ph-H), 7.52 (1 H, ddd, 18.2, 8.0, 2.0, 7-H), 7.66 (1 H, dd, 18.0, 1.2, 8-H), 
7.79 (1 H, ddd, J 8.2, 8.0, 1.2, 6-H) and 8.27 (1 H, dd, J 8.0, 2.0, 5-H); 8c51.76 (CH2), 120.55 
(4a-C), 126.88 (6/8-C), 127.49 (2 x Ph-H), 127.56 (6/8-C), 127.73 (5-C), 127.94 (7-C), 
127.77 (2 x Ph-H), 135.12 (Ph-H), 135.36 (Ph-C), 136.20 (8a-C), 147.19 (2-C) and 161.65 (4-
C); m/z(Electrospray) 316 (M+, 15%), 314 (16), 235 (75), 144 (39), 129 (22) and 91 (100). 
Radical cyclisation of 3-benzyl-2-bromo-3H-quinazolin-4-one 
sMro1 s~N~ 1~~~ 1 ~ 1~:)2 V 
6 - 2 S Sa 
4 3 
233 
Method A- Bu3SnH (slow) and Et3B 
232 
Tributyltin hydirde (0.59 cm3, 2.2 mmol) in toluene (10 cm3) was added over 6 h to a solution 
of triethylborane ( 10 cm3, 10.0 mmol) and 3-benzyl-2-bromo-3H-quinazolin-4-one (0.31 g, 
1.0 mmol) in dry toluene ( 40 cm3) with an air bleed into the round bottom flask through a 
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needle. More triethylborane (10 cm3, 10.0 mmol) was added and the reaction left to stir for a 
further 5 h. Dilute hydrochloric acid was added to the reaction to extract the protonated 
quinazolinone products into the aqueous layer. The aqueous layer was washed with light 
petroleum (3 x 50 cm3} to remove tributyltin residues. The aqueous layer was basified with a 
solution of sodium hydroxide to pH 14 and extracted with DCM (3 x 50 cm3). The combined 
organic layers were dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (2:1) yielding the reduced product 3-benzyl-3H-quinazolin-4-one 232 as 
colourless crystals (0.15 g. 0.62 mmol, 62%). 
The data were consistent to previous synthesis and literature. 144 
Method B - Bu3GeH (slow) and EhB 
Tributylgermanium hydride (0.53 g. 2.2 mmol) in toluene (1 0 cm3} was added over 6 h to a 
solution of triethylborane (10 cm3, 10 mmol) and 3-benzyl-2-bromo-3H-quinazolin-4-one 
(0.31 g. 1.0 mmol) in dry toluene ( 40 cm3} with an air bleed into the round bottom flask 
through a needle. Additional triethylborane (10 cm3, 10 mmol) was added to the reaction 
mixture after 3 h. Dilute hydrochloric acid was added to the reaction mixture to extract the 
protonated quinazolinone products into the aqueous layer. The aqueous layer was washed 
with light petroleum (3 x 50 cm3} to remove tributylgermanium residues. The aqueous layer 
was basified with a solution of sodium hydroxide to pH 14 and extracted with DCM (3 x 50 
cm3}. The combined organic layers were dried over MgS04 and the solvent removed under 
reduced pressure yielding 3-benzyl-3H-quinazolin-4-one 232 (0.11 g. 0.47 mmol, 47%). 
Method C- Photolysis with hexamethylditin 
The reaction mixture between 3-benzyl-2-bromo-3H-quinazolin-4-one (0.30 g. 0.95 mmol) 
and (Me3Sn)z (0.93 g. 2.85 mmol) in t-butylbenzene (20 cm3} was purged with nitrogen for 30 
min. refluxed and irradiated with 300 W sun lamp for 10 h. Dilute hydrochloric acid was 
added to the cooled reaction mixture to extract the protonated quinazolinone products into the 
aqueous layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to remove 
trimethyltin residues. The aqueous layer was basified with a solution of sodium hydroxide to 
pH 14. The basic solution was extracted with DCM (3 x 50 cm3}. The combined organic 
layers were dried over MgS04 and the solvent removed under reduced pressure. 1H NMR 
spectroscopy revealed a mixture of cyclised 12H-isoindolo-[1,2-b]-quinazolin-10-one 233 
155 
---------------- ------
(27%) and reduced product 3-benzyl-3H-quinazolin-4-one 232 (41 %) as inseparable 
colourless crystals. 
The amounts of products were determined using 1H NMR spectroscopy. 
The data were consistent to the previous synthesis and literature. 144 
2-Bromo-3-phenylethyi-3H-quinazolin-4-one 
0~ 6~1 ~ 7lJh~~2 Br 
8 
243 
Sodium hydride (0.14 g, 3.6 mmol) and sodium iodide (2.2 g, 15.0 mmol) were added to 2-
bromo-3-H-quinazolin-4-one (0.53 g, 3.0 mmol) in dry DMF (20 cm3) and stirred for 1 h. 2-
Bromoethylbenzene (0.82 cm3, 6.0 mmol) was added to the reaction mixture and stirred for a 
further 12 h. The reaction mixture was extracted into EtOAc and washed with H20 (5 x 50 
cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica gel as absorbent with light petroleurn/EtOAc as eluent (10: 1) yielding 2-bromo-3-
phenylethyl-3H-quinazolin-4-one as colourless crystals (0.06 g, 0.18 mmol, 6%); mp 109-110 
OC; (Found: M+, 328.0206. c,6H1379J3rNzO requires 328.0206.); Vmax(thin film)/cm·' 3060, 
2930, 2359, 1866, 1714, 1655, 1621, 1604, 1493, 1452, 1405, 1072, 1028, 938 and 908; oH 
2.99 (2 H, t, J7.6, CHz), 4.37 (2 H, t, J7.6, NCHz), 7.26-7.15 (5 H, m, ArH), 7.34-7.30 (1 H, 
m, 6-H), 7.49 (1 H, d, J 7.6, 8-H), 7.67-7.63 (1 H, m, 7-H) and 8.20 (1 H, d, J 7.6, 5-H); oc 
33.98 (CHz), 42.25 (NCHz), 114.55 (4a-C), 114.88 (ArH), 123.12 (8-C), 126.39 (6-C), 128.27 
(5-C), 128.42 (2 x ArH), 128.93 (2 x ArH), 134.85 (7-C), 138.54 (ArC), 138.75 (ArC), 
151.17 (2-C) and 162.28 (4-C); mlz(EI) 330 (M+, 26%), 328 (25%) 145 (25), 130 (33), 104 
(100), 90 (95), 65 (30) and 39 (40). 
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Radical cyclisation of 2-bromo-3-phenylethyi-3H-quinazolin-4-one 
237 
Method A- Photolysis and hexamethylditin 
The reaction mixture of 2-bromo-3-phenylethyl-3H-quinazolin-4-one (28 mg, 0.085 mmol) 
and (Me3Sn)2 (82 mg, 0.25 mmol) in t-butylbenzene (20 cm3) was purged with nitrogen for 30 
min, refluxed and irradiated with a 300 W sunlamp for 24 h. Dilute hydrochloric acid was 
added to the cooled reaction mixture to extract the protonated quinazolinone products into the 
aqueous layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to remove 
trimethyltin residues. The aqueous layer was basified with a solution of sodium hydroxide to 
pH 14 and extracted with DCM (3 x 50 cm3). The combined organic layers were dried over 
MgS04 and the solvent removed under reduced pressure yielding 5,6-dihydroisoquino[1,2-
b]quinazolin-8-one 237 as colourless crystals (0.02 g, 0.082 mmol, 97%). 
The data were consistent to the previous synthesis and literature.146 
3-(3-Chloropropyi)-3H-quinazolin-4-one 
253a 
Sodium hydride (1.78 g, 44.6 mmol) was added at 0 octo 3H-quinazolin-4-one (6.50 g, 44.6 
mmol) in dry DMF (50 cm3), warmed to 60 oc and stirred for 1 h. 1-Chloro-3-iodopropane 
(4.0 cm3, 37.2 mmol) was added and stirred for a further 12 h. The reaction mixture was 
extracted into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer 
was dried over MgS04 and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography using silica gel as absorbent with light 
petroleurn!EtOAc (2: 1) as eluent yielding 3-(3-chloropropyl)-3H-quinazolin-4-one as 
colourless crystals (5.06 g, 22.8 mmol, 51%); mp 97-99 oc (lit. 147 98-100 °C); (Found: MH+, 
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223.0635. C11H1235ClN20 requires 223.0633.); Vmax(thin film)/cm·' 3439, 1659, 1613, 1469, 
1366, 774 and 696; ()H 2.34-2.28 (2 H, m, CH2), 3.60 (2 H, t, J 9.9, ClCH2), 4.19 (2 H, t, J 
10.4, NCHz), 7.51 (1 H, ddd, J 8.1, 6.4, 1.5, 6-H), 7.81-7.69 (2 H, m, 7,8-H), 8.11 (1 H, s, 2-
H) and 8.30 (1 H, dd, J 8.1, 1.5, 5-H); <ic 31.02 (CHz), 41.58 (ClCHz), 44.49 (NCHz), 122.00 
(4a-C), 126.57 (5-C), 127.42 (6-C), 127.49 (8-C), 134.38 (7-C), 146.61 (2-C), 148.05 (Sa-C) 
and 161.15 (3-C); m/z(Electrospray) 225 (M+, 23%), 223 (79%), 187 (46), 160 (48), 129 (36), 
77 (41), 63 (29), 49 (39) and 41 (100); Anal. Calcd for CuHuNzClO. C, 59.33; H, 4.98; N, 
12.58. Found: C, 58.98; H, 4.98; N, 12.31. 
The data were consistent to the literature.147 
3-(3-Iodopropyi)-3H-quinazolin-4-one 
0 
6~N~I 
7~:)2 
8 
254a 
3-(3-Chloropropyl)-3H-quinazolin-4-one (4.43 g, 20.0 mmol) and sodium iodide (14.9 g, 
100.0 mmol) were added to dry acetone (50 cm3) and stirred under reflux for 12 h in the dark. 
The precipitated sodium chloride was removed by filtration on a celite bed and the solvent 
removed under reduced pressure. The solid residue was triturated with diethyl ether and the 
solution filtered a second time. The organic layer was dried over MgS04 and the solvent 
removed under reduced pressure to afford 3-(3-iodopropyl)-3H-quinazolin-4-one propane as 
colourless crystals (3.35 g, 10.6 mmol, 53%); mp 119-121 oc (lit.147 120-122 °C); (Found: 
MH+, 314.9990. CuH12INzO requires 314.9989.); Vmax(thin film)/cm"13421, 1667, 1614, 1470, 
1364, 1118, 775 and 698; <iH2.37-2.30 (2 H, m CHz), 3.20 (2 H, t, J 6.4, ICHz), 4.13 (2 H, t, J 
6.8, NCHz), 7.52-7.48 (1 H, m, 6-H), 7.74-7.68 (2 H, m, 7,8-H), 8.13 (1 H, s, 2-H) and 8.27 (1 
H, dd, J8.0, 1.6, 5-H); 8c2.31 (ICHz), 31.91 (CHz), 47.42 (NCHz), 121.94 (4a-C), 126.22 (5-
C), 126.52 (6-C), 126.70 (8-C), 134.31 (7-C), 146.52 (2-C), 147.98 (8a-C), 161.03 (3-C); 
m/z(Electrospray) 187 (M+, 37%), 127 (35), 76 (28) and 41 (100). 
The data were consistent to the literature.147 
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1-Chloro-3-(phenylselanyl) propane148 
CI~SePh 
256 
Diphenyl diselanide (4.67 g, 15.0 mmol) was dissolved in methanol (250 cm3) at rt. Sodium 
borohydride (1.41 g, 37.5 mmol) was added slowly to the stirred solution at 0 °C. Hydrogen 
gas was allowed to escape through a needle. After 30 min, 3-bromo-1-chloropropane (2.97 
cm3, 30.0 mmol) was added dropwise and the mixture was stirred for 12 h. The reaction 
mixture was extracted into Et20 and washed with H20 (3 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure yielding 
1-chloro-3-(phenylselanyl)propane as a yellow oil (5.67 g, 24.2 mmol, 81%); Vmax(neat)/cm·1 
2952, 1576, 1476, 1436, 1261, 1021, 734 and 690; 8H2.09-1.98 (2 H, m, CH2), 2.96 (2 H, t, J 
7.0, PhSeCH2), 3.56 (2 H, t, J6.2, CICH2), 7.23-7.17 (3 H, m, ArH) and 7.44-7.42 (2 H, m, 
ArH); 8c 24.64 (CH2), 32.56 (PhSeCH2), 44.46 (ClCH2), 127.17 (ArH), 129.32 (2 x ArH), 
129.74 (ArC) and 132.87 (2 x ArH). 
The data were consistent to the literature. 148 
1-Iodo-3-(phenylselanyl)propane148 
I~SePH 
257 
1-Chloro-3-(phenylselanyl)propane (3.50 g, 15 mmol) and sodium iodide (22.50 g, 150 
mmol) were added to dry acetone (100 cm3) and stirred under reflux for 18 h in the dark. The 
precipitated sodium chloride was removed by filtration on a celite bed and triturated with 
diethyl ether. The organic layer was dried over MgS04 and the solvent removed under 
reduced pressure yielding 1-iodo-3-(phenylselanyl)propane as a yellow oil (1.08 g, 3.4 mmol, 
22%); Vmax(neat)/cm·1 1577, 1476, 1436, 1201, 1021, 732 and 689; OH 2.10-1.99 (2 H, m, CH2), 
2.87 (2 H, t, J 7.0, PhSeCH2), 3.16 (2 H, t, J 6.7, ICH2), 7.24-7.19 (3 H, m, ArH) and 7.49-
7.24 (2 H, m, ArH); 8c 6.36 (ICH2), 28.56 (PhSeCH2), 33.34 (CH2), 126.99 (ArH), 129.17 (2 
x ArH), 130.02 (ArC) and 132.77 (2 x ArH). 
The data were consistent to the literature. 148 
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3-( 4-Ch1orobutyi)-3H-q uinazolin-4-one 
0 
6a::5 4a ~Cl I 4 N 
7 ~ NJ2 
8 8a 
253b 
Sodium hydride (0.19 g, 4.8 mmol) was added at 0 oc to 3H-quinazolin-4-one (0.70 g, 4.8 
mmol) in dry DMF (50 cm3) and warmed to 60 oc and stirred for 1 h. 1-Chloro-4-iodobutane 
(0.49 cm3, 4.0 mmol) was added and the reaction stirred for a further 12 h. The reaction 
mixture was extracted into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (3:1) as eluent yielding 3-(4-chlorobutyl)-3H-quinazolin-4-one as 
colourless crystals (0.61 g, 2.6 mmol, 65%); mp 74-76 oc; (Found: MH+, 237.0792. 
c,2Ht435ClN20 requires 237.0789.); Vmax(thin film)/cm·' 3446, 2953, 1662, 1609, 1471, 1367, 
908, 875, 769 and 696; OH 1.86-1.89 (2 H, m, CH2CH2Cl), 2.05-1.97 (2 H, m, NCH2CH2), 
3.61 (2 H, t, J 6.5, CH2Cl), 4.06 (2 H, t, J7.6, NCH2), 7.52 (1 H, m, 6-H), 7.77-712 (2 H, m, 
7,8-H), 8.05 (1 H, s, 2-H) and 8.32-8.30 (1 H, m, 5-H); oc 26.89 (NCH2CH2), 29.47 
(CH2CH2Cl), 44.16 (NCH2), 46.10 (CH2Cl), 122.06 (4a-C), 126.67 (5-CH), 127.34 (6-C), 
127.46 (8-C), 134.26 (7-C), 146.30 (2-C), 148.06 (8a-C) and 161.06 (4-C); m/z(Electrospray) 
238 (M+, 7%), 236 (50%), 201 (29), 146 (39), 77 (28), 63 (25), 55 (42), 49 (74); Anal. Calcd 
for C12H13N20CI. C, 60.89; H, 5.54; N, 11.84. Found: C, 60.76; H, 5.44; N, 12.00. 
3-( 4-Iodobutyi)-3H-quinazolin-4-one 
254b 
3-(3-Chlorobutyl)-3H-quinazolin-4-one (0.37 g, 1.6 mmol) and sodium iodide (2.25 g, 15.0 
mmol) were added to dry acetone (50 cm3) and stirred under reflux for 12 h in the dark. The 
precipitated sodium chloride was removed by filtration on a celite bed and the solution 
evaporated to dryness. The solid residue was triturated with diethyl ether and the solution 
filtered a second time. The organic layer was dried over MgS04 and the solvent removed 
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under reduced pressure to afford 3-( 4-iodobutyl)-3H-quinazolin-4-one as colourless crystals 
(0.34 g, 1.1 mmol, 67%); mp 79-80 °C; (Found: M+, 329.0253. C12H13IN20 requires 
329.0254.); Vmax(thin film)/cm·13424, 2949, 1656, 1614, 1471, 1372, 1172, 1111, 888, 769 and 
697; oH 1.89-1.91 (4 H, m, CH2CH2), 3.24 (2 H, t, J 6.4, CH2l), 4.04 (2 H, t, J 6.8, NCH2), 
7.51 (1 H, ddd, J 8.2, 6.8, 1.2, 6-H), 7.78-7.70 (2 H, m, 7,8-H), 8.06 (1 H, s, 2-H) and 8.32-
8.29 (1 H, dd, J 8.2, 1.0, 5-H); oc 5.21 (CHzl), 30.25 (CHz), 30.38 (CH2), 45.71 (NCH2), 
122.05 (4a-C), 126.67 (5-C), 127.35 (6-C), 127.58 (8-C), 134.26 (7-C), 146.29 (2-C), 148.05 
(8a-C) and 161.02 (4-C); m/z(EI) 201 (M+, 43%), 141 (27), 90 (100), 76 (53), 62 (41) and 50 
(30). 
Radical cyclisation of 3-(3-iodopropyl)-JH-quinazolin-4-one 
0 0 
:~p OCD 
8 H 
6~N~ 
7~:J2 
8 
147 259 260 
Method A- Photolysis and hexamethylditin 
The reaction mixture of 3-(3-iodopropyl)-3H-quinazolin-4-one (0.31 g, 1.0 mmol) and 
(Me3Sn)2 (0.96 g, 3.0 mmol) in t-butylbenzene (20 cm3) was purged with nitrogen for 30 min, 
retluxed and irradiated with a 300 W sunlamp for 24 h. Dilute hydrochloric acid was added to 
the cooled reaction mixture to extract the protonated quinazolinone products into the aqueous 
layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to remove trimethlytin 
residues. The aqueous layer was basified with a solution of sodium hydroxide to pH 14. The 
basic solution was extracted with EtOAc (5 x 50 cm3). The combined organic layers were 
dried over MgS04 and the solvent removed under reduced pressure and purified by column 
chromatography using silica gel as absorbent with light petroleum/EtOAc (2: 1) as eluent 
yielding: 
147 2,3-Dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one as colourless crystals (0.04 g, 0.2 mmol, 
20%); mp 190-192 °C (lit. 149 196-198 °C); Vmax(thin film)/cm·l 3418, 2355, 1651, 1621, 1470, 
1385, 1285,775,695 and 667; oH2.35-2.23 (2 H, m, CH2), 3.18 (2 H, t, J8.2, CH2), 4.21 (2 H, 
t,J7.4, NCHz), 7.47-7.62 (1 H, m, 6-H), 7.76-7.62 (2 H, m, 7,8-H) and 8.28 (1 H, dd, J7.8, 
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1.5, 5-H); oc I9.52 (CH2), 32.5I (CHz), 46.5I (NCHz), I20.45 (4a-C), I26.25 (5-C), 126.38 
(6-C), I26.76 (8-C), 134.19 (7-C), I49.07 (8a-C), I59.47 (2-C) and I6l.OI (4-C). 
The data were consistent to the literature. 149 
259 2,3,3a,4-Tetrahydro-IH-pyrrolo[2, 1-b ]quinazolin-9-one as colourless crystals (0.02 g, 
0.12 mmol, I2%); mp I87-188 °C (lit. 150 I84-185 °C}; Vmax(thin film)/cm·1 342I, I633, I503, 
I470, 1434, 1337, II5I, 752 and 695; 8H2.32-2.29 (2 H, m, CHz), 3.19 (I H, t, J8.0, I-H), 
3.75-3.67 (2 H, m, CHCHz), 4.2I (1 H, t, J7.2, 1-H), 5.03 (1 H, t, J7.2, CH), 6.69 (1 H, d, J 
8.1, 8-H), 6.92-6.88 (1 H, m, 6-H), 7.27-7.24 (1 H, m, 7-H) and 7.90 (1 H, dd, J 7.7, 1.5, 5-
H); oc 21.73 (CHz), 33.22 (CHCHz), 44.29 (NCHz), 69.86 (CH), 114.88 (5-C), 118.39 (4a-C), 
1I9.95 (6-C), I26.78 (8-C), 132.92 (7-C), I47.31 (8a-C) and I62.22 (4-C). 
The data were consistent to the Iiterature. 150 
260 3-Propyi-3H-quinazolin-4-one as colourless crystals (O.OI g, 0.06 mmol, 6%); mp 99-IOO 
°C (lit. 151 96-98 °C); OH 1.01 (3 H, t, J 7.6, CH3), 1.89-1.79 {2 H, m, CHz), 3.98 {2 H, t, J 8.4, 
NCH2), 7.49-7.26 (I H, m, 5-H), 7.76-7.7I (2 H, m, 7,8-H), 8.04 (I H, s, 2-H) and 8.33-8.3I 
(I H, m, 5-H); oc Il.I4 (CH3), 22.66 (CHz), 48.6I (NCHz), I22.I9 (4a-C), I26.7I (5-C), 
126.82 (6-C), I27.23 (8-C), 134.16 (7-C), I46.12 (2-C), 148.12 (8a-C) and 161.10 (4-C). 
The data were consistent to the literature. 151 
Method B - Et3B only 
The reaction mixture of 3-(3-iodopropyi)-3H-quinazolin-4-one (0.31 g, 1.0 mmol) and 
triethylborane (4 cm3, 4.0 mmol) in t-butylbenzene (20 cm3) was stirred for 10 h with an air 
bleed into the round bottom flask through a needle. Dilute hydrochloric acid was added to the 
cooled reaction mixture to extract the protonated quinazolinone products into the aqueous 
layer. The aqueous layer was washed with light petroleum (3 x 50 cm3). The aqueous layer 
was basified with a solution of sodium hydroxide to pH 14 and extracted with DCM (3 x 50 
cm3). The combined organic layers were dried over MgS04 and the solvent removed under 
reduced pressure yielding 2,3-dihydro-IH-pyrrolo[2, 1-b ]quinazolin-9-one 147 ( 40%), 
2,3,3a,4-tetrahydro-1H-pyrrolo[2, I-b ]quinazolin-9-one 259 ( 1 0%) and 3-propyi-3H-
quinazolin-4-one 260 (30%). 
The data were consistent with the previous synthesis. 149· 150· 151 
The yields were calculated from 1H NMR spectral calculations. 
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Method C- Bu3SnH (fast) and EtJB 
Tributyltin hydride (0.54 cm3, 2.0 mmol) and triethylborane (0.20 cm3, 0.20 mmol) were 
added to 3-(3-iodopropyl)-3H-quinazolin-4-one (0.31 g, 1.0 mmol) in dry toluene ( 40 cm3) 
and stirred for 1 h with an air bleed into the round bottom flask through a needle. More 
triethylborane (0.20 cm3, 0.2 mmol) was added and the reaction stirred for a further 10 h. 
Dilute hydrochloric acid was added to the reaction mixture to extract the protonated 
quinazolinone products into the aqueous layer. The aqueous layer was washed with light 
petroleum (3 x 50 cm3) to remove tributyltin residues. The aqueous layer was basified with a 
solution of sodium hydroxide to pH 14. The basic solution was extracted with DCM (3 x 50 
cm3). The combined organic layers were dried over MgS04 and evaporated to dryness under 
reduced pressure yielding 3-propyl-3H-quinazolin-4-one 260 (78%). 
The data were consistent to the previous synthesis. 
3-Propyl-3H-quinazolin-4-one 
260 
Sodium hydride (0.29 g, 7.2 mmol) was added at 0 oc to 3H-quinazolin-4-one (0.87 g, 6.0 
mmol) in dry DMF (50 cm3), warmed to 60 °C and stirred for 1 h. 1-Iodopropane (1.75 cm3, 
18.0 mmol) was added and stirred for a further 2 h. The reaction mixture was extracted into 
DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer was dried 
over MgS04 and the solvent removed under reduced pressure. The crude product was purified 
·by column chromatography using silica gel as absorbent with light petroleurn!EtOAc (2:1) as 
eluent yielding 3-propyl-3H-quinazolin-4-one as colourless crystals (0.72 g, 3.8 mmol, 64%); 
mp 93-95 °C (lit.ISI 96-98 °C); Vmax(thin film)/cm·' 3416, 2963, 2875, 2462, 1674, 1611, 1473, 
1376, 1324, 1091, 899, 767, 695, 610 and 552; 8H0.99 (3 H, t, J7.4, CH3), 1.88-1.79 (2 H, m, 
CH2), 3.97 (2 H, t, J7.2, NCHz), 7.48 (1 H, ddd, J 8.1, 6.8, 1.5, 6-H), 7.75-7.67 (2 H, m, 7,8-
H), 8.06 (1 H, s, 2-H) and 8.30 (1 H, dd, J 8.1, 1.5, 5-H); 8c 11.02 (CH3), 22.20 (CHz), 48.38 
(NCH2), 122.03 (4a-C), 126.48 (5-C), 126.62 (6-C), 126.81 (8-C), 133.65 (7-C), 146.60 (2-C), 
148.00 (8a-C) and 160.84 (4-C); Anal. Calcd for CuH,zNO. C, 70.19; H, 6.43; N, 14.88. 
Found: C, 69.91; H, 6.43; N, 14.78. 
The data were consistent to previous synthesis and the literature.151 
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148 264 
Method A- photolysis with hexamethylditin 
The reaction mixture of 3-( 4-iodobutyl)-3H-quinazolin-4-one (0.32 g, 1.0 mmol) and 
(Me3Sn)z (0.96 g, 3.0 mmol) in t-butylbenzene (20 cm3) was purged with nitrogen for 30 min, 
refluxed and irradiated with a 300 W sunlamp for 10 h. Dilute hydrochloric acid was added to 
the cooled reaction mixture to extract the protonated quinazolinone products into the aqueous 
layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to remove trimethyltin 
residues. The aqueous layer was basified with a solution of sodium hydroxide to pH 14 and 
extracted with DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 and 
the solvent removed under reduced pressure and purified by column chromatography using 
silica gel as absorbent with light petroleum/EtOAc (2: 1) as eluent yielding: 
148 6,7,8,9-Tetrahydropyrido[2,1-b]quinzolin-11-one as colourless crystals (0.06 g, 0.3 
mmol, 30%); mp 94-95 oc (lit. 180 96-97 °C); (Found: MH+, 201.1020. c,2H13N20 requires 
201.1022.); Vmax{thin film)/cm·' 3423, 2948, 2110, 1655, 1614, 1565, 1477, 1173, 1102, 990, 
870, 771 and 583; oH 2.18-1.91 (4 H, m, CHzCHz), 3.00 {2 H, t, J 6.6, NCCHz), 4.09 {2 H, t, J 
6.3, NCH2), 7.44-7.40 (1 H, m, 6-H), 7.59 (1 H, dd, J 8.3, 0.5, 8-H), 7.73-7.69 (1 H, m, 7-H) 
and 8.26 (1 H, dd, J 8.0, 1.5, 5-H); 8c 19.33 (CHz), 22.10 (CHz), 31.93 (CHz), 42.32 (CHz), 
120.40 (4a-C), 126.06 (5-C), 126.37 (6-C), 126.61 (8-C), 134.15 (7-C), 147.39 (Sa-C), 154.86 
(2-C) and 162.17 (4-C); m/z(Electrospray) 200 (M+, 50%), 199 (40), 90 (33), 76 (34), 63 (33), 
50 (34), 41 (90) and 39 (100). 
The data were consistent to the literature. 180 
264 5,5a,6, 7,8,9-Hexahydropyrido[2, 1-b ]quinazolin-11-one as colourless crystals (0.05 g, 
0.23 mmol, 23%); mp 128-130 oc (lit. 152 134 °C}; (Found: MH+, 203.1180. C12H,sN20 
requires 203.1179.); Vmax(thin film)/cm·' 3398, 3058, 2938, 2224, 1632, 1518, 1416, 1218, 
1153, 1026, 754 and 692; oH 1.52-1.49 (2 H, m, 2-H), 1.91-1.75 (4 H, m, CHz), 2.66-2.59 (1 
H, m, 1-H), 4.25 (1 H, m, NH), 4.64-4.59 (1 H, m, 1-H), 4.78 (1 H, dd, J 10.2, 3.1, CH), 6.57 
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(1 H, d, J7.1, 8-H), 6.79 (1 H, ddd, J7.8, 2.9, 1.0, 6-H), 7.25 (1 H, m, 7-H) and 7.90 (1 H, dd, 
J7.8, 1.6, 5-H); oc22.30 (CH2), 24.16 (CH2), 33.43 (CH2), 41.99 (CH2), 68.51 (CH), 113.70 
(8-C), 115.18 (4a-C), 118.81 (6-C), 128.71 (5-C), 133.41 (7-C), 145.89 (8a-C) and 164.32 (4-
C); m/z(Electrospray) 201 (M+, 30%), 146 (42), 119 (48), 92 (42), 55 (79) and 41 (100). 
The data were consistent to the literature. 152 
Method B- EhB only 
3-(4-Iodobutyl)-3H-quinazolin-4-one (0.32 g, 1.0 mmol) and triethylborane (4 cm3, 4.0 mmol) 
in t-butylbenzene (20 cm3) were stirred for 10 h with an air bleed into the round bottom flask 
through a needle. Dilute hydrochloric acid was added to the cooled reaction mixture to extract 
the protonated quinazolinone products into the aqueous layer. The aqueous layer was washed 
with light petroleum (3 x 50 cm3). The aqueous layer was basified with a solution of sodium 
hydroxide to pH 14 and extracted with DCM (3 x 50 cm3). The combined organic layers were 
dried over MgS04 and the solvent removed under reduced pressure yielding 6,7,8,9-
tetrahydropyrido[2, 1-b ]quinzolin-11-one 148 (61 %) and 5,5a,6, 7,8,9-hexahydropyrido[2, 1-
b]quinazolin-11-one 264 (23%). 
The data were consistent to the previous synthesis. 80• 152 
The yields were calculated from 1H NMR spectral calculations 
6.4 Experimental for Chapter 3 
2-Chloro-3-(hydroxymethyl)q uinoline153 
5 4 6dXOH 
7 Sa ~2 Cl 
8 
275 
Sodium borohydride (0.18 g, 4.8 mmol) was added to a stirred solution of 3-carboxaldehyde-
2-chloroquinoline (0.76 g, 4.0 mmo1) in EtOH (50 cm3) at 0 OC and left stirring for 2 h. The 
crude reaction mixture was extracted into EtOAc and washed with H20 (3 x 50 cm3} and 
brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed under 
reduced pressure yielding 2-chloro-3-(hydroxymethyl)quinoline as colourless crystals (0.58, 
3.0 mmol, 75 %); mp 151-152 °C (lit. 153 149 °C}; (Found: MH+, 194.0368. CwHl5ClNO 
requires 194.0367.); Vmax(thin film)/cm·13410, 1256, 1201, 1187, 1016, 942, 896, 778, 756 and 
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670; 8H 4.94 (2 H, d, J 3.0, CH2), 7.57 (1 H, ddd, J 8.3, 6.8, 1.3, 6-H), 7.73 (1 H, ddd, J 8.1, 
6.8, 1.5, 7-H), 7.85 (1 H, dd, J 8.3, 1.5, 5-H}, 8.03 (1 H, dd, J 8.1, 1.3, 8-H) and 8.30 (1 H, s, 
4-ArH); 8c 62.05 (CH2), 127.25 (6-C), 127.38 (4a-C), 127.59 (5-C), 128.24 (8-C), 130.29 (7-
C}, 132.24 (3-C), 136.25 (4-C}, 146.94 (8a-C) and 149.07 (2-C); m/z(Eiectrospray) 195 (M+, 
15%}, 193 (38), 163 (42}, 156 (38}, 140 (30}, 130 (42}, 129 (45}, 128 (100}, 75 (36}, 63 (44}, 
62 (88}, 50 (53) and 39 (59); Anal. Calcd for C10H7NCIO. C, 62.03; H, 4.16; N, 7.23. Found: 
C, 61.92; H, 4.16; N, 7.23. 
The data were consistent to the literature. 153 
2-Bromo-3-(bromomethyl)quinoline102 
5 4 
6~ ~t.i~~o. Br 
7 sa N~ 2 Br 
8 
276 
Phosphorous tribromide (1.5 cm\ 16.0 mmol) was added to a stirred solution of 2-chloro-3-
(hydroxymethyl)quinoline (0.77 g, 4.0 mmol) in THF (20 cm3} at 0 oc and stirred for a further 
24 h. The _crude reaction mixture was extracted into DCM and washed with H20 (3 x 50 cm3} 
and brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed under 
reduced pressure. The crude product was purified by column chromatography using silica gel 
as absorbent with light petroleum/EtOAc (10:1) as eluent to yield 2-bromo-3-
(bromomethyl)quinoline as colourless crystals (0.66 g, 2.2 mmol, 55%); mp 137-138 oc 
(lit. 102 139-140 °C}; Vmax(thin film)/cm·11559, 1490, 1430, 1399, 1249, 1210, 1131, 1022, 968, 
920, 858, 776, 757,695,594 and 474; 8H4.74 (2 H, s, CH2), 7.60 (1 H, ddd, J8.0, 6.8, 2.0, 6-
H), 7.76 (1 H, ddd, J 8.6, 6.8, 1.7, 7-H), 7.82 (1 H, dd, J 8.0, 1.7, 5-H), 8.05 (1 H, dd, J 8.6, 
2.0, 8-H) and 8.23 (1 H, s, 4-H); 8c 28.98 (CH2}, 127.25 (4a-C), 127.55 (5-C), 127.64 (6-C), 
128.47 (8-C}, 131.12 (7-C), 131.45 (3-C}, 138.66 (4-C}, 143.10 (2-C) and 147.94 (Sa-C). 
The data were consistent to the literature. 102 
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3-[(2-Bromoquinolin-3-yl)methyl]-3H-quinazolin-4-one102 
0 
JJJ' 4a' N -?' I ~ J ~ ~ 
Sa N Br 2' N Sa' 
277 
Potassium t-butoxide (0.14 g, 1.28 mmol) was added to a solution of 3H-quinazolin-4-one 
(0.17 g, 1.16 mmol) in DMF (20 cm3) and stirred 1 h. 2-Bromo-3-(bromomethyl)-quinoline 
(0.42 g, 1.4 mmol) was added and stirred for a further 12 h. The crude reaction mixture was 
extracted into Et20 and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer 
was dried over MgS04 and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (1: 1) as eluent to yield 3-[(2-bromoquinolin-3-yl)methyl]-3H-quinazolin-4-
one as colourless crystals (0.279 g, 0.76 mmol, 65%); mp 200-202 oc (lit. 102 201-203 °C); 
Vmax(thin film)/cm-1 3424, 1664, 1470, 1359, 1318, 1220, 1164, 960, 858, 774, 693 and 494; OH 
5.42 (2 H, s, CH2), 7.59-7.53 (2 H, m, ArH), 7.83-7.16 (4 H, m, ArH), 8.04-7.99 (1 H, m, 
ArH), 8.05 (1 H, s, ArH), 8.34-8.30 (1 H, m, ArH) and 8.35 (1 H, s, ArH); Be 49.53 (CH2), 
122.07 (4a-C), 126.84 (ArH), 127.04 (4a'-C), 127.67 (ArH), 127.72 (ArH), 127.78 (ArH), 
127.83 (ArH), 128.31 (ArH), 128.73 (3'-C), 131.03 (ArH), 134.69 (ArH), 138.29 (ArH), 
142.02 (2'-C), 146.52 (ArH), 147.91 (8a'-C), 148.02 (8a-C) and 161.21 (4-C). 
The data were consistent to the literature. 102 
Radical cyclisation of 3-[(2-bromoquinolin-3-yl)methyl]-3H-quinazolin-4-one 
~N ~N~ lJlN~ lJlNJ ~N~ 
144a 278 
Method A- Photolysis with hexamethylditin 
The reaction mixture between 3-[(2-bromo-quinolin-3-yl)methyl]-3H-quinazolin-4-one (0.16 
g, 0.43 mmol) and (Me3Sn)2 (0.42 g, 1.29 mmol) in t-butylbenzene (20 cm3) was refluxed and 
irradiated with UV lamp for 24 h. Dilute hydrochloric acid was added to the cooled reaction 
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mixture to extract the protonated quinazolinone products into the aqueous layer. The aqueous 
layer was washed with light petroleum (3 x 50 cm3) to remove trimethlytin residues. The 
aqueous layer was basified with a solution of sodium hydroxide to pH 14 andextracted with 
DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleum/EtOAc ( 1:1) as eluent yielding: 
144a Luotonin A as colourless crystals (62 mg, 0.22 mmol, 51%); Vmax(thin film)/cm·• 3430, 
2100, 1640, 1551, 1466, 1438, 1337, 741 and 691; oH 5.35 (2 H, s, CH2), 7.59 (1 H, t, J 8.2, 
ArH), 7.69 (1 H, t, J 8.2, ArH), 7.88-7.82 (2 H, m, ArH), 7.95 (1 H, d, J 8.2, ArH), 8.21 (1 H, 
d, J 8.2, ArH) and 8.49-8.42 (3 H, m, ArH); Oc 47.33 (CH2), 121.32 (ArC), 126.46 (ArH}, 
127.47 (ArH), 127.98 (ArH), 128.55 (ArH), 128.78 (ArH), 129.42 (ArC), 130.72 (ArH), 
130.74 (ArC), 131.59 (ArH), 134.62 (2 x ArH), 149.37 (ArC), 149.45 (ArC), 151.19 (ArC), 
152.57 (ArC) and 160.69 (ArC). 
The data were consistent to the literature. 73 
278 3-[(Quinolin-3-yl)methyl]-3H-quinazolin-4-one as colourless crystals (19 mg, 0.07 
mmol, 15%): mp 252-253 oc; (Found: MH+, 288.1131. CtsHt4N30 requires 288.1130.); 
Vmax(thin film)/cm·1 3420, 2357, 2107, 1646, 1558, 1450, 1361, 1332, 510 and 454; OH 5.39 (2 
H, s, CH2), 7.58-7.53 (2 H, m, ArH}, 7.81-7.70 (4 H, m, ArH), 8.10 (1 H, dd, J8.9, 0.4, ArH), 
8.17 (1 H, d, J 1.8, ArH), 8.35-8.32 (1 H, m, ArH) and 8.99 (1 H, d, J 1.8, ArH); 8c 47.73 
(CH2), 122.14 (ArC), 126.89 (ArH), 127.28 (ArH), 127.66 (2 x ArH), 127.86 (ArH), 128.60 
(2 x ArC), 129.29 (ArH), 130.04 (ArH), 134.59 (ArH), 135.41 (ArH), 145.90 (ArH), 147.88 
(ArC}, 148.02 (ArC), 150.11 (ArH) and 161.07 (ArC); m/z(Electrospray) 287 (M+, 47%}, 270 
(45}, 142 (100), 115 (68) and 89 (20). 
Method B - BuJSnH (fast) and Et3B 
Tributyltin hydride (0.049 cm3, 0.17 mmol) was added to a solution oftriethylborane (1 0 cm3, 
10 mmol) and 3-[(2-bromo-quinolin-3-yl)methyl]-3H-quinazolin-4-one (0.025 g, 0.068 
mmol) in dry toluene (40 cm3} with an air bleed into the round bottom flask through a needle 
and stirred 5 h. Triethylborane (10 cm3, 10 mmol) was added and the reaction mixture stirred 
for a further 5 h. Dilute hydrochloric acid was added to the reaction mixture to extract the 
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protonated quinazolinone products into the aqueous layer. The aqueous layer was washed 
with light petroleum (3 x 50 cm3} to remove tributyltin residues. The aqueous layer was 
basified with a solution of sodium hydroxide to pH 14. The basic solution was extracted with 
DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 and the solvent 
removed under reduced pressure yielding 3-[(quinolin-3-yl)methyi]-3H-quinazolin-4-one 278 
(10.3 mg, 0.036 mmol, 53%). 
The d~ta were consistent to the previous synthesis. 
Method C - Bu3SnH (slow) and EhB 
Tributyltin hydride (0.034 cm3, 0.14 mmol) was added to a solution oftriethylborane (10 cm3, 
10 mmol) and 3-[(2-bromoquinolin-3-yl)methyi]-4(3H)-quinazolinone (0.02 g, 0.055 mmol) 
in dry toluene ( 40 cm3} via a syringe pump over 5 h. The round bottom flask had a needle to 
bleed air through. After 3 h, triethylborane (10 cm3, 10 mmol) was added and stirred for a 
further 3 h. Dilute hydrochloric acid was added to the reaction mixture to extract the 
protonated quinazolinone products into the aqueous layer. The aqueous layer was washed 
with light petroleum (3 x 50 cm3} to remove tributyltin residues. The aqueous layer was 
basified with a solution of sodium hydroxide to pH 14. The basic solution was extracted with 
DCM (3 x 50 cm3). The combined organic layers were dried over MgS04 and the solvent 
removed under reduced pressure yielding luotonin A 144a (22 mg, 0.0076 mmol, 14%) and 
[(3-quinolin-3-yl)methyi]-3H-quinazolin-4-one 278 (50 mg, 0.174 mmol, 32%). 
The data were consistent to the previous synthesis and literature. 73 
Method D - Bu3GeH (slow) and EhB 
Tributylgermanium hydride (0.034 cm3, 0.14 mmol) was added to a solution oftriethylborane 
(10 cm3, 10 mmol) and 3-[(2-bromoquinolin-3-yl)methyi]-3H-quinazolin-4-one (0.02 g, 0.055 
mmol) in dry toluene (40 cm3} over 5 h via a syringe pump, with an air bleed into the round 
bottom flask through a needle and stirred. After 3 h, triethylborane (10 cm3, 10 mmol) was 
added and stirred for a further 3 h. Dilute hydrochloric acid was added to the reaction mixture 
to extract the protonated quinazolone products into the aqueous layer. The aqueous layer was 
washed with light petroleum (3 x 50 cm3} to remove tributylgermanium residues. The aqueous 
layer was basified with a solution of sodium hydroxide to pH 14. The basic solution was 
extracted with DCM (3 x 50 cm3}. The combined organic layers were dried over MgS04 and 
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the solvent removed under reduced pressure yielding luotonin A 144a (28 mg, 0.0098 mmol, 
18%) and [(3-quinolin-3-yl)methyl]-38-quinazolin-4-one 278 (17 mg, 0.0059 mmol, 11 %). 
The data were consistent to the previous synthesis.73 
Quinoline-3-carbaldehyde89 
280 
Butylmagnesium chloride (1.25 cm3, 2.5 mmol) and n-butyllithium (2.0 cm3, 5.0 mmol) were 
stirred in toluene (10 cm3) at -10 ·c for 1 h. 3-Bromoquinoline (0.91 cm3, 6.7 mmol) was 
added slowly at -10 ·c and stirred for 2.5 h. DMF (0.51 cm3, 6. 7 mmol) was added at -10 ·c 
and stirred for a further 12 h. The crude reaction mixture was extracted into EtOAc and 
washed with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 
and the solvent removed under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent with light petroleum!EtOAc (9: 1) as eluent 
yielding quinoline-3-carbaldehyde as a yellow oil (0.73 g, 4.7 mmol, 70%); Vmax(thin film)/cm· 
1 3052, 2983, 2252, 1732, 1699, 1617, 1497, 1423, 1373, 1264 and 908; OH 7.62 (1 H, ddd, J 
8.4, 7.0, 1.0, 6-H), 7.84 (1 H, ddd, J8.4, 7.0, 1.4, 7-H), 7.92 (1 H, dd, J8.4, 1.4, 5-H), 8.14 (1 
H, dd, J 8.4, 1.0, 8-H), 8.54 (1 H, d, J2.0, 4-H), 9.31 (1 H, d, J 2.0, 2-H) and 10.19 (1 H, s, 
OCH); Oc 126.82 (3-C), 127.71 (6-C), 128.41 (4a-C), 129.18 (7-C), 129.52 (5-C), 132.48 (8-
C), 139.99 (4-C), 148.81 (2-C), 150.33 (8a-C) and 190.62 (CO). 
The data were consistent to the literature. 89 
3-Hydroxymethylquinoline 
281 
Sodium borohydride (0.55 g, 14.0 mmol) was added to a stirred s~lution of quinoline-3-
carbaldehyde (0.57 g, 3.4 mmol) in EtOH (50 cm3) at 0 ·c and left stirring for 2 h. The crude 
reaction mixture was extracted into EtOAc and washed with H20 (3 x 50 cm3) and brine (50 
170 
cm3}. The organic layer was dried over MgS04 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleum!EtOAc (4:1) yielding 3-hydroxymethylquinoline as a 
colourless oil (0.32 g, 2.0 mmol, 54%); mp 80-81 oc (lit. 154 81-83 °C}; Vmax(thin film)/cm·1 
3420, 2862, 1652, 1576, 1456, 1328, 1126, 1058, 886, 786, 667 and 472; 0H4.8 (2 H, s, CHz}, 
7.43 (1 H, ddd, J, 8.0, 7.0, 1.2, 6-H), 7.58 (1 H, ddd, J 8.6, 7.0, 1.4, 7-H), 7.64 (1 H, dd, J 8.0, 
1.4, 5-H}, 7.96 (1 H, dd, J 8.6, 1.2, 8-H}, 8.02 (1 H, d, J 1.6, 4-H) and 8.72 (1 H, d, J 1.6, 2-
H); oc 62.12 (Clh}, 126.87 (6-C}, 127.75 (7-C}, 127.88 (4a-C), 128.35 (5-C), 129.40 (8-C}, 
133.98 (4-C}, 134.29 (3-C}, 146.80 (8a-C) and 149.84 (2-C). 
The data were consistent to the literature. 154 
2-(2-Bromo-lH-indol-3-yl)ethanol 
3 OH 
~ Br 
2 
7a ~ 
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N-Bromosuccinimide (0.52 g, 4.0 mmol) was added to tryptophol (0.32 g, 2.0 mmol) in 
carbon tetrachloride (20 cm3} and heated under reflux for 5 h. After cooling to room 
temperature the succinimide was filtered off. The organic solution was dried over MgS04 and 
the solvent removed under reduced pressure. The crystalline solid was purified by column 
chromatography using alumina as absorbent with light petroleum!EtOAc (6:1) yielding 2-(2-
bromo-1H-indol-3-yl)ethanol as yellow crystals (55 mg, 0.3 mmol, 12%); mp 88.5-89.5 °C; 
(Found: M+, 238.9945. C10H1079BrNO requires 238.9946.); Vmax(thin film)/cm·1 3625, 2039, 
1817, 1784, 1699 and 580; OH 3.26-3.30 (2 H, t, J 6.5, CH2), 3.57-3.61 (2 H, t, J 6.5, CH20H), 
7.41-7.11 (3 H, m, ArH}, 7.50 (1 H, d, J7.0 ArH) and 8.03 (1 H, brs, NH); Oc 27.81 (CH2), 
30.35 (CH20H), 107.82(3-C}, 109.56(7-C}, 111.98(2-C) 116.89(6-C), 119.31 (4-C}, 121.51 
(5-C), 126.18 (3a-C) and 134.91 (7a-C); m/z{EI} 225 (M+, 79%}, 223 (81}, 208 (22}, 144 
(lOO), 130 (61), 115 (60), 89 (24), 77 (23) and 63 (21). The compound was unstable in air. 
171 
2-Bromo-3-methyi-1H-indole155 
289a 
A solution of N-bromosuccinimide (1.56 g, 12.0 mmol) and 3-methyl-1H-indole (1.31 g, 10.0 
mmol) in dry carbon tetrachloride (50 cm3) was refluxed for 2 h. The reaction mixture was 
cooled to rt before being filtered through a celite bed and washed with carbon tetrachloride (3 
x 20 cm3). The solvent was removed under reduced pressure, and the crude product purified 
using column chromatography with neutral alumina as absorbent with light petroleum/EtOAc 
(6: 1) as eluent yielding 2-bromo-3-methyl-1H-indole as colourless crystals (0.86 g, 4.8 mmol, 
48%); mp 93-94 oc (lit. 155 94-95 °C); (Found: M+, 208.9840. C9Hs79BrN requires 208.9840.); 
oH 2.27 (3 H, s, CH3), 7.11-7.21 (3 H, m, ArH), 7.46-7.48 (1 H, m, ArH) and 7.82 (1 H, brs, 
NH); oc 9.66 (CH3), 107.92 (3-C), 110.28 (7-C), 111.37 (2-C), 118.20 (4-C), 119.34 (6-C), 
121.60 (5-C), 128.00 (3a-C) and 135.94 (7a-C); m/z(EI) 211 (M+, 58 %), 209 (53), 210 (65), 
147 (100), 130 (90), 129 (49) and 119 (65). 
The data were consistent with the literature.155 
3-Methyl-2-(phenylselanyl)-lH-indole 
5~sePh 
6 7a ~ 7 
289b 
3-Methyl:.1H-indole (0.66 g, 5.0 mmol) and phenylselanyl chloride (1.05 g, 5.5 mmol) were 
placed in a round bottom flask containing dry carbon tetrachloride (50 cm3) and triethylamine 
(0.68 cm3, 5.0 mmol) was added dropwise. The solution was heated under reflux for 4 h. The 
reaction mixture was cooled, filtered through a celite bed and washed with carbon 
tetrachloride (3 x 20 cm3). The organic layer was dried using MgS04 and the solvent removed 
under reduced pressure. The resulting crude product was purified by column chromatography 
172 
using neutral alumina as absorbent with light petroleum/EtOAc (8:1) as eluent yielding 3-
methyl-2-(phenylselanyl)-1H-indole as yellow crystals (0.15 g, 0.5 mmol, 11%), mp 77.6-
77.8 oc; (Found: M+, 287.0215. CJsH13N80Se requires 287.0213.); Vmax(thin film)/cm"1 3452, 
3053, 1477, 1261, 896 and 706; oH 2.49 (3 H, s, CH3), 7.21-7.32 (8 H, m, ArH), 7.66-7.70 (1 
H, m, ArH) and 8.12 (1 H, brs, NH); oc 10.49 (CH3), 110.55 (7-C), 118.18 (3-C), 119.39 (4-
C), 119.61 (6-C), 120.62 (2-C), 123.22 (5-C), 126.44 (2 x ArH), 127.82 (ArC), 129.92 (ArH), 
129.34 (2 x ArH), 132.30 (3a-C) and 137.64 (7a-C); mlz(EI) 287 (M+, 51 %), 285 (26), 207 
(100) and 206 (48). 
The data were consistent with the literature. 156 
1-Benzyl-3-rnethyl-1H-indole157 
5Qj4 3a3 I ~ z 
6:::::..... 7a N 
7~ 
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A solution of 3-rnethylindole (0.66 g, 5.0 mmol) in dry DMF (15 cm3) was added to sodium 
hydride (0.24 g, 6.0 mmol) in dry DMF (50 cm3) and stirred for 1.5 h. Benzyl bromide (2.97 
ml, 25.0 mmol) was added and stirred the reaction stirred for a further 1 h. The reaction 
mixture was quenched with distilled water (5 cm3). The reaction mixture was extracted into 
EhO (50 cm3) and washed with distilled water (5 x 50 cm3) and brine (50 cm3) to remove the 
DMF. The crude product was dried with MgS04 and the solvent removed under reduced 
pressure before being purified by column chromatography using silica gel as absorbent with 
light petroleum!EtOAc (1 0:1) as eluent yielding 1-benzyl-3-methyl-1H-indole as colourless 
crystals (0.86 g, 3.9 mmol, 78%); mp 66-67 oc (lit.157 65-66 °C); Vmax(thin film)/cm·1 3057, 
1717, 1640, 1396, 1089 and 739; OH 2.85 (3 H, s, CH3), 5.48 (2 H, s, CH2), 6.76 (1 H, s, 2-H) 
and 7.01-7.49 (9 H, m, ArH); oc 9.76 (CH3), 49.82 (CH2), 109.56 (7-C), 110.93 (3-C), 118.88 
(6-C), 119.13 (4-C), 121.71 (5-C), 125.93 (2-C), 126.89 (2 x ArH), 127.56 (ArH), 128.79 (2 x 
ArH), 129.01 (3a-C), 136.73 (ArC) and 138.39 (7a-C). 
The data were consistent with the literature. 157 
173 
1-Benzyl-2-bromo-3-methyl-lH-indole 
4 
5:/"' 
7 
A solution of 1-benzyl-3-methyl-1H-indole (0.44 g, 2.0 mmol) and N-bromosuccinimde (0.31 
g, 2.4 mmol) in dry carbon tetrachloride (50 cm3) was heated under reflux in the dark for 3. 
The reaction mixture was cooled and filtered through a celite bed and washed with carbon 
tetrachloride (3 x 20 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica gel as absorbent with light petroleum as eluent in the dark yielding 1-benzyl-2-bromo-3-
methyl-1H-indole as a colourless oil (0.20 g, 0.7 mmol, 33%); Vmax(thin film)/cm·' 3059, 2901, 
1599, 1473, 778 and 657; ()H 2.15 (3 H, s, CH3}, 5.14 (2 H, s, CH2) 6.88-6.91 (2 H, m, ArH) 
and 7.06-7.52 (7 H, m, ArH); <>c 10.14 (CH3), 48.41 (CH2), 112.62 (7-C), 113.16 (3-C}, 
115.85 (2-C), 119.72 (4-C), 123.06 (6-C), 126.38 (2 x ArH}, 126.98 (3a-C}, 127.68 (ArH}, 
128.86 (5-C}, 128.89 (2 x ArH), 136.88 (ArC) and 137.66 (7a-C). Compound was unstable in 
air and no further characterisation could be carried out. 
The data were consistent with the literature. 158 
1,3-Dimethyl-1H-indole159 
sffi4 3a I ~ 2 
6~ 7a N 
7 \ 
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3-Methyl-1H-indole (1.87 g, 14.3 mmol) was added to sodium hydride (0.69 g, 17.1 mmol) in 
dry DMF (50 cm3} and stirred for 1 h. Methyl iodide was added slowly over 1 h and the 
mixture was left stirring for a further 2 h. The reaction mixture was quenched with distilled 
water (5 cm3). The reaction mixture was extracted into EhO (50 cm3) and washed with 
distilled water (5 x 50 cm3} and brine (50 cm3) to remove the DMF. The organic layer was 
dried using MgS04 and the solvent removed under reduced pressure. The crude product was 
purified by column chromatography using silica gel absorbent with light petroleum as eluent 
to afford 1,3-dimethyl-1H-indole as colourless crystals (1.54 g, 10.6 mmol, 74%); mp 139-
174 
140 °C (lit.159 142 °C}; Vmax(thin film)/cm·1 3055, 2918, 1618, 1473 and 740; OH 2.56 (3 H, s, 
CH3), 3.84 (3 H, s, NCH3), 6.96 (1 H, s, 2-H), 7.49-7.59 (2 H, m, ArH) and 7.78-7.93 (2 H, m, 
ArH); oc 9.89 (CH3), 32.59 (NCH3), 109.33 (7-C}, 110.27 (3-C), 118.83 (6-C), 119.08 (4-C}, 
121.71 (5-C}, 126.85 (2-C}, 128.99 (3a-C) and 137.30 (7a-C). 
The data were consistent with the literature. 159 
2-Bromo-1,3-dim ethy1-1H-indole 
Br 
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N-Bromosuccinimide (0.52 g, 4.0 mmol) was added to a solution of 1,3-dimethyl-1H-indole 
(0.29 g, 2.0 mmol) in dry carbon tetrachloride (20 cm3) and refluxed in the dark for 2 h. The 
reaction mixture was cooled, filtered through a celite bed and washed with carbon 
tetrachloride (3x 20 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The resulting crude product was purified using column 
chromatography using silica gel as absorbent with light petroleum as eluent to yield 2-bromo-
1,3-dimethyl-1H-indole as a colourless oil (less than 5%); oH 2.25 (3 H, s, CH3), 3.67 (3 H, s, 
NCH3) and 6.91-7.63 ( 4 H, m, ArH); oc 9.86 (CH3), 31.66 (NCH3), 112.12 (7-C), 113.90 ( 4-
C), 115.40 (3-C), 116.86 (2-C}, 119.86 (6-C), 122.51 (5-C}, 126.25 (3a-C) and 137.33 (7a-C). 
Compound was unstable in air and no further characterisation could be carried out. 
3-Methyl-1 ,3-dihydroindol-2-one99 
(X}= a 
H 
296 
N-Bromosuccinimide (2.60 g, 20 mmol) was added to a solution of 3-methyl-1H-indole (2.64 
g, 20 mmol) in t-BuOHIH20 (155 cm3 10:1) and stirred for 1 h. The reaction mixture was 
extracted into Et20 and washed with H20 (3 x 50 cm3) and brine (50 cml The organic layer 
was dried over MgS04 and the solvent removed under reduced pressure. The crude product 
was purified by column chromatography using alumina as absorbent with light 
175 
petroleum!EtOAc (5:1) as eluent yielding 3-methyl-1,3-dihydroindol-2-one as colourless 
crystals (1.29 g, 8.6 mmol, 43%); mp 120-122 oc; (lit.99 122-124 °C); (Found: MH+, 
148.0755. C9HtoNO requires 148.0757.); Vmax(thin film)/cm·1 3216, 2972, 2873, 1731, 1624, 
14 70, 1331, 1223, 1174 and 749; oH 1.51 (3 H, d, J 6.4, CH3), 3.48 (1 H, q, J 6.4, CH), 6.93 (1 
H, d, J7.4, ArH), 7.02 (1 H, t, J7.4, ArH), 7.32-7.17 (2 H, m, ArH) and 9.57 (1 H, brs, NH); 
oc 15.11 (CH3), 41.28 (CH), 109.94 (ArH), 121.81 (ArH), 123.02 (ArH), 127.89 (ArH), 
128.54 (ArC), 141.43 (ArC) and 181.99 (ArC); m/z(Electrospray) 147 (M+, 58%), 119 (64), 
118 (75), 91 (50), 63 (46), 52 (52), 51 (68) and 50 (44). 
The data were consistent to the literature. 99 
2-Chloro-3-methyl-lH-indole 
~Cl 
H 
297 
3-Methyl-1,3-dihydroindol-2-one (0.29 g, 2.0 mmol) were heated under reflux in phosphorous 
oxychloride (0.8 cm3, 1.2 mmol) under for 10 min. The solution was poured onto an ice and 
saturated sodium carbonate solution. The reaction mixture was extracted into DCM and 
washed and with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over 
MgS04 and the solvent removed under reduced pressure. The crude product was purified by 
column chromatography using silica gel as absorbent with light petroleurn!EtOAc (12:1) as 
eluent yielding 2-chloro-3-methyl-lH-indole as colourless crystals (0.06 g, 0.4 mmol, 20%); 
mp 124 °C (lit. 160 125 °C); Vmax(thin film)/cm·l 3209, 2974, 1730, 1620, 1469, 1333, 1223, 
1104, 752, 666, 540 and 493; oH2.24 (3 H, s, CH3), 7.21-7.11 (3 H, m, ArH) and 7.46 (1 H, d, 
J7.5, ArH); oc 8.32 (CH3), 107.95 (ArC), 110.35 (ArH), 118.32 (ArH), 119.94 (ArH), 120.60 
(ArC), 122.22 (ArH), 128.32 (ArC) and 134.40 (ArC). 
The data were consistent with the literature. 160 
176 
2-(1-Methyi-1H-indol-3-yl)ethanol 
OH 
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Sodium hydride (1.37 g, 34.2 mmol) was added to a solution oftryptophol (5.0 g, 31.1 mmol) 
in dry DMF (50 cm3) and stirred for 30 min. Methyl iodide (2.3 cm3, 37.3 mmol) was added 
to the solution and stirred for 3 h. The reaction mixture was quenched by dropwise addition of 
H20 (5 cm3). The reaction mixture was extracted into DCM and washed with H20 (5 x 50 
cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude reaction mixture was purified using column 
chromatography with silica gel as absorbent with light petroleum!EtOAc (2:1) yielding 2-(1-
methyl-1H-indol-3-yl)ethanol as a yellow oil (2.98 g, 17.0 mmol, 55%); (Found: M+, 
175.0999. C11H13NO requires 175.0997.); Vmax(thin film)/cm-1 3388, 2947, 1656, 1620, 1444 
and 1328; oH 3.01 (2 H, t, J6.7, CHz), 3.36 (3 H, s, CH3), 3.64 (2 H, t, J6.7, CHzOH), 6.84 (1 
H, s, 2-H), 7.24-7.06 (3 H, m, ArH) and 7.58 (1 H, d, J 6.9, ArH); oc 28.52 (CHz), 32.32 
(CH3), 62.60 (CH20H), 109.50 (7-C), 110.73 (3-C), 118.50 (6-C), 119.10 (4-C), 121.63 (5-C), 
126.74 (2-C), 127.85 (3a-C) and 137.00 (7a-C); mlz(EI) 175 (M+, 11%), 144 (100), 129 (4), 
115 (6), 103 (5) 102 (6) and 77 (7). 
2-Bromo-3-(2-hydroxyethyl)-1-methyi-1H-indole 
301 
A solution of N-bromosuccinimide (5.20 g, 40.0 mmol) and 2-(1-methyl-1H-indol-3-yl)-
ethanol (0.70 g, 4.0 mmol) in dry carbon tetrachloride (20 cm3) was heated under reflux for 1 
h. The reaction mixture was cooled, filtered and washed with carbon tetrachloride (3 x 15 
cm3). The organic layer was dried over MgS04 and th.e solvent removed under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleum/EtOAc (10:1) as eluent yielding 2-bromo-3-(2-hydroxyethyl)-
177 
1-methyl-lH-indole as a colourless oil (0.30 g, 1.2 mmol, 30%); (Found M+, 256.0155. 
C11H1281BrNO requires 256.0155.); Vmax(thin film)/cm·1 3427, 1724, 1612, 1471, 1373 and 750; 
oH 2.96-2.75 (2 H, m, CH2), 3.23 (3 H, s, CH3), 3.40-3.26 (2 H, m, HOCH2), 6.87 (1 H, d, J 
7.7, 4-H), 7.14 (1 H, t, J7.7, 6-H) and 7.41- 7.34 (2 H, m, ArH); oc 26.27 (CH2), 26.89 (CH3), 
41.93 (HOCH2) 109.14 (7-C), 109.14 (2-C), 123.95 (4-C), 124.56 (6-C), 128.79 (3-C), 130.67 
(5-C), 142.30 (3a-C) and 173.28 (7a-C); m/z(CI) 256 (M+, 3%), 254 (80), 252 (82), 173 (100), 
172 (93), 158 (85), 144 (90), 130 (96), 115 (55), 89 (43) and 77 (51). 
Methanesulfonic acid 2-(1-methyl-1H-indol-3-yl)ethyl ester 
5 ~0Ms 
sU/ 2 
7 7a \ 
303 
Methanesulfonyl chloride (0.19 cm3, 2.4 mmol) was added to a solution of 2-(1-methyl-1H-
indol-3-yl)ethanol (0.35 g, 2.0 mmol) in dry DCM (50 cm3) over 30 min. Triethylamine (0.41 
cm3, 3.0 mmol) was added and the reaction stirred for a further 18 h. The reaction mixture 
was washed with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over 
MgS04 and the solvent removed under reduced pressure yielding methanesulfonic acid 2-(1-
methyl-1H-indol-3-yl)ethyl ester as a colourless oil (0.44 g, 1.7 mmol, 87%); oH 2.75 (3 H, s, 
S02CH3), 3.13 (2 H, t, J7.0, CH2), 3.63 (3 H, s, NCH3), 4.35 (2 H, t, J7.0, MsOCHz), 6.86 (1 
H, s, 2-H), 7.26-7.06 (3 H, m, ArH) and 7.54 (1 H, d, J 7.7, ArH); 8c 25.47 (CH2), 32.49 
(S02CH3), 37.16 (NCH3), 70.37 (MsOCHz), 108.82 (3-C), 109.62 (7-C), 118.46 (6-C), 119.10 
(4-C), 121.92 (5-C), 127.62 (2-C), 127.68 (3a-C) and 137.05 (7a-C). 
1-Benzyl-3-(2-hydroxyethyl)-1H-indole 
305 
Sodium hydride (0.19 g, 4.8 mmol) was added to a solution oftryptophol (0.64 g, 4.0 mmol) 
in dry DMF (20 cm3) at 0 oc and stirred 40 min at rt. Benzyl bromide (0.57 cm\ 4.8 mmol) 
178 
was added and the reaction mixture stirred for a further 3 h. The crude reaction was quenched 
by dropwise additi~n of H20 (5 cm3). The mixture was extracted into DCM and washed with 
H20 (5 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the 
solvent removed under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent with light petroleum/EtOAc (2: I) as eluent to 
yield 1-benzyl-3-(2-hydroxyethyi)-1H-indole as a yellow oil (0.68 g, 2.7 mmol, 68%); 
(Found: M+, 251.1311. CI7HI7NO requires 251.1310.); 8H 3.02 (2 H, t, J6.5, CH2), 3.90 (2 H, 
t, J 6.5, OCH2), 5.26 (2 H, s, BnCH2), 7.00 (1 H, s, 2-H), 7.23-7.08 (8 H, m, ArH) and 7.83 (1 
H, d, J 8.2, ArH); 8c 26.03 (CH2), 49.98 (BnCH2), 62.85 (HOCH2), 110.01 (7-C), 111.78 (3-
C), 119.23 (6-C), 119.31 (4-C), 122.10 (5-C), 126.78 (Ph 4-C), 127.01 (Ph 3,5-C), 127.71 (2-
C), 128.20 (3a-C), 128.94 (Ph 2,6-C), 136.96 (Ph 1-C) and 137.94 (7a-C); m/z(EI) 251 (M+, 
44%), 220 {93}, 130 (28), 97 (21}, 91 (100) and 57 (21). 
The data were consistent to the literature.161 
3-(2-Hydroxyethyl)-lH-indole-1-carboxylic acid t-butyl ester 
Triethylamine (0.56 cm3, 4.0 mmol) was added to a solution oftryptophol (0.32 g, 2.0 mmol) 
in dry THF (20 cm3) with stirring. DMAP (0.02 g, 0.2 mmol) was added and the reaction 
stirred for a further 15 min. Di-t-butyl dicarbonate (0.44 g, 2.0 mmol) in dry THF (10 cm3) 
was added slowly over 12 h using a syringe pump. The reaction mixture was washed with 
H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the 
solvent removed under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent with light petroleum/EtOAc (10:1) as eluent to 
yield 3-(2-hydroxyethyl)-1H-indole-1-carboxylic acid t-butyl ester as a yellow oil (0.06 g, 0.2 
mmol, 11%); Vmax(thin film)/cm·1 3687, 3384, 3064, 1733, 1683, 1456, I255, 1161 and 792; OH 
1.48 (9 H, s, t-BuH), 3.I4 (2 H, t, J7.8, CH2), 4.37 (2 H, t, J7.8, HOCH2), 7.00 (1 H, s, 2-H), 
7.12 (1 H, t, J 8.0, ArH), 7.19 (I H, t, J 8.0, ArH), 7.35 (1 H, d, J 8.0, ArH) and 7.63 (I H, d, 
J 8.0, ArH); 8c 24.91 (CH2), 27.82 (3 x CH3), 66.94 (HOCH2), 82.01 (CMe3}, 111.17 (7-C), 
I79 
111.53 (3-C), 118.77 (4-C), 119.47 (6-C), 122.11 (5-C), 122.23 (2-C), 127.41 (3a-C), 136.19 
(7a-C) and 153.62 (C=O). 
The date were consistent to the literature. 162 
Methanesulfonic acid 2-[1-(methanesulfonyl)-1H-indol-3-yl]ethyl ester 
oS'OMs 
Ms 
309a 
Methanesulfonyl chloride (3.26 cm3, 33.2 mmol) was added slowly at 0 °C to a solution of 
tryptophol (3.34 g, 16.6 mmol) and triethylamine (8.9 cm3, 64.0 mmol) in dry toluene (50 
cm3). The reaction mixture was stirred for 12 h and extracted into EtOAc and washed with 
H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleum/EtOAc (5:1) as eluent yielding 
methanesulfonic acid 2-[1-(methanesulfonyl)-1H-indol-3-yl]ethyl ester as yellow crystals 
(0.74 g, 2.45 mmol, 15%); mp 98-99 oc; (Found: MNH/, 335.0733. C12H19NzOsSz requires 
335.0730.); Vmax(thin film)/cm·1 3111, 3022, 2932, 1606, 1448, 1351, 1281, 1167, 1121, 959, 
909, 781, 748 and 589; oH2.90 (3 H, s, NMsCH3), 3.03 (3 H, s, OMsCH3), 3.12 (2 H, t, J 6.8, 
CH2), 4.45 (2 H, t, J 6.8, OMsCH3), 7.35-7.25 (3 H, m, ArH), 7.57 (1 H, d, J 7.6, ArH) and 
7.86 (1 H, d, J 8.0, ArH); 8c 25.00 (CHz), 37.15 (OMsCH3), 40.49 (NMsCH3), 70.49 (OCHz), 
113.20 (ArH), 117.31 (ArC), 118.39 (ArH), 123.18 (ArH), 123.71 (ArH), 125.17 (ArH), 
130.43 (ArC) and 136.25 (ArC); m/z(Electrospray) 317 (M+, 36%), 221 (0), 208 (32), 142 
(100), 130 (78), 115 (60), 101 (48), 79 (80) and (62). 
1-Tosyl-3-(2-tosyloxyethyl)-3H-indole 
309b 
Sodium hydride (0.40 g, 10.0 mmol) was added to tryptophol (0.60 g, 4.0 mmol) in dry THF 
(20 cm3) and stirred for 40 min. Tosyl chloride (1.67 g, 8.8 mmol) was added at 0 oc and 
stirred for 2 h. The crude reaction mixture was quenched with H20 (5 cm3). The crude 
180 
reaction mixture was extracted into DCM and washed with H20 (3 x 50 cm3) and brine (50 
cm3). The organic layer was dried over MgS04 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleurn!EtOAc (2:1) as eluent to yield 1-tosyl-3-(2-tosyloxyethyl)-3H-
indole a yellow oil (0.45 g, 1.0 mmol, 25%); (Found: M+, 469.1009. C24H23NOsS2 requires 
469.1001.); Vmax(thin film)/cm·1 3055,2923, 1596, 1495, 1269, 1020, 813 and 704; 0H2.30 (3 
H, s, TsCH3), 2.37 (3 H, s, TsCH3), 3.00 (2 H, t, J 6.6, CH2), 4.24 (2 H, t, J 6.6, OCH2), 7.32-
7.13 (8 H, m, ArH), 7.57-7.54 (2 H, m, TsH), 7.75-7.72 (2 H, m, TsH) and 7.94-7.92 (1 H, m, 
ArH); oc21.52 (TsCH3), 21.60 (TsCH3), 24.88 (CH2), 68.75 (OCH2), 113.67 (7-C), 117.18 (3-
C), 119.05 (4-C), 123.13 (6-C), 124.09 (2-C), 124.74 (5-C), 126.78 (2 x TsH),127.62 (2 x 
TsH-C), 129.70 (2 x TsH), 129.92 (2 x TsH), 130.17 (3a-C), 132.49 (3-C), 135.03 (TsC), 
135.17 (TsC), 144.80 (2 x TsC); m/z(EI) 297 (M+, 39%), 155 (49), 142 (80), 129 (26), 115 
(50), 91 (100) and 65 (39). 
3-[2-(t-Butyl-dim ethylsilanyloxy )ethyl] -lH-ind ole163 
5~0TBDMS 
slt./2 
7 H 
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Imidazole (0.93 g, 13.6 mmol) was added to a solution of tryptophol (1.0 g, 6.2 mmol) in 
THF (50 cm3) with stirring at cooled to 0 °C. TBDMSCl (1.02 g, 6.8 mmol) was added and 
stirred for 16 hat rt. The reaction mixture was diluted with EtOAc (20 cm3) and washed with 
H20 (5 x 50 cm3). The organic layer was dried over MgS04 and the solvent removed under 
reduced pressure. The crude product was purified by flash sinter chromatography using silica 
gel as absorbent with light petroleurn!EtOAc (3:1) as eluent to yield 3-[2-(t-butyl-
dimethylsilanyloxy)ethyl]-1H-indole as a yellow oil (1.67 g, 6.1 mmol, 88%); (Found: MH+, 
276.1778. Ct6H26NOSi requires 276.1778.); Vmax(thin film)/cm·1 3398, 3195, 2850, 1712, 1328, 
and 723; OH 0.42 (6 H, s, 2 x CHJ), 1.29 (9 H, s, 3 x CHJ), 3.46 (2 H, t, J7.3, CH2), 4.24 (2 H, 
t, J 7.3, SiOCH2), 7.13 (I H, s, 2-H), 7.50-7.42 (3 H, m, ArH), 7.94 (1 H, d, J 7.8, ArH) and 
8.54 (1 H, brs, NH); oc--4.95 (2 x CHJ), 21.84 (3 x t-Bu), 26.36 (3 x CHJ), 31.53 (CH2), 64.35 
(SiOCH2), 111.83 (7-C), 112.66 (3-C), 118.74 (6-C), 119.07 (4-C), 122.22 (5-C), 122.70 (2-
181 
C), 129.71 (3a-C) and 136.57 (7a-C); m/z(Electrospray) 276 (M+, 46 %), 179 (23), 162 (100) 
and 144 (24). 
The data were consistent with the literature. 163 
3-[2-(t-Butyldimethylsilanoxyl)ethyl]-1-tosyi-1H-indole164 
5d93a OTBDMS ~I ~ 2 
6~ N 
7 7a Ts 
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Sodium hydride (1.20 g, 30.0 mmol) was added to 3-[2-(t-butyl-dimethylsilanyloxy)ethyl]-
1H-indole (5.50 g, 20.0 mmol) in dry DMF (75 cm3) and stirred for 1 h. Tosyl chloride (4.57 
g, 24.0 mmol) was added at 0 °C and stirred for 24 h. The crude reaction was quenched with 
H20 (5 cm3). The crude reaction mixture was extracted into DCM and washed with H20 (5 x 
50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica gel as absorbent with light petroleum!EtOAc (15: 1) to yield 3-[2-(t-
butyldimethylsilanoxyl)ethyl]-1-tosyl-IH-indole as yellow crystals (7.35 g, 17.13 mmol, 
86%); mp 99-101 oc; (Found: MNH/, 447.2136. C23H3sN203SSi requires 447.2132.); 
Vmax(thin film)/cm·1 2925, 1448, 1371, 1174, 1095, 812 and 669; OH 0.01 (6 H, s, 2 x SiMe), 
0.90 (9 H, s, t-Bu), 2.31 (3 H, s, TsMe), 2.88 (2 H, t, J 7.2, CH2), 3.88 (2 H, t, J 7.2, OCH2), 
7.35-7.19 (4 H, m, ArH), 7.43 (1 H, s, 2-H), 7.52-7.48 (1 H, m, ArH), 7.76 (2 H, d, J8.4, 2 x 
TsH) and 7.99 (1 H, m, ArH); Oc-5.34 (2 x SiMe), 18.30 (q-t-Bu), 21.51 (TsMe), 25.96 (3 x 
t-Bu), 28.61 (CH2), 62.63 (OCH2), 113.68 (ArH), 119.60 (ArH), 120.16 (ArC), 112.97 (ArH), 
123.55 (ArH), 124.55 (ArH), 127.04 (2 x TsArH), 129.81 (2 x TsArH), 131.28 (ArC), 135.16 
(ArC), 135.50 (ArC) and 144.70 (ArC); m/z(Electrospray) 447 (M+, 100%), 298 (18), 276 
(22) and 144 (14). 
The data were consistent with the literature. 164 
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3-(2-Hydroxyethyl)-1-tosyl-3H-indole165 
313 
TBAF (21.40 cm3, 21.4 mmol) was added to 3-[2-(t-butyldimethylsilanoxyl)ethyl]-1-tosyl-
1H-indole (6.12 g, 14.3 mmol) in THF (50 cm3) and stirred for 24 h. The crude reaction 
mixture was extracted into EtOAc and washed with H20 (3 x 50 cm3) and brine (50 cm3). The 
organic layers were dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (2:1) as eluent to yield 3-(2-hydroxyethyl)-1-tosyl-3H-indole as yellow 
crystals (3.34 g, 11.1 mmol, 78%); mp 66-67 oc; (Found: MNH/, 333.1269. C11H2,N203S 
requires 333.1267.); Vmax(thin film)/ cm·' 3568, 1647, 1446, 1172,860 and 570; ~H2.32 (3 H, 
s, CH3), 2.92 (2 H, t, J6.4, CH2), 3.87 (2 H, t, J6.4, OCH2), 7.26-7.19 (4 H, m, ArH), 7.32 (1 
H, s, 2-H), 7.43 (1 H, m, ArH), 7.75 (2 H, d, J 8.4, ArH) and 7.90 (1 H, d, J 8.4, ArH); ~c 
21.54 (CH3), 28.42 (CH2), 61.84 (OCH2), 113.80 (7-C), 119.33 (3-C), 119.46 (6-C), 123.13 
(4-c), 123.76 (5-c), 124.81 (2-C), 126.79 (2,6 TsH), 129.86 (3,5 TsH), 130.87 (7a-C), 135.30 
(3a-C), 135.33 (1-TsC) and 144.86 (4-TsC); m/z(Electrospray) 155 (M+, 33%), 130 (60), 91 
(100), 77 (25), 65 (30), 44 (41) and 40 (11). 
The data were consistent with the literature. 165 
3-[2-(t-Butyl-dimethylsilanyloxy)-ethyl]indole-1-carboxylic acid tert butyl ester 
318 
3-[2-(t-Butyl-dimethylsilanyloxyethyl]-lH-indole (1.66 g, 6.05 mmol) was dissolved in dry 
THF (20 cm3). Triethyl amine (1.66 cm3, 12.1 mmol), DMAP (0.036 g, 0.3 mmol) and di-t-
butyl dicarbonate (1.44 g, 6.6 mmol) were added and stirred for 12 h. The crude reaction 
mixture was extracted into EtOAc and washed with H20 (3 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
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crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc ( 4:1) as eluent to yield 3-[2-(t-butyldimethylsilanyloxy)-ethyl]indole-1-
carboxylic acid t-butyl ester as a yellow oil (2.0 g, 5.4 mmol, 8 %); (Found: MH+, 376.2304. 
C21H34N03Si requires 376.2302.); Vmax (thin film)/cm·1 3050, 2979, 2855, 1718, 1609, 1471, 
166, 1369, 1163, 1090, 919, 838, 706 and 665; 8H 0.01 (6 H, s, 2xSiMe), 0.86 (9 H, s, SiC-t-
Bu), 1.62 (9 H, s, OC-t-Bu), 2.88 (2 H, t, J 6.8, CHz}, 3.86 (2 H, t, J 6.8, OCH2), 7.19 (1 H, 
dd, J 7.8, 6.8, 5-H) 7.27 (1 H, dd, J 6.8, 6.0, 6-H}, 7.41 (1 H, s, 2-H) 7.49 (1 H, d, J 7.8, 4-H) 
and 8.12 (1 H, d, J 6.0, 7-H); Oc -5.29 (2 x Me), 21.06 (Si t-BuC), 26.15 (3 x Si t-Bu), 27.84 
(3 x 0 t-Bu), 28.59 (CHz}, 62.89 (OCHz}, 83.21 (0 t-BuC), 115.25 (7-C), 117.25 (3-C}, 
122.35 (5-C}, 123.36 (2-C}, 124.23 (6-C), 130.88 (4-C}, 135.45 (3a-C}, 149.80 (7a-C) and 
171.08 (CO); m/z(Electrospray) 262 (M+, 22%}, 218 (64}, 216 (20), 144 (26}, 130 (30), 75 
(28}, 73 (32), 57 (100) and 41 (54). 
3-(2-Hydroxyethyl)-2-(phenylselanyl)-indole-1-carboxylic acid tert butyl ester 
319 
n-Butyllithium (0.66 cm\ 1.65 mmol) was added to 2,2,6,6-tetramethylpiperidine (0.28 cm3, 
1.65 mmol) at -78 ·c and stirred for 30 min in dry THF (20 cm3}. 3-[2-(t-
Butyldimethylsilanyloxy)-ethyl]indole-1-carboxylic acid tert butyl ester (0.56 g, 1.5 mmol) 
was added and stirred for 40 min. Phenylselanyl chloride (0.34 g, 1.8 mmol) was added and 
stirred for a further 12 at rt. The crude reaction mixture was extracted into EtOAc and washed 
with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the 
solvent removed under reduced pressure. The crude product was added to a solution ofTBAF 
in (15 cm3, 15 mmol) in THF (20 cm3} and stirred for 24 h. The crude reaction was extracted 
into EtOAc and washed with H20 (3 x 50 cm3} and brine (50 cm3}. The organic layer was 
dried over MgS04 and the solvent removed under reduced pressure. The crude product was 
purified by column chromatography using silica gel as absorbent with light petroleum/EtOAc 
( 4: 1) as eluent to yield 3-(2-hydroxy-ethyl)-2-phenylselanyl-indole-1-carboxylic acid t-butyl 
ester as yellow crystals (0.14 g, 0.34 mmol, 22%); mp 93-94 ·c (Found: MH+, 418.0919. 
C21H24N0380Se requires 418.0916.); Vmax(thin film)/cm·1 3363, 3050, 2987, 1727, 1576, 1476, 
1444, 1399,1354, 1250,1156, 1101, 1067 and 998;8H2.17 (9 H, s, t-Bu), 3.04 (2 H, t, J6.8, 
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CH2), 3.72 (2 H, t, J6.8, OCHz), 7.16-7.14 (3 H, m, ArH), 7.27-7.24 (3 H, m, ArH), 7.36-7.28 
(1 H, m, ArH) 7.59-7.57 (2 H, m, ArH) and 8.14 (1 H, d, J8.0, 1.5, ArH); oc28.00 (3 x t-Bu), 
29.85 (CHz), 62.47 (OCHz), 84,58 (t-BuC), 115.48 (7-C), 119.18 (ArH), 121.55 (3-C), 122.77 
(ArH), 126.07 (ArH), 128.74 (2-C), 128.87 (2xArH), 129.16 (ArH), 129.43 (2 x ArH), 129.47 
(ArC), 133.92 (3a-C), 138.09 (7a-C) and 149.88 (CO); m/z(Electrospray) 417 (M+, 28%), 415 
(14), 363 (21), 361 (100), 359 (53) and 358 (21). 
3-(2-Bromoethyi)-1H-indole166 
oSBr 
H 
320 
Phosphorous tribromide (1.2 cm3, 11.0 mmol) was added slowly at 0 oc to a solution of 
tryptophol (1.78 g, 11.0 mmol) in dry DCM (10 cm3) and stirred for 2 h. The crude reaction 
mixture was quenched with H20 (5 cm3) and extracted into EtOAc and washed with H20 (3 x 
50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica gel as absorbent with light petroleum/EtOAc (9: 1) as eluent to yield 3-(2-bromoethyl)-
1H-indole as yellow crystals (1.40 g, 6.2 mmol, 56%); mp 96-97 oc (lit. 166 97-98 °C); Vmax(thin 
film)/cm·1 3412, 3053, 2919, 2480, 1620, 1455, 1264, 1008, 744 and 564; oH 3.33 (2 H, t, J 
7.4, CH2), 3.63 (2 H, t, J 7.4, BrCHz), 7.05 (1 H, s, 2-ArH), 7.13 (1 H, ddd, J 7.0, 6.6, 1.3, 
ArH), 7.20 (1 H, ddd, J7.9, 7.0, 1.5, ArH), 7.35 (1 H, dd, J 6.6, 1.5, ArH) and 7.58 (1 H, dd, 
J7.9, 1.3, ArH); 8c29.32 (CHz), 32.90 (BrCHz), 111.29 (ArH), 113.47 (ArC), 118.46 (ArH), 
119.57 (ArH), 122.21 (ArH), 122.25 (ArH), 126.93 (ArC) and 136.14 (ArC). 
The data were consistent to the literature. 166 
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3-[2-(lH-Indol-3-yl)ethyi]-3H-qninazolin-4-one 
0 $ 2'~ 
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Potassium t-butoxide (0.14 g, 1.28 mmol) was added to a solution of 3H-quinazolin-4-one 
(2.24 g, 15.4 mmol) in DMF (20 cm3) and stirred for 1 h. 3-(2-Bromoethyl)-1H-indole (4.13 
g, 18.4 mmol) was added and the reaction stirred for a further 12 h. The crude reaction 
mixture was extracted into EtOAc and washed with H20 (5 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (2: 1) as eluent to yield 3-[2-(1H-indol-3-yl)ethyi]-3H-quinazolin-4-one as 
colourless crystals (1.72 g, 5.9 mmol, 39%); (Found: MH+, 290.1291. CisH16NJO requires 
290.1288.); mp 170-171 °C (lit.102 173-174 °C); Vmax(thin film)/cm·1 3441, 2099, 1650, 1643, 
1530, 1474, 1376, 1021, 996, 642 and 631; OH 3.28 (2 H, t, J 7.0, CH2), 4.31 (2 H, t, J 7.0, 
NCH2), 6.86 (1 H, d, J2.0, 2'-H), 7.14 (1 H, ddd, J8.0, 6.8, 0.8, ArH), 7.21 (1 H, ddd, J8.0, 
6.8, 0.8, ArH), 7.37-7.35 (1 H, m, ArH), 7.54-7.50 (2 H, m, ArH), 7.67-7.63 (2 H, m, ArH), 
7.76-7.772 (1 H, m, ArH) and 8.38-8.35 (1 H, m, ArH); 8c24.96 (CH2), 47.55 (NCH2), 111.37 
(4a-ArC), 111.52 (ArH), 118.42 (ArH), 119.81 (ArH), 122.14 (3'-ArC), 122.44 (ArH), 122.77 
(2'a-ArH), 126.67 (ArH), 126.83 (3'a-ArC), 127.14 (ArH), 127.41 (ArH), 134.16 (ArH), 
136.47 (7'a-ArC), 146.74 (ArH), 148.19 (Sa-ArC) and 161.14 (4-ArC); m/z(Eiectrospray) 143 
(M+, 100%), 129 (58), 115 (13), 102 (14) and 77 (27). 
The data were consistent to the literature. 102 
186 
3-[2-(2-Bromoindol-3-yl)ethyl]-3H-quinazolin-4-one 
OC
o 
N 
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N-Bromosuccinimide (0.12 g, 0.65 mmol) was added to a solution of 3-[2-(1H-indol-3-
yl)ethyl]-3H-quinazolin-4-one (0.19 g, 0.65 mmol) at ooc in DCM and stirred for 30 min. The 
crude reaction mixture was extracted into EtOAc and washed with H20 (5 x 50 cm3) and 
brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed under 
reduced pressure. The crude product was purified by column chromatography using silica gel 
as absorbent with light petroleum/EtOAc (2:1) as eluent to yield 3-[2-(2-bromoindol-3-
yl)ethyl]-3H-quinazolin-4-one as yellow crystals (0.09 g, 0.24 mmol, 38%); mp 198-200 oc; 
(Found: MH+, 368.0395. C1sH1/ 9BrNJO requires 368.0393.); Vmax(thin film)/cm·1 3407, 2358, 
1651, 1611, 1471, 1446, 1376, 1157 and 742; OH 3.23 (2 H, t, J 6.4, CH2), 4.27 (2 H, t, J 6.4, 
NCH2), 7.06 (1 H, ddd, J 8.0, 6.8, 0.8, ArH), 7.15-7.10 (1 H, m, ArH), 7.19 (1 H, d, J 8.8, 
ArH), 7.39 (1 H, s, 2-H), 7.53-7.51 (2 H, m, ArH), 7.64 (1 H, dd, J9.2, 0.8, ArH), 7.73 (1 H, 
ddd, J 8.4, 6.8, 1.2, ArH), 8.37 (1 H, dd, J 8.0, 1.6, 5-H) and 8.98 (1 H, brs, NH); oc 24.13 
(CH2), 46.82 (NCH2), 109.69 (ArC), 110.83 (ArC), 110.85 (ArH), 117.58 (ArH), 120.43 
(ArH), 122.10 (ArC), 122.69 (ArH), 126.65 (ArH), 127.14 (ArC), 127.18 (ArH), 127.24 
(ArH), 134.19 (ArH), 136.21 (ArC), 146.56 (ArH), 147.95 (ArC) and 161.36 (4-ArC); 
m/z(Electrospray) 369 (M+, 5%), 367 (5), 288 (21), 221 (100), 208 (36), 147 (22), 129 (74), 
115 (28), 102 (54), 90 (20) and 77 (61). 
The data were consistent to the literature. 102 
Radical cyclisation of3-[2-(2-Bromoindol-3-yl)ethyl]-3H-quinazolin-4-one 
~N aeON U~--~ .& ~I ) N N 
145 322 
Method A- Bu3SnH (slow) and EtJB 
3-[2-(2-Bromoindol-3-yl)ethyl]-3H-quinazolin-4-one (0.094 g, 0.26 mmol) was added to 
toluene (20 cm3) which had been degassed with nitrogen for 30 min. Triethylborane (3 cm3, 
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3.0 mmol) was added and Bu3SnH (0.18 g, 0.64 cm3) in toluene (10 cm3) was added over 12 
h. At 3 h intervals the solution was purged with nitrogen for 30 min and triethylborane (3 cm3, 
3.0 mmol) was added. The reaction mixture was washed through a sinter containing silica 
absorbent with light petroleum (1 00 cm3). The sinter was flushed with EtOAc (200 cm3). The 
filtrate was dried over MgS04 and the solvent removed under reduced pressure. The crude 
product was purified initially by a column chromatography using silica absorbent with light 
petroleurn!EtOAc (4:1) as eluent yielding: 
145 Rutaecarpine as colourless crystals (11 mg, 0.038 mmol, 15%); (Found: MH+, 288.1131. 
C18H14N30 requires 288.1132.); Vmax(thin film)/cm·1 3338, 2923, 2359, 1851, 1753, 1659, 
1592, 1468, 1326, 1228, 1140, 796, 726 and 667; OH 3.24 (2 H, t, J 8.0, CH2), 4.59 (2 H, t, J 
8.0, NCH2), 7.19 (1 H, d, J 8.0, ArH), 7.35 (1 H, d, J 8.0, ArH), 7.47-7.41 (2 H, m, 2-H and 
ArH), 7.67-7.63 (2 H, m, 4-H and ArH), 7.73 (1 H, t, J8.0, 3-H), 8.38 (1 H, d, J8.0, 1-H) and 
9.10 (1 H, brs, NH); oc 20.72 (CH2), 39.22 (NCH2), 112.05 (2-C), 118.29 (ArC), 120.12 
(ArH), 120.66 (ArH), 125.61 (ArH), 126.20 (ArH), 126.69 (4-C), 127.23 (7-C), 128.22 (ArC), 
129.04 (ArC), 134.32 (3-C), 138.22 (ArC), 144.82 (ArC), 147.53 (ArC), 159.72 (ArC) and 
169.26 (ArC); m/z(Electrospray) 286 (M+, 100%), 155 (27), 140 (24), 128 (38), 115 (25), 102 
(37), 91 (28), 77 (54), 63 (37) and 51 (34). 
The data were consistent to the literature. 102 
322 3-[2-(1H-Indol-3-yl)ethyl]-3H-quinazolin-4-one as colourless crystals (0.42 g, 0.15 
mmol, 57%). 
The data were consistent to the previous synthesis and literature. 102 
Method B- Photolysis with hexamethylditin 
The reaction between 3-[2-(2-bromoindol-3-yl)ethyl]-3H-quinazolin-4-one (0.52 g, 1.41 
mmol) and (Me3Sn)2 (1.39 g, 4.25 mmol) in t-butylbenzene (20 cm3) was purged for 30 min 
with nitrogen, refluxed and irradiated with a 300 W sunlamp for 6 h. The reaction mixture 
was washed through a sinter containing silica absorbent with petrol (100 cm3). The sinter was 
flushed with EtOAc (200 cm3). The filtrate was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica absorbent with light petroleurn!EtOAc ( 4:1) yielding the sole product rutaecarpine 145 
(0.22 g, 0.77 mmol, 55%). 
The data were consistent with the previous synthesis and literature. 102 
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6.4 Experimental for Chapter 4 
2-(4-0xo-4H-quinazolin-3-yl)benzoic acid methyl ester110 
0~ o) co2H 
330 
Isatoic anhydride (7.5 g, 45.9 mmol) and anthranilic acid (6.9 g, 50.4 mmol) were heated 
under reflux in water for 12 h. The reaction mixture was cooled over ice water. The 
precipitate was collected by filtration, washed with EtOAc and dried. The yellow precipitate 
was refluxed with triethyl orthoformate (17 cm3, 108 mmol) in MeOH (50 cm3) for 4 h. The 
reaction mixture was cooled and the precipitate collected by filtration and dried yielding 2-( 4-
oxo-4H-quinazolin-3-yl)benzoic acid methyl ester as colourless crystals ( 4.85 g, 18.2 mmol, 
40%); mp 281-283 (lit. 110 282-284 ·q; (Found: MH+, 267.0764. C,sHuNz03 requires 
267.0764.); Vmax(thin film)/cm·' 3405, 1873, 1785, 1762, 1690, 1657, 1639, 1629, 789 and 
669; oH (CD3)zSO 7.62-7.57 (2 H, m, ArH), 7.69-7.66 (1 H, m, ArH), 7.83-7.74 (2 H, m, 
ArH), 7.91-7.87 (1 H, m, ArH), 8.09 (1 H, d, J9.2, ArH), 8.17 (1 H, d, J9.2, ArH) and 8.33 
(1 H, s, 2-H); oc(CD3)zSO 121.85 (4a-C), 126.33 (ArH), 127.25 (ArH), 127.28 (ArH), 129.13 
(ArC), 129.56 (ArH), 129.76 (ArH), 131.08 (ArH), 133.41 (ArH), 134.64 (ArH), 137.12 
(ArC), 147.14 (2-C), 147.93 (8a-C), 160.29 (4-C) and 165.86 (COzH); m/z(Electrospray) 266 
(M+, 30%), 221 (100), 145 (22), 119 (24), 102 (29), 90 (37), 76 (35) and 65 (30). 
The data were consistent to the literature. 110 
2-(4-0xo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester 
0~ o6 ~OSePh 
N 
329 
Tributyl phosphine (2.5 cm3, 10.4 mmol) was slowly added to diphenyl diselanide (2.47 g, 7.9 
mmol) in dry DCM and left to stir for 15 min. 2-(4-0xo-4H-quinazolin-3-yl)benzoic acid 
methyl ester (1.40 g, 5.2 mmol) was added and stirred for 12 h until no solid was visible. The 
crude reaction mixture was extracted into DCM and washed with HzO (3 x 50 cm3) and brine 
(50 cm3). The organic layer was dried over MgS04 and the solvent removed under reduced 
189 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleum!EtOAc (4:1) the yellow solid was recrystallised from hot 
EtOH yielding 2-(4-oxo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester as yellow 
crystals (1.55 g, 3.8 mmol, 73%); mp 234-236 ·c; (Found: MH+, 407.0289. C2,H,sN20280Se 
requires 407.0293.); Vmax(thin film)/cm·' 3165,2831, 2063, 1798, 1519, 1367, 1118, 960 and 
915; oH 7.36-7.30 (3 H, m, ArH), 7.42 (1 H, dd, J 9.2, 1.6, ArH), 7.55-7.45 (3 H, m, ArH), 
7.70-7.66 (1 H, m, ArH), 7.81-7.72 (3 H, m, ArH), 8.02 (1 H, s, 2-H), 8.14 (1 H, dd, J 9.2, 
1.6, ArH) and 8.34-8.32 (1 H, m, ArH); oc 122.34 (ArC), 125.91 (ArC), 127.14 (5-C), 127.58 
(6-C), 127.71 (ArH), 129.25 (ArH), 129.44 (2 x ArH), 129.74 (ArH), 129.85 (ArH), 130.11 
(ArH), 133.64 (ArC), 133.72 (ArH), 134.65 (ArH), 136.02 (2 x ArH), 136.91 (ArC), 145.62 
(2-C), 147.99 (ArC), 160.71 (4-C) and 192.72 (CO); m/z(E1ectrospray) 407 (M+, 100%), 251 
(39), 235 (55) and 223 (46). 
Radical cyclisation of2-(4-xo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester 
146 
Method A- Photolysis with reflux (benzene) 
2-(4-0xo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester (240 mg, 0.59 mmol) was 
refluxed in benzene (20 cm3) for 10 h and irradiated with a 300 W sun lamp. The solvent was 
removed under vacuum and the crude reaction product was purified by column 
chromatography using silica gel as absorbent and light petroleum/EtOAc (2:I) as eluent 
yielding tryptanthrin 146 as yellow crystals (20 mg, 0.07 mmol, 13%); mp 213-214 ·c (lit. 107 
2I5-2I7 ·q; (Found: MH+, 249.0659. C,sH9N202 requires 249.0660.); oH 7.43 (1 H, t, J 8.0, 
ArH), 7.68 (1 H, t, J 8.0, ArH), 7.79 (1 H, t, J 8.0, ArH), 7.86 (1 H, t, J 8.0, ArH), 7.92 (1 H, 
d, J 8.0, ArH), 8.04 (1 H, d, J 8.0, ArH), 8.44 (1 H, d, J 8.0, ArH) and 8.64 (I H, d, J 8.0, 
ArH); oc 117.98 (ArH), I21.96 (ArC), I23.76 (ArC), I25.40 (ArH), I27.20 (ArH), 127.56 
(ArH), 130.24 (ArH), 130.74 (ArH), 135.13 (ArH), 138.27 (ArH), 146.36 (ArC), 146.66 
(ArC), 158.11 (ArC) and 171.13 (2 x ArH); m/z(Electrospray) 248 (M+, 51%), 220 (22), 130 
(28), I 02 (54), 90 (I 00), 76 (8I ), 63 (55) and 50 (74). 
The data were consistent to the literature. 107 
I90 
Method B- Photolysis only 
2-(4-0xo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester (240 mg, 0.59 mmol) in 
benzene (20 cm3) was irradiated with a 300 W sunlamp for 30 min. The solvent was removed 
under reduced pressure and the crude reaction product was purified by column 
chromatography using silica gel as absorbent with light petroleum!EtOAc (2: 1) as eluent 
yielding tryptanthrin 146 (23 mg, 0.081 mmol, 15%). 
The data were consistent with the previous synthesis and literature.107 
Method C- Photolysis with hexamethylditin 
The reaction mixture of2-(4-oxo-4H-quinazolin-3-yl)selenobenzoic acid Se-methyl ester (290 
mg, 0.72 mmol) and (Me3Sn)z (700 mg, 2.15 mmol) in tert-butylbenzene (20 cm3) was 
refluxed and irradiated with a 300 W sunlamp for 4 h. Dilute hydrochloric acid was added to 
the cooled reaction mixture to extract the protonated quinazolone products into the aqueous 
layer. The aqueous layer was washed with light petroleum (3 x 50 cm3) to remove tin 
residues. The aqueous layer was basified with a solution of sodium hydroxide to pH 14. The 
basic solution was extracted with DCM (3 x 50 cm3). The combined organic layers were dried 
over MgS04 and the solvent removed under reduced pressure and purified by column 
chromatography using silica gel as absorbent and light petroleum!EtOAc (2:1) yielding 
tryptanthrin 146 (5 mg, 0.02 mmol, 3%). 
The data were consistent with the previous synthesis and literature. 107 
Tryptanthrin107 
146 
Non-radical synthesis 
lsatin (0.88 g, 6.0 mmol), isatoic anhydride (0.97 g, 6.0 mmol) and triethyl amine (0.97 cm3, 
7.0 mmol) were refluxed in toluene for 12 h under Dean Stark conditions. The crude reaction 
mixture was extracted into DCM and washed with H20 (3 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (2:1) as eluent yielding tryptanthrin as yellow crystals (1.32 g, 5.3 mmol, 
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88%); mp 213-214 ·c (lit.97 215-217 ·q; (Found: MH+, 249.0659. CtsH9NzOz requires 
249.0660.); ()H 7.43 (1 H, t, J 8.0, ArH), 7.68 (1 H, t, J 8.0, ArH), 7.79 (1 H, t, J 8.0, ArH), 
7.86 (1 H, t, J 8.0, ArH), 7.92 (1 H, d, J 8.0, ArH), 8.04 (1 H, d, J 8.0, ArH), 8.44 (1 H, d, J 
8.0, ArH) and 8.64 (1 H, d, J8.0, ArH); <ic 117.98 (ArH), 121.96 (ArC), 123.76 (ArC), 125.40 
(ArH), 127.20 (ArH), 127.56 (ArH), 130.24 (ArH), 130.74 (ArH), 135.13 (ArH), 138.27 
(ArH), 146.36 (ArC), 146.66 (ArC), 158.11 (ArC) and 171.13 (2 x ArC); m/z(EI) 248 (M+, 
51%), 220 (22), 130 (28), 102 (54), 90 (100), 76 (81), 63 (55) and 50 (74). 
Data were consistent with the previous synthesis and Iiterature.107 
2-[(4-0xo-4H-quinazolin-3-yl)methyl]benzoic methyl ester 
344 
N-Bromosuccinimide (19.0 g, 107.1 mmol), methyl o-toluate (7.5 g, 50 mmol) and AIBN 
(1.16 g, 7.1 mmol) were heated under reflux in cyclohexane in the dark for 5 h. The reaction 
mixture was cooled to 0 ·c and filtered. The filtrate was extracted into DCM, washed with 
H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04and evaporated 
to dryness under reduced pressure. The crude residue was added to a solution of 3H-
quinazolin-4-one (7.3 g, 50 mmol) and potassium t-butoxide (7.3 g, 65 mmol) in DMF (50 
cm3) for 40 min. The reaction mixture was stirred for 12 h, extracted into DCM, washed with 
H20 (5 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04and the solvent 
removed under reduced pressure. The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleurn!EtOAc ( 4:1) as eluent yielding 2-[( 4-oxo-
4H-quinazolin-3-yl)methyl]benzoic methyl ester as a colourless oil (4.98 g, 16.6 mmol, 34%); 
(Found: MH+, 295.1077. C11HtsN203 requires 295.1077.); Vmax(thin film)/cm·1 3541, 3417, 
1715, 1681, 1563, 1367, 1322, 1079, 968 and 774; ()H3.88 (3 H, s, OMe), 5.62 (2 H, s, CH2), 
7.31-7.22 (2 H, m, ArH), 7.44-7.41 (2 H, m, ArH) 7.70-7.69 (2 H, m, ArH), 7.97 (1 H, dd, J 
7.8, 1.4, ArH) and 8.28-8.23 (2 H, m, ArH); <>c 47.86 (CH2), 52.41 (Me), 122.20 (4a-C), 
126.91 (ArH), 127.33 (ArH), 127.54 (ArH), 128.03 (ArH), 128.59 (ArC), 129.06 (ArH), 
131.31 (ArH), 132.96 (ArH), 134.36 (ArH), 137.36 (ArC), 147.14 (ArH), 148.12 (Sa-C), 
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161.36 (4-C) and 167.37 (COzMe); m/z(Electrospray) 421 (M+, 4%), 262 (53}, 132 (80}, 118 
(30), 102 (60), 91 (100}, 77 (58}, 63 (33) and 50 (23). 
2-[ ( 4-0xo-4H-quinazolin-3-yl)methyl]-benzoic acid 
ro~H 
N 
2-[(4-0xo-4H-quinazolin-3-yl)methyl]benzoic methyl ester (1.93 g, 6.14 mmol) and LiOH (1 
M, 200 cm3} were stirred in EtOHIHzO (100 cm3, 10:1) for 18 h. The reaction mixture was 
acidified with HCl and extracted with EtOAc (3 x 50 cm3}. The organic layers were combined 
and washed with H20 (5 x 50 cm3} and brine (50 cm3}. The organic layer was dried over 
MgS04 and the solvent removed under reduced pressure yielding 2-[(4-oxo-4H-quinazolin-3-
yl)methyl]benzoic methyl acid as a colourless oil (1.26 g, 4.16 mmol, 68%); (Found: MH+, 
281.0918. Ct6H13N20 3 requires 281.0921.); Vmax(thin film)/cm·1 3160, 2825, 2059, 1801, 1511, 
1380, 1111, 930 and 904; 8H 5.58 (2 H, s, CHz), 6.96 (1 H, d, J 8.0, ArH}, 7.41-7.39 (1 H, m, 
ArH}, 7.50-7.49 (1 H, m, ArH), 7.58 (1 H, ddd, J8.0, 6.8, 1.0, ArH}, 7.74 (1 H, dd, J, 8.2, 1.0, 
ArH), 7.88 ( 1 H, ddd, J 8.2, 6.8, 1.2, ArH), 7.97 ( 1 H, dd, J 8.0, 1.2, ArH}, 8.16 ( 1 H, d, J 8.0 
ArH) and 8.51 (1 H, s, ArH); m/z(Electrospray) 262 (M+, 31%), 146 (35), 132 (86}, 118 (38}, 
104 (47}, 90 (58}, 77 (100}, 63 (28}, 51 (32) and 43 (53). 
The acid was converted to the acyl selanide without further characterisation 
2-[ ( 4-0xo-4H-quinazolin-3-yl)methyl]seleno benzoic acid Se-methyl ester 
341 
Tributyl phosphine (0.51 cm3, 1.3 mmol) was slowly added to diphenyl diselanide (480 mg, 
1.5 mmol) in dry DCM and left to stir for 15 min. 2-[(4-0xo-4H-quinazolin-3-
yl)methyl]benzoic acid (31 0 mg, 1.0 mmol) was added and stirred for 12 h until no precipitate 
was visible. The crude reaction mixture was extracted into DCM and washed with HzO (3 x 
50 cm3) and brine (50 cm3}. The organic layer was dried over MgS04 and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography using 
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silica gel as absorbent with light petroleum!EtOAc (2: 1) yielding 2-( 4-oxo-4H-quinazolin-3-
ylmethyl)-seleno benzoic acid Se-methyl ester as colourless crystals (31 0 mg, 0. 71 mmol, 
68%); mp 314-316 ·c; (Found: MH+, 421.0450. c22H17N20280Se requires 421.0451.); Vmax(thin 
film)/cm·1 3361, 1911, 1659, 1589, 1542, 1392, 1336, 1188, 801, 760 and 722; oH5.43 (2 H, s, 
CH2), 7.37-7.35 (1 H, m, ArH), 7.53-7.45 (6 H, m, ArH), 7.61-7.59 (2 H, m, ArH), 7.79-7.73 
(2 H, m, ArH), 8.04 (1 H, dd, J 7.6, 1.3, ArH), 8.13 (1 H, s, 2-H) and 8.33-8.30 (1 H, m, 
ArH); oc 47.24 (CH2), 122.14 (4a-C), 126.29 (ArC), 126.91 (ArH), 127.41 (ArH), 127.52 
(ArH), 128.53 (ArH), 129.43 (ArH), 129.59 (2 x ArH), 129.62 (ArH), 129.74 (ArH), 133.21 
(ArH), 133.60 (ArC), 134.45 (ArH), 136.23 (2 x ArH), 137.65 (ArC), 147.03 (ArH), 147.99 
(Sa-C), 161.29 (4-C) and 196.73 (CO); m/z(Electrospray) 263 (M+, 60%), 156 (45), 129 (100), 
102 (43), 89 (46), 77 (60), 63 (23) and 51 (33). 
Radical cyclisation of 2-[(4-oxo-4H-quinazolin-3-yl)methyl]seleno benzoic acid Se-
methyl ester 
d.:~ 
0 
345 
The reaction mixture between 2-[(4-oxo-4H-quinazolin-3-yl)methyl]seleno benzoic acid Se-
methyl ester (0.044 g, 0.1 mmol) and (Me3Sn)2 (0.099 g, 0.3 mmol) in benzene (20 cm3) were 
heated under reflux and irradiated with a sunlamp lamp for 3 h. The benzene was removed 
under reduced pressure. The crude product was purified by column chromatography using 
silica gel as absorbent with light petroleum!EtOAc (4:1) as eluent and recrystallised from 
CDCb yielding 11-hydroxy-11H-isoquinolino[3,2-b ]quinazolin-6, 13-dione 345 as colourless 
crystals (11 mg, 0.04 mmol, 39%); mp 164-165 oc; (Found: MH+, 279.0768. C16H 11N203 
requires 279.0764.); Vmax(thin film)/cm·1 3421, 2919, 2360, 1699, 1683, 1653, 1559, 1461, 
1260, 1100, 936, 910, 728 and 667; oH5.29 (1 H, d, J 4.6, OH), 7.21 (1 H, d, J 4.6, CH), 7.69-
7.65 (2 H, m, ArH), 7.80 (1 H, d, J 8.0, ArH), 7.93-7.84 (2 H, m, ArH), 8.10 (1 H, d, J 8.0, 
ArH), 8.32 (1 H, dd, J 7.6, 1.2, ArH) and 8.39 (1 H, dd, J 8.0, 1.2, ArH); oc 75.48 (CH), 
121.89 (ArC), 126.70 (ArH), 128.03 (ArH), 128.71 (ArH), 129.20 (ArC), 129.57 (ArH), 
130.01 (ArH), 130.35 (ArH), 135.58 (ArH), 135.68 (ArH), 137.01 (ArC), 142.61 (ArC), 
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146.74 (ArC), 162.74 (ArC) and 176.58 (ArC); m/z(Electrospray) 278 (M+, 50%), 262 (43), 
249 (40), 221 (26), 135 (38), 119 (36), I 05 (I 00), 91 ( 45), 84 (60), 77 (68) and 51 (69). 
The structure was confinned by X-ray crystallography (see appendix). 
3-(2-Hydroxypropyl)-3H-quinazolin-4-one167 
0 
6~N~OH 
7U~J2 
8 8a 
368 
Anthranilic acid (11.3 g, 82.0 mmol) and triethyl orthofonnate (273 cm3, 1650 mmol) were 
refluxed for 24 h. The excess triethyl orthofonnate was removed under vacuum. 3-
Aminopropan-1-ol (50 cm3) was added to the slurry and the reaction mixture stirred for 48 h. 
The excess 3-aminopropan-1-ol was removed under vacuum yielding 3-(2-hydroxypropyl)-
3H-quinazolin-4-one as brown crystals (6.53 g, 32.0 mmol, 40%); mp 148-49 °C (lit. 167 150-
152 °C}; Vmax(thin film)/cm·1 3400, 1652, 1475, 1379, 1325, 1160, 1060 and 775; 8H2.76-2.00 
(2 H, m, CH2), 3.65 (2 H, t, J 6.2, NCH2), 4.21 (2 H, t, J 6.2, OCH2), 7.52 (1 H, ddd, J 8.0, 
6.8, 1.2, 6-H), 7.72 (1 H, dd, J 8.2, 1.2, 8-H), 7.77 (1 H, ddd, J 8.2, 6.8, 1.4, 7-H), 8.14 (1 H, 
s, 2-H) and 8.30 (1 H, dd, J8.0, 1.4, 5-H); 8c 31.85 (CH2), 43.51 (CH2), 58.06 (NCH2), 121.78 
(4a-C}, 126.67 (5-C}, 127.35 (8-C}, 127.46 (6-C}, 134.44 (7-C), 146.83 (2-C}, 148.05 (8a-C) 
and 161.81 (4-C). 
The data were consistent to the literature. 167 
3-( 4-0xo-4H-q uinazolin-3-yl)propionaldehyde 
0 
~N~o U~.J2 8a N 
367 
3-(2-Hydroxypropyl)-3H-quinazolin-4-one (0.40 g, 2.0 mmol) and 2-iodoxy benzoic acid 
(1.68 g, 6.0 mmol) were refluxed in EtOAc (50 cm3) for 4 h. The reaction mixture was filtered 
and the filtrate was washed with brine (20 cm3}. The organic layer was dried over MgS04 and 
the solvent removed under reduced pressure yielding 3-(4-oxo-4H-quinazolin-3-
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yl)propionaldehyde as a yellow oil (370 mg, 1.86 mmol, 93%); Vmax(thin film)/cm·1 3341, 
2837, 2248, 1668, 1564, 1472, 1384, 1263, 1066, 962 and 880; OH 3.11 (2 H, m, CHz), 4.26 (2 
H, t, J 6.0 NCHz), 7.48-7.46 (1 H, m, ArH), 7.72-7.69 (2 H, m, ArH), 8.23-8.22 (1 H, m, 5-
H), 8.29 (1 H, s, 2-H) and 9.78 (1 H, s, OCH); Oc42.15 (CHz), 43.44 (NCHz), 122.59 (4a-C), 
12.38 (ArH), 127.27 (ArH), 127.32 (ArH), 134.35 (ArH), 147.38 (ArH), 147.79 (8a-C), 
161.22 (4-C) and 199.20 (CO). Compound was unstable in air and no further characterisation 
could be carried out. 
3-( 4-Bromobut-3-enyi)-3H-quinazolin-4-one 
0 
6cx::4a ~Br -:?" 4 N 7~ I N)2 
8 Ba 
366 
Bromomethylenetriphenylphosphorane (1.97 g, 4.5 mmol) was stirred with potassium t-
butoxide (500 mg, 4.5 mmol) at -78 oc in THF for 15 min. 3-(4-0xo-4H-quinazolin-3-
yl)propionaldehyde (0.83 g, 4.10 mmol) was added and stirred for 12 h at rt. The crude 
reaction mixture was extracted into DCM and washed with H20 (3 x 50 cm3) and brine (50 
cm3). The organic layer was dried over MgS04 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleurn!EtOAc (2:1) yielding 3-(4-bromobut-3-enyl)-3H-quinazolin-4-
one as a yellow oil (170 mg, 0.61 mmol, 15%); (Found: MH+, 279.0130. C12H1/9BrNzO 
requires 279.0128.); Vmax(thin film)/cm·1 3508, 3076, 1668, 1608, 1472, 1373, 1261, 1152, 
1048,878,775 and 700; oH2.76- 2.56 (2 H, m, CHz), 4.12 (2 H, t, J8.0, NCHz), 6.22-6.13 {1 
H, m, CH), 6.33 (1 H, d, J 9.2, BrCH), 7.53-7.48 (1 H, m, 6-H), 7.78-7.70 (2 H, m, 7,8-H), 
8.08 (1 H, s, 2-H) and 8.29-8.20 (1 H, m, 5-H); Oc 29.41 (CHz), 45.01 (NCHz), 111.97 
(BrCH), 121.94 (4a-C), 126.61 (5-C), 127.35 (ArH), 127.38 (6-H), 129.65 (CH), 134.36 
(ArH), 146.49 (2-C), 147.81 (8a-C) and 160.95 (4-C); m/z(Electrospray) 279 (M+, 13%), 277 
(13), 199 (62), 159 (28), 145 (75), 129 (60), 102 (47), 76 (48), 50 (50) and 40 (100). 
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2-Bromo-5-chloropent-1-ene116 
370 
HBr (33% in AcOH) (30.0 cm3, 160 mmol) was added dropwise using a syringe pump, over 1 
hat 0 octo a neat solution of5-chloro-1-pentyne (14.0 cm3, 133 mmol). The reaction mixture 
was stirred at rt for 24 h. DCM (100 cm3) and water (100 cm3) were added and the reaction 
mixture basified with sodium bicarbonate (Na2C03) to pH 8. The organic phase was washed 
with dilute Na2C03 solution (50 cm3) and water (3 x 50 cm3). The organic layer was dried 
over MgS04 and the solvent removed under reduced pressure. The crude product was distilled 
under reduced pressure and temperature yielding 2-bromo-5-chloropent-1-ene as a yellow oil 
(16.0 g, 87.3 mmol, 66%); Vmax(thin film)/cm-1 3416, 2925, 1436, 1179, 1121, 896, 749 and 
694; 8H 2.07-2.00 (2 H, m, 4-H), 2.61 (2 H, t, J 7 .8, 3-H), 3.57 (2 H, t, J 6.3, 5-H), 5.31 (1 H, 
d, J 1.7, Ha) and 5.66 (1 H, dt, J 1.7, 1.1, Hb); 8c30.35 (4-C), 38.31 (3-C), 43.34 (5-C), 118.08 
(1-C) and 132.46 (2-C). 
The data were consistent to the literature. 116 
2-Bromo-5-iodopent-1-ene168 
371 
Sodium iodide (107.0 g, 714 mmol) and 2-bromo-5-chloropent-1-ene (16.0 g, 87 mmol) were 
refluxed in dry acetone (300 cm3) for 20 h. The reaction mixture was extracted into DCM 
(100 cm3) and washed with water (3 x 50 cm3) and brine (50 cm3). The organic layer was 
dried over MgS04 and the solvent removed under reduced pressure yielding 2-bromo-5-
iodopent-1-ene as a yellow oil (17.3 g, 62.8 mmol, 72%); (Found: M+, 273.8849. CsHs79Brl 
requires 273.8848.); Vmax(thin film)/cm·13413, 2920, 1456, 1230, 1125, 896, 888, 845, 749 and 
684; 8H2.09-2.05 (2 H, m, 4-H), 2.58-2.54 (2 H, m, 3-H), 3.22-3.18 (2 H, m, 5-H), 5.47 (1 H, 
d, J 1.7, Ha) and 5.68 (1 H, dt, J 1.7, 1.1, Hb); Oc 5.37 (5-C), 31.06 (4-C), 41.06 (3-C), 118.34 
(l-C) and 135.76 (2-C); mlz(EI) 276 (M+, 20%), 374 (21), 148 (43), 126 (20), 67 (100), 64 
(21) and 41 (65). 
The data were consistent to the literature. 168 
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3-( 4-Bromopent-4-enyl)-3H-quinazolin-4-one 
372 
Potassium t-butoxide (5.40 g, 48.30 mmol) was added to a solution of 3H-quinazolin-4-one 
(48.3 g, 7.05 mmol) in DMF (100 cm3) and stirred for 1 h. 2-Bromo-5-iodopent-1-ene (17.26 
g, 62.80 mmol) was added and stirred for a further 12 h. The crude reaction mixture was 
extracted into EtOAc and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic 
layer was dried over MgS04 and the solvent removed under reduced pressure. The crude 
product was purified by column chromatography using silica gel as absorbent with light 
petroleum!EtOAc (3:1) as eluent to yield 3-(4-bromopent-4-enyl)-3H-quinazoline-4-one as 
colourless crystals (6.65 g, 22.7 mmol, 47%); mp 157-158 oc; (Found: MH+, 293.0285. 
C13H1479BrN20 requires 293.0284.); Vmax(thin film)/cm·1 3498, 2945, 1673, 1608, 1562, 1471, 
1372, 1321, 1291, 1180, 1118 and 883; oH 2.19-2.12 (2 H, m, CH2), 2.56-2.48 (2 H, m, 
BrCCH2), 4.09-4.00 (2 H, m, NCH2), 5.49 (1 H, d, J 1.7, Ha), 5.69-5.68 (1 H, dt, J 1.7, 1.1, 
Hb), 7.54-7.49 (1 H, m, 6-H), 7.79-7.70 (2 H, m, 7 and 8-H), 8.04 (1-H, s, 2-H) and 8.32-8.30 
(1 H, m, 5-H); oc27.65 (CH2), 38.21 (BrCCH2), 46.24 (NCH2), 118.09 (CHaHb), 122.07 (4a-
C), 126.67 (5-C), 127.38 (6-C), 127.47 (ArH), 132.52 (8a-C), 134.29 (ArH), 146.43 (2-C), 
148.06 (BrC) and 161.10 (4-C);,m/z(Electrospray) 295 (M+, 11%), 293 (10), 213 (100), 147 
(32), 129 (40), 102 (33), 77 (36), 67 (72) and 53 (35). 
3-(Pent-4-ynyi)-3H-quinazolin-4-one 
373 
Potassium t-butoxide (3.17 g, 33.3 mmol) was added to a solution of 3H-quinazolin-4-one 
(4.50 g, 31.0 mmol) in DMF (100 cm3) and the reaction mixture stirred for 1 hat 60 °C. 5-
Chloropent-1-yne (3.40 cm3, 32.25 mmol) and sodium iodide (4.7 g, 30.60 mmol) were added 
and stirred for 20 h at rt. The crude reaction mixture was extracted into EtOAc and washed 
with H20 (5 x 100 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the 
solvent removed under reduced pressure. The crude product was purified by column 
198 
chromatography using silica gel as absorbent with light petroleum!EtOAc (2: 1) as eluent to 
yield 3-(pent-4-ynyl)-3H-quinazolin-4-one as colourless crystals (0.64 g, 3.00 mmol, 10%); 
mp 127-128 oc; (Found: MH+, 213.1023. Cl3Hl3N20 requires 213.1022.); Vmax(thin film)/cm·l 
2963,2923, 1617, 1614, 1472, 1367, 1324, 1156,775 and 634; oH2.0S-2.01 (2 H, m, b-CHz), 
2.16 (1 H, s, CH), 2.32-2.27 (2-H, m, c-CHz), 4.14 (2 H, t, J6.S, NCHz), 7.45 (1 H, ddd, JS.O, 
7.0, 1.2, 6-H), 7.64 (1 H, dd, J S.O, 1.2, 8-H), 7.70 (1 H, ddd, J S.O, 7.0, 1.4, 7-H), S.04 (1 H, 
s, 2-C) and S.24 (1 H, dd, J S.O, 1.4, 5-H); oc 15.60 (b-CHz), 27.19 (a-CHz), 45.S7 (NCHz), 
70.19 (CH), S2.32 (C), 122.14 (4a-C), 126.65 (5-C), 127.34 (6-C), 127.50 (S-C), 134.2S (7-
C), 146.70 (2-C), 14S.15 (Sa-C) and 161.1S (4-C); m/z(Electrospray) 169 (M+, 36%), 159 
(100), 146 (35), 129 (2S) and 50 (35); Anal. Calcd for C13H1zNzO. C, 73.56; H, 5.70; N, 13.20. 
Found: C, 73.33; H, 5.6S; N, 13.12. 
3-(Pent-4-enyi)-3H-quinazolin-4-one 
376 
Potassium t-butoxide (O.S2 g, 7.4 mmol) was added to a solution of 3H-quinazolin-4-one 
(0.9S g, 6.7 mmol) in DMF (100 cm3) and stirred for 1 h. 5-Bromopent-1-ene (1.20 cm3, S.OS 
mmol) was added and stirred for 20 h. The crude reaction was extracted into EtOAc and 
washed with H20 (5 x 100 cm3) and brine (50 cm3). The organic layer was dried over MgS04 
and the solvent removed under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent with light petroleum/EtOAc (4:1) as eluent to 
yield 3-(pent-4-enyl)-3H-quinazolin-4-one as colourless crystals (0.63 g, 3.0 mmol, 44%); mp 
134-135 oc; (Found: MH+, 215.1179. CnHisNzO requires 215.1179.); Vmax(thin film)/cm·l 
3415, 3069, 2S66, 1666, 1613, 1474, 1175, '1112, 1003 and 91S; SH 1.95-l.SS (2 H, m, CbH2), 
2.1S-2.13 (2 H, m, CcH2), 4.03-3.99 (2 H, m, NCH2), 5.11-5.02 (2 H, m, CH2), 5.S2-5.76 (1 H, 
m, CH), 7.49 (1 H, ddd, J S.l, 5.4, 1.4, 6-H), 7.76-7.6S (2 H, m, 7+S-H), S.04 (1 H, s, 2-H) 
and S.30 (1 H, dd, JS.l, 1.4, 5-H); Sc2S.07 (Cb), 30.51 (Cc), 46.39 (C.), 115.90 (CH2), 122.0S 
(4a-C), 126.55 (5-C), 126.94 (6-C), 127.14 (ArH), 134.06 (ArH), 136.S3 (CH), 146.59 (2-C), 
14S.05 (Sa-C) and 160.96 (4-C); m/z(Electrospray) 160 (M+, 3S%), 147 (2S), 6S (29), 55 (36) 
and 40 (100). 
199 
4-(Cyclopropylidenemethyl)toluene117 
~ 
381 
A solution of cyclopropyltriphenylphosphonium bromide (10.20 g, 26.60 mmol), p-
toluylaldehyde (3.03 cm3, 26.6 mmol) and potassium t-butoxide (6.25 g, 55.86 mmol) in 
DCM (100 cm3) were refluxed for 48 h. The reaction mixture was cooled and the DCM 
removed under reduced pressure. The crude mixture was partially dissolved in MeOH (200 
cm3), NaBH4(3.01 g, 79.8 mmol) was added and the reaction mixture stirred for a further 12 h 
to reduce the remaining aldehyde. The MeOH was removed under reduced pressure and the 
crude slurry was extracted with DCM (1 00 cm3). The DCM solution was washed with H20 (3 
x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the solvent was 
removed under reduced pressure. The crude product was purified with column 
chromatography using silica gel as absorbent with light petroleum as eluent yielding 4-
(cyclopropylidenemethyl)toluene as a colourless oil (1.53 g, 11.6 mmol, 44%); Vmax(thin 
film)/cm·1 3044, 2973, 1784, 1512, 1456, 1408, 1109, 1043, 973, 930, 832, 754 and 512; 8H 
1.16-1.23 (2 H, m, CHz), 1.40-1.47 (2 H, m, CHz), 2.20 (3 H, s, CH3), 6.55 (1 H, t, J 1.6, CH), 
7.17 (2 H, d, J8.0, ArH) and 7.46 (2 H, d, J8.0, ArH); 8c0.00 (CH2), 3.63 (CH2), 20.56 (Me), 
117.59 (CH), 122.54 (C), 126.02 (2 x ArH), 129.20 (2 x ArH), 135.02 (ArC) and 135.86 
(ArC). 
The data were consistent to the literature. 117 
(E)-4-(2,4-Dibromo but-1-enyl)toluene117 
380 
The reaction between 4-(cyclopropylidenemethyl)toluene (1.31 g, 9.9 mmol) and copper (11) 
bromide (4.42 g, 18.8 mmol) was heated under reflux in MeCN (50 cm3) for 14 h. The 
reaction mixture was cooled and washed with sat. NH4Cl and extracted light petroleum ( 4 x 
50 cm3). The combined organic layers were dried over MgS04 and the solvent removed under 
reduced pressure yielding (E)-4-{2,4-dibromobut-1-enyl)toluene as a colourless oil (1.80 g, 
5.9 mmol, 60%); (Found: M+, 301.9299. CuH1279Br2 requires 301.9300.); Vmax(thin film)/cm·' 
200 
2919, 1511, 1417, 1257, 1212, 1147, 1008,912, 865, 802 and 709; oH2.33 (3 H, S, Me), 3.08 
(2 H, t, J 6.9, CH2), 3.62 (2 H, t, J 6.9, BrCHz), 6.80 (1 H, s, CH), 7.16 (2 H, d, J 8.0, H.) and 
7.49 (2 H, d, J 8.0, Hb); oc 21.33 (Me), 30.58 (BrCHz), 46.03 (CHz), 121.98 (BrC), 128.84 (2 
x Hb), 128.86 (2 x H.), 130.52 (CH), 132.51 (p-C) and 137.99 (i-C); m/z(EI) 306 (M+, 15%), 
304 (27), 302 (14), 210 (14), 142 (31), 129 (100), 115 (70), 93 (41), 63 (30) and 51 (39). 
The data were consistent to the literature. 117 
(E)-3-(3-Bromo-4-p-toluylbut-3-enyl)-3H-quinazoline-4-one 
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Potassium t-butoxide (0.57 g, 4.67 mmol) was added to a solution of 3H-quinazolin-4-one 
(0.68 g, 4.67 mmol) in DMF (1 00 cm3) and stirred for 1 h. (E)-4-(2,4-Dibromobut-1-
enyl)toluene (1.70 g, 5.60 mmol) was added and stirred for a further 12 h. The crude reaction 
mixture was extracted into EtOAc and washed with HzO (5 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum/EtOAc (3: I) as eluent to yield (E)-3-(3-bromo-4-p-toluylbut-3-enyl)-3H-
quinazoline-4-one as colourless crystals (0.05 g, 0.13 mmol, 20%); mp 201-202 oc; (Found: 
MH+, 369.0595. c,9H!s79BrNzO requires 369.0597.); Vmax(thin film)/cm·' 3021, 2918, 1716, 
1675, 1609, 1507, 1472, 1373, 1321, 1259, 1154, 909, 805, 774, 698, 537 and 452; oH2.31 (3 
H, s, Me), 3.10 (2 H, t, J 6.4, CHz), 4.31 (2 H, t, J 6.4, NCHz), 6.63 (I H, s, CH), 7.10 (2 H, d, 
J8.0, Ha), 7.29 (2 H, d, J8.0, Hb), 7.51 (I H, ddd, J8.2, 6.8, 1.2, 6-H), 7.69 (I H, dd, J8.2, 
1.2, 8-H), 7. 75 (1 H, ddd, J 8.2, 6.8, 1.4, 7-H), 8.04 (I H, s, 2-H) and 8.32 (I H, dd, J 8.2, 1.4, 
5-H); oc 21.31 (Me), 42.02 (CHz), 45.63 (NCHz), 121.00 (C), 121.97 (C), 126.59 (5-C), 
127.31 (6-C), 127.61 (8-C), 128.67 (2 x ArH), 128.85 (2 x ArH), 131.60 (CH), 132.30 (p-C), 
134.33 (7-C), 138.07 (i-C), 146.73 (2-C), 148.17 (8a-C) and 161.15 (4-C); m/z(Electrospray) 
371 (M+, 4%), 369 (4), 289 (75), 143 (79), 128 (100), 115 (54), 102 (33), 77 (46) and (51). 
201 
5-Bromo-1-phenylpent-1-yn118 
Br 
386 
Phenylacetylene (0.69 cm3, 6.3 mmol) was slowly added to n-butyllithium (2 cm\ 5 mmol) in 
THF. The reaction was refluxed for 1 h until no gas evolution. The reaction mixture was 
cooled tort and 1,3-dibromopropane (0.76 cm3, 7.5 mmol) was added and refluxed for 12 h. 
After cooling to rt the crude reaction was quenched with water (2 cm3). The crude reaction 
mixture was extracted into EtOAc and washed with H20 (3 x 100 cm3) and brine (50 cm3). 
The organic layer was dried over MgS04 and the solvent removed under reduced pressure 
yielding 5-bromo-1-phenylpent-1-yne as a colourless oil (1.11 g, 5.0 mmol, 80%); Vmax(thin 
film)/cm·1 2929, 2858, 1489, 1441, 1246, 1069, 1033, 998, 913 and 775; 8H2.14 (2 H, sep, J 
6.6, CH2) 2.61 (2 H, t, J 6.6, CH2), 3.58 (2 H, t, J 6.6, CH2Br), 7.35-7.32 (3 H, m, ArH) and 
7.51-7.48 (2 H, m, ArH); 8c 18.15 (CHz), 32.19 (CH2Br), 34.86 (CH2), 81.63 (1-C), 87.94 (2-
C), 123.55 (ArC), 127.82 (ArH), 128.26 (2 x ArH) and 131.77 (2 x ArH). 
The data were consistent to the literature. 118 
6.5 Experimental for Chapter 5 
2,4-Dichloroquinazoline119 · 
393 
Phosphorous oxychloride (14.3 cm3, 154 mmol) was added to a solution of benzoyleneurea 
(5.0 g, 30.8 mmol) in N,N-dimethylaniline (1.8 cm\ 15.0 mmol) and refluxed for 4 h. The 
reaction mixture was cooled and carefully quenched with chilled water. The reaction mixture 
was extracted into DCM and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic 
layer was dried over MgS04 and the solvent removed under reduced pressure. The crude 
product was purified by column chromatography using silica gel as absorbent with 
EtOAc/light petroleum (3: 1) as eluent yielding 2,4-dichloroquinazoline as colourless crystals 
(1.04 g, 5.3 mmol, 17%); mp 115-116 °C (lit. 119 116-118 °C}; Vmax(thin film)/cm·1 3290, 2901, 
202 
1340, 1245, 1109, 1097,956 and 779; oH(CD3)2SO 7.71 (1 H, ddd, J8.8, 7.1, 1.2, 7-H), 7.88 
(1 H, dd, J 8.3, 1.2, 5-H), 8.00 (1 H, ddd, J 8.3, 7.1, 1.2, 6-H) and 8.15 (1 H, dd, J 8.8, 1.2, 8-
H); oc (CDJ)zSO 121.13 (4a-C), 125.42 (5-C), 129.11 (8-C), 130.78 (6-C), 134.54 (7-C), 
148.90 (8a-C), 162.01 (4-C) and 164.58 (2-C). 
The data were consistent to the literature.119 
2-Chloro-3H-quinazolin-4-one119 
d.:xCI 
394 
To a stirred solution of 2,4-dichloroquinazoline (5.0 g, 25.4 mmol) in THF (50 cm3) was 
added 1 N NaOH (127 cm3, 127 mmol) and the reaction mixture was stirred for 6 h. The 
organic solvent was removed under reduced pressure and the solid triturated with H20. The 
precipitate was recrystallised from hot EtOH to afford 2-chloro-3H-quinazolin-4-one as 
colourless crystals (0.58 g, 3.2 mmol, 12%); mp 210-211 °C (lit. 119 214-218 °C); Vmax(thin 
film)/cm·• 3410, 1699, 1653, 1601, 1582, 1523, 1399, 1124, 958, 762, 734, 659, 620 and 542; 
~(CD3)2SO 7.73 (1 H, ddd,J8.6, 7.0, 1.2, 6-H), 7.78 8.15 (1 H, dd,J8.6, 1.2, 8-H) 8.00 (1 
H, ddd, J 8.2, 7.0, 1.2, 7-H) and 8.24 (1 H, dd, J 8.2, 1.2, 5-H); ~ (CD3)2SO 119.37 (4a-C), 
123.42 (5-C), 128.78 (8-C), 128.80 (6-C), 134.40 (7-C), 146.81 (8a-C), 153.56 (2-C) and 
164.78 (4-C). 
The data were consistent to the literature. 119 
2-Iodoquinoline 
400 
Trifluroacetic acid (1.53 cm3, 20 mmol) was added to a solution of2-chloroquinoline (0.65 g, 
4 mmol) and sodium iodide (11 g, 80 mmol) in 2-butanone (20 cm 3) and stirred for 48 h. The 
crude reaction mixture was extracted into DCM and washed with H20 (3 x 50 cm3) and brine 
203 
(50 cm3). The organic layer was dried over MgS04 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleum/EtOAc (8:1) yielding 2-iodoquinoline as red crystals (0.57 g, 
2.22 mmol, 56%); mp 49-50 °C (lit.89 51-53 °C); Vmax(thin film)/cm·• 1577, 1557, 1491, 1415, 
1282, 1122, 1073, 934, 829, 815, 772 and 764; 8H 7.52 (1 H, ddd, J 8.0, 7.2, 1.2, 6-H), 7.77-
7.65 (4 H, m, ArH) and 8.00 (1 H, dd, J 8.0, 1.2, 8-H); Oc 119.09 (2-C), 127.10 (4a-C), 127.26 
(6-C), 127.96 (5-C), 128.52 (8-C), 130.44 (3-C), 131.97 (7-C), 137.32 (4-C) and 149.35 (Sa-
C). 
The data were consistent to the literature. 89 
2-Phenylselanyi-3H-quinazolin-4-one 
8 
401 
K-selectride in 1 N THF (1.1 cm3, 1.1 mmol) was added to diphenylselanide (0.16 g, 0.5 
mmol) in dry THF (20 cm3) and stirred for 10 min. 2-Chloro-3H-quinazolin-4-one (0.22 g, 1.0 
mmol) was added and the mixture was stirred for 12 h. The solvent was removed under 
reduced pressure. The crude product was triturated hot petrol yielding 2-phenylselanyl-3H-
quinazolin-4-one as colourless crystals (12 mg, 0.36 mmol, 36%); mp 120-121 OC; (Found: 
MH+, 303.0031. c.4HnN2080Se requires 303.0028.); Vmax(thin film)/cm·• 3644, 2357, 1694, 
1573, 1557, 1465, 1337, 1304, 1168, 940 and 870; 8H 7.29 (1 H, dd, J 8.0, 1.1, 8-H), 7.49-7.41 
(4 H, m, ArH), 7.73-7.68 (3 H, m, ArH) and 8.04 (1 H, dd, J7.6, 0.8, 5-H); 8c 120.42 (ArC), 
125.87 (ArH), 125.99 (ArH), 126.06 (ArC), 127.84 (ArH), 129.02 (ArH), 129.31 (ArH), 
129.49 (ArH), 129.94 (ArC), 130.72 (ArH), 134.33 (ArH), 135.79 (ArH), 148.51 (ArC) and 
161.80 (ArC); m/z(Electrospray) 302 (M+, 18%), 300 (8) 145 (51), 117 (26), 90 (100), 77 
(38), 64 (29), 63 (37) and 51 (45). 
204 
Methanesulfonic acid 2-( chloroquinolin-3-yl)methyl ester 
0 
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Methanesulfonyl chloride (0.15 g, 1.56 mrnol) and triethyl amine (0.43 cm3, 4.2 mmol) were 
added to a solution of 2-chloro-3-(hydroxymethyl)quinoline (0.15 g, 0.78 mmol) in toluene 
(20 cm3) and stirred for 24 h. The crude reaction mixture was extracted into DCM and washed 
with H20 (3 x 50 cm3) and brine (50 cm3). The organic layer was dried over MgS04 and the 
solvent removed under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent with light petroleurn!EtOAc (9: 1) as eluent 
yielding methanesulfonic acid 2-(chloroquinolin-3-yl)methyl ester as a yellow oil (0.11 g, 
0.48 mrnol, 62%); mp 130-131 oc; (Found: MH+, 272.0144. CuHu35ClN03S requires 
272.0143.); Vmax(thin film)fcm·1 3399, 3049, 2915, 2852, 1646, 1616, 1550, 1455, 1351, 1243, 
1092, 1008, 825, 777, 751,586 and 514; 8H3.14 {3 H, s, CH3), 5.46 (2 H, s, CHz), 7.60 {1 H, 
ddd, J 8.0, 6.8, 1.0, 6-H), 7.76 (1 H, ddd, J 8.4, 6.8, 1.6, 7-H), 7.85 (1 H, dd, J 8.0, 1.6, 5-H), 
8.04 (1 H, dd, J8.4, 1.0, 8-H) and 8.30 (1 H, s, 4-H); 8c38.10 (CHz), 67.78 (CH3), 125.62 (4a-
H), 126.83 (3-C), 127.76 (6-H), 127.88 (5-H), 128.38 (8-H), 131.47 (7-H), 138.97 (4-H), 
147.63 (Sa-C) and 148.96 (2-C); m/z(Electrospray) 272 (M+, 20%), 271 (63), 172 (24), 175 
(43), 140 (100), 128 (71), 101 (32), 79 (89) and 63 (27). 
2-Bromo-3-[(2-chloroquinolin-3-yl)methyi]-3H-quinazolin-4-one 
OCo 4• N ~ I-...::::: N'J]:)O 
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Potassium t-butoxide (0.13g, 1.2 mmol) was added to a solution of2-bromo-3H-quinazolin-4-
one (0.22 g, 1.0 rnmol) in DMF (20 cm3) and stirred 1 h. Methanesulfonic acid 2-
(chloroquinolin-3-yl)methyl ester (0.27 g, 1.2 mmol) was added and stirred for a further 12 h. 
The crude reaction mixture was extracted into EtzO and washed with H20 (5 x 50 cm3) and 
brine (50 cm3). The organic layer was dried over MgS04 and the solvent removed under 
205 
reduced pressure. The crude product was purified by column chromatography using silica gel 
as absorbent with light petroleum/EtOAc (5:1) as eluent to yield 2-bromo-3-[(2-
chloroquinolin-3-yl)methyl]-3H-quinazolin-4-one as colourless crystals (0.058 g, 0.15 mmol, 
16%); mp 180-181 oc; (Found: MH+, 399.9847. C1sHiz79B~5ClN30 requires 399.9847.); 
Vmax(thin film)/cm·13423, 2093, 1735, 1641, 1561, 1555, 1467, 1407 and 671; OH 5.68 (2 H, s, 
CH2), 7.45 (1 H, ddd, JS.l, 7.0, 1.2, ArH), 7.54-7.50 (2 H, m, ArH), 7.68-7.61 (3 H, m, ArH), 
7.78 (1 H, ddd, J 8.3, 6.8, 1.1, ArH), 7.97 (1 H, d, J 8.5, ArH) and 8.24 (1 H, dd, J 8.0, 1.5, 
4'-H); Be 49.37 (CHz), 120.23 (ArC), 127.02 (ArC), 127.05 (ArC), 127.15 (ArH), 127.44 
(ArH), 127.48 (ArH), 127.70 (4'-C), 128.15 (ArH), 128.31 (ArH), 130.64 (ArH), 134.59 
(ArH), 135.56 (ArH), 135.57 (ArC), 146.97 (ArC), 147.26 (ArC), 148.62 (ArC) and 161.39 
(4-C); m/z(Electrospray) 405 (M+, 7%), 404 (22), 402 (98), 400 (81), 364 (50), 316 (24), 286 
(25), 178 (29), 176 (84), 140 (1 00), 89 (34), 83 ( 48), 51 (52) and 49 (76). 
3-AIIyl-2-bromo-3H-quinazolin-4-one 
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Potassium t-butoxide (0.12 g, 3.0 mmol) was added to a stirred solution of 2-bromo-3H-
quinazolin-4-one (0.35 g, 2.0 mmol) in DMF (20 cm3) and stirred for 1 h. Allyl bromide (0.34 
cm3, 4.0 mmol) was added and stirred for 12 h. The crude reaction mixture was extracted into 
EtOAc and washed with HzO (5 x 50 cm3) and brine (50 cm3). The organic layer was dried 
over MgS04 and the solvent removed under reduced pressure. The crude product was purified 
by column chromatography using silica gel as absorbent with light petroleum/EtOAc as eluent 
(5:1) yielding 3-allyl-2-bromo-3H-quinazolin-4-one as colourless crystals (0.17 g, 0.65 mmol, 
33%); mp 106-107 ·c; (Found: MH+, 264.9974 CuH1079BrNzO requires 264.9971.); Vmax{thin 
film)/cm·1 3447, 1687, 1583, 1470, 1332, 1154, 1121, 592, 810, 768, 691, 577 and 523; oH 
4.94-4.92 (2 H, m, NCHz), 5.33-5.27 (2 H, m, CHz), 6.02-5.92 (1 H, m, CH), 7.49 (1 H, ddd, 
J 8.6, 8.4, 2.0, 6-H), 7.62 (1 H, dd, J 8.6, 1.6, 8-H), 7.74 (1 H, ddd, J 8.6, 8.4, 1.6, 7-H) and 
8.22 (1 H, dd, J 8.6, 1.6, 5-H); Be 50.74 (NCHz), 118.82 (CH2), 120.45 (4a-C), 126.76 (8-C), 
127.32 (5-C), 127.58 (6-C), 130.69 (CH), 134.94 (7-C), 135.88 (Sa-C), 147.11 (2-C) and 
161.01 (4-C); m/z(Electrospray) 266 (M+, 16%), 264 (15), 249 (20), 185 (100), 129 (52), 102 
(23), 90 (35) and 40 (53). 
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2-(Phenylethylsulfanyi)-3H-quinazolin-4-one 
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Sodium hydride (0.35 g, 8.8 mmol) was added to a stirred solution of 2-mercapto-3H-
quinazolin-4-one (0.71g 4.0 mmol) in DMF (20 cm3) and stirred for 1 hat rt. 2-Bromoethyl 
benzene (0.58 cm3, 4.2 mmol) in DMF (10 cm3) was added to the reaction over 1 h. The 
reaction was stirred for a further 12 h. The crude reaction mixture was extracted into EtOAc 
and washed with H20 (5 x 50 cm3) and brine (50 cm3). The organic layer was dried over 
MgS04 and the solvent removed under reduced pressure. The crude product was purified by 
column chromatography using silica gel as absorbent with light petroleum!EtOAc (2: 1) as 
eluent yielding 2-(phenylethylsulfanyi)-3H-quinazolin-4-one as colourless crystals (0.84 g, 
2.99 mmol, 75%); mp 121-122 oc; (Found: MH+, 283.0898. C16HisNzOS requires 283.0900.); 
Vmax(thin film)/cm·1 3417, 1732, 1698, 1666, 1581, 1556, 1446, 1398, 1247, 958, 872, 765, 
722, 687, 620 and 558; oH 3.11 (2 H, t, J7.8, CHz), 3.54 (2 H, t, J7.8, SCHz), 7.27-7.21 (1 H, 
m, ArH), 7.35- 7.31 (4 H, m, ArH), 7.43 (1 H, ddd, J 8.1, 6.7, 0.3, 6-H), 7.58 (1 H, dd, J 8.5, 
0.3, 8-H), 7.78 (1 H, ddd, J 8.5, 6.7, 1.5, 7-H), 8.05 (1 H, dd, J 8.1, 1.5, 5-H) and 12.55 (1H, 
brs, NH); 8c 31.01 (SCHz), 34.81 (PhCHz), 119.98 (4a-C), 125.56 (6-C), 126.00 (8-C and 
ArC), 126.36 (5-C and ArH), 128.40 (2 x ArH), 128.59 (2 x ArH), 134.57 (7-C), 140.02 (Sa-
C), 157.31 (2-C) and 161.24 (4-C); m/z(Eiectrospray) 283 (M+, 36%), 179 (20), 164 (23), 147 
(100) and 52 (26). 
3-Methyl-2-methylsulfanyi-3H-quinazolin-4-one 
449 
Sodium hydride (0.60 g, 15.0 mmol) was added to a solution of2-mercapto-3H-quinazolin-4-
one (1.06 g 6.0 mmol) in DMF (20 cm3) and stirred for 1 hat 80 °C. Methyl iodide (0.93 cm3, 
207 
15.0 mmol) was added to the reaction mixture and stirred for a further 12 h. The crude 
reaction was extracted into EtOAc and washed with H20 (5 x 50 cm3) and brine (50 cm3). The 
organic layer was dried over MgS04 and the solvent removed under reduced pressure. The 
crude product was purified by column chromatography using silica gel as absorbent with light 
petroleum!EtOAc as eluent (5:1) yielding 3-methyl-2-methylsulfanyl-3H-quinazolin-4-one as 
colourless crystals (0.63 g, 3.0 mmol, 50%); mp 208 oc (lit. 169 210 °C}; 8H2.57 (3 H, s, SMe), 
3.50 (3H, s, NMe), 7.28 (1 H, ddd, J 8.8 7.0 0.8, 6-H), 7.44 (1 H, dd, J 8.8 0.8 8-H), 7.59 (1 
H, ddd, J 8.8 7.0 1.2, 7-H) and 8.14 (1 H, dd, J 8.8 1.2, 5-H); Oc 14.93 (SMe), 30.03 (NMe), 
118.86 (4a-C), 125.03 (8-C), 127.57 (6-C), 126.73 (5-C), 133.96 (7-C), 147.30 (8a-C) and 
161.56 (4-C). 
The data were consistent to the literature. 169 
3-(2-Hydroxyethyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one170 
0 
6 (5 4a ~OH I 4 N 
7 ~ 8 N~S 
8 aH 
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The reaction between 2-(methoxycarbonyl)-phenyl isothiocyanate (0.62 cm3, 4.0 mmol) and 
2-hydroxyethylamine (0.24 cm3, 4.0 mmol) was heated under reflux in 2-propanol (20 cm3) 
for 2 h. The reaction mixture was cooled and the precipitate triturated with cold water and 
dried yielding 3-(2-hydroxyethyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one as colourless 
crystals (820 mg, 3.97 mmol, 99%); mp 237-239 °C (lit. 170 240 °C}; Vmax(thin film)/cm·1 3403, 
3002, 1690, 1653, 1546, 1529, 1439, 1132, 998, 775 and 694; oH (CD3)2SO 3.65 (2 H, t, J 6.6, 
OCH2), 4.48 (2 H, t, J 6.6, NCH2), 7.33-7.27 (2 H, m, ArH), 7.69 (1 H, ddd, J 8.8, 6.8, 1.2, 7-
H) and 7.90 (1 H, dd, J 8.8, 1.2, 5-H); 8c(CD3)2SO 47.06 (NCH2), 56.81 (OCH2), 115.39 (4a-
C), 115.41 (6-C), 124.41 (8-C), 127.21 (5-C), 135.31 (7-C), 138.88 (8a-C), 159.42 (4-C) and 
175.18 (2-C). 
The data were consistent with the literature. 170 
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3-(2-Phenylethyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one171 
0 ~ 6~N~ 7U~~s 
8 H 2 
456 
The reaction between 2-(methoxycarbonyl)-phenyl isothiocyanate (0.31 cm3, 2.0 mmol) and 
2-phenylethylamine (0.25 cm\ 2.0 mmol) was heated under reflux in 2-propanol (10 cm3) for 
2 h. The reaction mixture was cooled and the precipitate collected by filtration and 
recrystallised with hot propanol yielding 3-(2-phenylethyl)-2-thioxo-2,3-dihydro-1H-
quinazolin-4-one as colourless crystals (520 mg, 1.83 mmol, 92%); mp 237-238 °C (lit. 171 
239-240 °C}; (Found: MH+, 283.0897. C16H15N20S requires 283.0900.); Vmax(thin film)/cm·1 
3422, 2999, 1698, 1643, 1540, 1502, 1440, 1099, 996, 745 and 684; oH 3.10 (2 H, t, 1 7.6, 
CH2), 4.74 (2 H, t, 17.6, NCH2), 7.17 (1 H, d, 18.2, 8-H), 7.28-7.23 (2 H, m, ArH), 7.37-7.32 
(2 H, m, ArH), 7.43-7.40 (2 H, m, ArH), 7.68 (1 H, ddd, 18.2, 6.4, 1.2, 7-H), 8.17 (1 H, dd, 1 
8.0, 1.2, 5-H) and 10.33 (1 H, brs, NH); oc 32.82 (CH2), 48.37 (NCH2), 114.51 (8-C), 116.15 
(ArC), 125.10 (ArH), 126.61 (ArH), 128.57 (2 x ArH and 5-C), 129.05 (2 x ArH), 135.53 (7-
C), 138.33 (ArC), 138.35 (ArC), 159.46 (2-C) and 175.67 (4-C); m/z(Electrospray) 282 (M+, 
21%), 178 (38), 162 (18), 104 (100), 91 (38), 77 (35), 65 (34), 63 (21) and 51 (26). 
The structure was confirmed by X-ray crystallography (see appendix). 
The data were consistent to the literature. 171 
3-(2-Ph enylethyl)-lH-q uinazolin e-2,4-dion e172 
0 ~ 6~N~ 7lJlN~o 
8 H 
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A solution of 3-(2-phenylethyl)-2-thioxo-2,3-dihydro-18-quinazolin-4-one (200 mg, 0.71 
mmol) and bromine (0.04 cm3, 0.85 mmol) in MeOH (20 cm3) were stirred for 1 h. The 
precipitate was collected by triturated with cold EtOAc yielding and dried yielding 3-(2-
phenylethyl)-18-quinazoline-2,4-dione as colourless crystals (160 mg, 0.61 mmol, 87%); mp 
177-178 oc (lit. 172 179-180 °C); (Found: MH+, 267.1131. C16H1sN202 requires 267.1128.); 
209 
Vmax(thin film)/cm·1 3417, 1697, 1632, 1556, 1503, 1366, 1172, 1061, 889 and 789; oH 
(CD3)zSO 3.03 (2 H, t, J 8.0, CHz), 4.33 (2 H, t, J 8.0, NCHz), 7.13 (1 H, dd, J 8.0, 0.4, 8-H), 
7.37-7.24 (6 H, m, ArH), 7.64 (1 H, ddd, J 8.0, 7.2, 1.2, 7-H), 8.15 (1 H, dd, J 8.0, 1.2, 5-H) 
and 10.42 (1 H, brs, NH); oc (CD3)zSO 34.06 (CHz), 42.34 (NCHz), 114.64 (ArC), 115.10 
(ArH), 123.48 (ArH), 126.55 (ArH), 128.88 (ArH), 128.95 (2 x ArH), 128.98 (2 x ArH), 
135.08 (ArH), 138.55 (ArC), 138.58 (ArC), 152.03 (4-C) and 162.27 (2-C); m/z(Electrospray) 
266 (M+, 26%), 162 (20), 145 (23), 103 (100) and 91 (24). 
The data were consistent to the literature. 172 
Di-[3-(2-phenylethyl)quinazolin-4-on-2-yl] disulfide 
(~X::i 
2 
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3-(2-Phenylethyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one (0.56 mg, 2.0 mmol) and 
bromine (0.20 cm3, 4.0 mmol) were stirred in anhydrous MeOH (20 cm3) for 4 h. The white 
precipitate was collected and triturated with MeOH and dried yielding di-[3-(2-
phenylethyl)quinazolin-4-on-2-yl] disulfide as colourless crystals (330 mg, 0.59 mmol, 59%); 
mp 223-225 ·c; (Found: MH+, 563.1566. c32H27N402S2 requires 563.1570.); Vmax(thin 
film)/cm·1 3607, 2354, 1672, 1555, 1469, 1336, 1130, 768 and 690; oH 3.13 (4 H, t, J 8.2, 
CHz), 4.59 (4 H, t, J 8.2, NCHz}, 7.28-7.48 (14 H, m, ArH}, 7.66-7.61 (2 H, m, ArH) and 
8.23-8.20 (2 H, m, ArH); oc34.90 (2 x CHz}, 46.85 (2 x NCHz}, 119.80 (2 x ArC), 126.69 (2 
x ArH}, 126.81 (2 x ArH), 127.05 (2 x ArH}, 127.11 (2 x ArH), 128.91 (4 x ArH}, 129.10 (4 
x ArH}, 134.63 (2 x ArH), 137.47 (2 x ArC}, 147.10 (2 x ArC}, 152.69 (2 x ArC) and 161.50 
(2 x ArC); m/z(Electrospray) 563 (M+, 5%}, 529 (100), 497 (27}, 401 (17) and 321 (20). 
N-Phenylselanylphthalimide173 
0 a=?-Se Ph 
0 
Potassium phthalimide (3.87 g, 21.0 mmol) and phenylselanyl chloride (4.80 g, 25.1 mmol) 
were placed in a three necked flask (250 cm3). The flask was connected to a vacuum line and 
210 
after several evacuations and purges with nitrogen, dry hexane (50 cm3) was added. The 
reaction mixture was stirred at rt for 2 h. DCM was added and the solid removed by filtration. 
The solution was concentrated on a rotary evaporator to 20 cm3 and was diluted with hexane 
(80 cm3). The resulting precipitate was collected by filtration yielding N-
phenylselanylphthalimide as yellow crystals (6.34 g, 21.0 mmol, 83%); mp 172-174 oc (lit.173 
171-175 °C); Vmax(thin film)/cm·1 3419, 1720, 1643, 1282 and 711; 8H 7.57-7.85 (9 H, m, 
ArH); 8c 122.91 (ArH), 125.78 (2 x ArH), 128.96 (2 x ArH), 131.58 (2 x ArH), 132.57 
(ArC), 132.79 (ArC), 134.30 (2 x ArH), 148.85 (ArC), 168.66 (ArC) and 169.22 (ArC). 
The data were consistent to the literature.173 
Tributylgermanium hydride174 
Tetrachlorogermanium (4.38 g, 20.8 mmol) and butylmagnesium chloride (2 M solution in 
diethyl ether, 50 cm3) were successively added dropwise to a solution ofCp2TiCb (0.38 g, 1.5 
mmol) in freshly distilled diethyl ether (100 cm3) at -78 °C over 45 min. The reaction mixture 
was warmed to room temperature over 45 min and refluxed for 15 h. After cooling to 0 °C the 
aqueous phase was extracted with EhO. The combined organic layer was dried over MgS04 
and the solvent removed under reduced pressure. The crude product was distilled under 
reduced pressure and temperature yielding tributylgermanium hydride as a colourless oil ( 1.89 
g, 7.75 mmol, 37%); Vmax(thin film)/cm·1 2955, 2925, 2857, 2005, 1463, 1457, 1375, 1339, 
1172, 1082, 962, 882, 773, 724, 696 and 557; 8H 0.56-0.69 (15 H, m, BuH), 1.10-1.20 (12 H, 
m, BuH) and 3.46 (1 H, sep, J 3.0, GeH); 8c 11.66 (3-C), 13.76 (4-C), 26.15 (2-C) and 28.53 
(1-C). 
The data were consistent to the literature.174 
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Appendix A. X-ray crystallography 
Structure determination by single X-ray crystallography of 11-hydroxy-11H-
isoquinolino[3,2-b]quinazolin-6,13-dione 345. The compound was placed in a small 
sample vial and dissolved in a minimal amount of CDCb. The small sample vial was 
sealed. Crystals developed upon storage at room temperature for 24 h, and were 
submitted in the mother liquor. 
Table 1. Crystal data and structure refmement for 345. 
Identification code 
Chemical formula 
Formula weight 
Temperature 
Radiation, wavelength 
Crystal system, space group 
Unit cell parameters 
Cell volume 
z 
Calculated density 
Absorption coefficient J..l 
F(OOO) 
Crystal colour and size 
Reflections for cell refinement 
Data collection method 
goniostat 
e range for data collection 
Index ranges 
Completeness to 8 = 27.54° 
Intensity decay 
Reflections collected 
345 
C11Hu Cl3N203 
397.63 
120(2) K 
MoKa, 0. 71073 A 
triclinic, P 1 
a= 6.6511(3) A 
b = 8.6274(3) A 
c = 14.5395(7) A 
819.97(6) A3 
2 
1.610 g/cm3 
0.579 mm-1 
404 
a= 90.123(2)0 
~ = 94.525(3)0 
y = 99.594(3)0 
pale yellow, 0.55 x 0.17 x 0.09 mm3 
3181 (8 range 1.0 to 27 .48°) 
Bruker-Nonius 95mm CCD camera on K-
~ & ro scans 
3.12 to 27.54° 
h -8 to 8, k -11 to 11, 1 -18 to 18 
98.4% 
0% 
11250 
212 
Independent reflections 
Reflections with F2>2cr 
Absorption correction 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data I restraints I parameters 
Final R indices [F2>2cr] 
R indices (all data) 
Goodness-of-fit on F2 
Extinction coefficient 
Largest and mean shiftlsu 
Largest diff. peak and hole 
3715 (Rint = 0.0370) 
2898 
none 
direct methods 
Full-matrix least-squares on F2 
0.0492, 0.1456 
3715101230 
R1 = 0.0353, wR2 = 0.0851 
R1 = 0.0550, wR2 = 0.0939 
1.028 
0.0071(18) 
0.000 and 0.000 
0.353 and -0.328 eA -J 
Table 2. Atomic coordinates and equivalent isotropic displacement parameters 
(A2) for 345. Ueq is defined as one third of the trace of the orthogonalized Uij 
tensor. 
X y z Ueq 
N(1) 0.14244(19) 0.63569(15) 0.92173(9) 0.0146(3) 
C(1) -0.0378(2) 0.66563(18) 0.87709(11) 0.0158(3) 
N(2) -0.1702(2) 0.73348(15) 0.91529(9) 0.0166(3) 
C(2) -0.1214(2) 0. 79209(18) 1.00469(11) 0.0167(3) 
C(3) -0.2519(2) 0.88209(19) 1.04353(12) 0.0196(4) 
C(4) -0.2003(3) 0.94848(19) 1.13003(12) 0.0222(4) 
C(5) -0.0183(3) 0.92780(19) 1.18015(12) 0.0213(4) 
C(6) 0.1089(2) 0.83740(19) 1.14387(11) 0.0192(4) 
C(7) 0.0580(2) 0.76842(18) 1.05619(11) 0.0158(3) 
C(8) 0.1965(2) 0.67843(18) 1.01500(11) 0.0157(3) 
0(1) 0.35078(17) 0.64334(14) 1.05530(8) 0.0212(3) 
C(9) 0.3060(2) 0.58892(19) 0.86974(11) 0.0159(3) 
0(2) 0.42678(17) 0.72966(13) 0.84351(8) 0.0176(3) 
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C(10) 0.2222(2) 0.49033(18) 0. 78584(11) 0.0165(3) 
C(ll) 0.3409(3) 0.39065(19) 0.74902(11) 0.0197(4) 
C(12) 0.2740(3) 0.3093(2) 0.66742(12) 0.0243(4) 
C(13) 0.0874(3) 0.3263(2) 0.62048(12) 0.0266(4) 
C(14) -0.0312(3) 0.4249(2) 0.65622(12) 0.0238(4) 
C(15) 0.0355(2) 0.50622(19) 0.73902(11) 0.0174(3) 
C(16) -0.0910(2) 0.61045(19) 0.77812(11) 0.0186(3) 
0(3) -0.23696(18) 0.65190(16) 0.73531(8) 0.0282(3) 
C(17) 0.4419(3) 0.8143(2) 0.62829(12) 0.0232(4) 
Cl(1) 0.46117(8) 0.68003(6) 0.53965(3) 0.03290(14) 
Cl(2) 0.62940(7) 0.98375(6) 0.62257(4) 0.03665(15) 
Cl(3) 0.19517(7) 0.86669(6) 0.62000(3) 0.03135(14) 
Table 3. Bond lengths [A] and angles [0 ] for 345. 
N(1}-C(1) 1.3805(19) N(1}-C(8) 1.408(2) 
N(1}-C(9) 1.481(2) C(1}-N(2) 1.294(2) 
C(1}-C(16) 1.511(2) N(2}-C(2) 1.388(2) 
C(2}-C(7) 1.402(2) C(2}-C(3) 1.405(2) 
C(3}-C(4) 1.375(2) C(4}-C(5) 1.401(2) 
C(5}-C(6) 1.375(2) C(6}-C(7) 1.398(2) 
C(7}-C(8) 1.461(2) C(8}-0(1) 1.2237(18) 
C(9}-0(2) 1.4109(19) C(9}-C(10) 1.501(2) 
C(10}-C(11) 1.393(2) C(10}-C(15) 1.396(2) 
C(11}-C(12) 1.381(2) C(12}-C(13) 1.398(2) 
C(13}-C(14) 1.379(3) C(14}-C(15) 1.395(2) 
C(15}-C(16) 1.471(2) C(16}-0(3) 1.2161(19) 
C(17}-Cl(1) 1.7573(17) C(17}-Cl(2) 1.7629(18) 
C(17}-Cl(3) 1.7690(17) 
C(1}-N(1}-C(8) 121.36(13) C(1}-N(1}-C(9) 121.27(13) 
C(8)-N(1}-C(9) 116.16(12) N(2}-C(1 }-N(l) 124.41(15) 
N(2}-C(1 }-C(16) 116.85(13) N(1 }-C(1 }-C(16) 118.69(14) 
214 
C(1 )-N(2)-C(2) 118.17(13) N(2)-C(2)-C(7) 
N(2)-C(2)-C(3) 119.06(14) C(7)-C(2)-C(3) 
C(4)-C(3)-C(2) 119.91(15) C(3)-C( 4)-C(5) 
C( 6)-C( 5)-C( 4) 120.03(16) C( 5)-C( 6)-C(7) 
C(6)-C(7)-C(2) 120.31(14) C( 6)-C(7)-C(8) 
C(2)-C(7)-C(8) 119.15(14) O(l)-C(8)-N(1) 
0(1)-C(8)-C(7) 124.61(15) N(1 )-C(8)-C(7) 
0(2)-C(9)-N(1) 106.36(12) 0(2)-C(9)-C(1 0) 
N(1 )-C(9)-C(1 0) 112.35(12) C(11)-C(10)-C(15) 
C(11)-C(10)-C(9) 119.39(14) C(15)-C(10)-C(9) 
C(12)-C(11)-C(10) 120.23(16) C(11)-C(12)-C(13) 
C(14)-C(13)-C(12) 119.65(16) C(13 )-C(14 )-C(15) 
C(14)-C(15)-C(l 0) 120.77(15) C( 14)-C(15)-C(16) 
C(1 O)-C(15)-C(16) 119.07(14) 0(3 )-C( 16)-C(15) 
0(3)-C(16)-C(l) 118.83(14) C(15)-C(16)-C(l) 
Cl(1)-C(17)-Cl(2) 110.52(10) Cl(1)-C(17)-Cl(3) 
Cl(2)-C(17)-Cl(3) 110.03(9) 
Table 4. Hydrogen coordinates and isotropic displacement parameters (.A?) for 
345. 
X y z u 
H(3) -0.3755 0.8971 1.0101 0.024 
H(4) -0.2890 1.0090 1.1561 0.027 
H(5) 0.0174 0.9763 1.2392 0.026 
H(6) 0.2311 0.8218 1.1783 0.023 
H(9) 0.3919 0.5290 0.9111 0.019 
H(2) 0.539(3) 0.723(2) 0.8595(14) 0.026 
H(ll) 0.4683 0.3786 0.7801 0.024 
H(12) 0.3555 0.2411 0.6430 0.029 
H(13) 0.0426 0.2703 0.5643 0.032 
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121.82(14) 
119.08(15) 
120.73(15) 
119.91(15) 
120.45(14) 
120.76(14) 
114.61(13) 
110.04(13) 
118.94(15) 
121.42(14) 
120.62(16) 
119.78(16) 
120.15(14) 
123.32(15) 
117.84(13) 
110.12(9) 
H(14) 
H(17) 
-0.1578 
0.4644 
0.4374 
0.7632 
Table 5. Torsion angles [0 ] for 345. 
C(8)-N(1 )-C(1 )-N(2) -0.1(2) 
C(8)-N(1 )-C(1 )-C(16) -177 .39(13) 
N(1 )-C(1 )-N(2)-C(2) 5.6(2) 
C(1 )-N(2)-C(2)-C(7) -5.2(2) 
N(2)-C(2)-C(3)-C( 4) -176.39(15) 
C(2)-C(3)-C(4)-C(5) 0.1(3) 
C( 4 )-C( 5)-C( 6)-C(7) 1.1(3) 
C( 5)-C( 6)-C(7)-C(8) 177.03(15) 
C(3)-C(2)-C(7)-C( 6) -1.9(2) 
C(3)-C(2)-C(7)-C(8) -178.38(14) 
C(9)-N(1 )-C(8)-0(1) -16.6(2) 
C(9)-N(l )-C(8)-C(7) 161.98(13) 
C(2)-C(7)-C(8)-0(1) -175.76(15) 
C(2)-C(7)-C(8)-N ( 1) 5.7(2) 
C(8)-N(l )-C(9)-0(2) -81.07(15) 
C(8)-N(1 )-C(9)-C(l 0) 158.48(13) 
N(1)-C(9)-C(10)-C(11) -156.63(14) 
N(1)-C(9)-C(10)-C(15) 29.1(2) 
C(9)-C(10)-C(11)-C(12) -174.41(15) 
C(11)-C(12)-C(13)-C(14) -0.2(3) 
C(13)-C(14)-C(15)-C(1 0) 0.7(3) 
C(11)-C(10)-C(15)-C(14) -0.6(2) 
C(11)-C(10)-C(15)-C(16) 179.52(15) 
C(14)-C(15)-C(16)-0(3) -12.7(3) 
C( 14 )-C( 15)-C( 16)-C( 1) 166.13(15) 
N(2)-C(1 )-C(16)-0(3) 10.8(2) 
N(2)-C(1 )-C(16)-C(15) -168.14(14) 
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0.6246 
0.6891 
0.029 
0.028 
C(9)-N(1 )-C(1 )-N(2) 
C(9)-N(1 )-C(1 )-C(16) 
C(16)-C(1 )-N(2)-C(2) 
C(1 )-N(2)-C(2)-C(3) 
C(7)-C(2)-C(3)-C( 4) 
C(3 )-C( 4 )-C( 5)-C( 6) 
C( 5)-C( 6)-C(7)-C(2) 
N(2)-C(2)-C(7)-C(6) 
N(2)-C(2)-C(7)-C(8) 
C(1 )-N(1 )-C(8)-0(1) 
C(1 )-N(1 )-C(8)-C(7) 
C( 6)-C(7)-C(8)-0( 1) 
C(6)-C(7)-C(8)-N(l) 
C(1 )-N(1 )-C(9)-0(2) 
C(1 )-N(1 )-C(9)-C(1 0) 
0(2)-C(9)-C(1 O)-C(11) 
0(2)-C(9)-C(1 O)-C(15) 
C(15)-C(10)-C(11)-C(12) 
C(10)-C(11)-C(12)-C(13) 
C(12)-C(13)-C(14)-C(15) 
C( 13 )-C( 14 )-C( 15)-C( 16) 
C(9)-C(l O)-C(15)-C(14) 
C(9)-C(1 O)-C(15)-C(16) 
C(l O)-C(15)-C( 16)-0(3) 
C(1 O)-C(15)-C(16)-C(1) 
N(1 )-C(1 )-C(16)-0(3) 
N(1 )-C(1 )-C(16)-C(15) 
-166.96(15) 
15.7(2) 
-177.00(13) 
172.63(15) 
1.5(2) 
-1.5(3) 
0.5(2) 
175.98(14) 
-0.6(2) 
175.81(15) 
-5.6(2) 
7.7(3) 
-170.85(14) 
86.48(16) 
-34.0(2) 
85.06(17) 
-89.25(18) 
0.0(2) 
0.4(3) 
-0.3(3) 
-179.40(16) 
173.78(15) 
-6.1(2) 
167.21(16) 
-13.9(2) 
-171.71(15) 
9.4(2) 
Table 6. Hydrogen bonds for 345 [A and 0 ]. 
D-H ... A 
0(2)-H(2) ... N(2') 
0(2)-H(2) ... 0(3 ') 
d(D-H) 
0.78(2) 
0.78(2) 
Symmetry operations for equivalent atoms 
' x+1,y,z 
d(H ... A) 
2.02(2) 
2.57(2) 
d(D ... A) <(DHA) 
2.7935(17) 171(2) 
2.9963(17) 116. 7(17) 
Structure determination by single X-ray crystallography of 3-(2-phenylethyl)-2-
thioxo-2,3-dihydro-1H-quinazolin-4-one 457. The compound was placed in a small 
sample vial and dissolved in a minimal amount of hot propanol. The small sample vial 
was sealed. Crystals developed upon storage at room temperature for 24 h, and were 
submitted in the mother liquor. 
Table 1. Crystal data and structure reimement for 457. 
Identification code 
Chemical formula 
Formula weight 
Temperature 
Radiation, wavelength 
Crystal system, space group 
Unit cell parameters 
Cell volume 
z 
Calculated density 
Absorption coefficient J..1 
F(OOO) 
Crystal colour and size 
wrb9 
C16H14N20S 
282.35 
150(2) K 
MoKa., 0.71073 A 
monoclinic, Cc 
a = 4.6405(7) A 
b = 25.329(4) A 
c = 12.1910(17) A 
1422.1(4) A3 
4 
1.319 glcm3 
0.224 mm-1 
592 
a.= 90° 
~ = 97.047(2)0 
y=900 
colourless, 0.56 x 0.16 x 0.02 mm3 
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Reflections for cell refinement 
Data collection method 
diffractometer 
e range for data collection 
Index ranges 
Completeness to 8 = 26.00° 
Intensity decay 
Reflections collected 
Independent reflections 
Reflections with F2>2cr 
Absorption correction 
Min. and max. transmission 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data I restraints I parameters 
Final R indices [F2>2cr] 
R indices (all data) 
Goodness-of-fit on F2 
Absolute structure parameter 
Largest and mean shiftlsu 
Largest dif£ peak and hole 
2505 (8 range 2.33 to 27.77°) 
Broker SMART 1000 CCD 
ro rotation with narrow :frames 
1.61 to 28.73° 
h -6 to 6, k -32 to 32, 1-15 to 16 
99.7% 
0% 
5350 
3005 {Rint = 0.0368) 
2351 
semi-empirical from equivalents 
0.885 and 0.996 
direct methods 
Full-matrix least-squares on F2 
0.1005, 0.0000 
3005121184 
R1 = 0.0602, wR2 = 0.1444 
R1 = 0.0837, wR2 = 0.1590 
1.026 
0.13(13) 
0.000 and 0.000 
0.432 and -0.202 e A -J 
Table 2. Atomic coordinates and equivalent isotropic displacement parameters 
(A2) for 457. Ueq is delmed as one third of the trace of the orthogonalized Uij 
tensor. 
N(1) 
C(1) 
S(1) 
X 
0.5300(6) 
0.4066(7) 
0.1436(2) 
y z Ueq 
0.19362(12) 0.6679(2) 0.0236(7) 
0.21118(14) 0.5651(3) 0.0240(7) 
0.17829(4) 0.48714(9) 0.0331(3) 
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N(2) 0.5072(6) 0.25707(12) 0.5303(2) 0.0260(6) 
C(2) 0.7275(8) 0.28714(14) 0.5880(3) 0.0238(7) 
C(3) 0.8156(9) 0.33469(15) 0.5442(3) 0.0329(9) 
C(4) 1.0351(9) 0.36289(16) 0.6036(4) 0.0364(9) 
C(5) 1.1700(9) 0.34463(16) 0.7053(3) 0.0353(9) 
C(6) 1.0816(8) 0.29799(15) 0.7483(3) 0.0284(8) 
C(7) 0.8576(8) 0.26890(13) 0.6899(3) 0.0236(7) 
C(8) 0.7576(8) 0.21945(14) 0.7327(3) 0.0242(7) 
0(1) 0.8619(6) 0.19952( 10) 0.8208(2) 0.0320(6) 
C(9) 0.4292(8) 0.14396(14) 0.7137(3) 0.0275(8) 
C(lO) 0.6053(9) 0.09659(15) 0.6836(4) 0.0353(9) 
C(11) 0.5129(9) 0.04717(15) 0.7388(3) 0.0343(9) 
C(12) 0.2967(11) 0.01529(17) 0.6871(5) 0.0504(12) 
C(13) 0.2124(16) -0.0295(2) 0.7395(6) 0.0722(18) 
C(14) 0.3406(16) -0.0432(2) 0.8437(7) 0.075(2) 
C(15) 0.5500(16) -0.0116(3) 0.8949(6) 0.079(2) 
C(16) 0.6382(13) 0.0335(2) 0.8429(5) 0.0619(14) 
Table 3. Bond lengths [A] and angles [0 ] for 457. 
N(1)-C(1) 1.386(4) N(1)-C(8) 1.400(4) 
N(1)-C(9) 1.475(4) C(1)-N(2) 1.341(5) 
C(1)-S(1) 1.674(4) N(2)-C(2) 1.394(4) 
C(2)-C(7) 1.392(5) C(2)-C(3) 1.398(5) 
C(3)-C(4) 1.375(6) C(4)-C(5) 1.398(6) 
C(5)-C(6) 1.375(6) C(6)-C(7) 1.396(5) 
C(7)-C(8) 1.455(5) C(8)-0(1) 1.231(4) 
C(9)-C(10) 1.521(5) C(10)-C(11) 1.508(5) 
C(11)-C(16) 1.373(7) C(11)-C(12) 1.379(6) 
C(12)-C(13) 1.382(7) C(13)-C(14) 1.379(10) 
C(14)-C(15) 1.351(11) C(15)-C(16) 1.393(8) 
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C(1)-N(1)-C(8) 124.0(3) C(l)-N(1)-C(9) 120.0(3) 
C(8)-N(1)-C(9) 116.0(3) N(2)-C(1 )-N(1) 116.3(3) 
N(2)-C(1 )-S(1) 120.6(3) N(1 )-C(1 )-S(1) 123.1(3) 
C(1 )-N(2)-C(2) 125.2(3) C(7)-C(2)-N(2) 118.6(3) 
C(7)-C(2)-C(3) 120.8(3) N(2)-C(2)-C(3) 120.6(3) 
C( 4)-C(3)-C(2) 118.6(4) C(3 )-C( 4 )-C( 5) 121.2(4) 
C( 6)-C( 5)-C( 4) 120.0(4) C( 5)-C( 6)-C(7) 119.8(3) 
C(2)-C(7)-C( 6) 119.6(3) C(2)-C(7)-C(8) 118.9(3) 
C( 6)-C(7)-C(8) 121.4(3) 0(1 )-C(8)-N ( 1) 119.2(3) 
0( 1 )-C(8)-C(7) 123.9(3) N(1 )-C(8)-C(7) 116.9(3) 
N(1)-C(9)-C(10) 112.1(3) C(11 )-C(l O)-C(9) 110.9(3) 
C(16)-C(11)-C(12) 118.5(4) C(16)-C(11 )-C(l 0) 120.7(4) 
C(12)-C(11)-C(10) 120.8(4) C(11)-C(12)-C(13) 120.1(5) 
C(14)-C(13)-C(12) 121.2(6) C(15)-C(14)-C(13) 118.7(5) 
C(14)-C(15)-C(16) 120.7(6) C(11)-C(16)-C(15) 120.8(6) 
Table 4. Hydrogen coordinates and isotropic displacement parameters (A 2) for 
457. 
X y z u 
H(2) 0.429(9) 0.2667(16) 0.467(4) 0.031 
H(3) 0.7257 0.3472 0.4749 0.039 
H(4) 1.0961 0.3954 0.5750 0.044 
H(5) 1.3229 0.3644 0.7448 0.042 
H(6) 1.1726 0.2856 0.8176 0.034 
H(9A) 0.2224 0.1383 0.6852 0.033 
H(9B) 0.4439 0.1469 0.7951 0.033 
H(10A) 0.5779 0.0917 0.6024 0.042 
H(10B) 0.8140 0.1032 0.7070 0.042 
H(12) 0.2055 0.0241 0.6154 0.061 
H(13) 0.0636 -0.0513 0.7031 0.087 
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H(14) 
H(15) 
H(16) 
0.2828 
0.6379 
0.7869 
-0.0743 
-0.0202 
0.0551 
Table 5. Torsion angles [0 ] for 457. 
C(8)-N(1 )-C(1 )-N(2) -3.2(5) 
C(8)-N(1 )-C(l )-S(1) 177.5(3) 
N(1)-C(1)-N(2)-C(2) 1.6(5) 
C(l )-N(2)-C(2)-C(7) 0.2(5) 
C(7)-C(2)-C(3)-C( 4) 0.5(6) 
C(2)-C(3)-C(4)-C(5) 0.4(6) 
C( 4 )-C( 5)-C( 6)-C(7) 0.2(6) 
C(3)-C(2)-C(7)-C(6) -1.0(5) 
C(3)-C(2)-C(7)-C(8) 179.5(3) 
C(5)-C(6)-C(7)-C(8) -179.9(3) 
C(9)-N ( 1 )-C(8)-0( 1) 1.2(5) 
C(9)-N ( 1 )-C(8)-C(7) -179.1(3) 
C( 6)-C(7)-C(8)-0( 1) -0.9(6) 
C( 6)-C(7)-C(8)-N ( 1) 179.5(3) 
C(8)-N(1 )-C(9)-C(1 0) -86.5(4) 
C(9)-C(1 O)-C(11 )-C(16) -88.1(5) 
C(16)-C(11)-C(12)-C(13) -0.6(7) 
C(11)-C(12)-C(13)-C(14) 0.2(9) 
C( 13 )-C( 14)-C( 15)-C( 16) -1.0(10) 
C(1 O)-C(11 )-C(16)-C(15) 178.9(5) 
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0.8788 
0.9672 
0.8798 
0.090 
0.095 
0.074 
C(9)-N(l )-C(1 )-N(2) 
C(9)-N(1)-C(1)-S(1) . 
S(1)-C(1)-N(2)-C(2) 
C(1)-N(2)-C(2)-C(3) 
N(2)-C(2)-C(3)-C(4) 
C(3 )-C( 4 )-C( 5)-C( 6) 
N(2)-C(2)-C(7)-C(6) 
N(2)-C(2)-C(7)-C(8) 
C( 5)-C( 6)-C(7)-C(2) 
C(l )-N(1 )-C(8)-0(l) 
C( 1 )-N (1 )-C(8)-C(7) 
C(2)-C(7)-C(8)-0(1) 
C(2)-C(7)-C(8)-N(1) 
C(l )-N(1 )-C(9)-C(1 0) 
N(1)-C(9)-C(10)-C(11) 
C(9)-C(10)-C(11)-C(12) 
C(10)-C(11)-C(12)-C(13) 
C(12)-C(13)-C(14)-C(15) 
C( 12)-C( 11 )-C( 16)-C( 15) 
C( 14 )-C( 15)-C( 16)-C( 11) 
179.0(3) 
-0.4(4) 
-179.1(3) 
-179.8(3) 
-179.6(3) 
-0.8(6) 
179.1(3) 
-0.4(5) 
0.6(5) 
-176.7(3) 
2.9(5) 
178.6(4) 
-1.0(5) 
91.5(4) 
175.5(3) 
90.5(5) 
-179.2(4) 
0.6(10) 
0.3(8) 
0.6(10) 
Table 6. Hydrogen bonds for 457 [A and 0 ]. 
D-H ... A d(D-H) 
N(2)-H(2) ... 0(1 ') 0.85(5) 
Symmetry operations for equivalent atoms 
' x-1/2,-y+l/2,z-1/2 
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d(H ... A) 
1.97(5) 
d(D ... A) <(DHA) 
2.787(4) 162(4) 
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Alkyl, aryl, heteroaryl and acyl radicals have been cyclised onto the 2-position of 3H -quinazolin-4-one. 
The side chains containing the radical precursors were attached to the nitrogen atom in the 3-position. 
The cyclisations take place by aromatic homolytic substitution hence retain the aromaticity of the 
3H-quinazolin-4-one ring. The highest yields were obtained using hexamethylditin to facilitate 
cyclisation rather than reduction without cyclisation. The alkaloids deoxyvasicinone 2, 
mackinazolinone 3, tryptanthrin 4, luotonin A 5 and rutaecarpine 8 were synthesised by radical 
cyclisation onto 3H-quinazolin-4-one. 
The 3H-quinazolin-4-one ring system is important to the bio-
logical activity of both naturally occurring alkaloids, biosynthe-
sised from anthranilic acid, and pharmaceuticals. The alkaloids 
include vasicinone 1 and deoxyvasicinone 2,1 mackinazolinone 3,1 
tryptanthrin 4,3 Iuotonins A 5, B 6 and E 74 and rutaecarpine 
8.5 3H-Quinazolin-4-one alkaloids have been recently reviewed.6 
All the 3H-quinazolin-4-one natural products have interesting 
biological activity and have therefore been extensively investigated 
for useful pharmaceutical activity. The 3H-quinazolin-4-one ring 
is regarded as a 'privileged structure' in combinatorial synthesis. 7 
These are structures which represent molecules that are capable 
of binding at multiple sites with high affinity and facilitate more 
rapid discovery of useful medicinally active compounds. 7 
vasicinone 1, R =OH mackinazolinone 3 tryptanthrin 4 
deoxyvasicinone 2, R = H 
luotonin A. 5, R = H 
luotonin B, 6, R =OH 
luotonin E, 7, R = OMe 
rutaecarpine 8 
Our study involved the development of protocols involving 
radical cyclisation for the synthesis of polycyclic 3H -quinazolin-
3-ones (Scheme 1). The protocols have also been used for the 
synthesis of novel polycyclic quinazolinones including the natural 
Department of Chemistry, Loughborough University, Loughborough, Leics. 
UK LE11 3TU. E-mail: g. w.weaver@lboro.ac.uk; Fax: 44{0) 1509 223925; 
Tel: 44(0) 1509 222584 
t Electronic supplementary information (ESI) available: Preparation and 
analytical details of 3H -quinazolin-4-one radical precursors and products. 
See DOl: 10.1039/b614075k 
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Scheme I General synthetic protocol. 
products deoxyvasicinone 2, mackinazolinone 3, tryptanthrin 4, 
luotonin A 5 and rutaecarpine 8. 
Radical cyclisation onto heteroarenes has been developed in 
recent years to considerable advantage for the synthesis of 
novel polycyclic heteroarenes. Examples of these cyclisations 
include: a. alkyl radicals onto pyrroles,•·• imidazoles, 8 pyrazoles, 10 
indoles,9•11•12 1,2,3-triazoles,u pyridinium salts, 14 and quinolones;" 
b. acyl radicals onto pyrroles,16 quinolines,17 pyridines18 and 
arenes;19 c. aryl radicals onto indoles,10•11 pyrroles,9 pyridones,11 
and 5-amino- and 5-hydroxyuracils/1 2-quinolones,14 quinolines15 
and pyridines.16 
All of the above cyclisations are 'oxidative' i.e. the intermedi-
ate 7t-radicals are not reduced by triorganometal hydrides [e.g. 
tributyltin hydyride (Bu3SnH)] as normally observed for these 
reagents. The cyclisations proceed by aromatic homolytic substi-
tution with abstraction of hydrogen in a rearomatisation process. 
Aromatic homolytic substitution has been recently reviewed17 
and the mechanism of Bu3SnH mediated 'oxidative' cyclisation 
elaborated.18 The pyrimidin-4-one ring of the quinazolin-4-ones 
has some aromaticity and therefore aromatic homolytic substitu-
tion could be predicted, and was observed in our studies, as shown 
in Scheme I (9 to 11 via the 7t-radical 10). However, the lower aro-
maticity could favour reductive cyclisation in which the interme-
diate 7t-radical 10 is intercepted by reagents such as Bu3SnH. Our 
prediction that radical cyclisation onto the quinazolin-4-one ring 
would be 'oxidative' was supported by the 'oxidative' radical cycli-
sation onto related ring systems, e.g. pyrimidine-2,4-diones/1•14 
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quinolinones15 and pyridinones.22.29•30 However, the lower aro-
maticity in the pyrrole ring of indole, facilitates both reductive 
and oxidative cyclisation depending on the conditions. 11•12.31 The 
radical intermediate 10, whether a Tt-radical or not, is still a 
strongly stabilised anilyl radical and therefore the rate of reduction 
by Bu3SnH to yield 12 is probably too low to be competitive with 
loss of hydrogen to yield the 'oxidised' product. The reactions 
could also be regarded as exo-cyclisations onto imines which are 
well known. 
We used two general methodologies to synthesise the radical 
precursors. Firstly, heteroarenes containing an NH group facilitate 
N-alkylation and provide a suitable synthetic route to radical 
precursors for cyclisation. The radical leaving group is introduced 
as part of theN -alkyl substituent. Secondly, there is a wide variety 
of protocols for the synthesis of 3-substituted quinazolinones 
using ring synthesis from anthranilic acid derivatives, which were 
employed as required. 
Aryl radical cyclisation 
Aryl radicals have been successfully cyclised onto pyrroles, indoles 
and pyrazoles.32 Aryl radicals are very reactive and the most 
likely to cyclise onto quinazolinones. Therefore, suitable radical 
precursors for 5- and 6-exo cyclisation were prepared (Scheme 2). 
The 5-membered ring cyclisation with the precursor 16 using 
Bu3SnH gave only the reduced uncyclised product 19 (Scheme 3). 
Even syringe pump addition of Bu3SnH, with either Et3B (r.t.) 
or AIBN (110 oq as initiators, gave only 19. We considered that 
the lack of cyclisation could be due to 1,5-hydrogen abstraction 
from the 2-position of the quinazolinone as shown in Scheme 3 
(route b: 18 to 21). This possibility was eliminated by repeating 
the reaction with Bu3SnD which gave only deuteriation on the aryl 
13 
~)n 
U. y 
14, n = 1,X =.Br, Y= I 
15, n = 2, X= OMs, Y = Br 
~xy 
UN) 
16,n=1,Y=I 
17,n=2, Y=Br 
Scheme 2 Reagents and conditions: i, tert-BuOK, DMF, 63% (16 from 
14), 38% (17 from 15). 
19 ~ 0 d.\~ 20 
Scheme 3 Reagents and conditions: i, Et,B, PhMe, r.t., Bu3SnH (fast 
addition) 96% (19), slow addition, 30% (19); AIBN, Bu3SnH (slow 
addition), PhMe, reflux, 45% (19); Et3 B, TIMSS, 35% (19); (Me,Sn)2 , 
tert-BuPh, reflux, 18% (20), 65% (19). 
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radical position, and none on the 2-position of the quinazolinone, 
and these results indicated that the rate of cyclisation was 
not favourable compared to reduction with Bu3SnH. Therefore, 
hexamethylditin [(Me3Sn)2] was used so that the intermediate 
radical (cf. 9 in Scheme 1) was not reduced. The reaction was 
repeated with (Me3Sn)2 which resulted in a small amount of the 
cyclised product 20 (18%) as well as uncyclised 19 (65%) as the 
major compound. 
The analogous six-membered ring aryl radical cyclisation using 
precursor 17 gave an excellent yield of the cyclised product 22 
(92%) with no reduction using (Me3Sn)2 (Scheme 4). The reaction 
with Bu3SnH again gave largely the uncyclised reduced product 
23 (55%) but did also yield a small amount of the cyclised 
product22 (8%). We have observed before that 5-ringcyclisation of 
radicals onto heteroarenes is difficult due to strain whereas 6-ring 
cyclisation is more favourable. 8•10•16,32 Therefore, the higher yields of 
cyclisation from 17 relative to 16 are expected. The results indicate 
that the oxidative route is dominant (i.e. loss of hydrogen from the 
Tt-radical intermediate 10) for cyclisation onto quinazolinones as 
observed for other heteroarenes. 
, ~ ctxo + 
N :? I 
22 ~ 23 
Scheme 4 Reagents and conditions: i, (Me,Sn)2, tert-BuPh, reflux, 92% 
(22), 0% (23); Et,B, PhMe, r.t., Bu3SnH (fast addition), 8% (22), 55% (23). 
3H-4-0xoquinazolin-2-yl radical cyclisation 
As shown in Scheme 5 we envisaged an alternative route to 
polycyclic quinazolinones by cyclisation of 3H-4-oxoquinazolin-
2-yl radicals onto pendant side chains attached to the 3-position 
instead of cyclisation of side chain radicals onto the quinazoli-
none moiety. 3H-4-0xoquinazolin-2-yl radicals,33 generated pho-
tolytically from 3-(but-1-en-4-yl)-38-quinazolin-4-one, have been 
reported to undergo 5-exo cyclisation onto the pendant alkene.334 
The procedure however was not suitable for synthetic application. 
During our studies, a synthesis of luotonin A analogues using 
3H-4-oxoquinazolin-2-yl radicals was reported. 33b 
0 0 0 
~NH ~ ~~NH ...!.:_ oc~ NH U .. ~ u.~Jl. Br - ~ A N S N. S"' -(HSBr) N Br 
H H 
24 25 26 
.. aGO ;lhn aGO ;)hn 
~ 1 N ~ 1 N _ n=1: 19 + 20 ~ A ~ ). n = 2: 23 + 22 
N Br N 
27, n = 1 
28, n = 2 
29a, n = 1 
29b, n = 2 
Scheme 5 Reagents and conditions: i, Br2, EtOH, 50"/o (26); ii, NaH, DMF, 
BnBr, 46% (27); Nal, PhCH,CH,Br, 6% (28); iii, 27: Bu,SnH, Et,B, slow 
addition, 62% (19); Bu3GeH, Et3B, slow addition, 41% (19); (Me,Sn)2 , 
tert-BuPh, reflux, 41% (19), 27% (20); 28: (Me,Sn), tert-BuPh, reflux, 0% 
(23), 97% (22). 
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The plan of our protocol was to alkylate 2-bromo-
3H-quinazolin-4-one to provide suitable radical precursors 
(Scheme 5). 2-Bromo-3H-quinazolin-4-one 26 was prepared by an 
adapted literature procedure from 2-mercapto-3H-quinazolin-4-
one 24.34 Alkylations with activated halides, e.g. benzyl bromide, 
allyl bromide and methyl iodide were successful but alkylations 
with unactivated halides were very poor or failed. Alkylation with 
activated propargyl halides has also recently been reported. 33b 
A maximum yield (6%) of alkylation was obtained with 2-
phenylethyl bromide and alkylation with 3-phenylpropyl bromide 
failed. Alkylation with the corresponding triflates failed to give 
improved results. We suggest that the anion of 2-bromo-3H-4-
oxoquinazoline is too stabilised and hence not nucleophilic enough 
to react with unactivated halides. 
Various protocols were attempted to circumvent the alky-
lation problem. For instance, the successful bromination sug-
gested that other 2-thioxo-2,3-dihydro-1H -quinazolin-4-ones with 
the 3-alkyl side chain in place could also be converted to 
the corresponding 2-bromo compounds. In order to test this 
hypothesis, 2-(phenylethyl)-2-thioxo-2,3-dihydro-1 H -quinazolin-
4-one 30 was prepared by ring synthesis using the reaction 
between 2-(methoxycarbonyl)phenyl isothiocyanate and amines.3' 
The structure of 30 was confirmed by X-ray crystallography 
(Fig. 1). However, the bromination procedure yielded only the 
corresponding disulfide instead of the 2-bromoquinazolinone 28. 
The mechanism of these brominations is unknown. The most 
likely intermediate is the sulfenyl bromide 25 which can either 
lose a proton and undergo substitution with bromide, or undergo 
direct substitution with bromide. The intermediate sulfenyl bro-
mide from 2-(phenylethyl)-2-thioxo-2,3-dihydro-1 H -quinazolin-
4-one cannot lose a proton which is possibly significant in directing 
the reaction towards disulfide formation. Examples from the 
literature show bromoimine formation for thioureas with N,N'-
substitution (i.e. can lose a proton)36 and disulfides and sulfides 
from thioamides.37 
We carried out radical cyclisations with the precursors 27 and 
28 (Scheme 5). As observed for the cyclisation of precursor 16, the 
5-membered ring cyclisation from 27 was unfavourable with both 
Bu3SnH and Bu3GeH and yielded only the reduced uncyclised 
product 19. Radical abstraction of hydrogen from Bu3GeH is 
20 times slower than from Bu3SnH which would favour cyclisation 
over reduction/8 but still only reduction was observed from the 
intermediate 29a. When (Me3Sn)2 was used, a moderate yield of 
cyclisation product (27%) was obtained but reduction was still 
the major route (41%). The 6-membered ring cyclisation from 
precursor 28 via 29b gave a quantitative yield of cyclisation 
to 22 with none of the reduced compound 23 formed. This 
cyclisation could either proceed by 5-exo cyclisation followed by 
a neophyl rearrangement or directly by 6-endo cyclisation. The 
results show that radical cyclisation can be used onto, or from, 
the quinazolinone moiety, but that a useful method of synthesis 
of the 2-bromoquinazolinones is still required. Addition of3H-4-
oxoquinazolin-2-yl radicals onto isonitriles has also recently been 
reported. m 
Alkyl radical cyclisation 
Several methods have been used for the synthesis of both 
deoxyvasicinone 2 and mackinazolinone 3 but none involving 
radicals. 39 Our protocol using cyclisation of an alkyl radical 
onto 3H-quinazolin-4-one rings was aimed at the synthesis of 
both natural products (Scheme 6). Routine alkylation yielded the 
required radical precursors 31a,b. An initial study with Bu3SnH 
using precursor 31a yielded only reduced uncyclised product 33a 
(78%). The rate ofcyclisation of the alkyl radical is obviously slow, 
and it is intercepted by Bu3SnH to yield the respective reduced 
uncyclised product 33a. Therefore, (Me3Sn)2 was used to facilitate 
cyclisation which gave moderate yields of deoxyvasicinone 2 and 
mackinazolinone 3. 
The use of Et3B mediated reactions gave better yields of both 
2 and 3 (Scheme 6). We suggest that the ethyl radical generated 
from the reaction between Et3B and oxygen is able to abstract 
iodine from the radical precursors 31a,b to yield alkyl radicals 
and ethyl iodide, which is lost from the reaction. The hydrogen in 
the 7t-radical intermediates (cf 10) is also most likely abstracted 
by ethyl radicals to facilitate rearomatisation.40 Unusually, some 
cyclised reduced material32a,b was obtained suggesting dispro-
portionation was also taking place. GCMS analysis of the crude 
product from the Et3B facilitated reaction with 31a indicated 
traces (ea. 5%) of 2-ethyl-3-propyl-3H-quinazolin-4-one and 
CI1Sl 
Fig. 1 X-Ray structure of 3-(2-phenylethyl)-2-thioxo-2,3-dihydro-IH-quinazolin-4-one 30 with atom labelling. 
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Scheme 6 Reagents and conditions: i, NaH, DMF, a. 1-chloro-3-
iodopropane, 51%; b. 1-chloro-4-iodobutane, 65%; ii, N al, acetone, reflux, 
53% (3la), 67% (31b); iii, (Me3Sn)2, tert-BuPh, reflux, hv: a. 31a gave 20"/o 
(2), 13% (32a) and 6% (33a); b. 3lb gave 30"/o (3), 23% (32b) and 0"/o (33b); 
Et3B (20 equiv.), tert-BuPh, air (yields by 1H NMR analysis): a. 31a gave 
40% (2), IO"/o(32a) and 30"/o (33a); b. 32b gave 61% (3), 23% (32b) and 0"/o 
(33b). 
3-pentyi-3H-quinazolin-4-one indicating addition of ethyl radi-
cals to intermediates. No uncyclised reduced material 33b was 
observed for the 6-ring cyclisation of 3lb. Again, this provides 
evidence that 5-ring cyclisation onto heteroarenes is strained 
and that 6-ring cyclisation (84% of cyclised products) is more 
favourable. 
Heteroaryl radical cyclisation 
During our studies, Pd(O) catalysed cyclisations were reported 
for 2-bromoindole41 and 2-bromoquinoline41•42 moieties onto the 
2-position of quinazolin-4-one to yield rutaecarpine in poor 
yield (24% maximum) and luotonin A in good yield (86%) res-
pectively. 
Luotonin A 5. The luotonins make up a group of pyrrolo-
quinazolino-quinoline alkaloids of which the pentacyclic luo-
tonins A 5, B 6 and E 7 are of most interest. The luotonins 
are used in traditional Chinese medicine and are reported to 
exhibit activity against a range of ailments including rheumatism, 
inflammation, influenza, hepatitis and leukemia_.3 Luotonin A has 
been reported to show activity as an antitumour compound and is 
an inhibitor for human DNA topoisomerase 1.0 The compounds 
were isolated some ten years ago• and luotonin A has been a 
popular synthetic target.0 •44 Two radical syntheses of luotonin A 
have been reported; a radical domino cyclisation reaction using 
vinyl radical cyclisation onto nitriles45 and a bimolecular reaction 
involving radical addition onto isonitriles.33b 
The synthesis of luotonin A 5 using 2-quinolinyl radicals was 
carried out as a further example of cyclisation onto the quinazoli-
none moiety (Scheme 7). The use of 2-quinolinyl radicals in cy-
clisation has two literature precedents; synthesis of camptothecin 
using cyclisation of2-quinolinyl radicals onto a pyridone moiety29 
and synthesis of IO,II-methylene-14-azaxamptothecin and 14-
azacamptothecin using cyclisation of 2-quinolinyl radicals onto 
3H -pyrimidin-4-one moieties. 30 These cyclisations also proceeded 
by 'oxidative cyclisation' as observed for the 3H-quinazolin-4-
ones. 
The required starting material 34 was prepared by a literature 
procedure from 2-chloroquinoline-2-carbaldehyde46 and reacted 
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36 luotonin A, 5 
Scheme 7 Reagents and conditions: i, (Me,Sn), tert-BuPh, reflux, hv: 51% 
(5), 15% (36); Et,B (20 equiv.), PhMe, r.t., air: Bu,SnH (fast addition), 0"/o 
(5), 53% (36) Bu,SnH (slow addition), 14% (5), 32% (36); Bu,GeH (fast 
addition), 18% (5), 11% (36). 
under several radical conditions. Unusually, the yield from 5-exo 
cyclisation was significant. The use of (Me3Sn)2 gave a reasonable 
yield (53%) ofluotonin A 5 but also some of the reduced product 
36. The yield was high in comparison to the 5-exo cyclisation 
of the phenyl analogue 16. Luotonin A was even obtained with 
Bu3SnH and Bu3GeH, clearly indicating that the cyclisation 
is more favourable for 2-quinolinyl radicals as compared to 
phenyl radicals. The yield was not as high as the Pd(O)-catalysed 
cyclisation41 but further optimisation could improve the yield. 
Rutaecarpine 8. Rutaecarpine 8 has been synthesised by a 
wide variety of protocols but none involving radicals. 47 Our 
synthesis of rutaecarpine uses indol-2-yl radical cyclisation onto 
the quinazolinone motif as a further example of natural product 
synthesis using the general protocol (Scheme 8). Indol-2-yl radicals 
have been previously used in radical cyclisation onto pendant I-oo-
alkenes48 and -arenes49 and in H-translocation reactions towards 
the synthesis of mitomycin. 5° 
o{x 
H 
137,X=OH 
L.._38,X= Br 
rutaecarpine 8 + 39 
ii 
38-
... c39,Y=H 
Ill 
40, Y= Br 
iv 1 
d:Atu ~ ·?' ~ ~
41 HN -
Scheme 8 Reagents and conditions: i, PBr,, DCM, 56% (38); ii, tert-
BuOK, DMF, 3H-quinazolin-4-one, 39% (39); iii, NBS, DCM, 0 °C, 
30 min, 38% (40); iv, (Me,Sn)2, tert-BuPh, reflux, hv: 55% (8), 0% (39); 
Et3B (20 equiv.), PhMe. r.t., air: Bu,SnH (slow addition), 15% (8), 57% 
(39). 
The preparation of the 2-bromoindole part of the precursor 
proved troublesome even with protection of the side chain and 
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the NH. The use of NBS has been reported in the literature but 
the reaction is very sensitive, and can be adversely affected by 
the NH and side chain groups. 48•49•51 We finally used an adapted 
literature procedure•• whereby the 3H-quinazolin-4-one moiety 
was used as the 'protective group' for the indole side chain (i.e. 
39). The bromination was rapid and short reaction times and low 
temperature gave the best yields of the 2-bromoindole precursor 
40. As reported in the literature for 2-bromoindoles,48•49•51 .52 decom-
position of the product was a problem until it was purified. The free 
indole-NH did not interfere and was therefore not protected. A 
blank reaction between NBS and 3-methylquinazolin-4-one gave 
no reaction after two days indicating that in the NBS reaction 
with 39, bromination of the quinazolinone ring is unlikely to be 
the cause of the decomposition. 
3-[2-(1H-Indol-3-yl)ethyi]-4(3H)-quinazolinone 39 was pre-
pared by alkylation of 4(3H)-quinazolinone with 3-(2-
bromoethyl)-lH-indole 38 which was prepared by bromination 
oftryptophol37. 
Radical cyclisation of the precursor 40 gave the predicted 6-exo 
cyclisation of the intermediate radical 41 to yield rutaecarpine 
8. Only cyclisation was obtained when (Me3Sn)2 was used and 
even reductive conditions with Bu,SnH yielded a small amount 
of cyclisation product. The 6-exo cyclisation yields were similar 
to the equivalent cyclisation with aryl radicals (see Scheme 4). 
Longer reactions times led to decomposition. 
Acyl radicals-synthesis of tryptanthrin 
Tryptanthrin has been synthesised by a range of protocols. 3•6.53 
We prepared an authentic. sample of tryptanthrin 4 by a 
literature procedure in order to obtain full spectroscopic data for 
comparison. 53 
Aromatic acyl radical cyclisation has recently been shown to 
be a useful synthetic technique.17" 19•54 Although 5-membered ring 
cyclisation was reported to be unsuccessful, 19 we have shown 
that 5-ring cyclisation onto the 3H-quinazolin-4-one moeity 
was possible (e.g. the luotonin synthesis). Therefore, we carried 
out the syntheses as shown in Scheme 9. The aryi-CO bond 
in the intermediate acyl radical 44 is strong enough to avoid 
decarbonylation which is a rapid reaction for alkyi-CO radicals.'' 
However, it is possible that we failed to isolate products resulting 
from CO loss. 
The starting material42 was prepared in one step by a literature 
procedure'6 and converted to the acyl selenide 43 by standard 
procedures.16 Several conditions were used based on literature 
reports.17- 19•54 The highest yield (15%) was obtained by photolysis 
at r.t. Although the yield is poor, we believe this is the first example 
of a 5-exo acyl radical cyclisation onto a heterocycle. When AIBN 
was added to the reaction, an intractable mixture was obtained. 
Heating under reflux was not required and UV photolysis alone 
was enough to facilitate the reaction, presumably by homolysis 
of the carbonyi-SePh bond. In a blank reaction, heating under 
reflux in benzene yielded only unaltered starting material after 
24 h. The mechanism is unclear, other than 5-exo acyl radical 
cyclisation followed by hydrogen abstraction from the resulting 7t-
radical intermediate. Large amounts of diphenyl diselenide were 
isolated indicating CO-Se bond homolysis. 
We also investigated the 6-membered ring cyclisation because 
these had proved to be more successful than the 5-ring cyclisations 
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Scheme 9 Reagents and conditions: i, Bu3P, PhSeSePh, DCM, 73% (42); 
ii, LiOH, EtOH, H20; iii, Bu3P, PhSeSePh, DCM, 68% (47); iv, (Me3Sn)2, 
tert-BuPh, reflux, hv, 3% (4); PhH, r.t., hv, 12 h, 15% (4); PhH, reflux, hv, 
I 0 h, 11% ( 4); AIBN, PhH, reflux, hv, 0% ( 4); v, (Me3Sn)2, PhH, reflux, hv, 
39%(50). 
(Scheme 9). The acyl radical precursor 47 was prepared by 
standard procedures. The ester 45 was synthesised by alkylation 
of 3H-quinazolin-4-one with methyl 2-(bromomethyl)-benzoate. 
Cyclisation using Et3B only, AIBN only, UV photolysis only and 
slow addition ofTTMSS with Et3B as initiator all gave intractable 
mixtures. However, reaction with (Me3Sn)2 gave a moderate yield 
of the unusual product 50 along with an intractable mixture of 
other products. The structure of the hydroxylated product 50 
was confirmed by X-ray crystallography (Fig. 2). The product 
indicated 6-ring cyclisation as expected but that the product 48 
was unstable to the reaction conditions and was readily oxidised 
introducing an OH group onto the newly formed ring. 
Analogous reactions with 2-indolyl acyl radicals have yielded 
a range of unexpected products which included a 'quinone' 
product caused by oxidation of the benzylic methylene during 
the reaction.17•18 2-Cyanoprop-2-yl radicals from the breakdown 
of AIBN were proposed as the abstracting radicals. In our 
reaction, no AIBN is present so we suggest that any of the 
intermediate radicals (e.g. intermediate acyl or 7t-radical, PhSe') 
can abstract the benzylic hydrogen, which is a favourable process, 
to form a stable radical intermediate 49. Although air was 
excluded, traces of oxygen are likely to be present and to react 
rapidly with trimethylstannyl radicals to form a peroxyl radical 
(Me3Sn00').45•57 Combination of the peroxyl radical with the 
benzylic radical 49 would yield a peroxide which could easily 
break down to yield 50. Alternatively, a standard auto-oxidation 
mechanism with the traces of oxygen present could explain this 
unusual product. 
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Fig. 2 X-Ray structure of Il-hydroxy-IIH-isoquinolino[3,2-b)quinazolin-6,13-dione 50 with atom labelling. 
Conclusions 
Our results show that radical cyclisation on the quinazolinone 
moiety can be used for synthesis. The results show that radical 
cyclisation is also favourable for radicals centred on the 2-position 
of the quinazolinone moiety but that a better method for the 
synthesis of2-bromoquinazolinones is still required. 
Experimental 
General 
Commercial dry solvents were used in all reactions except for light 
petroleum and ethyl acetate which were distilled from CaCiz and 
dichloromethane which was distilled from CaH2 • Light petroleum 
refers to the bp 40--60 °C fraction. Sodium hydride was obtained 
as 60% dispersion in oil. A 2.5 M solution of n-butyl lithium 
in hexane was used. A solution of Et3B in hexane (1.0 M) was 
used in all cases. Melting points were determined on a Stuart 
Scientific SMP3 melting point apparatus and are uncorrected. 
Elemental analyses were determined on a Perkin Elmer 2400 
CHN Elemental Analyser. Infrared spectra were recorded on a 
Perkin-Elmer Paragon 1000 FT-IR spectrophotometer on NaCI 
plates. 1H (400 MHz) and 13C (100 MHz) NMR spectra were 
recorded on a Broker DPX-400 instrument, or 1H (250 MHz) 
spectra were obtained using a Broker AC-250 spectrometer. 
Spectra were obtained from solutions in CDCI3 with TMS as the 
internal standard for 1H NMR spectra and deuteriochloroform 
as the standard for 13C NMR spectra unless otherwise specified. 
Chemical shifts are given in parts per million (ppm) and J values in 
hertz (Hz). Assignments were made using a combination of COSY 
and HMQC analysis. Mass spectra were recorded on a Jeol SXl 02 
high resolution mass spectrometer or were run by the EPSRC MS 
Service at the University of Wales, Swansea. GCMS was carried 
out on a Fisons 8000 series mass spectrometer using a 15 m x 
0.25 mm DB-5 GC column. TLC using silica as absorbent was 
carried out with aluminium backed plates coated with silica gel 
(Merck Kieselgel 60 F2,.), and TLC using alumina as absorbent 
was carried out with aluminium backed plates coated with neutral 
aluminium oxide (Merck 150 F254, TypeT). Silica gel (Merck 
Kieselgel60 H silica) was used for column chromatography unless 
otherwise specified. Column chromatography using alumina was 
carried out with Aldrich aluminium oxide, activated neutral, 
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Brockmann 1, STD Grade, 150 mesh size. Prep-TLC was carried 
out using aluminium oxide (Merck 60 PF2,., Type E). Bu3GeH 
was prepared from GeCI4 by a known procedure.38 
General procedure for alkylation of 3H-quinazolin-4-ones. 3-
(2-Iodobenzyi)-JH-quinazolin-4-one 16. Potassium tert-butoxide 
(1.35 g, 12 mmol) was added to 3H-quinazolin-4-one 13 (1.17 g, 
8 mmol) in dry DMF (50cm3) and the mixture stirred for 1 h under 
an atmosphere of nitrogen. 2-Iodobenzyl bromide 14 (2.84 g, 
9.6 mmol) was added and the reaction mixture stirred for a 
further 16 h. The mixture was diluted with DCM and washed 
with H20 and brine. The organic layer was dried and evaporated 
under reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent and light petroleum-
EtOAc (2: 1) as eluent yielding 3-(2-iodobenzyl)-38-quinazolin-
4-one 16 as pale yellow crystals (1.82 g, 5.0 mmol, 63%), mp 
94-95 °C; Found: M+, 362.9987. C15H 11 IN20 requires 362.9989; 
v ... ,(thin film)/cm-1 3055, 1689, 1469, 1230, 962 and 734; OH 5.71 
(2 H, s, CH2), 6.93 (1 H, ddd, J 7.9, 7.4, 1.7, BnH-4), 7.09 (1 H, 
dd, J7.9, 1.8, BnH-3), 7.22 (I H, ddd, J 8.0, 7.4, 1.2, BnH-5), 7.45 
(1 H, ddd, J 8.0, 5.5, 1.7, 6-H), 7.75-7.64 (2 H, m, 7,8-H), 7.81 
(1 H, dd, J 8.0, 1.2, BnH-6), 8.11 (1 H, s, 2-H) and 8.26 (1 H, dd, 
J 8.0, 1.6, 5-H); Oc 54.90 (CH2), 98.6 (C), 122.1 (4a-C), 126.9 (5-
C), 127.5 (6-C), 127.6 (8-C), 128.9 (CH), 129.1 (CH), 129.9 (CH), 
134.5 (7-C), 137.7 (Sa-C), 139.9 (CH), 146.4 (2-C), 148.0 (C) and 
161.1 (4-C); mlz (El) 252 (M+, 98%), 129 (43), 107 (41), 90 (100), 
89 (77), 76 (51), 63 (58), 50 (42) and 40 (85). 
3-)2-(Bromophenyl)ethyl)-3H-quinazolin-4-one 17. The gen-
eral procedure for alkylation with 2-(2-bromophenyl)ethyl 
methanesulfonate 15 ( 4.90 g, 18.6 mmol) for 48 h was used to yield 
3-[2-(bromophenyl)ethyi]-3H-quinazolin-4-one 17 as colourless 
crystals (1.93 g, 5.9 mmol, 38%), mp 119-120 °C; Found: M+, 
328.0206. C16H 1379 BrN20 requires 328.0206; v ... ,(thin film)/cm-1 
3423, 1972, 1609, 1470, 1069, 1027 and 773; o" 3.25 (2 H, t, J 7.2, 
CH2), 4.25 (2 H, t, J 6.9, NCH2), 7.22-7.07 (3 H, m, ArH), 7.58-
7.48, (2 H, m, ArH), 7.78-7.64 (3 H, m, ArH) and 8.34 (1 H, ddd, 
J 8.1 1.5 0.5, 5-H); Oc 35.3 (CH2), 46.7 (NCH2), 122.0 (C), 124.4 
(C), 126.6 (CH), 127.2 (CH), 127.5 (CH), 127.9 (CH), 128.9 (CH), 
131.4(CH), 133.1 (CH), 134.2(CH), 136.7(C), 146.4(CH), 148.1 
(C) and 161.1 (C); mlz (El) 330/328 (M+, 52/51%), 251 (49), 249 
(56) and 52 (14). 
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Cyclisation reactions of 3-(2-iodobenzyi)-JH-quinazolin-4-one 
16. 
General procedure for Bu1SnH reactions using Et1B as initiator. 
A solution of Bu3SnH (0.76 g, 2.6 mmol) and 3-(2-iodobenzyi)-
JH-quinazolin-4-one (0.44 g, 1.2 mmol) in dry toluene (40 cm3) 
was deoxygenated under an atmosphere of nitrogen and stirred 
for 1 h. Triethylborane (3.6 cm3, 3.6 mmol) was added via a needle 
through a septum; the needle was then left open to allow air 
(oxygen) to enter the reaction and the mixture stirred for 1 h. More 
triethylborane (3.6 cm\ 3.6 mmol) was added and the reaction 
mixture stirred for a further 10 h. Dilute hydrochloric acid was 
added to extract the protonated quinazolone products into the 
aqueous layer. The aqueous layer was washed with light petroleum 
to remove tributyltin residues. The aqueous layer was basified 
with sodium hydroxide to pH 14 and extracted with DCM. The 
combined organic layers were dried and evaporated under reduced 
pressure yielding the reduced product 3-benzyl-JH-quinazolin-4-
one 19 as colourless crystals (0.27 g, 1.2 mmol, 96%), mp 116--
117 oc (lit.,58 117-11S 0 C}; v,...(thin film)/cm- 1 3419, 1675, 1609, 
1559, 1473, 1369, 1332, 1161, 1026,773,709,694 and 645; t5" 5.08 
(2 H, s, CH2), 7.24-7.23 (5 H, m), 7.4S (1 H, ddd, J S.2 6.3 l.S, 
6-H), 7.74-7.6S (2 H, m, 7,S-H), S.l1 (1 H, s, 2-H) and S.32 (I H, 
dd, J S.2 2.0, 5-H); t5c 49.6 (CH2), 122.2 (4a-C), 126.9 (5-H), 127.4 
(6-H), 127.5 (S-H), 12S.O (CH), 12S.3 (CH), 129.0 (CH), 134.3 
(7-H), 135.S (C), 146.4 (2-H), 14S.O (Sa-C) and 161.1 (4-C). The 
data were identical to that in the literature. 58 The procedure was 
repeated using TTMSS in place of Bu3SnH to yield 3-benzyi-JH-
quinazolin-4-one 19 (35%). 
General procedure for slow addition of Bu3SnH reactions using 
Et3B as initiator. The general procedure for Bu3SnH reactions 
using Et3B as initiator was repeated except that Bu3SnH was added 
by a syringe pump over 6 h to give 3-benzyl-JH -quinazolin-4-one 
19(30%). 
General procedure for slow addition of Bu3SnH reactions using 
AIBN as initiator. The general procedure for Bu3SnH reactions 
using Et3B as initiator was repeated except that AIBN (0.25 
molar equiv.) was used as initiator and the reaction was heated 
under reflux for 6 h to yield 3-benzyi-JH-quinazolin-4-one 
19 (45%). 
General procedure for reactions using photolysis and hexa-
methylditin. A solution of 3-(2-iodobenzyi)-JH-quinazolin-4-
one 16 (0.36 g, 1.0 mmol) and hexamethylditin (0.99 g, 3.0 mmol) 
in tert-butylbenzene (20 cm3) in a two-necked pyrex flask (5 x 1 cm 
and 25 cm high, wall thickness= 1 mm), was purged with nitrogen 
for 30 min. The mixture was irradiated with a combined 300 W 
sunlamp at 150 °C for 10 h. The reaction mixture was cooled 
to room temperature, diluted with MeOH and evaporated under 
reduced pressure to a small volume. The residue was purified using 
column chromatography with light petroleum as eluent to remove 
the tert-butylbenzene. A precipitate of polymeric dimethyltin was 
produced. The product was eluted with ethyl acetate and further 
worked-up as for the general procedure for Bu3SnH reactions using 
Et3B as initiator. 3-Benzyi-JH-quinazolin-4-one 19 and cyclised 
12H-isoindolo[l,2-b]quinazolin-IO-one 20 were obtained as an 
inseparable white solid. Analysis using 1H NMR spectroscopy 
showed 19 (65%) and 20 (lS%). 12H-lsoindolo[l,2-b]quinazolin-
10-one 20 was identified in the mixture and therefore not fully 
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characterised. t5" 5.19 (2 H, s, CH2), 7.2S-7.35 (3 H, m), 7.51 (1 H, 
ddd, J S.O, S.O, 1.6, 7-H), 7.Sl (1 H, ddd, J S.O, S.O, 1.6, S-H), 
7.S5 (I H, dd, S.O, 1.6, 6-H), S.21 (I H, d, J 7.2, 4-H) and S.41 
(1 H, dd, J, S.O, 1.6, 9-H); t5c 49.6 (CH2), 120.6 (C), 123.4 (CH), 
123.5 (CH), 126.4 (CH), 126.4 (CH), 127.3 (CH), 12S.S (CH), 
132.3 (CH), 132.6 (C), 134.2 (CH), 139.6 (C), 149.4 (C), 154.9 (C) 
and 160.5 (C). The data were the same as that in the literature.59 
GC-MS analysis showed the ratio of the two products to be in the 
ratio 4 : 1 of the reduced produced and cyclised product: 12H-
isoindolo-[1,2-b]-quinazolin-10-one; RT 22.S min, mlz 234 (M+, 
95%), 205 (24), 179 (15), 151 (16), 130 (25), 102 (2S), 91 (100) and 
77 (20) and 3-benzyi-JH-quinazolin-4-one; RT 24.5 min, mlz 236 
(M+, 51%), 130, (37), 91 (100) and 65 (27). 
3-(2-Deuterio )benzyi-3H -quinazolin-4-one. The general proce-
dure for reductive reactions with EhB with Bu3SnD as reductant 
were used with 3-(2-iodobenzyi)-3H-quinazolin-4-one 16 to yield 
3-(2-deuterio )benzyi-3H -quinazolin-4-one as colourless crystals 
(41%); mp 100-101 °C (Found: M+, 23S.lOS4. C15DH11 N20 
requires 23S.IOS5); v,...(thin film)/cm- 1 3421, 2359, 1670, 1610, 
1471, 1396, 1153 and 773; t5" 5.21 (2 H, s, CH2), 7.3S-7.29 (4 H, 
m,PhH), 7.52(1 H,dd,JS.ll.4,6-H), 7.79-7.69(2H,m, 7,S-H), 
S.l2 (1 H, s, 2-H) and S.34 (1 H, ddd, J S.l 2.1 0.6, 5-H); t5c 49.7 
(CH2), 104.1 (CD), 122.2 (4a-C), 126.9 (5-C), 127.4 (6-C), 127.6 
(CH), 12S.O (CH), 12S.3 (CH), 12S.9 (CH), 129.1 (CH), 134.3 
(CH), 135.7 (C), 146.3 (5-C), 14S.l (Sa-C) and 161.1 (4a-C); mlz 
(El) 237 (M+, 4S%), 235 (21), 130 (33), 92 (100), 91 (75), 65 (21) 
and 51 (23). 
Cyclisation reactions of 3-(2-(bromophenyl)ethyl)-3H-quina-
zolin-4-one 17. 
Hexamethylditin. The general procedure for reactions using 
photolysis and hexamethylditin yielded 5,6-dihydroisoquino[l,2-
b]quinazolin-S-one 22 as colourless crystals (92%), mp 195-
197 °C (lit.,60 196 oC); Found: M+, 249.1025. C16H 12N20 requires 
249.1022; v .... (thin film)/crn-1 3421, 16S2, 1590, 1556, 1471, 1150, 
762 and 692; t5" 3.06 (2 H, t, J 6.4, CH2), 4.35 (2 H, t, J 6.4, NCH2), 
7.22-7.13 (1 H, m, ArH), 7.43-7.37 (3 H, m, ArH), 7.71-7.69 (2 H, 
m, ArH), S.25 (1 H, d, J 7.6, ArH) and S.43-S.40 (1 H, m, ArH); 
t5c 27.4 (CH2), 39.5 (NCH2), 120.7 (C), 126.5 (CH), 126.S (CH), 
127.5 (CH), 127.6 (CH), 127.9 (CH), 129.5 (C), 131.7 (CH), 134.2 
(CH), 137.0 (C), 147.7 (C), 149.3 (C) and 161.6 (CO); mlz (El) 
249 (M+, 17%), 247 (100), 12S (20), 116 (46), 104 (30), 90 (34), 
S9 (62), 77 (S5), 76 (97), 63 (53) and 39 (54). One CH signal was 
coincident or could not be detected. 
Bu1SnH and Et1B. The general procedure for Bu3SnH re-
actions using Et3B as initiator yielded an inseparable mixture 
of 3-[2-(phenylethyi)]-JH-quinazolin-4-one 23 (55%) and 5,6-
dihydroisoquino[l,2-b]quinazolin-S-one 22 (S%). The yields were 
estimated using 1H NMR spectroscopic analysis. 
3-Benzyl-2-bromo-3H-quinazolin-4-one 27. The general proce-
dure for alkylation of 3H-quinazolin-4-ones (3 h) yielded 3-benzyl-
2-bromo-JH-quinazolin-4-one 27 as colourless crystals (46%), 
mp 109-111 oc; Found: M+, 315.012S. C15H11 BrN20 requires 
315.012S; Vmax(thin film)/crn-1 3457,3064, 1653, 155S, 1494, 1430, 
1339, 1234, 1134, 1074, 1023, 901 and Sl9; t5" 5.56 (2 H, s CH2), 
7.29-7.37 (5 H, m, PhH), 7.52 (1 H, ddd, J S.2, S.l, 2.0, 7-H), 
7.66 (1 H, dd, J S.2, 1.2, S-H), 7.79 (1 H, ddd, J S.l, S.O, 1.2, 6-H) 
and S.27 (1 H, dd, J S.O, 2.0, 5-ArH); t5c 51.8 (CH2), 120.5 ( 4a-C), 
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126.9 (6/8-CH), 127.5 (CH), 127.6 (6/8-CH), 127.7 (5-CH), 127.8 
(CH), 127.9 (7-CH), 135.1 (CH), 135.4 (C), 136.2 (8a-C), 147.2 
(2-C) and 161.6 (4-C); mlz (El) 318 (M+, 15%), 317 (100), 315 
(100), 237 (75), 235 (39) and 52 (79). 
2-Bromo-3-(phenylethyl)-38-quinazolin-4-one 28. The general 
procedure for alkylation of 38-quinazolin-4-ones (12 h) yielded 
2-bromo-3-(phenylethyl)-38-quinazolin-4-one as colourless crys-
tals (6%), mp 109-110 °C; Found: M+, 328.0206. C16H 1379BrN20 
requires 328.0206; mp 195-197 °C; v.,.,(thin film)/cm-1 3060, 
2930,2359, 1866, 1714, 1655, 1621, 1604, 1493, 1452, 1405, 1072, 
1028,938 and 908; 15" 2.99 (2 H, t, J 1.6, CH2), 4.37 (2 H, t, J 1.6, 
NCH2), 7.26-7.15 (5 H, m, PhH), 7.34-7.30 (l H, m, 6-H), 7.49 
(1 H, d, J 7.6, 8-H), 7.67-7.63 (1 H, m, 7-H) and 8.20 (1 H, d, J 
7.6, 5-H); oc 34.0 (CH2), 42.2 (NCH2), 114.5 (4a-C), 114.9 (CH), 
123.1 (8-C), 126.4 (6-C), 128.3 (5-C), 128.4 (CH), 128.9 (CH), 
134.8 (7-C), 138.5 (C), 138.7 (C), 151.2 (2-C) and 162.3 (4-C); mlz 
(El) 266 (M+, 16%), 264 (15), 249 (20), 185 (lOO), 129 (52), 102 
(23), 90 (35) and 40 (53). 
Cyclisation reactions of 3-benzyl-2-bromo-38-quinazolin-4-one 
27. 
BuJSnH and EtJB. The general procedure for Bu3SnH reactions 
using Et3B as initiator were used with Bu3SnH added by syringe 
pump over 6 h and the reaction stirred for a further 5 h. Work-
up yielded 3-benzyi-3H -quinazolin-4-one 19 as colourless crystals 
(0.15 g, 0.62 mmol, 62%). The data were identical to authentic 
material. A repeat experiment using Bu3GeH in place of Bu3SnH 
gave 3-benzyl-38-quinazolin-4-one 19 in reduced yield (47%). 
8examethylditin. The general procedure for reactions using 
photolysis and hexamethylditin yielded an inseparable mixture of 
12H-isoindolo-[1,2-b]quinazolin-l0-one 20 (27%) and 3-benzyi-
3H-quinazolin-4-one 19 (41%). The yields were estimated using 
1H NMR spectroscopic analysis. 
Cyclisation reactions of 2-bromo-3-(phenylethyl)-38 -quinazolin-
4-one28. 
8examethylditin. The general procedure for reactions using 
photolysis and hexamethylditin (24 h) yielded 5,6-dihydroiso-
quino[1 ,2-b]quinazolin-8-one 22 as colourless crystals (97%). The 
data were identical to authentic material. 
Cyclisation reactions of 3-(3-iodopropyl)-38-quinazolin-4-one 
3la. 
8examethylditin. The general procedure for reactions us-
ing photolysis and hexamethylditin with 3-(3-iodopropyi)-3H-
quinazolin-4-one 3la (24 h) yielded: 2,3-dihydro-1H-pyrrolo[2,1-
b]quinazolin-9-one 2 as colourless crystals (20%), mp 190-192 oc 
(lit.,61 196-198 °C); Vma,(thin film)/cm-1 3418, 2355, 1651, 1621, 
1470, 1385, 1285, 775, 695 and 667; 15" 2.35-2.23 (2 H, m, CH2), 
3.18 (2 H, t, J 12.6, CH2), 4.21 (2 H, t, J 11.5, NCH2), 7.47-7.62 
(l H, m, ArH), 7.76-7.62 (2 H, m, ArH) and 8.28 (I H, dd, J 12.6, 
2.4, ArH);t5c 19.5 (CH2), 32.5 (CH2), 46.5 (NCH2), 120.4(C), 126.2 
(CH), 126.4 (CH), 126.8 (CH), 134.2 (CH), 149.1 (C), 159.5 (C) 
and 161.0 (C). 2,3,3a,4-Tetrahydro-1 H-pyrrolo[2, 1-b]quinazolin-
9-one 32a as colourless crystals (12%), mp 187-188 oc (lit./1 184-
185 °C); v,..,(thin film)/cm-• 3421, 1633, 1503, 1470, 1434, 1337, 
1151, 752 and 695; 15" 2.32-2.29 (2 H, m, 2-CH2), 3.19 (1 H, t, 
J 8.0, 1-H), 3.75-3.67 (2 H, m, CHCH2), 4.21 (I H, dd, J 8.0, 
7.2, 1-H), 4.5 (I H, bs, NH), 5.03 (I H, dd, J 7.2, 5.6, 3a-H), 6.69 
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(l H, d, J 12.9, ArH), 6.92-6.88 (l H, m, ArH), 7.27-7.24 (1 H, 
m, ArH) and 7.91-7.87 (I H, dd, J 12.3, 9.9, ArH);t5c 21.7 (CH2), 
33.2 (CHCH2), 44.3 (NCH2), 69.9 (CH), 114.9 (CH), 118.4 (CH), 
119.9 (C), 126.8 (CH), 132.9 (CH), 149.1 (C) and 162.2 (C). 3-
Propyl-38-quinazolin-4-one 33a as colourless crystals (6%). The 
data were identical with those from an independently prepared 
authentic sample. 
BuJSn8 and EtJB. 3-Propyi-3H-quinazolin-4-one 33a (78%) 
was the only product. 
EtJB only. The general procedure for Bu3SnH and Et3B re-
actions were used except that the Bu3SnH was not added .. 
1H NMR spectral analysis showed 2,3-dihydro-18-pyrrolo[2,1-
b]quinazolin-9-one 2 (40%), 2,3,3a,4-tetrahydro-1H -pyrrolo[2, 1-
b]quinazolin-9-one 32a (10%) and 3-propyl-38-quinazolin-4-one 
33a (30%). 
Cyclisation reactions of 3-(3-iodobutyl)-38-quinazolin-4-one 
31b. 
( Me1Sn) 1 and photolysis. The general procedure for reactions 
using photolysis and hexamethylditin (24 h) yielded: 6,7,8,9-
tetrahydropyrido[2,1-b]quinzolin-11-one 3 as colourless crystals 
(30%), mp 94-95 °C (lit.,63 96-97 °C); Found: MH+, 201.1020. 
C12H 13N20 requires 201.1022; v ... ,(thin film)/cm-• 3423, 2948, 
2110, 1655, 1614, 1565, 1477, 1173, 1102,990,870,771 and 583; 
15" 2.18-1.91 (4 H, m, CH2CH2), 3.00 (2 H, t, J 6.6, NCCH2), 
4.09 (2 H, t, J 6.3, NCH2), 7.44-7.40 (1 H, m, ArH), 7.59 (1 H, 
dd, J 8.3, 0.5, ArH), 7.73-7.69 (1 H, m, ArH) and 8.26 (1 H, 
dd, J 8.0 1.5, ArH); t5c 19.3 (CH2), 22.1 (CH2), 31.9 (CH2), 
42.3 (CH2), 120.4 (C), 126.1 (CH), 126.4 (CH), 126.6 (CH), 
134.1 (CH), 147.4 (C), 154.9 (C) and 162.2 (C); m/z (El) 200 
(M+, 50%), 199 (40), 90 (33), 76 (34), 63 (33), 50 (34) and 41 
(90). 5,5a,6, 7,8,9-Hexahydropyrido[2, 1-b]quinazolin-11-one 32b 
as colourless crystals (23%), mp 128-130 oc (lit.,1 132-133 °C); 
Found: MH+, 203.1180. C 12H 15N 20 requires 203.1179; Vmax(thin 
film)/cm-1 3398, 3058, 2938, 2224, 1632, 1518, 1416, 1218, 1153, 
1026, 754 and 692; 15" 1.52-1.49 (2 H, m), 1.91-1.75 (4 H, m), 
2.66-2.59 (1 H, m, 9-H), 4.25 (1 H, m, NH), 4.64-4.59 (1 H, m, 
9-H), 4.78 (1 H, dd, J 13.5, 3.1, Sa-H), 6.57 (1 H, d, J 1.1, ArH), 
6.79 (l H, ddd, 17.8, 2.9, 1.0, ArH), 7.27-7.22 (1 H, m, ArH) and 
7.90 (1 H, dd, J 7.8 1.6, ArH); t5c 22.3 (CH2), 24.2 (CH2), 33.4 
(CH2), 42.0 (CH2), 68.5 (CH), 113.7 (CH), 115.2 (C), 118.8 (CH), 
128.7 (CH), 133.4 (CH), 145.9 (C) and 164.3 (C); m/z (El) 202 
(M+, 30%), 146 (42), 119 (48), 92 (42), 55 (79) and 41 (lOO). 
EtJB only. The general procedure for Bu3SnH and Et3B re-
actions were used except that the Bu3SnH was not added. 
1H NMR spectral analysis showed 6,7,8,9-tetrahydro-pyrido[2,1-
b]quinzolin-ll-one 3 (61 %) and 5,5a,6, 7,8,9-hexahydropyrido[2, 1-
b]quinazolin-11-one 32b (23%). 
Cyclisation of 3-)(2-bromoquinolin-3-yl)methyl)-4(3H)-quina-
zolinone 34. 
( MeJSn)z and photolysis. The general procedure for reactions 
using photolysis and hexamethylditin (24 h) yielded: luotonin A 
5 (51%). All data were the same as reported." 3-[(Quinolin-3-
yl)methyl]-38-quinazolin-4-one 36, colourless crystals, mp 252-
253 °C; Found: MH+, 288.1130. C18H 13N30 requires 288.1131; 
Vmax(thin film)/cm-1 3420, 2357, 2107, 1646, 1558, 1450, 1361, 
1332, 510and454;15" 5.39 (2 H, s, CH2), 7.58-7.53 (2 H, m, ArH), 
7.81-7.70(4 H, m, ArH), 8.10(1 H, dd,J 8.9, 0.4, ArH), 8.17 (I H, 
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d, J 1.8, ArH), 8.35-8.32 (l H, m, ArH) and 8.99 (I H, d, J 1.8, 
ArH); be 47.7 (CH2), 122.1 (CH), 126.9 (CH), 127.3 (CH), 127.7 
(2 X CH), 127.9 (CH), 128.6 (2 X C), 129.3 (CH), 130.0 (CH), 
134.6 (CH), 135.4 (CH), 145.9 (CH), 147.9 (C), 148.0 (C), 150.1 
(CH) and l6l.l (C); m/z (El) 287 (M+, 45%), 270 (42), 132 (lOO), 
115 (70), 89 (20), and 63 (21 ). 
Bu3SnH and Et3B. The general procedure for Bu3SnH reactions 
using Et3B as initiator were used with Bu3SnH added by syringe 
pump over 5 h and the reaction stirred for a further 5 h to yield 
luotonin A 5 (14%) and 3-[(quinolin-3-yl)methyi]-3H-quinazolin-
4-one 36 (32%). When the Bu3SnH was added at the beginning of 
the reaction only 3-[(quinolin-3-yl)methyi]-JH-quinazolin-4-one 
36 was obtained (53%). 
Bu3GeH and Et3B. Luotonin A' (18%) and [(3-quinolin-3-
yl)methyi]-JH-quinazolin-4-one 36 (ll%) were obtained. 
Cyclisation of 3-[2-(2-bromoindol-3-yl)ethyi)-4(3H)-quinazoli-
none40. 
Bu3SnH addition. The general procedure for Bu3SnH reactions 
using Et3B as initiator were used with Bu3SnH added by sy-
ringe pump over 12 h to yield rutaecarpine 8 (15%), mp 254-
255 °C (lit.,'1 256-257 °C} and 3-[2-(lH-indol-3-yl)ethyi]-4(3H)-
quinazolinone 39 (57%), both as colourless crystals. The data for 
rutaecarpine were the same as those in the literature!• The data 
for 39 were the same as obtained in the previous synthesis. 
( Me3 Sn)1 and photolysis. The general procedure for reactions 
using photolysis and hexamethylditin (6 h) yielded rutaecarpine 
(55%) as the only product. 
2-(4-0xo-4H-quinazolin-3-yl)selenobenzoic acid Se-phenyl ester 
43. Tributylphosphine (2.5 cml, lO mmol) was slowly added 
to diphenyl diselenide (2.47 g, 7.9 mmol) in anhydrous DCM 
and the mixture left to stir for 15 min. 2-(4-0xo-48-quinazolin-
3-yl)benzoic acid 42 (1.40 g, 5.2 mmol) was then added and 
the reaction stirred for 12 h till no precipitate was visible. The 
reaction mixture was diluted with DCM and washed with H20 
(3 x 50 cm3) and brine (50 cm3). The organic layer was dried 
over MgS04 and evaporated to dryness under reduced pressure. 
The crude product was purified by column chromatography using 
silica gel as absorbent and light petroleum/EtOAc (4:1). The 
resulting yellow solid was recrystallised from hot EtOH yielding 
2-(4-oxo-4H-quinazolin-3-yl)selenobenzoic acid Se-phenyl ester 
43 as long yellow needles (1.55 g, 3.8 mmol, 73%); (Found: M+, 
407.0289. CJ1H 14N20 2Se requires 407.0293); mp 234-236 oc; 
Vm,.(thin film)/cm·• 3165,2831,2063, 1798, 1519, 1367, IllS, 960 
and 915; Or. 7.36 - 7.30 (3 H, m, ArH), 7.42 (I H, dd, J 9.2 1.6, 
ArH), 7.55- 7.45 (3 H, m, ArH), 7.70-7.66 (I H, m, ArH), 7.81-
7.72(3 H, m,ArH), 8.02(1 H, s, 2-H), 8.14(1 H, dd,J 9.2l.6,ArH) 
and 8.34-8.32 (l H, m, ArH); 0c 122.3 (C), 125.9 (C), 127.1 (5-C), 
127.6 (6-C), 127.7 (CH), 129.2 (CH), 129.4 (2 X CH), 129.4 (CH), 
129.8 (CH), 130.1 (CH), 133.6 (C), 133.7 (CH), 134.6 (CH), 136.0 
(2 x CH), 136.9 (C), 145.6 (2-C), 148.0 (C), 160.7 (4-C) and 192.7 
(CO); mlz (El) 407 (M+, lOO%), 251 (39), 235 (55) and 223 (46). 
Radical reactions of 2-( 4-oxo-4H -quinazolin-3-yl)selenobenzoic 
acid Se-methyl ester 43. 
UV and reflux. -( 4-0xo-4H -quinazolin-3-yl)selenobenzoic acid 
Se-phenyl ester 43 (0.24 g, 0.59 mmol) was heated under reflux 
in benzene (20 cm3) for 12 h under UV irradiation. The solvent 
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was removed under vacuum and the crude product was purified 
by column chromatography using silica gel as absorbent and light 
petroleum-EtOAc (2 : l) yielding tryptanthrin 4 as yellow crystals 
(0.02 g, 0.07 mmol, 13%), mp 213-214 °C (lit.53 215-217 °C); 
Found: MH+, 249.0659. C15H9N20 2 requires 249.0660; bH 7.43 
(I H, t, J 8.0, ArH), 7.68 (I H, t, J 8.0, ArH), 7.79 (l H, t, J 8.0, 
ArH), 7.86 (l H, t, J 8.0, ArH), 7.92 (I H, d, J 8.0, ArH), 8.04 (I H, 
d, J 8.0, ArH), 8.44 (I H, d, J 8.0, ArH) and 8.64 (I H, d, J 8.0, 
ArH);be ll8.0(CH), 122.0 (C), 123.8 (C), 125.4 (CH), 127.2 (CH), 
127.6 (CH), 130.2 (CH), 130.7 (CH), 135.1 (CH), 138.3 (CH), 
146.4 (C), 146.7 (C), 158.1 (C) and l7l.l (2 x CH); mlz (El) 248 
(M•, 51%),220(22), 130(28), 102(54), 90(100), 76(81), 63(55)and 
50 (74). The data were identical to the literature data 53 and those of 
authentic material. Repeating the reaction for 10 h gave a yield of 
ll% of 4. The procedure was repeated using the same conditions 
but with the addition of AIBN (2.0 equiv.) for 8 h. An intractable 
mixture was obtained. A blank reaction with no sunlamp 
photolysis or added AIBN, in benzene heated under reflux for 
24 h gave a quantitative recovery of unaltered starting material43. 
(Me3Sn}2. sun/amp. The reaction between 2-(4-oxo-4H-
quinazolin-3-yl)selenobenzoic acid Se-phenyl ester 47 (0.29 g, 
0.72 mmol) and hexamethylditin (0.70 g, 2.15 mmol) was carried 
out in tert-butylbenzene (20 cm3). The mixture was heated under 
reflux and irradiated with a sunlamp for 4 h. Dilute hydrochloric 
acid was added to the cooled reaction mixture to extract the 
protonated quinazolone products into the aqueous layer. The 
aqueous layer was washed with light petroleum to remove tin 
residues. The aqueous layer was basified with sodium hydroxide to 
pH 14 and extracted with DCM. The combined organic layers were 
dried and evaporated under reduced pressure. The residue was 
purified by column chromatography using silica gel as absorbent 
and light petroleum-EtOAc (2: l) yielding tryptanthrin 4 (5 mg, 
0.02 mmol, 3%). 
Sun/amp. When the sunlamp irradiation alone was used for 
30 min, the highest yield oftryptanthrin (15%) was obtained. 
2-1(4-0xo-4H-quinazolin-3-yl)methyl[benzoic methyl ester 45. 
N-Bromosuccinimide (19.0 g, 107.1 mmol, 1.5 equiv.), methyl 
2-methylbenzoate (10.0 cm3, 71.4 mmol) and AIBN (l.l6 g, 
7.1 mmol) were refluxed in cyclohexane in the dark for 5 h. The 
reaction mixture was cooled to 0 °C and filtered. The filtrate 
was diluted with DCM, washed with H20 (3 x 50 cm3) and 
brine (50 cm3) and then dried and evaporated to dryness under 
reduced pressure. The unpurified methyl 2-bromomethylbenzoate 
was added to a solution of 3H-quinazolin-4-one (7.3 g, 50 mmol) 
and potassium tert-butoxide (07.3 g, 65 mmol) in DMF (50 cm3) 
that had been stirred for 40 min. The resulting mixture was stirred 
for 12 h then diluted with DCM, and the solution washed with 
H20 and brine. The organic layer was dried and evaporated under 
reduced pressure. The crude product was purified by column 
chromatography using silica gel as absorbent and light petroleum-
EtOAc (4 : l) as eluent yielding 2-[(4-oxo-4H-quinazolin-3-
yl)methyl]benzoic methyl ester as a pale oi145 ( 4.98 g, 16.6 mmol, 
34%); (Found: M•, 295.1077. C17H 1,N20 3 requires 295.1077); 
Vmax(thin film)/cm·• 3541, 3417, 1715, 1681, 1563, 1367, 1322, 
1079,968 and 774;bH 3.88 (3 H, s, OMe), 5.62 (2 H, s, CH2), 7.31-
7.22 (2 H, m, ArH), 7.70-7.69 (2 H, m, ArH), 7.97 (I H, dd, J 7.8 
1.4, ArH) and 8.28-8.23 (2 H, m, ArH); be 47.9 (CH2), 52.4 (Me), 
122.2 (4a-C), 126.9 (CH), 127.3 (CH), 127.5 (CH), 128.0 (CH), 
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128.6 (C), 129.1 (CH), 131.3 (CH), 133.0 (CH), 134.7 (CH), 147.1 
(CH), 148.1 (Sa-C), 161.4 (4-C) and 167.4 (C02Me); mlz (El) 262 
(M+, 53%), 132 (80), 118 (30), 102 (60), 91 (100), 77 (58), 63 (33) 
and 50 (23). 
2-((4-0xo-4H-quinazolin-3-yl)methyl)benzoic methyl acid 46. 
A solution of 2-[( 4-oxo-4H -quinazolin-3-yl)methyl]benzoic 
methyl ester 45 (1.93 g, 6.14 mmol) in ethanolic LiOH (I M, 
200 cm3) and water (20 cm3) was stirred for 18 h. The mixture 
was acidified with HCI and extracted with EtOAc. The organic 
layers were combined and washed with H20 and brine. The 
organic extract was dried over MgS04 and evaporated to dry-
ness under reduced pressure yielding 2-[(4-oxo-4H-quinazolin-
3-yl)methyl]benzoic methyl acid 46 as a colourless oil (0.63 g, 
2.1 mmol, 34%); Found: M+, 281.0918. C16H 12N20 3 requires 
281.0921; mlz (El) 262 (M+, 31%), 146 (35), 132 (86), 118 (38), 
104 (47), 90 (58), 77 (100), 63 (28), 51 (32) and 43 (53). The 
carboxylic acid 46 was converted to the acyl selenide without 
further characterisation. 
2-((4-0xo-4H-quinazolin-3-yl)methyl)seleno benzoic acid Se-
phenyl ester 47. The same procedure as for the seleno-ester 43 
was used to convert 2-[(4-oxo-4H-quinazolin-3-yl)methyl]benzoic 
methyl acid 46 to 2-[(4-oxo-4H-quinazolin-3-yl)methyl]seleno 
benzoic acid Se-phenyl ester 47 as colourless crystals (0.31 g, 
0.71 mmol, 68%), mp 314-316 °C; Found: M•W, 421.0450. 
c22HI7N20280Se requires 421.0451; Vm,.(thin film)/cm·l 3361, 
l91I, 1659, 1589, 1542, 1392, 1336, 1188, 801, 760 and 722; «5H 
5.43 (2 H, s, CH2), 7.37-7.35 (l H, m, ArH), 7.53-7.45 (6 H, m, 
ArH), 7.61-7.59 (2 H, ArH), 7.79-7.73 (2 H, m, ArH), 8.04 (I H, 
dd, J 1.6 1.3, ArH), 8.13 (l H, s, 2-H) and 8.33-8.30 (l H, m, 
ArH); «5c 47.2 (CH2), 122.1 (4a-C), 126.3 (C), 126.9 (CH), 127.4 
(CH), 127.5 (CH), 128.5 (CH), 129.4 (CH), 129.6 (CH), 129.6 
(CH), 129.7 (CH), 133.2 (CH), 133.6 (C), 134.4 (CH), 136.2 (CH), 
137.6 (C), 147.0 (CH), 148.0 (Sa-C), 161.3 (4-C) and 196.7 (CO); 
mlz (Eiectrospray) 421 (M+, 7%), 263 (60), 156 (45), 129 (lOO), 
102 (43), 89 (46), 77 (60), 63 (23) and 51 (33). 
11-Hydroxy-11H -isoquinolino(3,2-h)quinazolin-6,13-dione 50. 
The reaction between 2-[( 4-oxo-4H-quinazolin-3-yl)methyl]seleno 
benzoic acid Se-phenyl ester 47 (0.044 g, 0.1 mmol) and 
hexamethylditin (0.099 g, 0.3 mmol) was carried out in benzene 
(20 cm3) and was refluxed and irradiated with a UV lamp for 
3 h. The benzene was removed under vacuum and the crude 
product was purified by column chromatography using silica gel 
as absorbent and light petroleum-EtOAc (4: l) as eluent yielding 
11-hydroxy-llH -isoquinolino[3,2-b]quinazolin-6,13-dione 50 as 
colourless needles (0.011 g, 0.04 mmol, 39%), mp 176-177 °C 
(CHCI3); Found: (M + H)+, 279.0768. C16H 11 N20 3 requires 
279.0764; v,..,(thin film)/ cm·' 3421,2919,2360, 1699, 1683, 1653, 
1559, I465, I260, IIOO, 963, 910, 728 and 667; «5H 5.29 (I H, d, J 
4.6, OH), 7.2I (I H, d, J 4.6, CH), 7.69-7.65 (2 H, m, ArH), 7.80 
(l H, d, J 8.0, ArH), 7.93-7.84 (2 H, m, ArH), 8.10 (I H, d, J 
8.0, ArH), 8.32 (I H, dd, J 1.6 1.2, ArH) and 8.39 (I H, dd, J 8.0 
1.2, ArH); Jc 75.5 (CH), I21.9 (C), 126.7 (CH), 128.0 (CH), 128.7 
(CH), 129.2 (C), 129.6 (CH), 130.0 (CH), 130.3 (CH), 135.6 (CH), 
135.7(CH),137.0(C),I42.6(ArC),I46.7(C),I62.7(C)and 176.6 
(C); mlz (Eiectrospray) 278 (M+, 50%), 262 (43), 249 (40), 221 
(26), 135 (38), 119 (36), 105 (100), 91 (45), 84 (60), 77 (68) and 51 
(69). The structure was confirmed by X-ray crystallography. 
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X-Ray crystallography 
Data were collected at 150(2) K on a Bruker SMART 1000 
diiTractometer with sealed tube source64 for 30 and Bruker-Nonius 
CCD diiTractometer with rotating anode source65 for 50. The 
structures were solved by direct methods and refined by full-matrix 
least-squares on P using the SHELXTL suite of programs. 66 All 
the non-hydrogen atoms were refined with anisotropic atomic 
displacement parameters and hydrogen atoms were inserted at 
calculated positions using a riding model except for H(2) for which 
coordinates were freely refined in both structures. In 30, molecules 
form into chains via intermolecular H-bonds N(2)-H(2) · · · 0(1'). 
The structure of 50 additionally contains one molecule ofCHCI3 in 
the asymmetric unit and molecules are linked into chains via strong 
intermolecular H-bonds 0(2)-H(2) · · · N(2'). OfT-set 7t-7t stacking 
is also dominant with separations in the range 3.33-3.5 A. 
Crystal data for 30: C16H 14N20S, M= 282.35, monoclinic, Cc, 
a= 4.6405(7), b = 25.329(4), c = 12.I9IO(I7) A, p = 97.047(2t, 
U = l422.I(4)A3, T= 150(2) K,Z =4,,u(Mo-Ka) =0.224mm·1, 
5350 reflections measured, 3005 unique (R,., = 0.0368) which were 
used in all calculations, wR = O.I590 for all data, RI = 0.0602 
for 2351 data with P ?: 2a(P). Absolute structure parameter= 
0.13(I3)-thus reliably determined. 
Crystal data for 50: C 17H 11 CI3N20 3, M= 397.63, triclinic, PI, 
a= 6.6511(3), b = 8.6274(3), c = 14.5395(7) A, a= 90.123, p = 
94.525(3), I' = 99.594(3t. u = 8I9.97(6) A3, T = I20(2) K, z = 
2, ,u(Mo-Ka) = 0.579 mm·', li250 reflections measured, 37I5 
unique (R,., = 0.0370) which were used in all calculations, wR = 
0.0939 for all data, RI = 0.0353 for 2898 data with P ?: 2a(P).t 
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Cascade radical cyclisation involving homolytic aromatic substitution has been used to synthesise new tetracycles. 
Treatment of vinyl iodide radical precursors with Me3Sn" radicals (from hexamethylditin) yielded intermediate vinyl 
radicals which undergo 5-exo cyclisation onto suitably placed nitrile groups to yield intermediate iminyl radicals. The 
iminyl radicals undergo aromatic homolytic substitution via 6-endo cyclisation (or 5-exo cyclisation followed by 
neophyl rearrangement) with loss of hydrogen (H") in a H-abstraction step. We propose that this abstraction was 
facilitated by tert-butoxyl (t-BuO") radicals from di-tert-butyl peroxide or methyl radicals, generated from breakdown 
oftrimethylstannyl radicals (Me3Sn"). The biologically active alkaloids mappicine and luotonin A were synthesised 
using the new methodology. A novel radical conversion ofnitriles to primary amides is proposed. 
Introduction 
Tetracyclic and pentacyclic alkaloids with the 2,3-dihydro-IH-
pyrrolo[3,4-b]quinoline ring system making up rings A-C have 
been of intense interest in recent years. In particular, interest has 
centred around the anticancer and antiviral camptothecin 1 and· 
analogues mappicine 2 and mappicine ketone (nothapodytine 
B) 3.1 The chemistry and pharmacology of camptothecins 
and analogues have been fully reviewed. 1 Camptothecin '.2 and 
mappicine'.2f.3 have been popular targets of synthesis and a 
wide variety of protocols have been reported including hetero 
Diels-Aider reactions, condensation to form the pyridone ring 
in the synthesis and biomimetic synthesis. Few of these studies 
have used radical methodology. The major studies using radical 
synthesis have been reported by Curran and eo-workers who 
have synthesised camptothecin and analogues4-6 and mappicine' 
via bimolecular radical additions of radicals derived from 6-
iodo-IH-pyridin-2-ones onto aryl-isonitriles. A synthesis of 
camptothecin using cyclisation of 2-quinolinyl radicals onto 
pyridones has also been reported.8 Synthetic studies towards 
mappicine using radical cyclisation onto enamides have also 
been reported.9 
Another group of alkaloids containing the 2,3-dihydro-IH-
pyrrolo[3,4-b]quinoline ring system are the recently discovered 
pyrroloquinazolinoquinoline alkaloids, luotonins A 4, B 5 
and E 6 and other congeners.10 Although the compounds 
were only isolated four years ago10 there are already several 
syntheses of luotonin A, which has proved a popular synthetic 
target." None of the syntheses have used radical protocols. 
The luotonins are used in traditional Chinese medicine and 
are reported to exhibit activity against a range of ailments 
including rheumatism, inflammation, influenza, hepatitis and 
luekemia.10•11 More recently, luotonin A has shown great promise 
as an antitumour compound and is a poison for human DNA 
topoisomerase 1.'06 
In our studies of radical reactions of nitriles we showed 
that the cyclisation onto the nitrile group could be used in 
synthesis with understanding of the reactivity and rates of 
reactions.12 The rates of cyclisation onto nitriles are slow, and 
faster, competing reactions need to be avoided in the design 
t Electronic supplementary information (ESI) available: preparation 
and analytical details for heteroarene compounds. See http://www.rsc. 
org/ suppdata/ ob/b5/b50 1509j/ 
of syntheses. For example, the rate cyclisation of 4-cyanobutyl 
radicals ["CH2(CH2) 3CN] is slow (4 x 103 s-• at 25 °C).13 We 
showed that 5-exo cyclisation of reactive aryl and vinyl radicals 
was faster than alkyl radicals thus providing more suitable 
reactions for synthesis and that cyclisation onto nitriles to 
generate intermediate iminyl radicals could be used for further 
tandem cyclisations onto alkenes.11 We have developed these 
studies to a new protocol for the synthesis of the 2,3-dihydro-1 H-
pyrrolo[3,4-b]quinoline ring system 7 which depends on several 
radical reactions in a cascade sequence (Scheme 1).14 
camptothecin 1 
mappicine 2, R1 = H, R2 = OH 
mappicine ketone 3, R1R2 = 0 
luotonin A, 4, R = H 
luotonin B, 5, R = OH 
luotonin E, 6, R = OMe 
~N~ ~-N~/ 
8 
Scheme 1 
==> 
In this synthetic protocol, the first of the radical cyclisations 
in the cascade sequence is 5-exo cyclisation of vinyl radicals onto 
nitriles, i.e. 9 to 8. Vinyl6•14•15 and imidoyJI6 radical cyclisations 
onto nitriles have been reported in a few examples. In the second 
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step of the cascade process (8 to 7), the newly formed iminyl 
radical intermediate 8 undergoes 6-endo (or 5-exo cyclisation 
followed by neophyl rearrangement) cyclisation onto the arene. 
The cyclisation reactions of the iminyl radical have been 
extensively studied by Zard and eo-workers. 17 The final step 
is formally an aromatic homolytic substitution in which the 
iminyl radical substitutes for a hydrogen radical (H"). Aromatic 
homolytic substitution is a much under-used and maligned 
synthetic reaction but importantly is usefully regioselective when 
intramolecular.18 In recent years many of the aromatic homolytic 
substitutions have been facilitated using tributyltin hydride to 
excellent synthetic application.19 While these reactions can be 
formally described as aromatic homolytic substitution, the exact 
mechanism is unclear. 19 
With the dual aim of further studying cyclisation onto nitriles 
and investigating its use in synthesis, we report the application 
of the methodology to the synthesis of mappicine (2) and 
mappicine ketone (nothapodytine B; 3) and luotonin A (4). 
Results and discussion 
Mappicine 2 and nothapodytine B 3 
Our first investigation was the synthesis of mappicine 2 and 
mappicine ketone 3. We sought to synthesise the simplest 
relay 21 which has been used in the synthesis of mappicine, 
thereby constituting a formal synthesis.21.2° The use of the 
electron-withdrawing substituent also provides an interesting 
test for the chemistry. The interconversion between the ketone of 
nothapodytine Band the alcohol ofmappicine are facile so both 
present a formal synthesis of each other. 
The radical precursor 16 was synthesised as shown in 
Scheme 2 using a similar procedure to our earlier study.14 
2,6-Dibromopyridine-4-carboxylic acid was synthesised from 
the commercially available citrazinic acid 11 in an 80% 
yield.'' SNAr substitution with methoxide yielded 2-bromo-
6-methoxypyridine-4-carboxylic acid 12 in a 96% yield. 14•22 
The usual procedure14 for the introduction of the nitrile 
group using CuCN and decomposition of the resultant copper 
complex to liberate the aryl nitrile proved problematic and 
black tars were observed. Therefore, the copper(I)-catalysed 
cyanation was carried out on the methyl ester, methyl 2-bromo-
6-methoxypyridine-4-carboxylate, instead of the free carboxylic 
acid. Various alternative procedures were attempted but the 
yield of 40% could not be further maximised, indicating that 
the ester group hinders the reaction. The product 13 was only 
obtained when methanol was used in place of water in the 
decomposition of the copper complex. The low yield is likely 
C02H C02H C02Me n~n~n 
HO N OH Br N/. OMe NC N OMe 
11 12 13 
Scheme 2 Reagents and conditions: i, POBr, 180 °C, 80%; ii, NaOMe, 
MeOH, 60 °C, 96% {12); iii, MeOH, cone. H2SO,, 87%; iv, CuCN, DMF, 
reflux, 48 h, 400/o {13); v, TMSC1, Nal, MeCN, 63% {14); vi, IS, NaH, 
LiC1, DME, DMF, 32% (16), 30% (17). 
to be due to some hydrolysis to 2-cyano-6-methoxypyridine-
4-carboxylic acid which binds to the copper in the reaction. 
Conversion of 13 to the cyanopyridone 14 was carried out 
using a literature procedure.'·14 The cyanopyridone 14 was 
alkylated with the a-iodocinnamyl bromide14 15 using conditions 
that normally favour N -alkylation of pyridones.14.21 The radical 
precursor 16 was obtained in only a 32% yield. The low 
yield was due to 0-alkylation (17, 30%) and the formation of 
small amounts of methyl 6-cyano-1 ,2-dihydro-1-methyl-2-oxo-
4-pyridine-carboxylate. The reasons for the low N -selectivity are 
not obvious. 
The radical precursor 16 was reacted under similar conditions 
to those reported in our earlier paper,14 i.e. hexamethylditin 
(7.5 equiv.) in tert-butylbenzene with sun lamp irradiation 
(Scheme 3). Hexamethylditin was used in order to prevent 
trapping of intermediate radicals with a reagent such as 
tributyltin hydride. Irradiation and heating at 150 °C gave 
considerable decomposition with an isolated yield of methyl 9-
oxo-9, 11-dihydroindolizino[ 1 ,2-b ]quinoline-7 -carboxylate 21 of 
only 15%. Reaction at a lower temperature of 85 °C with a 
smaller amount of hexamethylditin (2 equiv.) gave a better 
yield of21 (50% crude, 21% purified). These lower yields were 
disappointing compared with yields of up to 80% in earlier 
studies but indicate that the ester group makes the substrate 
16 more reactive.14 The use of di-tert-butyl peroxide as an 
initator14 largely resulted in decomposition with only a trace 
of 21. This may be related to the presence of the methoxy 
functional group, as decomposition under these conditions was 
also observed in the synthesis of the tetracyclic rings A-D of 
nothapodytine A which contains a 1-methoxy substituent.14 
Hydrogen-abstraction from methoxy groups is unfortunately 
common due to the formation of a stable radical. 
I 
16-
Scheme 3 Reagents and conditions: i, {Me,Sn), tert-BuPh, hv, 85 °C, 
24 h, 21% (21). 
Scheme 3 shows the putative mechanism of the cascade 
reaction.14 Abstraction of iodine by the trimethyltin radical 
(Me,Sn") yields the vinyl radical which undergoes 5-exo cycli-
sation onto the nitrile group to yield an intermediate iminyl 
radical 18. The rate of bromine abstraction by Bu,sn· radicals 
of bromine from vinyl bromides is fast (106-107 M-1 s-1),24 and 
therefore, abstraction of iodine by Me,Sn· will be faster and is 
unlikely to be rate determining in the reaction sequence. Both 
the 5-exo cyclisation onto the nitrile to yield 18 and cyclisation of 
the iminyl radical intermediate onto the phenyl ring (5-exo to 19 
or 6-endo to 20) are slow. The abstraction of the hydrogen from 
20 is the second step of the aromatic homolytic substitution. The 
mechanism of this step is not clear but we have proposed that the 
abstracting species are methyl radicals from the breakdown of 
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trimethyltin radicals.•• Blank reactions without hexamethylditin 
gave traces of 21 indicating iodine-homolysis or Diels-Alder 
cyclisation as possible minor mechanisms. 
Luotonin A (4) 
Our initial aim for the synthesis of luotonin A 4 was to use 
the same methodology, i.e. to alkylate a suitable a-cyano NH-
heteroarene (Scheme 4) and carry out the [4 + 2] cascade 
radical cyclisation as exemplified in Scheme 3 for the synthesis 
of mappicine and our earlier studies. 14 To this end we decided to 
use 4-oxo-3,4-dihydroquinazoline-2-carbonitrile 25 (Scheme 4). 
This model would allow study of the quinazoline ring system in 
the radical cascade protocol. 
22 23 
0 Ph~Br O 
oCNH ~~:~~~ X ocN~Ph A ... .... I ) X N CN 111 '-"' ~ N CN 
25 
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27,X=I 
28,X= H 
«ON Jl N CN 
30, X =_I) YPh 
31, (X- H) X 
Scheme 4 Reagents and conditions: i, pyridine, DCM, rt, 24 h, 92% 
(24); ii, NH, dioxane, rt, 5 d, 98% (25); iii, NaH, LiCI, DME, DMF, 
rt, 5 h: IS gave 16% (27), 0% (29, X= 1), 6% (30) and 26 gave 45% (28), 
9% (29, X= H), < 1% (31); NaH, DMF, 60 •c, 20 h, 26 gave 44% (28), 
trace (29, X= H), 0% (31). 
4-0xo-3,4-dihydroquinazoline-2-carbonitrile 25 was synthe-
sised in high yield (98%) from ethyl 2-[(4-chloro-5H-1,2,3-
dithiazol-5-yliden)amino]benzene-1-carboxylate 24 and ammo-
nia. This represents a new route to quinazoline-2-carbonitriles. 
This unusual reaction between amines and the (4-chloro-5H-
1,2,3-dithiazol-5-yliden)amino ring system, developed by Rees 
and co-workers/5 proved useful in our studies. A similar 
application has been reported by Kim and Mohanta for the 2-
cyanoquinazoline system.26 The protocol relies on the reaction 
between Appel's salt27 23 and anthranilate esters (e.g. 22) to yield 
24.25 
The procedure for regioselective N-alkylation over a-
alkylation which has been successfully applied to 6-cyano-
pyridones14 and to 6-iodopyridones23 again gave only small 
amounts of a-alkylation (Scheme 4). In contrast, a-alkylation 
can be selectively facilitated over N-alkylation by using the 
Mitsunobu reaction with alcohols instead of halides for quina-
zolines and isoquinolines based on low (hard) polarisabil-
ity factors.28 We have observed the same a-selectivity with 
the Mitsunobu reaction when attempting alkylation of 6-
oxo-1 ,6-dihydro-pyridine-2-carbonitrile with 1-[(Z)-3-bromo-2-
iodoprop-1-enyl]benzene 15 and DEAD.29 However, in this 
study the protocol was largely N-selective but it was not 
completely selective between alkylation at the !-Nand 3-N and 
the isomers were difficult to separate. At ambient temperatures, 
alkylation of25 with cinnamyl bromide 26 gave a moderate yield 
of the required 3-N alkylated product 28. When the temperature 
was raised, a-alkylation (to 29, X = H) and 1-N alkylation 
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(to 31) were largely eliminated. Unfortunately, the yields for 
alkylation with I-[(Z)-3-bromo-2-iodoprop-1-enyl]benzene14 15 
were poor and the two regio-isomers could not be separated even 
after extensive chromatography. 
We therefore developed a protocol which would be regioselec-
tive to the required 3-N product. Ethyl2-[(4-chloro-5H-1,2,3-
dithiazol-5-yliden)amino ]benzene-1-carboxylate 24 was reacted 
with the required cinnamylamines 32 and 33 (Scheme 5). The 
cinnamylamines were prepared by standard methodology. Both 
cinnamylamines gave moderate yields of the required products 
27 and 28. The quinazoline 28 was synthesised as a possible 
product of unsuccessful cascade cyclisation for comparison and 
identification purposes. The yields could not be optimised but 
are similar to reported reactions of similar compounds in the 
literature.2'·26 An excess (1.5 equiv.) of Appel's salt was used 
to ensure complete conversion of ethyl 2-aminobenzoate 22 
because it co-elutes with the product 24 creating yet further 
separation problems. The advantage of the Rees method in the 
synthesis of the radical precursor is that it avoids the possibility 
of alkylation at oxygen and 1-N. The Z-stereochemistry of the 
alkene 27 and the £-stereochemistry of 28 were determined by 
NOE difference NMR spectroscopy. 
24 + Ph~NH2 
X 
32,X=I 
33,X= H 
27(X= I) 
28(X=H) 
Scheme 5 Reagents and conditions: i, THF, rt, 48 h, 32 gave 42% (27); 
33 gave 40% (28). 
The radical precursor 27 was reacted under the general 
reaction conditions•• using hexamethylditin (14 equiv.) in tert-
butylbenzene with sun lamp irradiation at 150 •c for 46 h 
(Scheme 6). Luotonin A 4 was formed as predicted in 21% yield 
along with other products (30%, an EIZ isomeric mixture). 
We initially assumed that the other product was the reduced 
uncyclised compound 28. However, after independent syntheses 
of potential products, we realised that the unknown products 
were an El Z isomeric mixture of the primary ami des 38 and 39. 
No unaltered starting material or other products were observed 
in the radical reactions except for large amounts of a polymeric 
organotin compound.14 
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Scheme 6 Reagents and conditions: i, (Me3Sn), tert-BuPh, hv. 
In order to improve the yield ofluotonin A, milder conditions 
using di-tert-butyl peroxide were studied.14 tert-Butoxyl radicals 
are formed by thermal or photochemical homolysis at lower 
temperatures and react rapidly with hexamethylditin to yield 
trimethyltin radicals. The use of tert-butylperoxyl radicals also 
has the advantage of providing a reactive and efficient H-
abstractor for the final rearomatisation step (Scheme 6, 36 to 
4). The reaction was carried out with 27 (6.33 x I0-2 M) and 
fewer equivalents of hexamethylditin (3.8 equiv.) and di-tert-
butyl peroxide (2.0 equiv.) in a sealed tube at 120 oc and for a 
shorter reaction time (24 h) and yielded luotonin A (30%) and 
38/39(16%). The reaction was repeated at lower dilution (1.47 x 
to·2 M) to encourage cyclisation over potential bimolecular 
reactions. None of the unwanted products 38/39 were observed 
but the yield ofluotonin A dropped to 22%. This result indicates 
a bimolecular reaction in the formation of38 and39. However, it 
was not clear whether formation of38 and 39 had been prevented 
or whether there were subtle differences in the conditions of the 
reaction, e.g. traces of oxygen. All the starting material was con-
sumed in these reactions, therefore, it may be possible to improve 
the yield under milder conditions and shorter reaction times. 
The proposed mechanism of the cascade cyclisation is shown 
in Scheme 6. 5-exo-Cyclisation of the vinyl radical 34 onto 
the nitrile yields the iminyl intermediate 35 which undergoes 
cyclisation onto the phenyl ring (5-exo followed by a neophyl 
rearrangement, or 6-endo, to 36). In this case both 5-exo and 6-
endo routes yield the same product. We have provided evidence 
in previous examples of cyclisation proceeding via initial 5-exo 
cyclisation to a spirodienyl intermediate.14 The abstraction of the 
hydrogen from the lt-radical intermediate 36 to yield luotonin 
A 4 is formally the second step of the aromatic homolytic 
substitution. The mechanism of this step is not clear but we have 
proposed that the abstracting species are methyl radicals from 
the breakdown of trimethyltin radicals or tert-butoxyl radicals 
when di-tert-butyl peroxide was used.14 The synthesis provides 
a further example, albeit in moderate yield, of our cascade 
methodology indicating that cyanoquinazolines can also be used 
and furthermore represents the first synthesis of luotonin A 
using radical methodology. 
In order to gain further mechanistic understanding of the 
radical reactions of 27, blank reactions were carried out with 
the radical precursor 27 and also the equivalent non-iodo 3-
alkylated compound 28 in which the hexamethylditin (and di-
tert-butyl peroxide) were omitted. Both reactions gave near 
quantitative recovery of unaltered starting materials with only 
traces ofluotonin A (<I%). These blank reactions served several 
purposes. Firstly, the reaction with 27 proved that the radical 
reagents were required and hence that the reaction was radical 
mediated. A putative mechanism initiated by iodine-homolysis 
is also eliminated by the lack of reaction under these conditions. 
Secondly, a mechanism involving a purely thermal Diets-Alder 
reaction followed by loss of hydroiodic acid for the synthesis 
of luotonin A 4 could be envisaged for 27 but is ruled out 
by the blank reaction. There is literature precedence for an 
intramolecular Diets-Alder reaction in which a nitrile functional 
group behaves as the 27t component, the product in this case was 
also luotonin A."• 
The mechanism of formation of the primary amide by-
products 38 and 39 is difficult to explain. The products are 
clearly formed by a radical mechanism because they are not 
formed in the blank reaction. The most likely scenario is a 
competing reaction whereby the initial intermediate radical 34 
can either undergo cyclisation onto the nitrile or H-abstraction 
to yield 28 and 37 (Scheme 6). The isomerism to an EIZ 
mixture can be explained by the radical intermediate 34. We 
have previously observed the formation of primary ami des from 
reactions between nitrites and hexamethylditin under radical 
conditions. The mechanism is not obvious but we propose 
that the most likely explanation is that traces of oxygen react 
with the trimethylstannyl radicals as shown in Scheme 7. 30 
Even with careful freeze-thaw techniques traces of oxygen 
are difficult to eliminate completely. The nucleophilic peroxyl 
+[H•) 
Scheme 7 RCN = 38/37. 
radicals add to the electrophilic nitrile. The resulting iminyl 
radicals undergo 1,5-hydrogen abstraction or H-abstraction 
from lt-radical intermediates to yield unstable intermediates 
which rearrange under the high temperature conditions. The 
rearranged products rapidly hydrolyse on work-up to yield the 
primary amides. A precedent has been reported for an analogous 
compound which has an acyl group in place in the iminyl group. 31 
The characterisation of the unknown products 38/39 isolated 
from the radical reactions was ambiguous and the purification 
was hindered by two geometrical isomers which eo-eluted on 
chromatography. In order to be certain of the assignment of the 
structures, possible products were synthesised by unoptimised 
but unambiguous routes (Scheme 8). 
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Scheme 8 Reagents and conditions: i, NaH, DMF, DME, LiBr; ii, 
cinnamyl bromide, 2 h; iii, cinnamaldehyde, EtOH, reflux, 15 min (46%); 
iv, NaBH4 , MeOH, 30 min, 94% (44); v, methyl oxalyl chloride, Et,N 
followed by H+, 83%(45); vi, NH.OH, EtOH, 64%(46); vii, EDCI, 
HOAT (1-hydroxy-7-azabenzotriazole) (catalytic), DCM, reflux, 3 d, 
36% (31); viii, NaH, DMF; cinnamyl bromide, 50"/o (47); ix, NH3, EtOH, 
69%(38). 
The absence of a nitrile absorption in the IR spectrum and 
the absence of a molecular ion including the nitrile in the mass 
spectrum suggested a product without a nitrile group. 2-[(E)-
3-Phenylprop-2-enyi]-3H-quinazolin-4-one 41 was synthesised 
from anthranilamide 40 and the acid chloride of cinnamic 
acid using a protocol adapted from the literature.32.33 Radical 
abstraction of iodine and the nitrile group presents another 
possibility to yield 3-[(E)-3-phenylprop-2-enyi]-3H-quinazolin-
4-one 43. The 3-cinnamyl derivative 43 was prepared by 
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alkylation of 3H-quinazolin-4-one 42. The data for 41 and 43 
were similar to the unknown 38 but clearly different, thereby 
ruling out these structures. 
Although unlikely, we considered that a radical rearrange-
ment to the I-N-substituted 4-oxo-l-[(E)-3-phenylprop-2-enyl]-
3,4-dihyroquinazoline-2-carbonitrile 31 may be possible. The 
nitrile 31 was prepared by an adapted literature procedure 
for the synthesis of I-N-substituted 2-cyano-3H-quinazolin-
4-ones (Scheme 8).33•34 The conversion of the primary amide 
to the nitrile proved troublesome. The use of phosphorus 
oxychloride for dehydrating the primary amide to the nitrile led 
to removal of the cinnamyl group by SN2 substitution by chloride 
on the cinnamyl methylene group. An alternative method of 
dehydration using EDCI [l-(3-dimethylaminopropyl)-3-ethyl-
carbodiimide] proved satisfactory for converting 46 to 31.35 
Again, the data for46 and 31 were similar to 38 but not identical. 
Finally, we synthesised the unexpected primary amide 38 as 
shown in Scheme 8. The synthesised primary amide 38 was 
identical to the £-isomer of the isomeric mixture of unknown 
compounds isolated from the radical reactions. 
Our studies report novel cascade radical reactions and have in-
dicated that the methodology shown in Scheme l can be applied 
to a range of radical precursors. Further studies are underway 
to apply the general protocol to a wider range of syntheses. 
Experimental 
Commercial dry solvents were used in all reactions except for 
light petroleum and ethyl acetate which were distilled from CaCI2 
and dichloromethane (DCM) which was distilled over phos-
phorus pentoxide. Light petroleum refers to the bp 40-60 °C 
fraction. Sodium hydride was obtained as a 60% dispersion in 
oil and was washed with light petroleum. Mps were determined 
on an Electrothermal 9100 melting point apparatus and are 
uncorrected. Elemental analyses were determined on a Perkin 
Elmer 2400 CHN Elemental Analyser in conjunction with a 
Perkin Elmer AD-4 Autobalance. IR spectra were recorded 
on a Perkin Elmer Paragon 1000 FT-IR spectrophotometer on 
NaCI plates. 1H (250 MHz) and 13C (62.5 MHz) NMR spectra 
were recorded on a Bruker AC-250 spectrometer as solutions of 
CDCI3 with tetramethylsilane (TMS) as the internal standard 
for 1H NMR spectra and deuteriochloroform the standard for 
13C NMR spectra unless otherwise specified. Chemical shifts 
are given in parts per million (ppm) and J values in hertz 
(Hz). Mass spectra were recorded on a JEOL SX102 mass 
spectrometer or carried out by the EPSRC Mass Spectrome~ry 
Service at University of Wales, Swansea. GC-MS was earned 
out on a Fisons 8000 series GC-MS using a 15 m x 0.25 mm 
DB-5 column and an electron impact low resolution mass 
spectrometer. TLC using silica gel as adsorbent was carried 
out with aluminium-backed plates coated with silica gel (Merck 
Kieselgel 60 F254). Silica gel (Merck Kieselgel 60 H silica) was 
used for column chromatography unless otherwise specified. 
Methyl 6-cyano-2-oxo-1,2-dihydropyridine-<karboxylate 14 
Chlorotrimethysilane (0.560 g, 5.16 mmol) was added slowly to 
a mixture of methyl 2-cyano-6-methoxypyridine-4-carboxylate 
13 (0.323 g, 1.681 mmol) and sodiumiodide(0.773 g, 5.l6mmol) 
in acetonitrile (2.5 cm3) and the mixture stirred at 80 °C for 6 h. 
The solution was cooled to room temperature, evaporated under 
reduced pressure and water was added (2 cm3). This suspension 
was purified by column chromatography using DCM/Iight 
petroleum as eluent to yield methy12-cyano-6-methoxypyridine-
4-carboxylate 13 (0.12 g, 37%). Elution with a gradient mixture 
of DCM/EtOAc gave the product methyl 6-cyano-2-oxo-1,2-
dihydropyridine-4-carboxylate 14 (0.189 g, 63%), mp 201-
203 oc (Found: C, 53.8; H, 3.35; N, 15.51. CsH6N20J requires C, 
53.94; H, 3.39; N, 15.73%); Vm,. (Nujol)/cm-• 3100-2400 (broad 
NH); 2245 (CN), 1721, 1658 (C=O, pyridone), 1615, 1573, 1343, 
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1283, 1243, 1198, 1024, 993, 947, 909, 884, 775 and 759; 15" (d7-
DMF) 3.91 (3 H, s, OMe), 7.31 (l H, s, 5-H), 7.74 (I H, s, 3-H) 
and 12.38 (l H, br s, NH); t5c (d6-DMSO) 51.45 (OMe), 163.14 
and 161.83 (C=O ester and 2-C), 139.70 (4-C), 128.05 (6-C), 
ll7.49 (3-C), ll4.77 (5-C) and ll4.27 (CN); mlz (El) 178 (M+, 
93%, Found: 178.0381. C8H6N20 3 requires 178.0378), 147 (75), 
ll9 (lOO), llO (15), 91 (45), 76 (10) and 64 (18). 
Methyl 6-cyano-1-((Z)-2-iodo-3-phenylprop-2-enyl)-2-oxo-1,2-
dihydropyridine-4-carboxylate 16 
60% NaH (0.445 g, 11.13 mmol) was added portion-wise 
to a solution of methyl 6-cyano-2-oxo-l ,2-dihydropyridine-4-
carboxylate 14 (1.894 g, 10.64 mmol) in 1,2-dimethoxyethane 
(monoglyme) (21 cm3) and dimethylformamide after 10 min. 
The mixture was stirred for 15 min at room temperature, l-[(Z)-
3-bromo-2-iodoprop-l-enyl]benzene14 15 (1.6 g, 4.97 mmol) 
added, and the reaction heated at 65 °C for 20 h. The 
mixture was cooled to room temperature and poured into brine 
(50 cm3), extracted with EtOAc and dried. The solution was 
evaporated under reduced pressure to give an orange solid which 
was purified by column chromatography using EtOAc/DCM 
as eluent to give methyl 6-cyano-l-[(Z)-2-iodo-3-phenylprop-
2-enyl]-2-oxo-1,2-dihydro-pyridine-4-carboxylate 16 (1.398 g, 
31%), mp 122-123 oc (DCM/Iight petroleum) (Found: M•, 
419.9971. c.7HniN203 requires 419.9971); Vmax (DCM)/cm-• 
2230(CN), 1736, l674(C=O,pyridone), 1605,1543,1219,1080, 
988, 864, 772 and 694; 15" 3.95 (3 H, s, C02Me), 5.22 (2 H, d, 
J = l.2Hz, CH2N), 7.07 (l H, s, vinylic 3-H), 7.27 (3 H, d, 
J 2.0, pyridone 5-H), 7.32-7.38 (3 H, m, phenyl 3,4-H) and 
7.48-7.50 (3 H, m, phenyl 2,6-H and pyridone 3-H); t5c 53.41 
(OMe), 58.20 (CH2N), 95.70 (vinylic 2-C), 163.13, 160.34 (ester 
C=O, pyridone C=O), 139.33, 136.63 (pyridone 4-C, phenyli-
C), 139.18 (vinylic 3-C), 128.96 (pheny14-C), 128.61 (phenyl3-
C), 128.59 (pyridone 3-C), 128.19 (pheny12-C), 121.67 (pyridone 
6-C), ll4.40 (pyridone 5-C) and ll2.32 (CN); mlz 420 (M+, 
77%), 388 (3), 328 (7), 293 (13), 281 (4) 268 (30), 192 (7), 181 (6), 
133 (9), 115 (14), 91 (100), and 65 (5). Methyl 2-cyano-6-{[(Z)-
2-iodo-3-phenylprop-2-enyl]oxy}pyridine-4-carboxylate 17 was 
also eluted (1.37 g, 30%), Found: M+, 419.9973. C11HniN20J 
requires 419.9971; 15" 3.97 (3 H, s, C02Me), 5.25 (2 H, d, 
J = l.l Hz, CH20), 7.21 (l H, s, vinylic 3-H), 7.33-7.37 (3 
H, m, phenyl 4- and 3-H), 7.54-7.56 (2 H, m, phenyl 2-H), 
7.64 (l H, d, J l.l, 5-H) and 7.85 (1 H, d, J l.l, 3-H); t5c 
53.23 (ester OMe), 75.71 (CH20), 97.48 (vinylic 2-C), ll6.5l 
(CN), 116.67 (5-C), 121.78 (pyridine 3-C), 128.17 (phenyl CH), 
128.52 (phenyl CH), 128.62 (phenyl CH), 131.01 and 136.55 (2-
C,phenyll-C), l37.74(vinylic3-C), 141.55(4-C)and l63.43and 
163.69 (ester C=O, 6-C). Methyl6-cyano-l ,2-dihydro-l-methyl-
2-oxo-4-pyridine-carboxylate was eluted (0.2133 g), mp 144-
145 oc (DCM/Iight petroleum) (lit./6 143-144 oq (Found: M+, 
192.0536. C9H8N20 3 requires 192.0535); vmax (DCM)/cm-• 
2233, 1737 (C=O, ester), 1675 (C=O, pyridone), 1603, 1543, 
1220, ll28, 1081, 1000, 992,964,909 and 856; 15" 3.73 and 3.95 
(3 H each, s, C02Me, N-Me), 7.22 (l H, d, J = 2.0 Hz, 5-H), 
7.43 (I H, d, J 2.0, 3-H); t5c 34.83 (NMe), 53.36 (ester OMe), 
ll2.27 (6-C), 113.63 (5-C), 122.08 (CN), 128.31 (3-C), 139.12 
(4-C), 163.29, 161.00 (ester C=O, pyridine C=O); mlz 192 (M+, 
63%), 153 (8), 136 (8), 133 (100), ll5 (16), 105 (18), 91 (10), 89 
(14), 77 (36), 67 (25), 63 (9), 59 (19), 51 (18) and 43 (17). 
Methyl 9-oxo-9, 11-dihydroindolizino(1,2-h)quinoline-7-
carboxylate 21 using a 300 W sun lamp 
A solution of methyl 6-cyano-l-[(Z)-2-iodo-3-phenylprop-
2-enyl]-2-oxo-1,2-dihydropyridine-4-carboxylate 16 (0.10 g, 
0.24 mmol) in tert-butylbenzene (6.5 cm3) in a flat-bottomed, 
two-necked flask (Pyrex, 5 x l x 20 cm\ wall thickness l mm) 
was purged with nitrogen for 20 min. Hexamethylditin (0.156 g, 
0.48 mmol) was added by syringe and the resultant solution 
purged with nitrogen for a further 30 min. The mixture was 
irradiated with two 150 W sun lamps at SS °C for 24 h. 
The reaction was cooled to room temperature, diluted with 
methanol and evaporated under reduced pressure. Analysis 
by LCMS and 'H NMR spectroscopy showed 21 (50%) 
along with a number of unidentified products. The residue 
was purified using column chromatography with an eluent 
gradient of DCM/EtOAc/MeOH and gave methyl 9-oxo-9,11-
dihydroindolizino[l,2-b]quinoline-7-carboxylate 21 (14.6 mg, 
21%), mp IS4-IS6 °C(Iit./7 IS5-IS7 °C)(Found: M+, 292.0S48. 
C17H 12N20 3 requires 292.0S4S); bH 3.99 (3 H, s, C02Me), 5.30 
(2 H, s, 11-H), 7.37 (I H, s, 6-H), 7.66 (I H, ddd, J = 7.5, 7.8, 
1.0 Hz, 2-H), 7.SI (I H, s, S-H), 7.S3 (I H, ddd, J 7.5, 7.8, 1.2, 
3-H), 7.93 (I H, dd, J 7.S, 1.0, 1-H), 8.24 (I H, dd, J 7.8, 1.2, 
4-H), S.39 (I H, s, 12-H); be 50.59 (11-C), 53.39 (OMe), 100.09 
(6-C), 122.45 (S-C), 12S.37, 12S.53 (1-C, 2-C), 12S.59, 129.01 
(12a-C, lla-C), 130.24, 130.97, 131.46 (12-C, 4-C, 3-C), 142.36 
(7-C), 147.13, 149.37 (4a-C, Sb-C), 152.93 (Sa-C), 161.5S (9-C) 
and 165.50 (ester C=O); mlz 292 (M+, 100%), 277 (8), 263 (6), 
249 (2), 233 (12), 205 (27), 177 (6), 140 (S), 121 (6), 115 (14), 105 
(7), 95 (I I), S4 (30), 77 (14), 69 (29), 57 (23) and 49 (31). 
The reaction was carried out under similar conditions at 
ISO °C with a larger excess ofhexamethyditin (3.66 mmol) and 
16 (0.048 mmol) in tert-butylbenzene (6.5 cm3) which yielded 
21 (15%). The reaction was also repeated with the addition of 
di-tert-butyl peroxide in a sealed tube and heated which yielded 
21 in less than 5%. 
4-0xo-3,4-dihydroquinazoline-2-carbonitrile 25 
Ethyl 2-[( 4-chloro-SH -1,2,3-dithiazol-5-yliden)amino ]benzene-
1-carboxylate 24 (4.453 g, 14.S4 mmol) was added to an 
ammonia solution (0.5 M) in 1,4-dioxane (100 cm3, 0.05 mol). 
The solution was sealed under nitrogen and stirred at room tem-
perature for 5 d. The brown precipitate was filtered and washed 
with light petroleum to give 4-oxo-3,4-dihydroquinazoline-2-
carbonitrile 25 (2.4S g, 9S%). (Found: [M + NH4]+ IS9.0772, 
C.H5N30+NH4 requires IS9.0776; Found: M+, 171.0432. 
C.H5N30 requires 171.0433); v .... (Nujol)/cm·' 3134 (NH), 
2236 (CN), 169S (C=O), 160S, 1574, 1521, 140S, 1367, 1346, 
1112, 998 and 776; bH (DMSO-d6) 7.34-7.37 (I H, m, 6-H), 
7.50-7.52 (I H, m, S-H), 7.59-7.61 (I H, m, 7-H) and 7.99-S.OO 
(I H, m, 5-H); be 118.0S (CN), 123.75 (4a-C), 126.49 (5-C), 
126.03 (6-C, 8-C, overlap), 132.35 (7-C), 143.62 (Sa-C), 150.73 
(2-C) and 171.21 (C=O); mlz [Cl+(NH3)]1S9 [(M+ NH.y, 
50%], 172(92), 161 (30) and 147 (100); GC-MS shows one peak, 
(El) 171 (M+, 100%), 143(50), 116(25),90(25), 76(10),63(30), 
and 53 (25). 
4-0xo-3-)(E)-3-phenylprop-2-enyl)-3,4-dihyroquinazoline-2-
carbonitrile 28: procedure for the alkylation of 4-oxo-3,4-
dihydroquinazoline-2-carbonitrile 25 
NaH (93.9 mg, 2.35 mmol) was added slowly with stirring 
to a solution of 4-oxo-3,4-dihydroquinazoline-2-carbonitrile 25 
(0.402 g, 2.35 mmol) in anhydrous dimethyl sulfoxide (4.7 cm3) 
under an atmosphere of nitrogen. Cinnamyl bromide (0.4631 g, 
2.35 mmol) was added after I h and the solution stirred at 
room temperature under nitrogen for 5 h. Water was added and 
the mixture extracted with DCM. The organic fractions were 
evaporated under reduced pressure and the residue purified by 
column chromatography using DCM/Iight petroleum as eluent 
to give an inseparable mixture of 4-oxo-3-[(E)-3-phenylprop-2-
enyl]-3,4-dihyroquinazoline-2-carbonitrile 28 (0.302 g, 45%) and 
4-{[(E)-3-phenylprop-2-enyl]oxy }quinazoline-2-carbonitrile 29 
(X = H) (59 mg, 9%). Further elution gave 4-oxo-1-[(E)-
3-phenylprop-2-enyl]-1,4-dihydroquinazoline-2-carbonitrile 31 
(<I%). 
28: mp 147-148 °C (from DCM/Iight petroleum) (Found: C, 
75.4; H, 4.4; N, 14.4. C18H 13N 30 requires C, 75.25; H, 4.56; N, 
14.63%); Vm,. (Nujol)/cm·' 2207 (CN), 1693 (C=O), 1590, 1558, 
776 and 692; bH 5.02 (2 H, d, J = 6.7 Hz, CH2), 6.33 (I H, dt, 
J 6.7, IS.S, propenyi2-H), 6.SI (I H, d, J IS.S, propenyi3-H), 
7.24-7.31 (3 H, m, phenyi3,4,5-H), 7.36-7.3S (2 H, m, phenyl 
2,6-H), 7.63 (I H, dd, J 7.9, 7.9, 6-H), 7.7S-7.S3 (2 H, m, 7- and 
S-H) and S.32 (I H, d, J 7.9, 5-H); values were assigned using 
NOE difference spectroscopy; important NOEs were observed 
between the methylene protons and the propenyl 2-H (2.6%) 
and propenyl 3-H (3.6%) indicating the £-stereochemistry but 
not with S-H indicating the 3-N isomer; be 4S.II (CH2), 111.64 
(CN), 120.91 (propenyi2-C), 122.79 (4a-C), 126.75 (phenyi2,6-
C), 127.11 (S-C), 12S.45 and 12S.49 (propenyi3-C, phenyi4-C), 
12S.63 (phenyi3,5-C), 130.02 (6-C), 131.32 (phenyli-C), 135.09 
(5-C), 135.5S (Sa-C), 136.13 (7-C), 146.37 (2-C), and 159.72 
(C=O); mlz 2S7 (M+, 37%, Found: M+, 2S7.105S. C18H 13N30 
requires 2S7.105S), 25S (2), 196 (43), 117 (lOO), 102 (4), 91 (14), 
77 (5) and 76 (4). 
29 (X = H) (Found: M+, 2S7.105S. C18H 13N30 requires 
2S7.1059); bH 5.25 (2 H, d, J = 6.2 Hz, OCH2), 6.6.4-6.61 (I 
H, dt, J 6.2, 15.9, propeny12-H), 6.S3 (1 H, d, J 15.9, propenyl 
3-H), 7.24-7.31 (3 H, m, phenyl3, 4, 5-H), 7.41-7.43 (2 H, m, 
phenyl 2, 6-H), 7.6S (I H, dd, J 7.9, 7.9, 6-H), 7.S5 (I H, dd, 
J 7.9, 7.9, 7-H), 7.9S (I H, d, J 7.9, S-H) and S.21 (I H, d, 
J 7.9, 5-H); be 6S.S3 (OCH2), 116.27 and 116.94 (CN, 4a-C), 
122.0S (propenyi2-C), 139.60 (2-C), 123.71, 129.6S, 135.03 and 
135.55 (5,6,7,S-C), 150.50 (Sa-C), 166.90 (4-C), the remaining 
resonances overlap with those of28; mlz 244 (31 %), 230 (9), 171 
(4), 153 (4), 131 (49) and S4 (IS). 31 was not fully characterised 
but exhibited a similar mass spectrum using GC-MS. 
The alkylation was repeated with 25 (0.275 g) using only NaH 
and DMF with heating at 65 °C for 20 h after the addition of 
cinnamyl bromide. 28 (0.203 g, 44%) was obtained with only a 
trace of the O-alkyl29 and none of the N-1 alkylated product 
was observed. 
3-)(Z)-2-Iodo-3-phenylprop-2-enyl)-4-oxo-3,4-
dihydroquinazoline-2-carbonitrile 27 using amine 32 
(Z)-2-Iodo-3-phenylprop-2-en-1-amine 32 (0.7S56 g, 
3.03 mmol) was added to a solution of ethyl 2-[(4-chloro-
SH -I ,2,3-dithiazol-5-yliden)amino]benzene-1-carboxylate 24 
(0.2275 g, 0.76 mmol) in anhydrous tetrahydrofuran (20 cm3). 
The mixture was stirred for 2 d at room temperature under an 
atmosphere of nitrogen. The reaction mixture was evaporated 
under reduced pressure and the residue purified by column 
chromatography using DCM/Iight petroleum as eluent to yield 
27 (0.12S g, 42%), mp 152-152.5 °C (DCM/Iight petroleum). 
(Found: C, 52.4; H, 2.7; N, 9.S. C18H 12IN30 requires C, 52.32; 
H, 2.93; N, 10.17%); v .... (DCM)/cm·' 2234(CN), 169S (C=O), 
1605 (C=N), 15S6, 1561, 1471 and 13S3; bH 5.32 (2 H, s, CH2, 
NOE enhancement from propenyl 3-H, 6%), 7.17 (1 H, s, 
propenyl 3-H, NOE enhancement from CH2, 6%), 7.32-7.34 
(3 H, m, phenyl 3,4,5-H), 7.52-7.49 (2 H, m, phenyl 2,6-H); 
7.67-7.62 (I H, m, 6-H), 7.SI-7.S5 (2 H, m, 7,S-H), S.32-S.34 
(I H, m, 5-H); be 56.94 (CH2), 96.14 (propenyi2-C), 111.59 and 
122.61 (CN, 4a-C), 127.36 (CH), 12S.I6 (CH) and 128.59 (CH) 
with two overlapping CH peaks, 130.20 (CH), 131.25 (phenyl 
1-C), 135.31 (7-C), 136.48 (Sa-C), 139.26 (propenyi3-C), 146.13 
(2-C), and 159.51 (4-C); mlz (FAB), 414 [(M + H)+, 12%, 
Found: 414.0101. C18H 121N30 + H requires 414.0105], 2S6 
(100), 259 (41), 254 (35), 243 (45), 219 (IS), 20S (25), 165 (29), 
116 (70) and 105 (40); mlz (El) 354 (6%), 2S6 (92), 262 (4), 146 
(7), 125 (7), 115 (100), 97 (18), S3 (20), 69 (22), 63 (10), 57 (37) 
and 43 (33). 
11 ,13-Dihydroquino)2' ,3':3,4)pyrrolo(2,1-h)quinazolin-11-one 
(luotonin A) 4 and 4-oxo-3-(3-phenylprop-2-enyl)-3,4-
dihydroquinazoline-2-carboxylic acid amide 38/39 (El Z 
mixture 2 : 1) 
Sun lamp irradiation at 150 °C. A solution of 3-[(Z)-
2-iodo-3-phenylprop-2-enyl]-4-oxo-3,4-dihydroquinazoline-2-
carbonitrile 27 (107.0 mg, 0.26 mmol), hexamethylditin (1.20 g, 
Org. Blomo/. Chem., 2005, 3, 1460-1467 [bJ~s: ;J 
3.66 mmol, 14 equiv.) and tert-butylbenzene (6.5 cm3), in a 
flat-bottomed, two-necked Pyrex flask (5 x I cm and 25 cm high, 
wall thickness = 1 mm), was purged with nitrogen for 30 min. 
The mixture was irradiated with a combined 300 W sun lamp at 
ISO °C for 46 h. The reaction was cooled to room temperature, 
diluted with MeOH and evaporated under reduced pressure 
to a small volume. The residue was purified using column 
chromatography with light petroleum as eluent to remove the 
tert-butylbenzene. Further elution with DCM/diethyl ether 
gave luotonin A 4 as a white solid (15.4 mg, 21%) and 4-oxo-3-
[(E)-3-phenylprop-2-enyl]-3,4-dihydroquinazoline-2-carboxylic 
acid amide 38/39 (EIZ mixture= 2.8 : 1) (22.3 mg, 30%) as 
a mixture. Separation was achieved using preparative silica 
gel plates and DCM as eluent. Data for 4: mp 277-279 °C 
(DCM/Iight petroleum ether) (lit./0 281-283 °C} (Found M+, 
285.0904. C 18H 11 N 30 requires 285.0902); Vmax (DCM)/cm-1 
1674, 1628, 1605, 1465, 1352,1320,1234,1189, 1134, 1026,768 
and 686; J" 5.36 (2 H, s, 13-H), 7.57-7.61 (1 H, dd, J = 8.0, 
8.0 Hz, 9-H), 7.69-7.73 (1 H, ddd, J 0.8, 8.0, 8.0, 2-H), 7.86 
and 7.87 (2 H, dd and dd, J 8.0, 8.0, 3-H and 8-H, overlap), 
7.97 (I H, d, J 7.6, 1-H), 8.13 (1 H, d, J 8.0, 7-H), 8.44 (I H, 
dd, J 0.8, 8.0, 4-H H-4), 8.47 (l H, s, 14-H) and 8.49 (1 H, 
d, J 8.0, 4-H), values were assigned using NOESY and COSY 
correlation spectra; Oc 47.33 (13-C), 121.38 (lOa-C), 126.49 
(10-C), 127.49 (9-C), 128.00 (1-C), 128.59 (2-C), 128.79 (7-C), 
128.85 (14a-C), 129.45 (13a-C), 130.71 and 130.75 (3-C and 
4-C), 131.56 (14-C), 134.60 (8-C), 149.40 and 149.47 (6a-C, 
4a-C), 151.22 (Sa-C), 152.58 (Sb-C) and 160.68 (11-C); 
m/z(FAB)286[(M +H)', 1000/o, Found286.0984. C18H 11 N 30+ 
H requires 286.0980], 249 (45), 190 (30), 167 (12), 127 (14), 115 
(45) and 105 (25); mlz (El) 285 (M+, 100%), 257 (10), 229 (8), 
189 (3), 149 (8), 128 (5), 115 (11), 84 (28), 77 (9), 71 (18), 57 (29) 
and 43 (14). 
Data for 38/39 [(mixture of E/Z-isomers (2.8 : 1)]: [Found 
(M - CONH2)• 261.1027. C1sHuN30 - CONH2 requires 
261.1027]; Vmax (DCM)/cm-1 1682, 1587, 1265 and 727; JH 
(400 MHz) 5.40 (2 H, dd, J = 1.2, 6.6 Hz, CH2, £-isomer), 
5.50 (2 H, dd, J 2.0, 6.0, CH2, Z-isomer), 5.67 (1 H, dt, J 6.0, 
11.8, propenyi2-H, Z), 5.77 (1 H, brs, NH, E), 6.39 (I H, dt, J 
6.6, 15.8, propenyl 2-H, E), 6.61 (I H, dd, J 2.0, 11.8, propenyl 
3-H, Z; NOE with Z-propeny1 2-H of 8.4% but none with the 
methylene indicating Z-stereochemistry), 6. 73 [1 H, br d, J 1.2, 
15.8, propenyl 3-H, E; NOE with Z-propenyl 2-H (1.7%) and 
the methylene (3.8%) indicating £-stereochemistry], 7.21 (I H, 
ddd, J 8.0, 1.6, 1.6, phenyl o-H, Z), 7.22 (1 H, ddd, J 8.0, 8.0, 1.6, 
phenyl p-H, E), 7.25-7.31 (2 H each, m, phenyi-H, E,Z overlap), 
7.35-7.37 (2 H each, m, phenyi-H, E,Z overlap), 7.47 (I H, brs, 
NH), 7.56 (I H, ddd, J 1.3, 7.9, 7.9, 6-H, Z), 7.58 (I H, ddd, J 
1.3. 7.9, 7.9, 6-H, E), 7.69 (I H, ddd, J 0.6, 1.3, 7.9, 8-H, Z), 
7.70 (I H, ddd, J 0.6, 1.3, 7.9, 8-H, E), 7.75 and 7.77 (I H each, 
ddd, J 1.3, 7.9, 7.9, 7-H, E,Z overlap), 8.30 (I H, ddd, J 0.6, 
1.3, 7.9, ary!S-H, Z) and 8.34 (1 H, ddd, J 0.6, 1.3, 7.9, 5-H, E); 
values were assigned using COSY correlation; mlz (GC-MS, 
El) GC-MS showed two peaks with similar retention times and 
mass spectra; major isomer: 287 (25%), 279 (5), 258 (2), 196 
(50), 167 (10), 117 (lOO), 91 (34), 76 (13), 63 (12) and 51 (8). The 
structure of 38 was confirmed by unambiguous synthesis (TLC, 
IR and 1 H NMR spectra). 
With di-tert-butyl peroxide. A solution of 3-[(Z)-2-
iodo-3-phenylprop-2-enyl]-4-oxo-3,4-dihydroquinazoline-2-
carbonitrile 27 (90.6 mg, 0.219 mmo1), hexamethylditin 
(274.2 mg, 0.837 mmo1, 3.8 equiv.) and di-tert-butyl peroxide 
(98%, 64.9 mg, 0.423 mmol, 2.0 equiv.) in tert-butylbenzene 
(3.5 cm3) in a Schlenk tube was subjected to the freeze-thaw 
method (six times). The sealed tube was immersed in an oil bath 
at 120 oc for 24 h surrounded by a safety shield in a fumehood. 
The reaction mixture was cooled to room temperature and 
placed directly on a silica gel column. Elution with light 
petroleum removed the tert-butylbenzene. Further elution with 
i;1:4.6.~; Or g. Bio mo I; Ch em., 2 005, 3, 1460-146 7 
DCM/ diethyl ether gave luotonin A 4 as a white solid (18.8 mg, 
30%) and 38/39 (EIZ mixture 3.5 : 1) (10 mg, 16%) as a 
mixture. All data agreed with authentic materials. 
The reaction was repeated except that a higher dilution 
was used [tert-butylbenzene (15 cm3)). The reaction gave only 
luotonin A 4 as a white solid (13.8 mg, 22%). 
4-0xo-3-[(E)-3-phenylprop-2-enyl)-3,4-dihydroquinazoline-2-
carboxylic acid ethyl ester 47 
To a pre-dried flask was added 4-oxo-3,4-dihydroquinazoline-
2-carboxylic acid ester (1.00 g, 4.61 mmol), anhydrous DMF 
(30 cm3) and sodium hydride (60% mineral oil suspension, 
0.28 g, 6.92 mmol) and the reaction stirred for 10 min. Cinnamyl 
bromide (0.61 g, 3.09 mmol) was added and the mixture stirred 
for 1.5 h. The DMF was removed under reduced pressure and 
the residue washed with saturated brine and extracted into 
ethyl acetate. The product was purified by flash silica column 
chromatography to yield 47 as a pale yellow semi-solid (0.52 g, 
50%)(Found M• 334.1319. C20H 18N20 3 requires: 334.1317); Vmax 
(thin film)/cm-1 2359, 1734, 1683, 1596, 1464, 1301, 1262, 1153 
and 1033; .5" (400 MHz) 1.03 (3 H, t, J = 7.1 Hz, CH3), 4.14 
(2 H, q, J 7.1, CH20), 4.75 (2 H, dd, J 6.4, 1.4, CH2N), 5.97 
(I H, dt, J 15.9, 6.4, propenyl-2-H), 6.35 (1 H, dd, J 15.9, 1.4, 
propenyl-3-H), 6.91-7.08 (5 H, m, phenyl-H), 7.23-7.30 (I H, m, 
8-H), 7.48-7.50 (2 H, m, 6-H and 7-H) and 8.04 (I H, ddd, J 1.2, 
1.2, 8.1, 5-H); oc (lOO MHz) 161.6 (qC), 160.8 (qC), 146.7 (qC), 
146.2 (qC), 135.8 (qC), 134.7 (CH), 134.6 (CH), 128.6 (CH), 
128.4 (CH), 128.1 (CH), 128.0 (CH), 127.0 (CH), 126.5 (CH), 
122.9 (CH), 121.9 (qC), 63.3 (CH2), 45.9 (CH2) and 13.8 (CH3); 
mlz (El) 334 (M+, 8%), 261 (100), 145 (5), 115 (30) and 91(16). 
4-0xo-3-[(E)-3-phenylprop-2-enyl)-3,4-dihydroquinazoline-2-
carboxylic acid amide 38 
4-0xo-3-[(E)-3-phenylprop-2-enyl]-3,4-dihydroquinazoline-2-
carboxylic acid ethyl ester 47 (0.50 g, 1.5 mmol) was dissolved 
in a absolute ethanol (10 cm3) to which was added concentrated 
aqueous ammonia (100 cm3). The reaction was stirred for 
30 min and the resultant precipitate filtered off. The precipitate 
was washed with water and dried to yield the title compound 38 
as a white solid (0.315 g, 69%) (Found 306.1237. C 18H 15N30 2 + 
H requires 306.1237); Vmax (thin film)/cm-1 1675, 1653, 1585, 
1559, 1457 and 1436; o" (400 MHz, d6-DMSO) 4.93 (I H, J = 
6.8 Hz, CH2N), 6.36 (1 H, J 6.8, 16.1, propenyl-2-H), 6.55 (1 H, 
J 16.1, propenyi-3-H), 7.23 (1 H, t, J 7.6, Ph p-H), 7.31 (2 H, 
t, J 7.6, 7.6, Ph m-H), 7.40 (2 H, t, J 7.6, 7.6, Ph o-H), 7.62 
(1 H, ddd, J 1.2, 7.9, 7.9, 6-H), 7.74 (I H, ddd, J 0.5, 1.2, 7.9, 
8-H), 7.90 (1 H, ddd, J 1.2, 7.9. 7.9, 7-H), 8.19 (I H, ddd, 
J 0.5, 1.2, 7.9, 5-H), 8.15 (I H, brs, NH) and 8.45 (1 H, brs, 
NH); Jc (100 MHz, d6-DMSO) 50.8 (CH2), 126.3 (qC), 129.3 
(propenyi-2-C), 131.5 (Ph o-C), 131.6 (5-C), 132.6 (8-C), 133.0 
(6-C), 133.1 (Ph p-C), 133.8 (Ph m-C), 137.8 (propenyi-3-C), 
140.0 (7-C), 141.2 (qC), 151.5 (qC), 155.5 (qC), 165.5 (qC), 
and 168.8 (qC). The assignments were confirmed with COSY, 
HMQC and NOESY techniques; mlz (El) no M•; (Cl) 306 
([M+ H)+, 90%), 263, (lOO) and 190 (28). The 1H NMR spectra 
in CDCI3 and TLC were identical to those in the mixture from 
the radical reaction to synthesise luotonin A. All peaks in the 
IR spectrum taken in DCM were identified in the IR spectrum 
of the mixture. 
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